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Abstract 
 
The decline in dairy cow fertility is attributed to the intensive genetic selection that focused 
primarily on milk production traits and is associated with decreased conception rates 
resulting as a consequence of the increase in metabolic pressure due to increases in milk 
production. Another detrimental factor to cow fertility is the presence of an activated 
inflammatory system through infectious and/or immune challenge. Poor reproductive 
efficiency in dairy herds has resulted in fewer calves, reduced milk production, high 
involuntary culling rates and increased cow maintenance costs. Therefore, there is a critical 
need to identify dairy cows with markers of good fertility and/or resistance to diseases. This 
identification could lead to early intervention and higher survival rates resulting in 
reproductive success. Exosomes offer a potential route for the discovery of such markers. 
Furthermore, examination of exosome actions on cells in vitro could provide significant 
information on the pathways and processes altered in sub-fertile dairy cows. 
 
I hypothesised that differences in the fertility of dairy cows could be assessed by monitoring 
exosomal cargo differences and that these differences in cargo content could be manifested 
and reflected by changes in endometrial function (e.g. inflammatory mediator gene 
expression and cytokine production). 
 
This hypothesis was tested in aim three after the completion of two initial aims. The first aim 
was to characterise bovine endometrial cells to ascertain their appropriateness as an in vitro 
model for the study of the uterine environment. The cells tested responded in the manner 
expected when exposed to infectious and inflammatory stimuli as well as to hypoxia. This 
therefore provided reassurance of their suitability for subsequent in vitro studies in aim three. 
 
The second aim was to establish a robust and reproducible method for the isolation and 
enrichment of exosomes from body fluids of dairy cows (e.g. plasma and milk). The 
development of a method was required as no standardised procedure for exosome isolation 
was available. Buoyant density used previously by my group was labour intensive and time 
consuming. A better quality, high throughput method needed to be established. Following 
the trial of many methods, ultracentrifugation coupled with size exclusion chromatography 
was determined to be the best method of exosome isolation. A targeted mass spectrometric 
approach using a quadrupole-ion trap mass spectrometer was developed to detect several 
exosomal markers from bovine plasma and milk exosomes. 
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The third aim of this thesis was the critical study required to test the hypothesis and was 
further spilt into two parts. Part one was the characterisation and evaluation of exosomal 
cargo and part two was the effect of exosomes on endometrial cell function. The third aim 
combined the findings of the two previous aims and the clinical samples of a research dairy 
cow herd. This research herd was established by DairyNZ to better understand the key 
drivers of cow fertility. These drivers of which can then be used to improve the accuracy of 
predictions of fertility (i.e. fertility breeding value and biomarkers for fertility). This research 
herd consisted of heifers bred to be either higher or lower in fertility but having other similar 
key animal traits (e.g. live-weight, milk production, and percentage of North American 
genetics). In this final aim, plasma exosomes from high and low fertility heifers were isolated 
using methodology developed in aim two. The proteomic content of plasma exosomes from 
high and low fertility heifers was analysed and unique proteins were identified. 
 
Part two was the co-incubation of exosomes from low fertility heifers with bovine endometrial 
epithelial cells. This resulted in the upregulation of gene expression of pro-inflammatory IL-
1α and IL-8 (CXCL8) cytokines but downregulation of IL-4 gene expression compared to co-
incubation with exosomes from high fertility heifers. Additionally, co-incubation with 
exosomes from low fertility heifers, downregulated the gene expression of CXCL9, CXCL10, 
and CX3CL1 in stromal cells compared with co-incubation with exosomes from high fertility 
heifers. These findings demonstrate that exosomes can modulate endometrial cell functions 
by altering inflammatory mediator gene expression. Furthermore, the findings suggested 
that exosomes from low fertility heifers can activate a pro-inflammatory uterine 
microenvironment and can impact uterine receptivity through downregulation of CXCL9 and 
CXCL10 gene expression, which are key factors for mediating the attachment of trophoblast 
to the endometrium. 
 
In summary, I believe that this thesis has advanced our knowledge of how exosomes may 
be used to identify cows with varied fertility states and has provided greater understanding 
of the ability of exosomes to modulate female reproductive function, including inflammatory 
mediator gene expression in the maternal cells. This thesis has established a platform from 
which further investigations on the role of exosomes in maternal-foetal communication can 
be implemented. Furthermore, investigating novel exosomal biomarkers from easily 
accessible body fluids will permit the early diagnosis and prognosis of pregnancy and 
improved fertility in dairy cows that can be used to develop superior breeding stock to deliver 
higher industry productivity. 
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Chapter 1: General Introduction 
 
Background 
The term fertility is applied to humans and animals and is defined as the ability to reproduce 
and give birth to live offspring. In dairy cows, a fertility crisis has emerged in the past decade 
with reduced fertility being observed in major dairy producing countries like Australia and 
New Zealand (Pryce et al., 2014, Harris et al., 2006). The reduced fertility in dairy cows 
appears to be multi-factorial with research showing intensified genetic selection as the main 
cause. With the primary breeding focus in dairy cows being on  increased milk yield, the 
overall health of the dairy cows, in particular the uterine and udder health, has been 
compromised (Egger-Danner et al., 2015, Lucy, 2001). 
 
Dairy cows that are referred to as ‘lower fertility’ have a lower probability to be in calf within 
the first 42 days after the start of planned mating (Bowley et al., 2015). Good reproductive 
performance and compact calving (i.e. the ability to produce one healthy calf per cow within 
a calving interval of one year), especially in seasonal production systems, are essential for 
maximising milk production and minimising losses due to involuntary culling; traits that are 
particularly important to the overall profitability of the herd. 
 
Reproductive efficiency could be improved by identifying and addressing reproductive 
problems, like the inefficient detection of oestrus. Reproductive efficiency could also be 
improved by identifying animal health issues like the presence of an activated inflammatory 
system through infectious and/or immune challenges during pregnancy. Subsequently there 
is a need for the development and utilisation of biomarkers to monitor animal health and the 
effectiveness of interventions. Establishing management strategies to improve dairy cow 
fertility by detecting early onset of diseases and testing for fertility traits, without the need for 
biopsies and other more invasive techniques like rectal palpation and laparoscopy, can help 
to resolve many important problems associated with declining fertility in dairy cows. 
Exosomes may provide a source of potential biomarkers. 
 
Recent research has described the potential role of exosomes in the new paradigm for the 
complex inter-cellular signalling networks associated with health and diseases. Exosomes 
(30–120 nm) are stable endosome-derived membrane vesicles produced by the inward 
budding of multivesicular bodies that are released via an exocytic pathway to the 
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extracellular environment. Exosomes have the capacity to modify the biological function of 
target cells by delivering a diverse array of signalling molecules that include mRNA, 
microRNA (miRNA), proteins, and lipids (Record et al., 2011). Exosomes are remarkably 
stable (Taylor and Gercel-Taylor, 2013) and have been found in bodily fluids including milk 
(Yamada et al., 2012), blood (Lasser et al., 2011), urine (Keller et al., 2007) and saliva (Gallo 
et al., 2012). The ability of exosomes to contain and deliver an assortment of biomolecules, 
like proteins, nucleic acids, and lipids, to near and distant sites, as well as their involvement 
in inter-cellular signalling, has paved the way for investigation into the potential role of 
exosomes in reproduction. 
 
Exosomes have also been identified in bovine fluids with the exosomal miRNA, protein, and 
mRNA content characterised in follicular fluid, plasma, and milk. Furthermore, the role and 
potential use of exosomes as biomarkers in reproduction and pregnancy is supported by 
studies involving sheep (Burns et al., 2014) and horses (da Silveira et al., 2012) where 
exosomes have been shown to regulate the maternal immune system during early 
pregnancy. Collectively, these studies support the potential that exosomes carry biomarkers 
that may be utilised to determine the fertility status in dairy cows. 
 
Bovine Reproduction  
The reproductive cycle of dairy cows 
One of the fundamental principles for improving bovine reproductive performance and 
ensuring compact calving is to understand the reproductive biology and fertility of a cow. In 
New Zealand dairy cow (Jersey, Holstein-Friesian and Holstein-Friesian x Jersey 
crossbreeds) the average gestation period is approximately 282 days (Jenkins et al., 2016, 
Macmillan and Curnow, 1976), and in order for a cow to be mated, become pregnant, and 
calve at the same time the following year, the postpartum period (i.e. the period between 
calving and the first oestrus) should be no longer than 83 days (Figure 1.1). After giving 
birth, cows begin to lactate and produce colostrum - the initial secretion from the mammary 
glands that contains high concentration of immunoglobulins. Colostrum is critical for 
providing passive immunity needed for neonatal survival and for acquiring maternal 
immunoglobulins that cannot be transferred in utero (Kruse, 1983). Following parturition, the 
uterus undergoes involution, a process that involves the shedding of all foetal membranes, 
repair of reproductive tissue, and resumption of ovarian cyclicity, to a state where it can 
initiate and sustain another pregnancy. 
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Figure 1.1. A schematic representation of an ideal reproductive cycle of a cow. The 
average duration of pregnancy is approximately 282 days. In order for a 365 day calving 
interval to produce one healthy calf, the postpartum period, or the period from calving to first 
oestrus, should be no longer than 83 days (CEVA Santé Animale, 2009). 
 
Endocrinology of dairy cow reproduction 
The events of oestrus and pregnancy are regulated by hormones that are produced in 
endocrine tissues, such as the pituitary, hypothalamus, embryo, ovaries, and uterus 
(Dobson and Kamonpatana, 1986), and transported by the circulatory system throughout 
the body to perform their respective functions. High levels of oestrogen, a hormone 
produced by the follicles, bring the cow into heat in preparation for mating. During this time, 
oestrogen also triggers the release of gonadotropin, follicle stimulating and luteinizing 
hormones that enhance the growth of ovarian follicles. The surge of luteinizing hormone 
causes ovulation where the follicles mature, rupture and release an ovum. Following 
ovulation, the corpus luteum forms producing progesterone that helps prepare the uterus for 
pregnancy and prevents the cow from returning to heat. If the cow does not conceive, the 
endometrium secretes prostaglandin F2α and causes the corpus luteum to degrade and 
produce less progesterone that helps begin development of a new follicle for ovulation in 
the next oestrous cycle. However, if the ovum is fertilised and the cow conceives, the 
endocrine system undergoes a dramatic change during the onset of pregnancy. 
 
At the early onset of pregnancy, the conceptus produces interferon-tau (IFNτ), a pregnancy 
recognition signal that acts to suppress oestrogen and oxytocin receptors and blocks the 
release of the luteolytic prostaglandin F2α by the uterus. These events deactivate the 
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oxytocin-prostaglandin F2α feedback loop that is responsible for luteolysis (anti-luteolytic 
signalling mechanism) (Bazer, 2013), enabling levels of progesterone in plasma and milk to 
continually increase and remain high enough throughout the gestation period to prevent 
further oestrous cycles. Progesterone secreted by the corpus luteum prepares the uterus 
for the developing calf until the final trimester before the placenta will take over the role of 
maintaining the pregnancy. 
 
The bovine placenta, which serves as an interface between the mother and the developing 
foetus, functions as an immunological barrier and mediates nutrient, waste and gas 
exchange. The bovine placenta produces protein hormones such as placental lactogen and 
leptin that are involved in partitioning of maternal nutrition to the growing foetus and 
regulates placental and foetal growth (Ravelich et al., 2004). In addition, the placenta also 
produces steroids, mainly progesterone and oestrogen (Schuler et al., 2008). Placental 
progesterone production becomes elevated between 7 and 9 weeks of cow gestation 
(Safdar and Moradi-Kor, 2013), however, the placental contribution to maternal systemic 
progesterone levels was negligible since the corpus luteum is the main source of 
progesterone throughout gestation (Hoffmann and Schuler, 2002, Estergreen et al., 1967). 
The functions of placental progesterone in late pregnancy remains poorly understood but 
studies have suggested that they act as a paracrine factor involved in the local regulation of 
caruncular growth, differentiation, and functions (Hoffmann and Schuler, 2002, Schuler et 
al., 1999). Apart from progesterone, oestrogen produced by placenta during pregnancy 
stimulate growth of the myometrium, synthesis of actomyosin and consequently an increase 
of the contractile capacity of the uterus (Kindahl et al., 2004). And as pregnancy reaches 
term, oestrogen synergises with relaxin to soften the cervix and stimulate the release of 
prostaglandin F2α from the endometrium for the preparation of the maternal genital tract for 
parturition (Nguyen et al., 2012). 
 
The endocrine system also coordinates the development of the mammary gland with 
reproductive development and the demand of the offspring for milk. Progesterone, which is 
required for the maintenance of pregnancy is elevated throughout gestation, while oestrogen 
is particularly elevated during the second half of gestation. During the first half of gestation, 
progesterone stimulates the growth of the milk-producing cells in the mammary glands. In 
the second half of gestation, progesterone and oestrogen in combination promotes lobule-
alveolar development and stimulate the growth of the ducts that drain the milk to the teat 
(Ambrose and Emmanuel, 2008, Akers, 2017). In the last few weeks of pregnancy the 
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effects of progesterone and oestrogen on the udder are even more pronounced, and 
together with placental lactogen, growth hormone, and prolactin, these hormones prepare 
the mammary glands for milk production. 
 
At the end of the pregnancy, but prior to parturition, the hypothalamus produces oxytocin to 
stimulate the contraction of uterine muscles for expulsion of the calf. The correct 
synchronisation of endocrinological events is important not only in late pregnancy for 
coordinating parturition and for initiating the synthesis and secretion of milk by mammary 
tissue at birth, but also critical in directing foetal growth and development. That is, if any 
reproductive endocrine function is compromised during pregnancy, or lactation is absent or 
insufficient, the reproductive process may fail and the calf will not survive. 
 
Fertilisation, attachment, and placentation in dairy cows 
Fertilisation can be achieved after the heifer has undergone puberty and the first oestrous 
cycle, and has been successfully mated. Fertilisation can also occur postpartum following 
the first oestrous cycle after birth. The entire process of reproduction is reliant upon 
fertilisation, where the gametes (i.e. an egg and a sperm) fuse together to form a zygote. 
The zygote begins to develop into an embryo as it migrates towards the uterus where it 
becomes suspended in the uterine fluids. A blastocyst then emerges from the zona pellucida 
and elongates before attaching to the endometrium. 
 
The endometrium of a cow is comprised of many raised aglandular caruncles and intensely 
glandular intercaruncular areas (Figure 1.2). Attachment and placentation of the embryo is 
restricted to the aglandular maternal caruncles, where the foetal cotyledons come into 
contact with each other (Verduzco et al., 2012, Mansouri-Attia et al., 2009). Attachment is a 
non-invasive process where the outer embryonic membrane attaches to the uterine luminal 
epithelium with little or no destruction of maternal tissues. Following attachment, the 
placentome is formed for maternal-foetal exchange of oxygen, nutrients, and waste 
products. The glandular intercaruncular regions are involved with preservation of the uterus 
in a quiescent state allowing progressive uterine hypertrophy to accommodate the 
increasing needs of the growing feto-placental unit (Arosh et al., 2004). The uterine glands 
present in the intercaruncular endometrial areas secrete and release histotroph that is 
transported into foetal circulation via the placental areolae and is crucial for conceptus 
survival and growth (Gray et al., 2001). 
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Figure 1.2. A schematic representation adapted from (Senger, 2012) showing the 
cotyledonary placenta of the cow. The endometrium is composed of the glandular 
intercaruncular zone that consists of dilated uterine glands, and the aglandular caruncular 
zone that interdigitate with the foetal cotyledon to form the placentome exhibiting an 
epitheliochorial attachment where the foetal membrane does not invade into the uterine 
endometrium. In epitheliochorial placentation, the maternal and foetal capillaries are 
separated by six distinct layers and the maternal-foetal exchange is facilitated by a number 
of mechanisms including simple diffusion (gas and water), facilitated diffusion (glucose), and 
active transport (sodium pumps and amino acids). 
 
Reproductive failure in dairy cows 
Fertility problems and reproductive failure in dairy cows negatively impacts livestock 
production and adversely affect the future fertility of dairy cows. These problems are of great 
concern for dairy producers worldwide because poor reproductive efficiency results in a 
longer calving interval, reduced milk quality and production, increased veterinary costs, high 
herd replacement rates, less number of calves born (particularly in seasonal pasture-based 
systems), and higher in-voluntary reproductive culls rates (Grohn and Rajala-Schultz, 2000, 
Ghavi Hossein-Zadeh, 2013). Dairy cows also contribute to environmental pollution via 
methane emissions and nitrogen excretion in manure, subsequently there is also an 
environmental cost for poor fertility as more cows are required in the herd to maintain herd 
size and meet milk quotas (Garnsworthy, 2004, Niu et al., 2016). 
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Reduced fertility and poor reproductive performance in dairy cows have been linked to 
numerous factors that are discussed in the next sections. Dairy farms have developed 
reproductive management strategies and solutions to minimise the detrimental impact of 
lower pregnancy rates in cows including more effective methods to ascertain when cows are 
in heat and determine the correct timing of artificial insemination relative to oestrus. Other 
management strategies that have been implemented to minimise poor reproductive 
performance include the use of a body condition scoring system and adequate nutritional 
management of herd cows to ensure animals are in good health prior to breeding. To control 
disease, a number of methods have been employed like vaccination against likely diseases, 
regular monitoring of livestock health, early treatment of cows that show signs of disease, 
as well as disease surveillance and control measures to minimise the risk for introducing or 
spreading infectious diseases throughout the herd. 
 
The reproductive performance of a dairy cow is complicated by many factors that are 
discussed in the sections below. These factors determine whether or not the cows can 
become pregnant, however, having a healthy uterus and uterine environment is the basis 
for establishing higher conception rates in dairy cows and the key to achieving optimal 
fertility rates. 
 
Heat stress 
Heat stress in cows is caused by the combined effects of high temperature and humidity 
that can lead to an elevation in body temperature. Heat stress can impact reproduction by 
disrupting oocyte development and maturation (Rispoli et al., 2013, Kobayashi et al., 2013), 
early embryonic development (Roth et al., 2001), and foetal and placental growth (Dahl et 
al., 2016, Collier et al., 1982, Tao and Dahl, 2013). Chronic heat stress affects utero-
placental functions and foetal growth by reducing the uterine and umbilical blood flows 
(Roman-Ponce et al., 1978) inhibiting uptake of nutrients, like glucose and amino acids, by 
the uterine tissues. Changes in utero-placental oxygen uptake due to heat stress can also 
expose the foetus to a hypoxic state (Reynolds et al., 1985). High temperatures during 
pregnancy also appear to be associated with a diversion of blood from certain organs, like 
the uterus, toward others organs involved in the regulation of heat, such as the lungs and 
respiratory tract (Yeates, 1958). 
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Infectious diseases 
Infectious diseases, like the highly prevalent bovine viral diarrhoea virus, can cause 
reproductive dysfunction in cows. Common manifestations of infectious disease include 
abortions, early embryonic death, calves born weak or dead, and calves that die soon after 
birth (Barr and Anderson, 1993). Infectious diseases can vary from mild and non-persistent 
to severe and life-threatening depending upon pathogen, the degree of pathogen 
colonisation, and the ability of the cow to elicit an immune response (Herath et al., 2006). 
Reduced fertility associated with uterine disease is caused by damage to the endometrium 
and disruption of ovarian cyclic activity (Sheldon et al., 2009). These events may stimulated 
by an inflammatory process responding to bacteria, viruses, fungi, and/or protozoal 
parasites invading the body (Givens and Marley, 2008). 
 
Pathogen-associated molecular patterns (PAMPs) are epitopes of microbial components, 
such as bacterial lipopolysaccharide (LPS) (Magata et al., 2015), viral DNA (Donofrio et al., 
2007) and mycotoxins produced by fungi (Minervini et al., 2001, McCausland et al., 1987). 
PAMPs activate immune and inflammatory responses upon recognition by host pattern 
recognition receptors (PRRs) involved in the eradication of the pathogen (Sheldon et al., 
2014). Clinical and subclinical endometritis are commonly reported with inflammation and 
infections of the uterine endometrium in cows after parturition (McDougall et al., 2007) and 
often associated with elevated expression of pro-inflammatory cytokines, like tumor necrosis 
factor alpha (TNFα), interleukin-1β (IL-1β) and  interleukin-6 (IL-6) (Kasimanickam et al., 
2013), that can affect the quality of embryo and interfere with ovulation and conception. 
Subsequently, if inflammation is not addressed and actively treated, it can detrimentally 
impact fertility in cows due to impaired uterine and ovarian function (Williams et al., 2007). 
 
Genetic predisposition  
Genetic predisposition for reproductive failure can involve genes that compromise normal 
growth and development of a foetus in the uterus and contribute to foetal abnormalities and 
birth defects (Agerholm et al., 2001). Recently, a study reported that a nonsense mutation 
in the apoptotic protease activating factor 1 (APAF1) protein within HH1 haplotype is 
responsible for the reduction in conception rates and increased stillbirths in Holstein-Friesian 
dairy cattle (Adams et al., 2016). The HH1 haplotype has been traced back to a single sire 
that was born in 1962 as the earliest genotyped ancestor carrying the HH1 haplotype 
(VanRaden et al., 2011). The HH1 haplotype was identified as causing embryonic or foetal 
death when it is present in the homozygous form (VanRaden et al., 2011). A number of 
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studies have also reported causative mutations that have been associated with fertility 
problems (Charlier et al., 2012, Fritz et al., 2013, McClure et al., 2014, Berglund et al., 2004) 
and compromised the reproductive as well as rearing success in cattle (Pausch et al., 2015). 
 
Selective breeding 
Selective breeding of dairy cows to improve phenotypic and genetic gains, particularly 
increased milk production has been the main focus to maximise the efficiency of production 
and to meet the increasing demand for dairy products (Goddard, 2012, Hayes et al., 2009, 
Meuwissen et al., 2001). However, the intense genetic selection for increased milk quality 
and quantity in dairy cows is associated with a decline in fertility and reproductive 
performance in dairy cows (Oltenacu and Broom, 2010). The stresses for high milk 
production can cause negative energy balance that disrupts hormonal equilibrium and 
oestrous cyclicity and as a consequence affects oocyte maturation, comprise endometrial 
receptivity and lead to reduced fertility in dairy cows (Lucy, 2007, Dobson et al., 2007). 
Recently a 660-kb deletion, that encompasses four genes on bovine chromosome 12 (Kadri 
et al., 2014), was reported to positively effect milk yield and composition, but negatively 
impact fertility, causing early embryonic death of homozygous conceptuses. Kadri et al 
identified that the deletion is present as a heterozygote in 13%, 23%, and 32% of the Danish, 
Swedish and Finnish Red cattle, respectively. The segregation of this deletion in dairy cows 
may be a consequence of the fact that it is associated with increased milk production and 
therefore being selected for. Moreover, the increased levels of inbreeding resulting from the 
widespread use of artificial insemination, could also account for the segregation of the 
embryonically lethal recessive alleles that lead to a reduction in the fertility of dairy cows. 
Fertility remains to be an issue in high-yielding dairy cows. The ability for a dairy cow to 
balance both high milk production (e.g. selection for milk production traits), and timely and 
efficient pregnancy (e.g. selection for fertility traits), remains a challenge for both dairy 
producers and researchers. 
 
Exosomes in reproduction 
In the recent years, an increasing number of studies have reported the role of exosomes in 
reproduction. Studies in humans (Ng et al., 2013) and other mammalian species (Ruiz-
Gonzalez et al., 2015, Cleys et al., 2014, Burns et al., 2014, Sohel et al., 2013) have 
revealed that exosomes are secreted by reproductive cells including the endometrium and 
trophoblast cells. Exosomes may have important roles in the conceptus-endometrial 
interface during early pregnancy. 
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Exosomes as signalling molecules 
Exosomes are membraneous nanovesicles of endocytic origin that display a cup-shaped 
morphology with diameters ranging from 40–120 nm (Simons and Raposo, 2009). Exosome 
biogenesis begins within the multivescular bodies (MVBs) of the endosomal system (Figure 
1.3). Following endocytosis into early endosomes (EE), the cargo is packaged into 
intraluminal vesicles (ILVs) within the MVBs via inward budding of the membrane. 
Multivescular bodies can either fuse with lysosomes for degradation of the cargo, or MVBs 
can fuse with the plasma membrane and release the ILVs as exosomes in a process 
regulated by Rab GTPases (Bellingham et al., 2012). Exosomes can be secreted into 
extracellular space by various cell types, subsequently exosomes are present in many 
biological fluids like milk (Yamada et al., 2012), blood (Lasser et al., 2011), saliva (Gallo et 
al., 2012), urine (Keller et al., 2007), and cell culture supernatants (Lobb et al., 2015). 
 
In past research, the secretion of exosomes was considered a process that cells use to shed 
and removed unwanted cellular components (Vidal et al., 1997). However, in more recent 
research, exosomes have gained increased recognition as signalling molecules that 
package and deliver a variety of bioactive molecules, including proteins, nucleic acids, and 
lipids, for intercellular communication and modulation of target cell function (Simons and 
Raposo, 2009). Therefore, exosomes are involved in cell-to-cell communication in different 
physiological and pathological conditions. Exosomes can be assembled and secreted in 
response to instructions received from neighbouring cells, distant tissues, or local 
environmental factors (e.g. oxygen tension, infection etc.). A number of studies have shown 
the involvement of exosomes in providing autocrine (i.e. local signals between the same cell 
type, such as between cancer cells), paracrine (i.e. local signals between different cell types, 
such as between epithelial cancer cells and stromal cells), and endocrine (i.e. distant signals 
between many different types of cells usually carried in bodily fluids like blood). Several 
bovine studies have described exosomes role in intercellular communication, and are 
summarised in Supplemental Table S1.1. (see APPENDICES). 
 
Exosomes can be transported through the lymphatic system (Srinivasan et al., 2016) and 
blood vessels (Morishita et al., 2015) to enable communication with cells located in distant 
tissues at organs. A number of studies have reported the biodistribution of exosomes 
throughout the body (Morishita et al., 2017, Lai et al., 2014). In particular the biodistribution 
of labelled exosomes following introduction via oral, intravenous, or subcutaneous routes 
have been reported. Munagala et al. (Munagala et al., 2016) reported that fluorescent-
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labelled bovine milk derived exosomes were detected in the liver, lung, kidney, pancreas, 
spleen, colon, brain and the ovaries when these milk exosomes were administered orally or 
intravenously into mice. In another study (Wiklander et al., 2015), fluorescent-labelled 
exosomes from human embryonic kidney cells administered into mice systematically 
through intravenous, intraperitoneal or subcutaneous injections, displayed a different 
exosome distribution pattern. They found that although the fluorescent signal was detected 
in the lungs, spleen, pancreas, brain, and heart but was more predominantly detected in the 
liver and gastrointestinal tract (Wiklander et al., 2015). Moreover, in a mouse study, Sheller 
et al. (Sheller-Miller et al., 2016) demonstrated that exosomes can cross from the foetal to 
the maternal side of the uterine tissues through a systemic route during pregnancy, 
supporting the idea that foetal signals can be delivered via exosomes. Together these 
publications support the ability of exosomes to travel throughout the body and cross barriers 
(i.e. the brain and placenta) to delivery their protected cargo to near and distant sites. 
 
Figure 1.3. A schematic overview of exosome biogenesis and functions adapted from 
(Mitchell et al., 2015). Exosomes are membraneous nanovesicles of endocytic origin (with 
defined characteristics such as size, density, and morphology) that incorporate specific 
molecules (e.g. miRNA and proteins) and are packaged within multivescular bodies of the 
endosomal system. Exosomes are released into extracellular space and modulate the 
functions of target cells (e.g. immune response, cellular adhesion, development, and 
metabolism). 
12 
 
Exosomes in reproduction and maternal-foetal crosstalk 
The bi-directional regulation and transfer of genetic and protein material between the 
conceptus and endometrium via exosomes has been proposed as a relatively new paradigm 
of embryo-maternal signalling. Furthermore, this signalling appears to be essential for 
successful implantation, placental formation, and immune function for protection of the 
foetus (Saadeldin et al., 2015). Studies involving humans (Salomon et al., 2014) and other 
mammalian species (Cleys et al., 2014) have consistently shown increased exosome 
secretion during pregnancy, inferring that at least a portion of the secreted exosomes could 
originate from uterine tissue, the developing placenta, or from the conceptus (e.g. 
trophectoderm) during pregnancy. 
 
In an ovine study by Burns et al. (Burns et al., 2016), fluorescently labelled conceptus-
derived exosomes were infused into the uterine lumen of cycling sheep and after 6 days 
were found incorporated by the uterine epithelia, but not the uterine stroma, myometrium, 
ovary, or other maternal tissues. Consistent with the 2016 ovine study, Burns et al. also 
demonstrated in an earlier study that exosomal cargo contains a significantly higher number 
of small RNA species, including miRNAs (Burns et al., 2014), when compared with the 
number of intracellular small RNA species. In another study involving sheep and cattle 
(Racicot et al., 2012), mass spectrometry analysis of exosomes released by endometrial 
epithelia and/or conceptus trophectoderm identified the proteins cathepsin L1 (CTSL1), 
gastrin releasing peptide (GRP), lipoprotein lipase (LPL), prostaglandin synthase two 
(PTGS2), and myxovirus one (MX1). Notably, MX1 was expressed in the endometrium of 
both sheep and cattle in response to conceptus-produced interferon-tau. It was also reported 
by Mansouri-Attia et al. (Mansouri-Attia et al., 2009) that a high level of MX1 is found 
localised to the luminal epithelium of caruncles and intercaruncular regions of pregnant 
bovine endometrium. The MX1 protein is a member of the dynamin superfamily of large 
guanosine triphosphatases, which implies that it may have an important function in endocytic 
and intracellular membrane transport. Interestingly, it has been reported that MX1 interacts 
with tubulin β in ovine uterine glandular epithelial cells, suggesting that MX1 could play a 
role in transporting proteins or vesicles throughout the cells (Racicot and Ott, 2011). MX1 
may function in exosome secretion by uterine epithelial cells and may participate in cell 
adhesion mechanisms between the mother and foetus, such as blastocyst-endometrial 
interaction (Shirozu et al., 2016). 
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A successful pregnancy is dependent on synchronised signalling between a receptive 
endometrium and a functional blastocyst. Exosome-mediated transfer of protein and nucleic 
acids at the maternal-fetal interphase is only one of the many processes involved in embryo-
maternal signalling that is tightly regulated and determines whether or not pregnancy is 
initiated and established. Any disruptions to this process can compromise implantation and 
the ability of the growing fetus to develop properly in the uterus. The precise mechanisms 
involved in embryonic-maternal crosstalk and physiological relevance to conceptus 
development in utero, are not clearly understood and require further research. However, the 
role of exosomes in reproduction with respect to oxygen tension and immune response 
provide some insight and are discussed below. 
 
Oxygen tension in reproduction and the secretion of exosomes 
Optimal oxygen tension in the female reproductive tract is required for successful 
implantation and healthy placental function during pregnancy. However oxidative stress, the 
imbalance between reactive oxygen species and antioxidant function, can modify the 
phenotype of maternal and placental cells that could potentially modulate the content and 
release of exosomes disrupting reproductive processes and causing poor pregnancy 
outcomes. 
 
An oxygen gradient exists between the placenta and endometrium during various phases of 
pregnancy in cows (Gahlenbeck et al., 1968) and humans (Jauniaux et al., 2003) that are 
essential for implantation and foetal development (i.e. embryo development, trophoblast 
invasion, and differentiation) (Rodesch et al., 1992). The optimum oxygen concentration 
required for embryonic development ranges from 5-8% (Takahashi and Kanagawa, 1998, 
Balasubramanian et al., 2007) whilst the oviducts and uterine horns exhibit oxygen tension 
ranging from 2-9% in several species like rhesus monkeys, hamsters, and rabbits (Fischer 
and Bavister, 1993, Simon and Keith, 2008). Within an optimum oxygen tension range, 
embryo quality and development to the blastocyst stage improve, and the production of 
reactive oxygen species, that can cause oxidative damage to developing embryos, is 
reduced. 
 
Research has also demonstrated that hypoxia, a lower-than-normal physiologically oxygen 
tension condition, is a potent stimulant of microvesicle and exosome release (Gupta and 
Knowlton, 2007, Orriss et al., 2009, Wysoczynski and Ratajczak, 2009, King et al., 2012). 
Hypoxia in utero can influence many developmental events with potentially lifelong 
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consequences (Maltepe and Saugstad, 2009, Mallard et al., 1998). Our laboratory (Rice et 
al., 2015, Salomon et al., 2013a) has demonstrated that placenta-derived exosomes (i.e. 
from placental mesenchymal stem cells and cytotrophoblast cells) respond to changes in 
oxygen tension with exosome release increased and the content and bioactivity on cell 
targets affected. 
 
Interestingly, research has also shown that mRNA levels in placental vesicles are inversely 
related to the degree of oxidative stress present in the originating tissue (Rusterholz et al., 
2007) and that hypoxic cellular state are reflected in the protein and RNA content of 
endothelial cell-derived exosomes (de Jong et al., 2012). 
 
Lee et al. also reported that bioactive exosomes and activities of placental microvesicles on 
peripheral blood mononuclear cells (PBMCs) were more pronounced when vesicles were 
derived from hypoxic trophoblasts, compared with vesicles derived from normoxic 
trophoblasts (Lee et al., 2012). 
 
Exosomes and immune response in reproductive pathology 
Cows may be exposed to infections during gestation or may become pregnant whilst 
suffering from an existing subclinical asymptomatic infection (Whittington and Windsor, 
2009). Infections arise when pathogens gain access and invade the amniotic cavity by 
various routes including: through the cervix via the vagina; venereal infections; contaminated 
semen or transferred embryos; and pre-existing mucosal infections of the reproductive tract 
(Magombedze et al., 2013). Infections can compromise not only the health of the host, but 
maternal-to-foetal transmission of pathogens can be quite devastating to the developing 
foetus. Interactions between pathogens at the maternal–foetal interface and the 
mechanisms that trigger inflammation in the reproductive tract are poorly understood. 
However, it is clear that the maternal–foetal interface is an immunologically unique site that 
maintains host defenses against possible pathogens. Immune cells, such as macrophages 
and natural killer cells, are present at the maternal-foetal interface and can respond to 
invading pathogens (Mansouri-Attia et al., 2012, Oliveira et al., 2013). 
 
The identification of exosomes containing mRNAs and proteins for ovine jaagsiekte 
endogenous retroviruses (enJSRV), heat shock protein 70, interleukins and interferon-
regulatory factors had been recovered from the uterine luminal fluid of pregnant sheep (Ruiz-
Gonzalez et al., 2015). In the study by Ruiz-Gonzalez et al, the uptake of exosomal enJSRV 
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through trophectoderm induced Toll-like receptor (TLR)-mediated signalling in the 
conceptus, resulted in the secretion of interferon-tau for successful pregnancy recognition. 
Subsequently, this study also showed that the pathways activated by enJSRV during early 
pregnancy coincided with cellular TLR-mediated innate responses of macrophages and 
plasmacytoid dendritic cells to viral pathogens. 
 
Sabapatha et al. reported that placental exosomes from the sera of women with normal 
uncomplicated pregnancies suppress maternal T-cell signalling components, suggesting a 
role for the placenta in promoting a state of immune privilege during pregnancy (Sabapatha 
et al., 2006). Bioinformatic analyses by Luo et al. revealed that exosomal placental-specific 
miR-517A is possibly involved in TNFα signal transduction (Luo et al., 2009). Furthermore, 
Delorme-Axfordetal et al. demonstrated that miRNA members of the chromosome 19 
miRNA cluster (C19MC) released by trophoblast exosomes, could attenuate viral replication 
by inducing autophagy in recipient target cells (Delorme-Axford et al., 2013). 
 
Mammary glands have a causal relationship with dairy cow fertility given that the health of 
mammary glands affects fertility (Hansen et al., 2004). Mastitis is usually caused by 
pathogens infecting the udders producing inflammation in these glands. The immune 
mediators released during an inflammatory response can suppress the production of 
pregnancy hormones disrupting normal follicular development and proper attachment of the 
foetus (Roth et al., 2015, Hockett et al., 2005). These disruptions can lead to reduced fertility 
due to lower conception rates and pregnancy losses. Mastitis can also affect colostrum 
quality preventing calves from achieving full immunity (Ferdowsi Nia et al., 2010). 
 
A comprehensive study of the effects of mastitis on the milk proteome was provided by 
Reinhardt et al (Reinhardt et al., 2013) through the analysis of milk, collected  from healthy 
and Staphylococcus aureus infected cows, fractionated into whey, milk fat globule 
membranes and exosomes. This study identified more than 300 proteins associated with 
host defences with 94 differentially regulated during mastitis. Another study (Sun et al., 
2015) profiled the miRNA expression of bovine milk exosomes in response to 
Staphylococcus aureus infection of the mammary gland. This study found 14 miRNAs from 
exosomes known to be differentially expressed by infected and uninfected cows, and 22 
mammary-expressed genes involved in the regulation of host immune processes and 
responses to inflammation. Additionally, elevated levels of bta-miR-142-5p and −223 were 
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found in milk exosomes and as potential biomarkers for the early detection of bacterial 
infection of the mammary gland. 
 
Knowledge of the involvement of exosomes in host–pathogen interactions and reproduction 
is still a relatively new research field, however more research is required to unveil the 
importance of exosomes in host immune responses and in the pathogenic mechanisms of 
infection that affect fertility and pregnancy outcomes. 
 
Circulating exosomes in biofluids and their interaction with targeted cells 
Exosomes released from cells through exocytosis are known to be mediators of proximal 
and distant cell-to-cell signalling. Exosomes released into the circulation and other body 
fluids under different physiological and pathophysiological conditions are remarkably stable 
and functional (Sun et al., 2010, Malik et al., 2013). However, exosomes present in blood 
and other body fluids can be a mixed population of disease-related and normal exosomes 
that have originated from multiple cell types from different tissues and are highly dynamic. 
 
Elevated levels of exosomes in the peripheral circulation have been detected in pathologic 
conditions like cancer (Kim et al., 2005), and during pregnancy (Orozco et al., 2009). These 
increased levels appear to be influenced by the tumor (in cancer patients) or placenta 
(during pregnancy). 
 
A study of human and murine pregnancies has revealed the presence of placental 
exosomes and foetal exosomes in amniotic fluid (Keller et al., 2007). Placental and amniotic 
exosomes are considered to be two separate entities that differ in origin and function. 
Placental specific exosomes are syncytiotrophoblast-derived and are released through the 
intervillous space into the blood where they influence the physiological adaptation of the 
maternal body to pregnancy. Conversely, amniotic fluid remains in the amniotic cavity 
enclosed by amniotic membranes, preventing it from entering maternal circulation. The 
study by Keller et al. reported that amniotic exosomes expressed CD24, annexin-1, and 
aquaporin-2 that are also detected in exosomes from the renal system of the foetus and 
urine of newborn infants. This evidence suggests that the main source of amniotic fluid 
exosomes originates from the foetal kidney and the foetal renal system. At this stage, the 
presence of this exosome in the amniotic fluid is likely due to foetal urine production instead 
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of having a role in maternal immunomodulation (Keller et al., 2007, Mincheva-Nilsson and 
Baranov, 2014). 
 
Previous studies in our laboratory (Salomon et al., 2014, Sarker et al., 2014) demonstrated 
the presence of placental alkaline phosphatase positive (PLAP+; a marker for placental 
exosomes) exosomes in the peripheral circulation of pregnant females and were absent in 
non-pregnant females. PLAP is an integral membrane protein enzyme of the placenta 
produced mainly by syncytiotrophoblasts. PLAP+ placental exosomes increase in maternal 
circulation with gestational age whilst the presence of Fas ligand in PLAP+ placental 
exosome and the down-regulation of CD3-zeta chain and induced Fas-mediated apoptosis 
in T-lymphocytes demonstrates their bioactivity (Gercel-Taylor et al., 2002, Abrahams et al., 
2004), suggesting that these exosomes have a role in preventing maternal immune 
recognition by inducing apoptosis in Fas-bearing immune cells that may obstruct or impair 
implantation and pregnancy. 
 
Milk is a biofluid that supplies nutrition to the newborn and is also comprised of biologically 
active materials, like immune molecules, that provide immune protection to the newborn. 
Immune-related miRNAs in bovine milk-derived microvesicles, that were resistant to acidic 
conditions, were recently identified by Hata et al.  (Hata et al., 2010). It has been suggested 
that these microvesicular secretions containing miRNAs have a key role in the development 
of calf gastrointestinal and immune systems. Another recent study investigated the effect of 
bovine milk derived exosomes on human cells (Izumi et al., 2015) and found that THP-1 
human macrophages could uptake bovine raw milk whey-derived exosomes containing 
functional RNA. This study suggests that mRNA, as well as miRNA from milk-derived 
exosomes, can exert functions that in turn could affect the function of macrophages in the 
human body. 
 
Due to the complexity of body fluids, there is ongoing research to further elucidate how 
molecular signals, packed within exosomes and released from a specific cell type into 
biofluids, can interact with target cells. Furthermore, the role of exosomes in autocrine, 
paracrine, and endocrine functions requires investigation. 
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Hypotheses and aims 
The primary focus of my study is to help close the knowledge gap between the biology of 
cow fertility and exosomes, and to further unravel the potential roles and uses of exosomes 
in dairy cow fertility. Therefore, I hypothesised that differences in the fertility of dairy cows 
could be assessed by monitoring exosomal cargo differences and that the differences in 
cargo content could be manifested and reflected by changes in endometrial function (e.g. 
inflammatory mediator gene expression and cytokine production). 
 
The experimental approaches used to explore the hypothesis involved: the evaluation of 
bovine endometrial cell lines as a suitable in vitro model of the maternal cell component; the 
development of a robust and reproducible method for the isolation and enrichment of 
exosomes; and a targeted mass spectrometry approach for the validation and identification 
of exosomal markers.  
 
The specific aims of this research were: 
 
Aim 1. To characterise bovine endometrial cells under conditions that mimic physiological 
stress associated with reduced fertility in the dairy cow and evaluate their suitability as 
an in vitro model for the study of the uterine environment. 
Aim 1.1. To investigate the effect of an infectious agent (e.g. lipopolysaccharide) and 
pro-inflammatory stimuli (e.g. interleukin 1 beta (IL-1β) and tumor necrosis factor 
alpha (TNFα)) on inflammatory mediator gene expression and cytokine production 
by endometrial stromal and epithelial cells. 
Aim 1.2. To investigate the effect of hypoxia, a known stimulus of exosome release on 
bovine cellular function (i.e. cell migration, proliferative capacity and apoptotic 
protein caspase-3 activation) and exosome release by bovine endometrial cells. 
 
Aim 2. To develop a robust and reproducible method for the isolation and enrichment of 
exosomes from bovine body fluids. 
Aim 2.1. To isolate exosomes using differential and buoyant density ultracentrifugation 
and subsequently characterise and compare the exosomal proteomic profiles of 
bovine body fluids (e.g. plasma, milk, saliva, and urine). 
Aim 2.2. To evaluate the ultracentrifugation and size exclusion chromatography method 
for the isolation and enrichment of exosomes from bovine plasma. 
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Aim 2.3. To evaluate the ultracentrifugation and size exclusion chromatography method 
for the isolation and enrichment of exosomes from bovine milk. 
Aim 2.4. To develop a targeted mass spectrometry approach to screen for a panel of 
exosomal markers in bovine body fluids; with (i) at least two peptide precursors per 
exosomal marker and (ii) at least three transitions per peptide precursor. 
 
Aim 3. To characterise exosomes isolated from high and low fertility heifers and determine 
the effect of the isolated exosomes on bovine endometrial cells. 
Aim 3.1. To investigate the proteomic profiles of plasma exosomes from high and low 
fertility heifers. 
Aim 3.2. To evaluate inflammatory mediator gene expression and cytokine production 
in endometrial stromal and epithelial cells when co-incubated with exosomes from 
high and low fertility heifers. 
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Chapter 2: Characterisation of bovine endometrial cells under 
conditions that mimic physiological stress associated with 
reduced fertility in dairy cows. 
 
Overview 
 
A healthy uterine milieu is essential for successful mammalian reproduction. In dairy cows, 
the most common causes of reduced fertility are postpartum uterine diseases, like clinical 
and subclinical endometritis that are caused by infection or inflammation of the 
endometrium. Subsequently, a healthy uterus and uterine environment is fundamental for 
achieving higher conception rates and optimal fertility in dairy cows. 
 
In this chapter, I aimed to characterise bovine endometrial cells under conditions that mimic 
physiological stress associated with reduced fertility in dairy cows. Therefore, the main 
objective of this chapter was to assess how the bovine endometrial cells respond to stress 
conditions and determine the suitability of these cells as an in vitro model for other studies 
in my PhD research. 
 
Chapter 2 includes the characterisation of bovine endometrial cells by investigating: 
Chapter 2.1. The regulation of inflammatory mediator expression and cytokine production 
in bovine endometrial epithelial and stromal cells in response to an infectious agent (e.g. 
lipopolysaccharide) and pro-inflammatory stimuli (e.g. Interleukin 1 beta; IL-1β, and tumor 
necrosis factor alpha; TNFα). 
 
Chapter 2.2. The effect of hypoxia, a known stimulus of exosome release on the cellular 
function and exosome release from bovine endometrial cells. 
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Chapter 2.1 is comprised of the article ‘Regulation of inflammatory mediator expression in 
bovine endometrial cells: effects of lipopolysaccharide, interleukin 1 beta, and tumor 
necrosis factor alpha’ submitted to Physiological Reports: 
 
Koh, YQ, Mitchell, MD, Almughlliq, FB, Vaswani, K & Peiris, HN 2018, ‘Regulation of 
inflammatory mediator expression in bovine endometrial cells: effects of lipopolysaccharide, 
interleukin 1 beta, and tumor necrosis factor alpha', Physiol Rep, vol. 6, no. 9, p. e13676. 
 
As per the University of Queensland requirements, the submitted version of the manuscript 
is presented herein. However, in order to suit the thesis structure, the formatting of the 
original tables and figures were changed accordingly. The referencing citation numbering 
has also been updated to continue the citation sequence of the previous chapter. 
 
The following statement was adopted from the journal’s policy to acknowledge copyright 
reuse permission:  
All Physiological Reports articles are published under the terms of the Creative Commons 
Attribution License (CC BY), which allows users to copy, distribute and transmit an article 
and adapt the article and make commercial use of the article. The CC BY license permits 
commercial and non-commercial re-use of an open access article, as long as the author is 
properly attributed. For the details regarding Creative Commons Attribution License, please 
see: https://creativecommons.org/licenses/by/3.0/  
 
22 
 
Chapter 2.1: Regulation of inflammatory mediator expression in bovine 
endometrial cells: effects of lipopolysaccharide, interleukin 1 beta, and 
tumor necrosis factor alpha 
Yong Qin Koh, Murray D. Mitchell, Fatema B. Almughlliq, Kanchan Vaswani and 
Hassendrini N. Peiris  
University of Queensland Centre for Clinical Research, Faculty of Medicine, The University 
of Queensland, Brisbane, Australia.  
ABSTRACT 
An abnormal uterine environment can influence maternal-fetal communication, conception 
rate and disrupt normal embryo development, thereby affecting fertility and the reproductive 
performance of dairy cows. Animal variability means that development of endometrial cell 
lines with appropriate characteristic are required. We evaluated the effect of an infectious 
agent (i.e. bacterial lipopolysaccharide; LPS) and pro-inflammatory mediators (i.e. 
Interleukin 1 beta; IL-1β, and tumor necrosis factor alpha; TNFα) on inflammatory mediator 
gene expression and production by bovine endometrial epithelial (bEEL) and stromal 
(bCSC) cell lines. Expression of CXCL8/IL-8, IL-1α, IL-1β, and IL-6 cytokine genes was 
significantly upregulated in both epithelial and stromal cells when treated with LPS and IL-
1β. LPS treatment of epithelial cells (compared with treatment by IL-1β and TNFα) exhibited 
greater CXCL8/IL-8, IL-1α, IL-1β, and IL-6 cytokine gene expression. Whereas, in stromal 
cells, IL-1β treatment (compared with LPS and TNFα) exhibited greater CXCL8/IL-8, IL-1α, 
IL-1β, and IL-6 cytokine gene expression. Interestingly, bEEL and bCSC cells treated with 
IL-1β increased IL-1β gene expression, suggesting that IL-1β may act unusually in an 
autocrine positive feedback loop. Cytokine production was stimulated by these agents in 
both cell types. We suggest that the characteristics of these two cell lines make them 
excellent tools for the study of intrauterine environment. 
 
Keywords: bovine, epithelial, stromal, cytokines, endometrium 
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INTRODUCTION 
Bidirectional maternal-foetal communication (i.e. conceptus-endometrial cross-talk) is 
critical for the establishment, maintenance and progression of a successful pregnancy (Wolf 
et al., 2003). In cattle embryonic losses that occur in the early days of pregnancy (days 8-
17) have been attributed to poor communication between the conceptus and maternal 
environment (Thatcher et al., 2001). One major factor which can affect the maternal 
environment and thus the signals between the maternal side and foetal side is the presence 
of infectious agents in and/or inflammation of the uterus (Groebner et al., 2011). Postpartum 
uterine disease is one of the leading causes of reduced fertility in dairy cattle. The 
persistence of pathogenic microorganisms in the uterine lumen following parturition can 
delay the regeneration of endometrium (Lara et al., 2017, Sheldon et al., 2006) and disrupt 
the resumption of cyclic ovarian function (Huszenicza et al., 1999, Williams et al., 2008). 
Significant bacteria responsible for postpartum uterine disease are Escherichia coli, 
Trueperella pyogenes and pathogenic anaerobic bacteria (Sheldon and Owens, 2017). The 
presence of a large number of Escherichia coli and their endotoxins, lipopolysaccharides 
(LPS) are likely to precede and favour the development of uterine infections with other 
pathogens that disrupt endometrial structure and function in dairy cattle (Dohmen et al., 
2000, Magata et al., 2015, Williams et al., 2007). The consequences of uterine bacterial 
infection, and its associations with clinical and subclinical endometritis can lead to 
decreased reproductive performance of dairy cattle, compromise animal welfare and incur 
economic costs (Carneiro et al., 2016). 
 
Pathogenic microorganisms that invade the female reproductive tract are initially recognised 
by the innate immune system through the binding of pattern-recognition receptors (PRRs) 
to the pathogen-associated molecular patterns (PAMPs) (Amjadi et al., 2014). PAMPs 
including LPS; a major constituent of the cell wall unique to most gram-negative bacteria, 
strongly activates cells of the immune system and triggers an inflammatory response 
(Rosenfeld and Shai, 2006). The inflammatory intracellular signalling cascades initiated by 
the interactions between PAMPs and PRRs lead to the production of the primary pro-
inflammatory mediators, including IL-β and TNFα, as well as other cytokines and 
chemokines, which further the activation of complement and the acute phase response to 
achieve effective immune responses to eliminate the pathogens (Harju et al., 2005, Splichal 
and Trebichavsky, 2001, Healy et al., 2014). However, persistent uterine inflammation due 
to inadequate pathogen eradication from the uterus, prolonged inflammatory signalling, and 
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defects in anti-inflammatory mechanisms are likely to be detrimental to fertilisation and 
conception (LeBlanc, 2014, Sheldon and Owens, 2017). 
 
Most studies (Oguejiofor et al., 2015, Cronin et al., 2012, Swangchan-Uthai et al., 2012) 
have focused on the characterisation of the inflammatory response triggered by infectious 
agents. It is also generally considered that postpartum uterine diseases, including clinical 
and subclinical endometritis, are caused by bacterial infection of the uterus (Foldi et al., 
2006). However, the immune system, in particular, the cytokine network is also closely 
implicated in normal uterine functions including the oestrous or menstrual cycle and 
maintenance of pregnancy (Kelly et al., 2001, Oliveira et al., 2013). Nevertheless, emerging 
evidence indicates that prolonged pro-inflammatory events can negatively affect uterine 
function and impede embryonic development (Hansen et al., 2004, Siemieniuch et al., 
2016). The distinction between physiologic and pathologic inflammation of the endometrium, 
that influences the immune response and regulation, or both remains to be elucidated. 
 
Investigating the methods, processes and signals that are incorporated in maternal-foetal 
communication are critical in understanding the events that take place during embryo 
loss/pregnancy failure. Employing animal model systems (especially that of large animals) 
provides advantages for understanding female reproductive processes (Swanson and 
David, 2015, Bahr and Wolf, 2012, Cibelli et al., 2013) but there are limitations and 
challenges due to the complexities of multi-cell interactions (Bonney, 2013, Renard et al., 
2002). We are endeavouring to develop an in vitro model of maternal-foetal communication. 
The present study aims to characterise the maternal cells involved in this model (epithelial 
and stromal cells from bovine endometrium) to assess their basal and responsive states (to 
infectious and inflammatory stimuli known to be detrimental to success in pregnancy) and 
gauge their suitability as cells to be included in our in vitro model. 
 
We therefore evaluated the effect of an infectious agent (e.g. bacterial LPS) and pro-
inflammatory mediators (e.g. IL-1β and TNFα) on inflammatory mediator gene expression 
(e.g. cytokines and chemokines) from bovine endometrial epithelial and stromal cells. 
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MATERIALS AND METHODS 
Endometrial cell lines 
A well characterised bovine endometrial epithelial (bEEL) and stromal (bCSC) cell lines was 
utilised for the current study (Krishnaswamy et al., 2009, Fortier et al., 1988). bEEL and 
bCSC cell lines were a generous gift from Professor Michel A. Fortier (Université Laval, 
Québec). bEEL and bCSC endometrial cells were maintained in 175 cm2 (T175, Corning 
Costar) culture flasks supplemented with exosome-free media (1640 Roswell Park Memorial 
Institute (RPMI) medium (Invitrogen, Life Technologies) + 10% heat-inactivated exosome-
free fetal bovine serum (Bovogen, Interpath services Pty Ltd) + 1000 U/mL antibiotic-
antimycotic solution (Gibco, Life Technologies)) in a humidified cell culture incubator at 37°C 
under an atmosphere of 5% CO2-balanced N2. 
 
Endometrial epithelial and stromal cell culture experiments 
To evaluate the effects of an infectious agent and inflammatory mediators on the gene 
expression and cytokine production of endometrial cells, the endometrial epithelial cells 
(bEEL, seeded at 35,000 cells per well) and stromal (bCSC, seeded at 8,000 cells per well) 
were cultured in a 24-well culture plates (Corning Costar) supplemented with RPMI media 
containing bacterial lipopolysaccharide (LPS, 1 μg/mL; O111:B4; catalogue number L2630; 
Sigma-Aldrich, St. Louis, Missouri, USA), bovine IL-1β (10 ng/mL; catalogue number 
RBOIL1BI; Thermo Scientific; Frederick, Maryland, USA), bovine TNFα (50 ng/mL; 
catalogue number RPB-341; IBI Scientific, Peosta, Iowa, USA) or untreated cells (vehicle 
control) for 6 h and 24 h. The time of 6 h was chosen based on time-course studies in 
endometrium which previously had shown to induces changes in inflammatory genes (e.g. 
CXCL8/IL-8, IL-1β, IL-6 and/or fatty acid cyclooxygenase-2) that peaked by 6 h following the 
treatment with LPS (Oguejiofor et al., 2015, Swangchan-Uthai et al., 2012), IL-1β (Huang et 
al., 1998), and TNFα (Arici et al., 1993). While IL-6 and IL-10 production was assessed using 
enzyme-linked immunosorbent assays (ELISA) at 24 h (Healy et al., 2014, Rashidi et al., 
2015, Mitchell et al., 2012). Optimal concentrations of LPS, IL-1β and TNF-α and time-
course for treatments were determined by preliminary experiments (data not shown). The 
experiment was performed with 4 well replicates per treatment per cell line (n=3). After the 
treatment, the cells and media were collected and stored at -80°C until further analyses. 
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RNA extraction and cDNA synthesis 
Total RNA was extracted from the samples (bCSC and bEEL cells) according to Qiagen’s 
manufacturer’s protocol using a RNeasy Mini kit (Qiagen, Victoria, Australia) and the 
contaminating DNA was removed using RNase-free DNase (Qiagen, Victoria, Australia). 
The RNA concentration and purity was further determined using a Nanodrop ND-1000 
(Nanodrop Technologies, Wilmington, Delaware). 500 ng of RNA was reverse transcribed 
into complementary DNA (cDNA) using the RT2 First Strand Kit (Qiagen, Victoria, Australia). 
The cDNA samples were stored at –20°C until further analyses. 
 
Inflammatory mediator gene expression analyses 
RT-PCR quantification of inflammatory mediator gene expression was performed using the 
bovine cytokine and chemokine RT2 Profiler PCR Array (PABT-150Z; Qiagen, Victoria, 
Australia) and the reaction mixture was prepared using the RT2 Real-Timer SyBR 
Green/ROX PCR Mix kit (Qiagen, Victoria, Australia) following the manufacturer’s 
instructions. Briefly, RT-PCR was performed using the QuantStudio ™ 3 Real-Time PCR 
System (Applied Biosystems ™, Foster City, California) with an initial 10 min incubation at 
95°C followed by 40 cycles at 95°C for 15 seconds and 60°C for 60 seconds. The specificity 
of the RT-PCR products was confirmed by analysis of melting curves. PCR reproducibility, 
reverse transcription efficiency and the presence of genomic DNA contamination were 
verified prior further data analyses using SABiosciences web portal, 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). The results for the 
inflammatory mediator gene expression were normalised against the expression of the 
endogenous reference genes, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and 
TATA box binding protein (TBP) which had showed no significant differences in the gene 
expression between the treatment groups (LPS, IL-1β, and TNFα) and untreated (vehicle 
control) of bCSC and bEEL cells. 
 
Enzyme-linked immunosorbent assays (ELISA) 
The concentrations of IL-6 in the supernatant of cell cultures collected at 24 h were 
measured using ELISA kits following the manufacturer’s instructions (Bovine IL-6 ELISA 
reagent kit ESS0029; Thermo Fisher Scientific; Frederick, Maryland, USA). The IL-6 ELISA 
plate was prepared by coating the wells with  100μL per well of capture antibody diluted in 
0.2M sodium carbonate-bicarbonate buffer (pH 9.4), sealed with a plate sealer and 
incubated overnight at room temperature. The coating antibody solutions were aspirated 
and blocked in assay diluents at room temperature for 1 h. 100μL of standard or sample 
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was added to the wells and incubated at room temperature for 1 h with moderate shaking. 
The wells were then washed 3 times with wash buffer to remove non-specifically bound 
materials and added with 100μL of detecting antibody. After 1 h of incubation at room 
temperature in 100μL of detecting antibody, the liquid was aspirated and the wells were 
washed 3 times with wash buffer. 100μL of streptavidin-HRP diluted in reagent diluent were 
added to the well and incubated at room temperature for 30 min. Liquid was aspirated and 
the wells were washed 3 times with wash buffer to ensure any dried-on conjugate is 
resolubilised and washed away. 100μL of stop solution was added into each well after wells 
were incubated in the dark for 20 min in 100μL of substrate solution. The absorbance 
(absorbance at 450 nm minus absorbance at 550 nm) was measured by the SPECTROstar 
Nano microplate reader (BMG LABTECH, Offenburg, Germany). The detection range for IL-
6 is 78-5000 pg/mL. 
The concentrations of IL-10 in the supernatant of cell cultures collected at 24 h were 
measured by ELISA kits following the manufacturer’s instructions (Bovine IL-10 ELISA 
reagent kit MBS008726; San Diego; California, USA). In brief, 50μL of standard or sample 
was added to the wells and incubated at 37ºC for 1 h. The wells were then washed 4 times 
with wash buffer and added with 50μL of Chromogen Solution A and 50μL of Chromogen 
Solution B to each well successively. The plate was incubated in the dark at 37ºC for 15 min 
and the reaction was stopped with 50μL stop solution. The absorbance was measured at 
450nm by the SPECTROstar Nano microplate reader (BMG LABTECH, Offenburg, 
Germany). The detection range for IL-10 is 15.6-500 pg/mL. 
 
Statistical analyses 
The data analyses for inflammatory mediator gene expression were analyzed through 
SABiosciences web portal, 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php) as discussed previously. 
Statistical analyses were performed using a commercially-available software package 
(Prism 6, GraphPad Inc, La Jolla, CA 92037 USA). Student’s T tests (two-tailed) were 
utilised to compare the fold change in inflammatory mediator gene expression between each 
treatment group (LPS, IL-1β, and TNFα), and the vehicle control. The comparison of the IL-
6 and IL-10 production between the treatment groups and the vehicle control were analyzed 
using a non-parametric Kruskal-Wallis one-way ANOVA. For all statistical analyses, a P-
value of <0.05 was considered statistically significant and any value above it was considered 
not significant. The results were presented as means ± SEM (n = 3 independent 
experiments). 
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RESULTS 
The effect of LPS, IL-1β and TNFα on inflammatory mediator gene expression in 
bovine endometrial epithelial cells (bEEL) 
The RT-PCR array data for inflammatory mediator gene expression in bovine endometrial 
epithelial cells (bEEL) treated with LPS, IL-1β, and TNFα are presented in Figures 2.1.1-
2.1.3 and in Supplemental Table S2.1.1 (see APPENDICES). From a total of 84 genes 
analysed, 16 inflammatory mediator genes; which met the cycle threshold cut-offs (<35) for 
the gene expression data, were significantly altered in bEEL cells by LPS, IL-1β, and/or 
TNFα. We present the gene expression that was not determined by RT-PCR or was not 
altered by LPS, IL-1β, and/or TNFα treatment on bEEL cells in Supplemental Table S2.1.1 
(see APPENDICES). The data presented for the inflammatory mediator gene expression by 
RT-PCR is categorised into groups that showed upregulated chemokines (Figure 2.1.1), 
upregulated interleukins and TNF receptor superfamily members (Figure 2.1.2) and 
downregulated gene expression of inflammatory mediators (Figure 2.1.3) following 
treatment with LPS, IL-1β, and/or TNFα treatment on bEEL cells. bEEL cells challenged by 
LPS and IL-1β induced a pro-inflammatory response by upregulating the expression of 
chemokines; CCL22, CX3CL1, CXCL3, and GRO1 (Figure 2.1.1), interleukins; CXCL8/IL-8, 
IL-1α, IL-1β, and IL-6, and the TNF receptor superfamily members; TNF, TNFRSF11B, and 
LTβ (Figure 2.1.2). However, the gene expression of IL-21, LTα, and THPO expression was 
downregulated (Figure 2.1.3). LPS (1 µg/mL) treated bEEL cells (Figures 2.1.1-2.1.2) were 
shown to induce greater fold change in the gene expression of chemokines (CCL2, CCL20, 
CCL22, CX3CL1, and CXCL3), interleukins (CXCL8/IL-8, IL-1β, and IL-6) and TNF receptor 
superfamily members (TNF, TNFRSF11B, and LTβ), when compared with IL-1β (10 ng/mL) 
and untreated bEEL cells. In comparison with untreated bEEL cells, bEEL cells stimulated 
with 50 ng/mL TNFα (Figures 2.1.1-2.1.3) did not significantly alter the expression of 
inflammatory mediator genes. 
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Figure 2.1.1. Chemokine gene expression upregulated by LPS, IL-1β and/or TNFα in bovine endometrial epithelial cells (bEEL). 
The relative fold change of chemokine (A) CCL2, (B) CCL20, (C) CCL22, (D) CX3CL1, (E) CXCL3, and (F) GRO1 gene expression in 
bovine endometrial epithelial cells (bEEL) when treated for 6 h with 1 µg/mL LPS, 10 ng/mL IL-1β, and 50 ng/mL TNFα compared with 
untreated bEEL cells (no treatment control). Results are presented as means ± SEM (n=3 independent experiments), and the gene 
expression were normalised against the expression of the endogenous reference genes (GAPDH and TBP). Differences of * P < 0.05, ** 
P < 0.01 and *** P < 0.001 were considered statistically significant. 
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Figure 2.1.2. Interleukins and TNF receptor superfamily members’ gene expression upregulated by LPS, IL-1β and/or TNFα in 
bovine endometrial epithelial cells (bEEL). The relative fold change of interleukins (A) CXCL8/IL-8, (B) IL-1α, (C) IL-1β, and (D) IL-6, 
and TNF receptor superfamily members (E) TNF, (F) TNFRSF11B, and (G) LTβ gene expression in bovine endometrial epithelial cells 
(bEEL) when treated for 6 h with 1 µg/mL LPS, 10 ng/mL IL-1β, and 50 ng/mL TNFα compared with untreated bEEL cells (no treatment 
control). Results are presented as means ± SEM (n=3 independent experiments), and the gene expression were normalised against the 
expression of the endogenous reference genes (GAPDH and TBP). Differences of * P < 0.05, ** P < 0.01 and *** P < 0.001 were considered 
statistically significant. 
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Figure 2.1.3. Inflammatory mediator gene expression downregulated by LPS, IL-1β 
and TNFα in bovine endometrial epithelial cells (bEEL). The gene expression of 
inflammatory mediator (A) IL-21, (B) LTα, and (C) THPO when treated with 1 µg/mL LPS, 
10 ng/mL IL-1β, and 50 ng/mL TNFα for 6 h compared with untreated bEEL cells (no 
treatment control). Results are presented as means ± SEM (n=3 independent experiments), 
and the gene expression were normalised against the expression of the endogenous 
reference genes (GAPDH and TBP). Differences of * P < 0.05, ** P < 0.01 and *** P < 0.001 
were considered statistically significant. 
32 
 
The effect of LPS, IL-1β and TNFα on inflammatory mediator gene expression in 
bovine endometrial stromal cells (bCSC) 
The RT-PCR array data for inflammatory mediator gene expression in bovine endometrial 
stromal cells (bCSC) treated with LPS, IL-1β, and TNFα are presented in Figures 2.1.4-2.1.6 
and in Supplemental Table S2.1.2 (see APPENDICES). From a total of 84 genes analysed, 
18 inflammatory mediator genes; which met the cycle threshold cut-offs (<35) for the gene 
expression data, were significantly altered in bCSC cells by LPS, IL-1β, and/or TNFα. We 
present the gene expression that was not determined by RT-PCR or was not altered by LPS, 
IL-1β, and/or TNFα treatment on bCSC cells in Supplemental Table S2.1.2 (see 
APPENDICES). The data presented for the inflammatory mediator gene expression by RT-
PCR are categorised into groups that showed upregulated chemokines (Figure 2.1.4), 
upregulated interleukins and growth factors (Figure 2.1.5) and downregulated gene 
expression of inflammatory mediators (Figure 2.1.6) following treatment with LPS, IL-1β, 
and/or TNFα treatment on bCSC cells. bCSC cells challenged by LPS, IL-1β, and TNFα 
(Figures 2.1.4-2.1.6) significantly upregulated the expression of chemokines; CCL2, CCL20, 
CCL5, CX3CL1, and CXCL5 (Figure 2.1.4) and interleukins; IL-1α, IL-1β, and IL-6 (Figure 
2.1.5), and downregulated CXCL9, CXCL12, and SPP1 expression (Figure 2.1.6). The 
treatment with 10 ng/mL IL-1β onto bCSC cells (Figures 2.1.4-2.1.5) showed greater fold 
change in the gene expression of chemokines (CCL20, CXCL3, CXCL5, and GRO1), 
interleukins (CXCL8/IL-8, IL-1β, and IL-6) and growth factors (CSF2 and CSF3), when 
compared with untreated bCSC cells and treatment by 1 μg/mL LPS (Figures 2.1.4-2.1.5). 
bCSC cells stimulated with 50 ng/mL TNFα (Figure 2.1.4) only showed greater fold change 
of CCL2, CCL5 and CX3CL1 chemokine gene expression when compared with untreated 
bCSC cells and treatment by 1 μg/mL LPS and 10 ng/mL IL-1β. 
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Figure 2.1.4. Chemokine gene expression upregulated by LPS, IL-1β and/or TNFα in bovine endometrial stromal cells (bCSC). 
The relative fold change of chemokine (A) CCL2, (B) CCL20, (C) CCL5, (D) CX3CL1, (E) CXCL3, (F) CXCL5 and (G) GRO1 gene 
expression in bovine endometrial stromal cells (bCSC) when treated for 6 h with 1 µg/mL LPS, 10 ng/mL IL-1β, and 50 ng/mL TNFα 
compared with untreated bCSC cells (no treatment control). Results are presented as means ± SEM (n=3 independent experiments), and 
the gene expression were normalised against the expression of the endogenous reference genes (GAPDH and TBP). Differences of * P < 
0.05, ** P < 0.01 and *** P < 0.001 were considered statistically significant. 
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Figure 2.1.5. Interleukins and growth factors’ gene expression upregulated by LPS, 
IL-1β and/or TNFα in bovine endometrial stromal cells (bCSC). The relative fold change 
of interleukins (A) CXCL8/IL-8, (B) IL-1α, (C) IL-1β, and (D) IL-6, and growth factors (E) 
CSF2, and (F) CSF3 gene expression in bovine endometrial stromal cells (bCSC) when 
treated for 6 h with 1 µg/mL LPS, 10 ng/mL IL-1β, and 50 ng/mL TNFα compared with 
untreated bCSC cells (no treatment control). Results are presented as means ± SEM (n=3 
independent experiments), and the gene expression were normalised against the 
expression of the endogenous reference genes (GAPDH and TBP). Differences of * P < 
0.05, ** P < 0.01 and *** P < 0.001 were considered statistically significant.
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Figure 2.1.6. Inflammatory mediator gene expression downregulated by LPS, IL-1β and TNFα on bovine endometrial stromal cells 
(bCSC). The gene expression of inflammatory mediator (A) CXCL9 (B) CXCL10, (C) CXCL12, (D) IL1RN, and (E) SPP1 when treated with 
1 µg/mL LPS, 10 ng/mL IL-1β, and 50 ng/mL TNFα for 6 h compared with untreated bCSC cells (no treatment control). Results are 
presented as means ± SEM (n=3 independent experiments), and the gene expression were normalised against the expression of the 
endogenous reference genes (GAPDH and TBP). Differences of * P < 0.05, ** P < 0.01 and *** P < 0.001 were considered statistically 
significant. 
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The effects of LPS, IL-1β and TNFα on IL-6 and IL-10 production by bovine 
endometrial epithelial (bEEL) and stromal (bCSC) cells 
The changes in IL-6 and IL-10 cytokine production elicited by LPS, IL-1β, and TNFα on 
bovine endometrial epithelial (bEEL) and stromal (bCSC) cells are presented in Figure 2.1.7. 
IL-6 production was significantly higher when bEEL (Figure 2.1.7A) and bCSC cells (Figure 
2.1.7B) were treated with 1 μg/mL LPS, and with 10 ng/mL IL-1β when compared with 
untreated cells (vehicle control). The anti-inflammatory IL-10 production was only 
significantly increased when bEEL cells were treated with 10ng/mL IL-1β (Figure 2.1.7C). 
bCSC cell production of IL-10 was significantly greater when bCSC cells (Figure 2.1.7D) 
were treated with 1 μg/mL LPS, and with 10 ng/mL IL-1β when compared with untreated 
cells (vehicle control). No significant differences in the production of IL-6 and IL-10 were 
observed when bEEL and bCSC cells were treated with 50 ng/mL TNFα when compared 
with untreated cells (Figure 2.1.7A-D). 
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Figure 2.1.7. The effect of LPS, IL-1β and TNFα on IL-6 and IL-10 production by bovine 
endometrial epithelial (bEEL) and stromal (bCSC) cells. Bovine endometrial epithelial 
(bEEL) and stromal (bCSC) cells were treated with 1 µg/mL LPS, 10 ng/mL IL-1β, and 50 
ng/mL TNFα for 24 h. IL-6 and IL-10 production was determined using ELISAs. (A) IL-6 
production by bEEL cells treated with LPS, IL-1β, and TNFα. (B) IL-6 production by bCSC 
cells treated with LPS, IL-1β, and TNFα. (C) IL-10 production by bEEL cells treated with 
LPS, IL-1β, and TNFα. (D) IL-10 production by bCSC cells treated with LPS, IL-1β, and 
TNFα. Results are presented as means ± SEM (n=3 independent experiments). Differences 
of * P < 0.05, ** P < 0.01 and *** P < 0.001 were considered statistically significant. 
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DISCUSSION 
Bovine endometrial epithelial and stromal cells challenged by LPS in our study showed 
higher expression levels of pro-inflammatory interleukins (CXCL8/IL-8, IL-1α, IL-1β, and IL-
6) and chemokines (CCL2, CCL20, CCL22, CCL5, CX3CL1, CXCL3, CXCL5, and GRO1) 
than untreated cells. Treatment with LPS also induced the production of inflammatory 
mediator IL-6 above basal levels. Our findings are consistent with the published literature 
involving the upregulation of pro-inflammatory interleukins including CXCL8/IL-8, IL-1α, IL-
1β, and IL-6 in the pathogenesis of bacterial infection (Modat et al., 1990, Herath et al., 
2009); an example of which is the attraction of neutrophils in response to increased 
CXCL8/IL-8 production which can lead to the formation of pus in the uterine lumen (Haas et 
al., 2016, Turner et al., 2014).  Also reported are key roles for IL-1α, IL-1β, and IL-6 in the 
stimulation of acute phase responses as seen in animals with postpartum uterine diseases 
(Brodzki et al., 2015a, Fumuso et al., 2003, Brodzki et al., 2015b, Herath et al., 2009). 
Moreover, the elevated mRNA expression of chemokines CCL5 (Arima et al., 2000), CXCL5 
(Karlsson et al., 2015), and GRO1 (Oral et al., 1996) have been reported to have a role in 
the pathogenesis of endometriosis in human and canine (Karlsson et al., 2015). 
 
Many studies have shown that LPS promotes T helper 1 (Th1-type) responses and can also 
bias the immune responses towards the differentiation of other T helper lineages (McAleer 
and Vella, 2008, Shi et al., 2013). Upregulated interleukin (CXCL8/IL-8, IL-1α, IL-1β and IL-
6) and chemokine (CCL20 and CXCL5) have also been reported towards favouring T helper 
17 (Th17) responses (Gasch et al., 2014, Chung et al., 2009, Acosta-Rodriguez et al., 2007, 
Kimura et al., 2007, Hirota et al., 2007, Disteldorf et al., 2015). The responses to LPS 
identified in our study by bovine endometrial epithelial and stromal cells suggests that these 
cells may also favour T helper 17 (Th17) responses and if given the opportunity could 
promote neutrophilic infiltration to eliminate pathogens. 
 
Pathogens that are not eradicated by the host immune response may persist in the uterine 
lumen and can trigger aberrant expressions of pro-inflammatory cytokines which are 
associated with greater inflammation. In our study the treatment of bovine endometrial and 
stromal cells with pro-inflammatory mediatory IL-1β induced the gene expression of pro-
inflammatory interleukins and chemokines when compared with untreated cells. The genes 
with upregulated expression differed between each cell type. Epithelial cells showed an 
upregulation in genes associated with TNF receptor superfamily members however, stromal 
cells did not show any difference in these genes. Stromal cells did however show higher 
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expression of growth factors (CSF2 and CSF3) which were not identified in epithelial cells. 
Endometrial epithelial cells exposed to IL-1β induced the secretion of the anti-inflammatory 
IL-10 a response not seen when these cells were exposed to LPS. This suggests that the 
secretion of IL-10, by epithelial cells may help to suppress the activated pro-inflammatory 
response. In contrast, endometrial stromal cells exposed to IL-1β increased the production 
of both IL-6 and IL-10. This differential gene expression and cytokine production may be 
indicative of the responses evidenced in communications between the cells (Goffin et al., 
2002) to support individual cellular response i.e. stromal cells in supporting epithelial cell 
functions to respond in a controlled manner as the first line of defense against infectious 
agents and/or inflammatory mediators (Chen et al., 2013, Srivastava et al., 2013). 
 
The differences in the inflammatory mediator expression between bovine endometrial 
epithelial and stromal cells responding to IL-1β stimulation may be associated with their 
specific physiological functions during oestrous or menstrual cycle and pregnancy (Geisert 
et al., 2012, Sykes et al., 2012, Ross et al., 2003). The upregulation of these interleukins 
(CXCL8/IL-8 (Arici et al., 1993), IL-1β, and IL-6 (Chalpe et al., 2015)), chemokines (CCL20, 
CXCL3, CXCL5 (Rossi et al., 2005), and GRO1 (Nasu et al., 2001)) and growth factors 
(CSF2 and CSF3 (Chegini et al., 1999, Rossi et al., 2005)) by IL-1β has also been observed 
and reported previously by others, suggesting that IL-1β can have multiple roles in 
endometrial physiology including the modulation of endometrial prostaglandin secretion 
(Seo et al., 2012, Davidson et al., 1995). Interestingly, the upregulation of IL-1β expression 
in both endometrial stromal and epithelial cells treated with IL-1β implies that IL-1β can act 
in an autocrine and paracrine manner and plays an important role in mammalian endometrial 
physiology (Tanaka et al., 2000). 
 
The treatment of both the bovine endometrial epithelial and stromal cells with TNFα in our 
study resulted in a lower stimulatory response than treatment with LPS and IL-1β as the 
gene expression of many cytokines and chemokines and the secretion of pro-inflammatory 
IL-6 and anti-inflammatory IL-10 were unchanged. Similar finding was also reported by 
Chalpe et al. (Chalpe et al., 2015) that telomerase-immortalised human endometrial stromal 
cells (T-HESC) treated with TNFα did not enhance the gene expression of CXCL8/IL-8, IL-
1β, and IL-6. TNFα did however significantly induce chemokines CCL2, CCL20, CCL5, 
CX3CL1, and CXCL5 expression in bovine endometrial stromal cells, similar to the results 
of a study by Liu et al. (Liu et al., 2011), suggesting that TNFα can induce cells to release 
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chemokines to direct leukocytes migration to the site of inflammation, which is often 
associated with chronic inflammation and cancerogenesis (Zelova and Hosek, 2013). 
 
In conclusion, our findings show that epithelial and stromal cells of the endometrium have 
roles in immunity and can elicit an immune response to bacterial LPS and the pro-
inflammatory mediators (IL-1β, and TNFα). Although these events have been described in 
the endometrium of dairy cattle associated with postpartum uterine disease (Kasimanickam 
et al., 2013), the distinction between physiologic and pathologic inflammation of the 
endometrium that influences the immune response and regulation, or both remains 
controversial. Nevertheless, chemokines and cytokines are key modulators of inflammation 
and can be classified based on the nature of the immune response. The responsiveness of 
the cells reassures us of their suitability as the maternal cell component of the in vitro model 
of maternal foetal communication that we endeavour to develop and utilise in our future 
studies. In subsequent studies utilising these cells in the evaluation of maternal-foetal 
communication further mechanistic investigations should be included. Manipulating the 
response of these cells by for example with antagonists that block the signalling pathways 
involved in immune modulation (e.g. TLR4 inhibitors) and the use of treatments against 
inflammation (e.g. nonsteroidal anti-inflammatory drugs) will provide further information that 
may uncover the mechanism(s) at play or help in the development of potential therapies to 
reverse the disadvantageous effects of infection and inflammation in maternal-foetal 
communication.    
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In chapter 2.1 I characterised epithelial and stromal cells from the bovine endometrium 
under conditions that mimic physiological stress associated with reduced fertility (e.g. 
infection and inflammation) by measuring gene expression and production of inflammatory 
mediators (including cytokines and chemokines) in response to these conditions. 
 
In Chapter 2.2 I investigated the effect of hypoxia, a stimulus known to induce exosomal 
release, on the cellular function and release of exosomes by bovine endometrial cells. This 
study utilised bovine endometrial intercaruncular stromal cells as the experimental model 
because uterine glands are present in intercaruncular endometrial regions and are known 
to secrete histotroph that is essential for conceptus survival and growth. 
 
Chapter 2.2 is comprised of the article ‘Characterisation of exosomal release in bovine 
endometrial intercaruncular stromal cells’ submitted to Reproductive Biology and 
Endocrinology: 
 
Koh, YQ, Peiris, HN, Vaswani, K, Reed, S, Rice, GE, Salomon, C & Mitchell, MD 2016, 
'Characterisation of exosomal release in bovine endometrial intercaruncular stromal cells', 
Reprod Biol Endocrinol, vol. 14, no. 1, p. 78 
 
As per the University of Queensland requirements, the submitted version of the manuscript 
is presented herein. However, in order to suit the thesis structure, the formatting of the 
original tables and figures were changed accordingly. The referencing citation numbering 
has also been updated to continue the citation sequence of the previous chapter. 
 
The following statement was adopted from the journal’s policy to acknowledge for 
reproducing permission: 
As authors of articles published in Reproductive Biology and Endocrinology, you are the 
copyright holders of your article and have granted to any third party, in advance and in 
perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed 
Central’s license agreement. For the details regarding BioMed Central’s license agreement, 
please see: https://www.biomedcentral.com/about/policies/license-agreement  
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Chapter 2.2: Characterisation of exosomal release in bovine endometrial 
intercaruncular stromal cells 
Yong Qin Koh, Hassendrini N. Peiris, Kanchan Vaswani, Sarah Reed, Gregory E. Rice, 
Carlos Salomon, and Murray D. Mitchell 
University of Queensland Centre for Clinical Research, The University of Queensland, 
Brisbane, Australia. 
 
ABSTRACT 
Background: Cell-to-cell communication between the blastocyst and endometrium is 
critical for implantation. In recent years, evidence has emerged from studies in humans and 
several other animal species that exosomes are secreted from the endometrium and 
trophoblast cells and may play an important role in cell-to-cell communication maternal-
foetal interface during early pregnancy. Exosomes are stable extracellular lipid bilayer 
vesicles that encapsulate proteins miRNAs, and mRNAs, with the ability to deliver their 
cargo to near and distant sites, altering cellular function(s). Furthermore, the exosomal cargo 
can be altered in response to environmental cues (e.g. hypoxia). The current study aims to 
develop an in vitro system to evaluate maternal-embryo interactions via exosomes (and 
exosomal cargo) produced by bovine endometrial stromal cells (ICAR) using hypoxia as a 
known stimulus associated with the release of exosomes and alterations to biological 
responses (e.g. cell proliferation). 
Methods: ICAR cells cultured under 8% O2 or 1% O2 for 48 hours and changes in cell 
function (i.e. migration proliferation and apoptosis) was evaluated. Exosome release was 
determined following the isolation (via differential centrifugation) and characterisation of 
exosomes from ICAR cell-conditioned media. Exosomal proteomic content was evaluated 
by mass spectrometry.  
Results: Under hypoxic conditions (i.e. 1% O2), ICAR cell migration and proliferation was 
decreased (~20% and ~32%, respectively) and apoptotic protein caspase-3 activation was 
increased (∼1.6 fold). Hypoxia increased exosome number by ~3.6 fold compared with 
culture at 8% O2. Mass spectrometry analysis identified 128 proteins unique to exosomes 
of ICAR cultured at 1% O2 compared with only 46 proteins unique to those of ICAR cultured 
at 8% O2. Differential production of proteins associated with specific biological processes 
and molecular functions were identified, most notably ADAM 10, pantetheinase and 
kininogen 2.  
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Conclusions: In summary, we have shown that a stimulus such as hypoxia can alter both 
the cellular function and exosome release of ICAR cells. Alterations to exosome release and 
exosomal content in response to stimuli may play a crucial role in maternal-foetal crosstalk 
and could also affect placental development. 
 
Keywords: bovine, intercaruncular, hypoxia, exosomes 
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INTRODUCTION 
In dairy cattle, the average gestation length is approximately 282 days. The placenta is 
epitheliochorial, cotyledonary and non-deciduate (Banu et al., 2005). Placentation is 
restricted to the aglandular maternal caruncles, where the foetal cotyledons come into 
contact with each other (Verduzco et al., 2012, Mansouri-Attia et al., 2009). They then form 
the placentome for maternal-foetal exchange of oxygen, nutrients and waste products. The 
glandular intercaruncular regions are associated with preserving the uterus in a state of 
quiescence and allowing a progressive uterine hypertrophy to accommodate the increasing 
needs of the growing feto-placental unit (Arosh et al., 2004). The uterine glands present in 
the intercaruncular endometrial areas secrete and release histotroph that is crucial for 
conceptus survival and growth (Gray et al., 2001) and is transported into the fetal circulation 
via the placental areolae. The establishment of a successful pregnancy requires the 
interactions between the endometrial cells and the early conceptus during maternal 
recognition of pregnancy (Ashley et al., 2011, Bauersachs and Wolf, 2013).  
 
Cells located within intercaruncular region and associated with maternal fetal cross talk 
include cells of stromal (intercaruncular stromal cell; ICAR) and epithelial origin. Both cell 
types are known to produce prostaglandins (e.g. PGF2α) and have immunomodulatory 
functions (Asselin et al., 1998, Turner et al., 2014). Interactions between these cells may 
also play a pivotal role in endometrial receptivity during early pregnancy as was reported in 
a co-culture study that human endometrial stromal cells can mediate epithelial cell function 
by promoting differentiation and inhibiting proliferation of endometrial epithelial cells (Arnold 
et al., 2001). In the bovine, endometrial stromal cells (as utilised in the current study) are 
known to differentially regulate the production of prostaglandins and enzymes related to the 
production of prostaglandins, in response to specific stimuli (e.g. inflammatory mediators 
and interferon-tau) (Okuda et al., 2004, Asselin et al., 1998). ICAR cells were a kind gift from 
Professor Michel A. Fortier (Université Laval, Québec). ICAR cells are a transformed cell-
line derived from the intercaruncular region of the bovine endometrium (Asselin et al., 1996). 
ICAR cells can be propagated while still maintaining the phenotypical characteristics of 
these cells which include the presence of SV40 TAG and the vimentin-positive and 
cytokeratin-negative features that support the stromal phenotype of these cells (Asselin et 
al., 1998, Krishnaswamy et al., 2009). This study aimed to evaluate the effect of a known 
stimulus of exosome release on the production of exosomes by ICAR cells.  
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In recent years, evidence has emerged from studies in humans (Ng et al., 2013) and several 
other animal species (Ruiz-Gonzalez et al., 2015, Cleys et al., 2014, Burns et al., 2014, 
Sohel et al., 2013) that exosomes are secreted from the endometrium and trophoblast cells 
and may play important roles at the conceptus-endometrial interface during early pregnancy. 
Exosomes are specific subsets of extracellular vesicles (smaller than 1000 nm) (van der Pol 
et al., 2012) that could provide insights into an alternative new explanation for the crosstalk 
between cells. Exosomes (30–120 nm) are stable extracellular lipid bilayer vesicles arising 
from the inward budding of multivesicular bodies and released via an exocytic pathway to 
the extracellular environment with the capacity to modify the biological function of target 
cells (Simons and Raposo, 2009). Exosomes provide a mechanism of cell-to-cell 
communication in physiological and pathological conditions and may be influenced by 
neighbouring cells, distant tissues or local environmental factors. There is considerable 
evidence that hypoxia is a potent stimulant to the release of exosomes (Gupta and Knowlton, 
2007, Orriss et al., 2009, Wysoczynski and Ratajczak, 2009, King et al., 2012). It is also a 
useful investigatory modality since a lower-than-normal oxygen tension in utero can 
influence many developmental events with potentially lifelong consequences (Maltepe and 
Saugstad, 2009, Mallard et al., 1998). 
 
Hypoxia is a well-known stimulus of exosome release as seen in breast cancer cells, 
endothelial cells and human trophoblasts (Park et al., 2010, King et al., 2012, Salomon et 
al., 2013a). Alterations have been documented in both the number of exosomes release as 
well as differences in the content (cargo) of the exosomes (Park et al., 2010, King et al., 
2012, Onogi et al., 2011). This study aimed to test the hypothesis that hypoxia as a known 
stimulus of exosome release (and altered biological response) will modify the phenotype of 
bovine endometrial stromal cells affecting their migration, proliferation, apoptosis as well as 
altering both the release and cargo of the exosomes generated. 
 
AIM 
This study investigated the effect(s) of a hypoxic environment on the function of bovine 
endometrial cells. In particular alterations to migration proliferation and apoptosis. Moreover, 
this study evaluated alterations to the release and cargo content of exosomes generated by 
bovine endometrial cells, when cultured under hypoxia.  
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MATERIALS AND METHODS 
Endometrial Cell Line 
A well characterised bovine endometrial intercaruncular stromal cell line (ICAR cells) was 
utilised for the current study (Fortier et al., 1988, Asselin et al., 1998). ICAR cells were a 
kind gift from Professor Michel A. Fortier (Université Laval, Québec). ICAR cells were 
maintained in 175 cm2 (T175, Corning Costar) culture flasks supplemented with exosome-
free media (1640 Roswell Park Memorial Institute (RPMI) medium (Invitrogen, Life 
Technologies) with 10% heat-inactivated fetal bovine serum (Bovogen, Interpath services 
Pty Ltd) depleted of exosomes by ultracentrifugation (100,000 × g for 20 h at 4oC) and 1000 
U/mL antibiotic-antimycotic solution (Gibco, Life Technologies) in a humidified cell culture 
incubator at 37°C under an atmosphere of 5% CO2-balanced N2 to obtain a hypoxic (1% O2) 
environment or under physiologically relevant conditions (8% O2). Lactate dehydrogenase 
(LDH) assay was also performed accordingly to the manufacturer’s protocol using the 
commercially available kit Pierce LDH cytotoxicity assay kit (Thermo scientific) to measure 
LDH in supernatants of ICAR cells cultured at 8% O2 and 1% O2 and ICAR cell viability was 
accessed. No significant difference in the LDH activity was observed (data not shown) 
between 8% O2 and 1% O2, indicating that the viability of ICAR cells was not affected by 
experimental condition. 
 
Cell Migration Assay 
The effect of oxygen tension on cell migration was assessed using methods as previously 
published (Salomon et al., 2013b). Briefly, ICAR cells were plated (30,000 cells per well) 
and grown to confluence in a 96-well culture plate (Corning Costar) at 1% O2 or 8% O2 
oxygen tension and a wound scratch was made on confluent monolayers using a 96-pin 
WoundMaker (Essen BioScience). Migration assays were performed in the presence of 
Mitomycin C (100 ng/mL, Sigma–Aldrich) to minimise any confounding effects of cell 
proliferation. The wound images were automatically acquired every 2 h for 48 h and 
registered by the IncuCyte software system (Essen BioScience). Data are presented as the 
Relative Wound Density (RWD, Eizen, v1.0 algorithm). RWD is a representation of the 
spatial cell density in the wound area relative to the spatial cell density outside of the wound 
area at every time point (time-curve). 
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Cell Proliferation Assay 
Proliferation of ICAR cells was assessed using methods as previously published (Salomon 
et al., 2013a, Salomon et al., 2013b). In brief, the effect of oxygen tension on ICAR cell 
proliferation was assessed using a non-labelled cell monolayer confluence approach with a 
high density phase contrast real-time cell imaging system (IncuCyteTM). ICAR cells were 
seeded at 40,000 cells per well in a 12-well culture plate (Corning Costar) and exposed to 
oxygen tension at 1% O2 or 8% O2 and the cell confluence (as the proliferation parameter) 
was measured at 0, 24 and 48 h. 
 
Cell Apoptosis Assay 
To assess the effect of hypoxia on cell apoptosis, ICAR cells were seeded at 5,000 cells per 
well in 96-well culture plate (Corning Costar) in the presence of CellPlayer Kinetic Caspase-
3/7 Apoptosis Assay Reagent (1:5000; Essen Biosciences) and imaged at 48 h with 
IncuCyteTM. Cell apoptosis is determined by the measurement of the number of activated 
caspase 3/7 fluorescent objects count per mm2 divided by the percentage of cell confluence 
at 48 h (percentage of the area of field of view covered by cells with the metric ‘phase object 
confluence’) with the IncuCyte Zoom software using an integrated object counting algorithm. 
 
Exosome Isolation from Cell-Conditioned Media 
To study the effect of oxygen tension on exosome release, ICAR cells were incubated at 1% 
O2 or 8% O2 for 48 h. Exosomes were isolated from ICAR cell culture-conditioned media by 
successive differential centrifugation steps at 300 × g for 10 min and 2,000 × g for 30 min. 
The supernatant was filtered through a 0.22-µm filter (Corning Costar) and ultracentrifuged 
at 100,000 × g for 20 h at 4°C (Sorvall, SureSpin 630/360, Swinging-bucket ultracentrifuge 
rotor). Another round of ultracentrifugation washing steps was performed at 100,000 × g for 
2 h at 4°C (Beckman, Type 70.1 Ti, Fixed angle ultracentrifuge rotor).  Exosomes were 
further enriched by layering on top of a discontinuous iodixanol gradient (OptiPrep, Sigma–
Aldrich), which was centrifuged at 100,000 × g for 20 h (Beckman, Sw41Ti, Swinging-bucket 
ultracentrifuge rotor). Twelve fractions were obtained and diluted in 10 mL PBS (Gibco, Life 
Technologies). The fractions were washed with PBS and centrifuge at 100,000 × g for 2 h 
(Beckman, Type 70.1 Ti, Fixed angle ultracentrifuge rotor) and the exosomal pellets were 
suspended in 50 µL PBS.  
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Nanoparticle Tracking Analysis (NTA) 
NTA measurements were performed using a NanoSight NS500 instrument (NanoSight NTA 
3.0 Nanoparticle Tracking and Analysis Release Version Build 0064) as previously 
described (Kobayashi et al., 2014, Salomon et al., 2014). 
 
Western Blot Analysis and Transmission Electron Microscopy 
Exosomes were solubilised in RIPA buffer (Sigma–Aldrich) and separated by 
polyacrylamide gel electrophoresis, transferred to a polyvinylidene fluoride (PVDF) 
membrane (Bio-Rad) and probed with primary rabbit polyclonal antibody anti-CD63 (1:1000; 
EXOAB-CD63A-1, System Biosciences ) and TSG101 (1:500; sc-6037, Santa Cruz 
Biotechnology). For electron microscopy analysis, exosome pellets were fixed in 3% (w/v) 
glutaraldehyde and analyzed under an FEI Tecnai 12 transmission electron microscope 
(FEI, Hillsboro, Oregon, USA). 
 
Proteomic Analysis of Endometrial Exosomes by Mass Spectrometry (MS) 
Exosomes (10 µg of protein) were solubilised in RIPA buffer (Sigma–Aldrich) and separated 
by polyacrylamide gel electrophoresis. The gel was fixed in fixing solution (10:1:9; ethanol, 
acetic acid, MilliQ water respectively) for 15 min, washed in (1:1, ethanol and MilliQ water) 
for 10 min and washed three times with MilliQ water. Proteins were stained with Coomassie 
Brilliant Blue R-250 staining solution (Bio-Rad) for 1 h and the gel was allowed to destain in 
MilliQ water until a clear background was obtained. 
In-gel digestion methods for the mass spectrometric identification of exosomal proteins were 
performed by modification of previously published method (Brinkman et al., 2015). In brief, 
each sample lane was cut into 24 gel slices and destained twice with 200 mM ammonium 
bicarbonate in 50% acetonitrile solution for 45 min at 37°C, desiccated using a vacuum 
centrifuge and then resuspended with 20 mM dithiothreitol (DTT) in 25 mM ammonium 
bicarbonate solution and reduced for 1 h at 65°C. DTT was then removed, and the samples 
were alkylated in 50 mM iodoacetamide and 25 mM ammonium bicarbonate at 37°C in 
darkness for 40 min. Gel slices were washed three times for 45 min in 25 mM ammonium 
bicarbonate and then desiccated. Individual dried slices were then allowed to swell in 20 μL 
of 40 mM ammonium bicarbonate, 10% acetonitrile containing 20 μg/mL trypsin (Sigma) for 
1 h at room temperature. An additional 50 μL of the same solution was added and the 
samples were incubated overnight at 37°C. 
The supernatants were removed from the gel slices, and residual peptides were washed 
from the slices by incubating them three times in 50 μL of 0.1 % formic acid for 45 min at 
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37°C. The original supernatant and washes were combined and desalted according to a 
modified version of the stage tip protocol that we have published (Vaswani et al., 2015, 
Rappsilber et al., 2003) using a 3-mm piece of an Empore C18 (Octadecyl) SPE Extraction 
Disk and the eluted peptides were dried in a vacuum centrifuge prior to spectral acquisition. 
 
The digested protein samples were analysed using the TripleTOF® 5600 mass 
spectrometer (ABSciex, Redwood City, CA) and Eksigent 1D+ NanoLC system with the 
cHiPLC system to obtain initial high mass accuracy survey MS/MS data, identifying the 
peptides present in the samples. The ChromXP C18-CL TRAP cHiPLC (200 µm x 6 mm, 3 
µm, 120 Å) and analytical cHiPLC columns (200 µm x 15 cm; 3 µm, 120 Å) (Eksigent, 
Redwood City, CA) were used to separate the digested proteins. A 10 µL aliquot of digested 
material was injected onto the column and separated with a linear gradient of 5% to 10% 
Buffer B for 2 min (Buffer A: 0.1% Formic acid/water; Buffer B: acetonitrile/0.1% formic acid), 
10 to 40% Buffer B (58 min), 40 to 50% Buffer B (10 min), 50 to 95% (10 min) with a flow 
rate of 500 nL/min.  The column was flushed at 95% buffer B for 15 min and re-equilibrated 
with 5% Buffer B for 6 min.  The in-depth proteomic analysis was performed using the 
Information Dependent Acquisition (IDA) experiments on the TripleTOF® 5600 System 
interfaced with a nanospray source.  The source parameters were as follows: Curtain gas 
at 25 psi, ion source gas (GAS1) at 5 psi and interface heater temperature at 150˚C.  A 250 
msec accumulation time was set for the TOFMS survey scan and from this scan, the 10 
most intense precursor ions were selected automatically for the MS/MS analysis 
(accumulation time of 150 msecs per MS/MS scan).  Ions were isolated using unit resolution 
of the quadrupoles and rolling collision energy equation was used to calculate the collision 
energies of precursors.  The precursor selection criteria included a minimum intensity of 50 
counts per second (cps) and a charge state greater than 2+. 
 
Protein identification was determined using the ProteinPilot™ Software (v4.5 beta, AB Sciex, 
Redwood City, CA) with the Paragon algorithm.  The search parameters were as follows:  
sample type, identification; cys alkylation, iodoacetamide; digestion, Trypsin; Instrument, 
TripleTOF 5600; special factors, none; and ID focus, biological modifications.  The database 
was downloaded from the UniProt website in October 2015, which contained all proteins 
from Bos taurus. False discovery rate (FDR) was selected in the method and determined 
using a reversed sequence database. Data were subjected to ontology and pathway 
analysis using the protein analysis through evolutionary relationships tool (PANTHER) and 
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gene ontology algorithms and classified based on biological process and molecular function 
categories (Thomas et al., 2003). 
 
Statistical Analyses 
The effects of oxygen tensions on ICAR cells are presented as means ± SEM for migration, 
proliferation and apoptosis assays (n = 6 independent experiments in duplicate). The 
number of exosomes is presented as number of particles per mL (means ± SEM, n = 3 
independent isolations from 80 million cells each). The effects of oxygen tension on ICAR 
cells were identified by Student’s T tests (two-tailed) to compare the effect of hypoxia (i.e. 
1% O2) with the control group (i.e. 8% O2) using a commercially-available software package 
(Prism 6, GraphPad Inc, La Jolla, CA 92037 USA). 
 
RESULTS 
The Effect of Oxygen Tension on Bovine Endometrial (ICAR) Cell Migration and 
Proliferation 
The effect of normal oxygen tension (i.e. 8% O2) and hypoxia (i.e. 1% O2) on ICAR cell 
migration is presented in Figure 2.2.1. ICAR cell migration was significantly lower under 
hypoxia compared with normal oxygen tension (Figure 2.2.1A). Hypoxia decreased ICAR 
cell migration in a time-dependent manner (Figure 2.2.1B). Area under the curve analysis 
indicated that hypoxia decreased ICAR cell migration by ~20% compared with values 
observed at 8% O2 (2173 ± 36 and 2620 ± 50 for 1% O2 and 8% O2, respectively) (Figure 
2.2.1C). Interestingly, hypoxia decreased ICAR cell proliferation in a time-dependent 
manner (Figure 2.2.2A and 2.2.2B). Area under curve analysis showed that at 1% O2, the 
proliferative capacity of ICAR cells was inhibited (P < 0.05) ~32% compared with cell 
proliferation at 8% O2 (2.32 ± 0.18 and 3.41 ± 0.2 for 1% O2 and 8% O2, respectively) (Figure 
2.2.2C). 
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Figure 2.2.1. The effects of different oxygen tension on migration of bovine 
endometrial stromal cells (ICAR). (A) Graphical representation of the initial wound width 
(white) at 0 h and the area of the initial wound covered by advancing cells (grey) at 24 h and 
48 h, Scale bar 300µm. (B) Decreased ICAR cell migration under hypoxic conditions (1% 
O2 (●) compared with a normoxic 8% O2 (○)) over a period of 48 h. (C) Area under the curve 
analysis from (B); 8% O2 (white bar) and 1% O2 (black bar). Data are presented as means 
± SEM, n=6. In (B) and (C) P < 0.05. 
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Figure 2.2.2. The effects of different oxygen tension on proliferation of bovine 
endometrial stromal cells (ICAR). (A) Representative phase-contrast image of ICAR cells 
at 48 h when cultured under hypoxic conditions (1% O2) compared with a normoxic 8% O2, 
Scale bar 200µm. (B) Decreased (P < 0.01) ICAR cell proliferation under hypoxic conditions 
(1% O2 (●)) compared with a normoxic 8% O2 (○) over a period of 48 h. (C) Area under the 
curve analysis from (B); 8% O2 (white bar) and 1% O2 (black bar). Data are presented as 
means ± SEM, n=6. In (C) P < 0.05. 
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The Effect of Oxygen Tension on Bovine Endometrial (ICAR) Cell Apoptosis 
The effect of oxygen tension on cell apoptosis is presented in Figure 2.2.3. A hypoxic (1% 
O2) environment altered cell morphology compared with cells cultured under normal 
conditions (8% O2), displaying morphological hallmarks of apoptotic death (Figure 2.2.3A, a 
and d). Fluorescent images acquired with IncuCyteTM (Figure 2.2.3A, b and e) showed 
greater fluorescence in cells cultured under 1% O2, indicating a higher activation of caspase-
3/7 under hypoxic conditions compared with 8% O2 (Figure 2.2.3A, b and e). Apoptosis was 
quantified using the object counting algorithm in which the number of fluorescent objects 
was indicated with red x’s in Figure 2.2.3A (c and f). Quantification analysis showed that 
hypoxia increased (~ 1.6 fold) the apoptosis ratio (presented as activated caspase 3/7 
fluorescent objects count per mm2 divided by percentage of cell confluence at 48 h) 
compared with cells cultured under normal oxygen tension (Figure 2.2.3B). 
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Figure 2.2.3. The effects of different oxygen tension on activation of apoptotic protein 
caspase-3 of bovine endometrial stromal cells (ICAR). ICAR cells were cultured under 
normoxic (8% O2) or hypoxic (1% O2) conditions and the activated caspase-3/7 fluorescence 
was measured at 48 h. (A) Representative phase-contrast images (a and d), fluorescent 
signal images (b and e) and acquired fluorescent signal using integrated object counting 
algorithm with IncuCyteTM (Segmentation; c and f), Scale bar 400µm. (B) Increased 
apoptosis of ICAR cells under hypoxic conditions as determined by acquired fluorescent 
signal using integrated object counting algorithm with IncuCyteTM were normalised against 
cell confluence, 8% O2 (white bar) and 1% O2 (black bar). Data are presented as means ± 
SEM, n=6. In (B) P < 0.05. 
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The Effect of Oxygen Tension on Exosome Release from Bovine Endometrial Cells 
(ICAR). 
Exosomes were enriched by buoyant density gradient (see Material and Methods). We 
fractioned the 100,000 × g pellet into 12 fractions and the Western blot analysis for TSG101 
and CD63 showed positive protein abundance in fractions 1.17 and 1.18 g/mL (Figure 
2.2.4A). Exosomes were pooled between densities 1.16 and 1.18 g/mL. Morphology of 
exosomes was determined by electron microscopy (Figure 2.2.4B), exosomes displayed a 
cup-shaped morphology with an estimated diameter of 100 nm. Hypoxia did not alter the 
size distribution of exosomes compared with normal oxygen tension (123 ± 2.7 nm versus 
127 ± 1.7 nm for 8% O2 and 1% O2, respectively) (Figure 2.2.4C). Interestingly, hypoxia 
increased (~3.6 fold) the number of exosomes compared with values observed at normal 
oxygen tension (Figure 2.2.4D). 
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Figure 2.2.4. Characterisation of exosomes release from 8% O2 and 1% O2 ICAR cell-
conditioned media. Exosomes were characterised after enrichment from the 100,000 × g 
pellet by buoyant density centrifugation (see Materials and Methods). (A) Representative 
Western blot for exosome markers: TSG101 and CD63. (B) Representative electron 
micrograph exosome fractions, Scale bar 100 nm. (C) Representative Nanosight 
measurement of particle-size distribution exosomes from 8% O2 and 1% O2 cell-conditioned 
media after buoyant density gradient ultracentrifugation. (8% normoxic condition mean size 
(127 ± 1.7 nm) (○), 1% hypoxic condition mean size (123 ± 2.7 nm) (●) over a period of 48 
h).  (D) Exosomes concentration presented as vesicle per million cells per 48 h was higher 
(P < 0.05) at hypoxia (1% O2) compared to normal oxygen tension (8% O2); 8% O2 (white 
bar) and 1% O2 (black bar). Data are presented as means ± SEM, n=3. 
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Proteomic Analysis of Bovine Endometrial ICAR-Derived Exosomes  
Mass spectrometric analysis identified over 250 exosomal proteins with 113 similar proteins 
identified as present in both exosomes of ICAR cultured at 1% O2 and at 8% O2 128 proteins 
identified as unique to exosomes of ICAR cultured at 1% O2; 46 proteins were identified as 
unique to exosomes of ICAR cultured at 8% O2 (Table 2.2.1A-C (see APPENDICES); Figure 
2.2.5A). Data were subjected to ontology and pathway analysis using PANTHER and gene 
ontology algorithms and classified based on biological process (Figure 2.2.5B) and 
molecular function (Figure 2.2.5C). In biological process, the clusters identified from 
individual proteins that are unique to and present only in exosomes of ICAR cultured at 1% 
O2 but not those at 8% O2 were: growth (0.7%), locomotion (0.7%) and reproduction (1.4%) 
(Figure 2.2.5B). In molecular functions, the proteins related to binding and catalytic activity 
were the greatest recognised in both exosomes of ICAR cultured at 1% O2 and to those of 
ICAR cultured at 8% O2 (Figure 2.2.5C).  
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Figure 2.2.5. Proteomic analysis of bovine endometrial ICAR-derived exosomes. Mass 
spectrometric analyses of ICAR cell-derived exosome proteins. (A) Representative Venn 
diagram of common and unique proteins identified by 5600 Triple TOF MS (ABSciex) from 
exosomes released by ICAR cells at 48 h at both 8% O2 and 1% O2. (B) The gene ontology 
classification of ICAR cell-derived exosome proteins, on the basis of their involvement in 
biological process, identified clusters that are unique to and present only in exosomes of 
ICAR cultured at 1% O2 but not those at 8% O2. These biological processes were: growth 
(0.7%), locomotion (0.7%) and reproduction (1.4%). (C) Molecular function (using 
PANTHER and Gene Ontology algoritnms) of exosome proteins were mostly related to 
binding and catalytic activity in both ICAR cultured at 1% O2 and at 8% O2. 
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DISCUSSION 
A successful pregnancy is dependent of having a quality embryo and a receptive uterus 
synergizing with a synchronised crosstalk between the endometrium and embryo. Any 
insults or disturbances to its normal course can compromise implantation and the ability for 
the growing fetus to develop properly in the uterus (Mallard et al., 1998). The endometrium 
clearly has important functions in dairy cow pregnancy and we have now shown that 
exosomal release (30–120 nm) is part of its armamentarium which has analogous properties 
to similar tissues of other mammalian species. 
 
In the present case, we have shown for the first time the effects of hypoxia on the biological 
activities of endometrial ICAR cells, including actions on the release and protein content of 
exosomes. Although it remains to be determined whether exosomes released from ICAR 
cells at different oxygen tensions also serve different functional goals, our data underscore 
that the content of exosomes may reflect the physiological state of the cells. 
 
Our non-exosomal characterisation of the ICAR cells indicated that the migration and 
proliferative capacity of ICAR cells decreased, while activation of apoptotic caspase-3 was 
enhanced at 1% O2 (hypoxia), compared with an oxygen tension that was close to the bovine 
endometrial physiological oxygen levels (8% O2; (Gahlenbeck et al., 1968)). Moreover, the 
effect on migration was greater when exposed at 1% O2 (Ng et al., 2010). Interestingly, no 
relationship between oxygen tension and cell proliferation and apoptosis was observed in 
this previous study. Differences in cell types may explain this observation. Ito et al. described 
the rate of proliferation of human mesenchymal stem cell (MSCs) was observed to be 
highest in 5% O2 and the lowest in < 0.1% O2 conditions (Ito et al., 2015). The MSCs at 
severely induced hypoxic conditions (< 0.1% O2) showed a decrease in proliferative ability, 
but were able to maintain viability for at least 48 h through increased glucose availability, to 
facilitate the generation of energy. Similar results were obtained from an airway smooth 
muscle study (Cogo et al., 2003). Hence, our cells have relatively normal proliferation 
responses to decreased oxygen tension. 
 
Our study suggests that exosomes can serve as a vector for signalling molecules that harbor 
a variety of bioactive molecules including proteins at the conceptus-endometrial interface 
and that has the potential to modulate the functions of targeted cells during early pregnancy. 
Endometrial exosome release may also be modulated during an insult such as infection 
(Harp et al., 2016, Nudel et al., 2015). In the current study we utilised hypoxia (i.e. 1% O2) 
60 
 
as a known modulator of exosome release as documented by alteration to both the number 
of exosomes released as well as differences in the exosomal content (cargo) (Park et al., 
2010, King et al., 2012, Onogi et al., 2011).  
 
In our study, endometrial cells exposed to 1% O2 released ~3.6 fold more exosomes relative 
to the 8% O2 culture treatment, suggesting that hypoxia modulates cell function, including 
the release of exosomes. Hypoxia has already been reported to be a stimulus to increase 
secretion of exosomes by several groups (Kucharzewska et al., 2013, Sano et al., 2014, 
Lee et al., 2012). It is also suggested that the protein and RNA content of exosomes can 
reflect the physiological state of the cell as well as when the cells are in stress condition 
(Belting and Christianson, 2015, de Jong et al., 2012). However, the initial stress insult that 
contributed to an alteration of the exosomal content in relation to the functional effects of the 
subsequent cargo transfer and their role in cell-to-cell communication remains unclear. It is 
possible that exposure to other stressors such as adverse environmental hazards (Alvarez-
Erviti et al., 2011a, Fevrier et al., 2004, Pan-Montojo and Reichmann, 2014) will also 
increase secretion of exosomes and alter composition of the cargo. 
 
The protein content of exosomes from ICAR cells cultured under the 1% O2 contained 
unique proteins compared to the contents of the ICAR exosomes cultured at 8% O2. Our 
proteomic analyses detected the presence of tetraspanin-6 (TSPAN6), disintegrin and 
metalloproteinase domain-containing protein 10 (ADAM10) that are only unique to 
exosomes of ICAR cultured at 1% O2. These proteins are involved in the biological 
processes for reproduction. Interestingly, to evaluate TSPAN6, belonging to the 
transmembrane 4 superfamily that mediate the regulation of signal transduction events, as 
well as the disintegrin-like metalloproteinase ADAM10 which participates in ectodomain 
shedding activity could provide great insights into their functional role and regulation that is 
important for reproduction. 
 
Studies using immunohistochemistry of human placental explants (Zhao et al., 2010) have 
demonstrated that ADAM10 expression is significantly increased in preeclamptic placentas 
compared with normal placentas. Up-regulation of ADAM10 could induce placental release 
of soluble vascular endothelial growth factor receptor-1 (sFlt-1) and this cascade is 
associated with endothelial dysfunction, suggesting the significant role of oxidative change 
in preeclamptic placentas. ADAM10 is also a sheddase (Bouillot et al., 2011) that could 
induce CD46 shedding attributed to cell apoptotic processes (Hakulinen and Keski-Oja, 
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2006), as well as mediate E-cadherin shedding affecting cellular adhesion and cell migration 
(Maretzky et al., 2005). 
 
Mass spectrometry detection of pantetheinase (VNN1) in exosomes was unique to ICAR 
cultured at 8% O2. VNN1 is an enzyme that hydrolyses pantetheine to form pantothenic acid 
(a precursor of coenzyme A) and the antioxidant cysteamine (Martin et al., 2001). VNN1 
could promote tissue inflammation through peroxisome proliferator-activated receptor 
gamma as well as modulate levels of glutathione (Dammanahalli et al., 2012). It is proposed 
that VNN1 have innate immune functions and might contribute to tissue injury in endometritis 
(Hayes et al., 2012, Berruyer et al., 2004).  VNN1 was also reported being involved in 
proteolysis and can denature proteins by reducing disulfides (Kaskow et al., 2012), 
suggesting that it may have a role in regulating uterine receptivity for implantation and 
trophoblast invasion (Mullen et al., 2012). 
 
Mass spectrometry detected kininogen-2 (KNG2) in exosomes generated by ICAR cells 
cultured at either 1% or 8% O2. KNG2 is a precursor protein to high molecular weight 
kininogen, low molecular weight kininogen and bradykinin and the concentration were 
reported to fluctuate during ovulation, pregnancy, and parturition (Karkkainen and Hamberg, 
1986). Studies also showed that the release of vasoactive bradykinins from high molecular 
weight kininogen and low molecular weight kininogen are responsible for micro-vascular 
permeability and vascular growth, which plays an essential role in utero-placental 
vasculature and angiogenesis, necessary for embryonic and fetal survival (Vonnahme et al., 
2004). 
 
CONCLUSION 
Our present findings show that ICAR cell function, release of exosomes and exosomal 
content can be altered when subjected to adverse stimuli. These findings should be 
expanded to include cells of endometrial epithelial origin, interactions between these cells 
(i.e. stromal –epithelial cross talk) and in the presence of common pathophysiological factors 
associated with reduced fertility (e.g. infectious or inflammatory agents).  The identification 
of unique proteins (by mass spectrometry) in exosomes of ICAR cultured at 1% O2 compared 
to 8% O2 suggests that the cells respond and release proteins encapsulated within the 
exosomes to signal the environment in which they live. It is hoped that identification of unique 
proteins in exosomes following stimulation by factors affecting the physiological condition of 
cows may lead to novel targets for manipulation to aid fertility. Moreover, investigations into 
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the release, uptake and content of exosomes may offer the opportunity to evaluate maternal-
fetal crosstalk. 
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Summary for Chapter 2 
Understanding how immunity (i.e. gene expression and production of inflammatory 
mediators) is regulated by the bovine endometrium in the presence of pro-inflammatory 
stimuli (e.g. bacterial LPS or the pro-inflammatory cytokines IL-1β and TNFα) can facilitate 
a better understanding of endometrial physiology and the pathophysiology underlying 
postpartum uterine disease in dairy cows. This knowledge may help develop strategies to 
improve the health and welfare of dairy cows. 
 
Therefore, in Chapter 2.1 I characterised the regulation of inflammatory mediator expression 
in bovine endometrial epithelial and stromal cells in response to an infectious agent (LPS) 
and other pro-inflammatory stimuli (IL-1β and TNFα). Cytokine production was also 
increased in response to the same stimuli. 
 
In Chapter 2.2, I investigated the effect of hypoxia, a known stimulus of exosome release, 
on the cellular function and release of exosomes from bovine endometrial cells. This study 
utilised bovine endometrial intercaruncular stromal cells as the experimental model because 
uterine glands are present in intercaruncular endometrial regions and are known to secrete 
histotroph that is essential for conceptus survival and growth. Hypoxia modulated 
endometrial cell function (cell proliferation, migration, and apoptosis), exosomal release, and 
the proteomic content of exosomes. The differential release of exosomes and changes to 
the proteomic content of exosomes in response to stimuli like hypoxia, could be a crucial 
step during implantation, particularly in maternal-fetal crosstalk and placental development. 
 
Overall I have investigated and confirmed the responsiveness of bovine endometrial cells to 
an infectious agent (LPS), pro-inflammatory cytokines, and hypoxia to ensure suitability of 
the cells as in vitro model for further studies. 
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Chapter 3: Development of a robust and reproducible method 
for the isolation and enrichment of exosomes from plasma and 
milk from dairy cows. 
 
Overview 
 
The genetic improvement of production traits, like milk yield, is associated with a decrease 
in reproductive efficiency. Reduced fertility in dairy cows is also due to an activated 
inflammatory system responding to infectious and/or immune challenges. The field of 
biomarker discovery has attracted significant research interest as the need for early 
detection of disease (and vulnerability to disease) in dairy cows grows to improve survival 
rates. Similarly, the identification of potential biomarkers relating to fertility traits in dairy 
cows has also attracted more research interest and may help to improve dairy cow survival 
rates. 
 
Exosomes are vehicles of intercellular communication that transport and deliver a large 
cargo of proteins, nucleic acids, and lipids. Exosomes also modulate the functions of target 
cells. The stability, bioactivity, and high targeting specificity of exosomes, along with the 
preservation of the identity and state of their originating cells, has contributed to exosomes 
being investigated as potential diagnostic and/or prognostic biomarkers of disease. 
Encouraging results have already been achieved regarding exosomes as biomarkers. 
 
Chapter 3 includes the development for a robust and reproducible method for the isolation 
and enrichment of exosomes from plasma and milk from dairy cows. In this chapter, some 
approaches for the isolation and enrichment of exosomes were taken and evaluated: 
Chapter 3.1. Exosomes were isolated using differential and buoyant density 
ultracentrifugation from concurrently collected body fluids of dairy cows. 
Chapter 3.2. An exosome enrichment method for bovine plasma: coupling 
ultracentrifugation with size exclusion chromatography. 
Chapter 3.3. A method for the isolation and enrichment of purified bovine milk exosomes. 
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Chapter 3.1 is comprised of the article ‘Characterisation of exosomes from body fluids of 
dairy cows’ submitted to Journal of Animal Science: 
 
Koh, YQ, Peiris, HN, Vaswani, K, Meier, S, Burke, CR, Macdonald, KA, Roche, JR, 
Almughlliq, FB, Arachchige, BJ, Reed, S & Mitchell, MD 2017, 'Characterisation of 
exosomes from body fluids of dairy cows', J Anim Sci, vol. 95, no. 9, pp. 3893-904. 
 
As per the University of Queensland requirements, the submitted version of the manuscript 
is presented herein. However, in order to suit the thesis structure, the formatting of the 
original tables and figures were changed accordingly. The referencing citation numbering 
has also been updated to continue the citation sequence of the previous chapter. 
 
The following statement was adopted from the journal’s policy to acknowledge copyright 
reuse permission:  
Rights retained by ALL Oxford Journal authors 
 The right, after publication by Oxford Journals, to use all or part of the Article and 
abstract, for their own personal use, including their own classroom teaching 
purposes; 
 The right, after publication by Oxford Journals, to use all or part of the Article and 
abstract, in the preparation of derivative works, extension of the article into book-
length or in other works, provided that a full acknowledgement is made to the original 
publication in the journal; 
 The right to include the article in full or in part in a thesis or dissertation, provided that 
this not published commercially; 
 
For the uses specified here, please note that there is no need for you to apply for written 
permission from Oxford University Press in advance. Please go ahead with the use ensuring 
that a full acknowledgment is made to the original source of the material including the journal 
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ABSTRACT 
Exosomes are a specific subpopulation of extracellular vesicles that are widely released by 
cells of different origins with divergent functions that make their way into body fluids that can 
be conveniently sampled. In the current study, we isolated and evaluated exosomes from 
concurrently collected samples of milk, plasma, saliva and urine from a group of 6 pregnant 
Holstein-Friesian dairy cows (aged 7 years, body fluid sampled at 174-203 days gestation). 
The cows had body condition scores of 3.5-5.25 (on a scale of 1-10) and the milk production 
for the season to the time of sampling ranged between 5,118-6,959 kg. The low levels of 
extracellular vesicles in saliva and urine (more than 86% fewer compared to the extracellular 
vesicles in milk and plasma) precluded further detailed evaluation since utility for diagnostics 
was deemed unlikely. In exosomes isolated from milk and plasma, size distribution, 
morphology and the presence of exosome markers was confirmed by nanoparticle tracking 
analysis, electron microscopy and Western blot. In addition, a targeted proteomic approach 
using the quadrupole-ion trap mass spectrometer was also used in the study to screen for 
the exosome marker (e.g. Tumor susceptibility gene 101). Following confirmation of the 
presence of exosomes, the proteomic profiles of milk and plasma exosomes were evaluated 
using information-dependent acquisition-mediated liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). The milk exosomes contain proteins that differed greatly from 
the plasma exosomes, with only eight similar proteins harbored in both the milk and plasma 
exosomes. The milk and plasma exosomes were found to contain proteins (e.g. 
immunoglobulin J chain and α2 macroglobulin) associated with specific biological processes 
and molecular functions. Hence, the fluid of origin required for exosome analysis will be 
dependent upon the specific information needed. In conclusion, isolated exosomes from 
milk and plasma samples collected at the same time point, from the same dairy cows, 
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encapsulated different profiles of proteins associated with different biological processes and 
molecular functions.  
 
Keywords: bovine, milk, plasma, urine, saliva, exosomes  
 
INTRODUCTION 
Exosomes released from cells through exocytosis are known to be mediators of proximal, 
as well as distant, cell-to-cell signalling (Waldenstrom and Ronquist, 2014). Exosomes are 
functional vesicles released into the circulation and body fluids under physiological and 
pathophysiological conditions and are remarkably stable (Sun et al., 2010, Malik et al., 
2013). Higher exosome numbers have been detected in the peripheral circulation in cancer 
(Kim et al., 2005) contributed to in part by the tumor. Higher exosomes were also been 
identified during pregnancy (Orozco et al., 2009) which were in part contributed to by the 
placenta. Placental exosomes can modulate the maternal immune response and mediate 
immune protection of the fetus during normal pregnancy (Delorme-Axford et al., 2013, 
Mincheva-Nilsson and Baranov, 2014) and in major pathologies of pregnancy such as 
preterm birth and preeclampsia (Gilani et al., 2016, Sheller et al., 2016). 
 
Exosomes in circulating blood and other body fluids are a mixed population originating from 
various cells and tissues that can change under physiological or pathological states. Body 
fluids such as milk, blood, urine and saliva have been shown to contain extracellular vesicles 
and exosomes (Yamada et al., 2012, Mitchell et al., 2016, Sharma et al., 2011, Alvarez et 
al., 2012, Conde-Vancells and Falcon-Perez, 2012).  A characterisation of exosomes and 
exosomal content isolated from concurrently collected body fluids from a single animal may 
provide an overall understanding of the physiological status of that animal. This could be 
particularly useful and important for development of biomarkers to identify early functional 
genetic traits and for diagnosing diseases (e.g. mastitis in dairy cows). In this study, we have 
evaluated the utility of measuring exosomes and their cargo from several body fluids (i.e. 
milk, blood, saliva and urine). 
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MATERIALS AND METHODS 
 
Animal model 
Six milliliters of body fluids (e.g. milk, blood, saliva and urine) were concurrently collected 
from a group of 6 pregnant Holstein-Friesian dairy cows (aged 7 years, body fluid sampled 
at 174-203 days gestation). The cows had body condition scores between 3.5-5.25 (on a 
scale of 1-10) and the milk production for the season to the time of sampling ranged between 
5,118-6,959 kg. The animals and management have been described by Waghorn et al. 
(Waghorn et al., 2012) and Macdonald et al. (Macdonald et al., 2014), and the procedures 
for the sample collections was managed by DairyNZ (Hamilton, New Zealand; Table 3.1.1) 
with approval by the Ruakura Animal Ethics Committee (AEC 11385). 
 
Table 3.1.1. Sampling of milk, blood saliva and urine from dairy cows.*  
* All samples were kept on ice immediately after collection until they were aliquoted and 
stored at -80°C. 
Sample type Sample process 
Milk The first few (2-3) squirts of milk that comes out of the cow’s teat were 
discarded, and 10 mL of midstream milk were collected. 
Blood  Blood was drawn from the coccygeal tail vein into an EDTA Vaccutainer 
tube (Greiner Bio-one, Kremsmunster, Austria). The tubes were then 
centrifuged at 1,500 × g for 12 mins at 4°C, and the plasma was stored 
at -80°C. 
Saliva The cotton roll was gently manipulated (using long-handled forceps) 
backward and forward for 20 s between the jaw and cheek of the cow to 
absorb the saliva. The saliva from the cotton roll was collected into a 
collection tube. 
Urine The area directly below the vulva was massaged to stimulate the cow to 
urinate. The midstream urine was then collected into a collection tube. 
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Extracellular vesicle isolation from milk  
Extracellular vesicles (i.e. 100,000 × g pellet) were isolated from milk using a previously 
reported method (Yamada et al., 2013, Munagala et al., 2016), with slight modifications. In 
brief, milk samples (6 mL each) were made up to a total volume of 10 mL with PBS (Gibco, 
Life Technologies, Paisley, Scotland) and centrifuged at 3,000 × g for 15 min at 4°C to 
remove milk fat globules, somatic cells, and cell debris. An equal volume of 0.25 M EDTA 
(pH 7.0) was mixed with the supernatant and incubated for 15 min on ice to precipitate 
casein (Kusuma et al., 2016). The defatted milk samples were subjected to three successive 
ultracentrifugation steps at 12,000 × g for 60 min, 35,000 × g for 60 min, and then at 70,000 
× g for 60 min at 4°C (Beckman, Type 70.1 Ti, Fixed angle ultracentrifuge rotor). The 
supernatant was filtered through 0.22 µm filters and ultracentrifuged at 100,000 × g for 120 
min at 4°C to pellet the extracellular vesicles. The extracellular vesicles were resuspended 
in 500 µL PBS and stored at -80°C until analysis. 
 
Extracellular vesicle isolation from EDTA plasma  
Extracellular vesicles (i.e. 100,000 × g pellet) were isolated from EDTA plasma as described 
previously (Mitchell et al., 2016, Crookenden et al., 2016). In brief, the EDTA plasma 
samples (6 mL each) were made up to a total volume of 10 mL with PBS and ultracentrifuged 
at 2,000 × g for 30 min at 4°C, 12,000 × g for 30 min at 4°C and at 100,000 × g for 75 min 
at 4°C, filtered through a 0.22 μm filter and then ultracentrifuged at 100,000 × g for 120 min 
to pellet the extracellular vesicles. The extracellular vesicles were resuspended in 500 µL 
PBS and stored at -80°C until further analysis. 
 
Extracellular vesicle isolation from saliva  
Extracellular vesicles (i.e. 100,000 × g pellet) from saliva were isolated using methods as 
previously published (Sharma et al., 2011, Zlotogorski-Hurvitz et al., 2015) with slight 
modification. In brief, 6 mL saliva were made up to a total volume of 10 mL with PBS and 
centrifuged at 1,500 × g for 30 min at 4°C to remove cell debris.  The 1,500 × g supernatant 
fluid was centrifuged at 10,000 × g for 30 min at 4°C. The resultant supernatant fluid was 
filtered through a 0.22 μm filter and centrifuged at 100,000 × g for 70 min at 4°C to pellet the 
extracellular vesicles. The extracellular vesicles were resuspended in 500 µL PBS and 
stored at -80°C until further analysis. 
 
70 
 
Extracellular vesicle isolation from urine  
Extracellular vesicles (i.e. 100,000 × g pellet) from urine were isolated using methods as 
previously published (Alvarez et al., 2012, Conde-Vancells and Falcon-Perez, 2012). In 
brief, 6 mL urine were made up to a total volume of 10 mL with PBS and centrifuged at 1,500 
× g for 30 min at 4°C to remove cell debris and then centrifuged at 10,000 × g for 30 min at 
4°C. The resultant supernatant fluid was filtered through a 0.22 μm filter and centrifuged at 
100,000 x g for 70 min at 4°C to pellet the extracellular vesicles. The extracellular vesicles 
were resuspended in 500 µL PBS and stored at -80°C until further analysis. 
 
Exosome isolation from milk and plasma 
Exosomes from milk and plasma were purified and enriched following the isolation of 
extracellular vesicles (i.e. 100,000 × g pellet) described in the previous section. Extracellular 
vesicles from milk and plasma were layered on top of a discontinuous iodixanol gradient 
(OptiPrep, Sigma–Aldrich, Castle Hill, NSW, Australia), which was centrifuged at 100,000 × 
g for 20 h at 4°C (Beckman, Sw41Ti, Swinging-bucket ultracentrifuge rotor). Twelve fractions 
were obtained and diluted in 10 mL PBS (Gibco, Life Technologies). The fractions were 
washed with PBS and ultracentrifuged at 100,000 × g for 2 h at 4°C and the exosomal pellets 
were suspended in 50 µL PBS and stored at -80°C until further analysis. 
 
Nanoparticle tracking analysis  
The nanoparticle tracking analysis was conducted using a NanoSight NS500 instrument 
(NanoSight NTA 3.0 Nanoparticle Tracking and Analysis Release Version Build 0064, 
NanoSight Ltd., Amesbury, United Kingdom) as previously described (Kobayashi et al., 
2014, Koh et al., 2016, Salomon et al., 2014). This method was utilised to determine the 
size distribution and concentration of extracellular vesicles and exosomes of the body fluids. 
 
Western blot analysis  
Proteins from exosomes were extracted using radioimmunoprecipitation assay buffer 
(Sigma–Aldrich). The extracted proteins were incubated for 10 min at 70°C in 20× reducing 
agent (NuPAGE Sample Reducing Agent, Life Technologies Australia Pty Ltd, Mulgrave, 
VIC Australia) and 4× loading buffer (NuPAGE LDS sample buffer, Life Technologies 
Australia Pty Ltd). Electrophoresis was performed on the reduced proteins loaded and 
separated in NuPAGE Novex 4–12% Bis-Tris Gels (Life Technologies Australia PtyLtd., 
Mulgrave, Victoria, Australia). Proteins were transferred to a polyvinyl difluoride (PVDF) 
membrane using the Trans-Blot Turbo system with pre-packed transfer packs and the 7-min 
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protocol (Bio-Rad Laboratories Pty. Ltd., Gladesville, New South Wales, Australia). 
Membranes were blocked for 1 hour in blocking solution (5 g non-fat milk powder and 1 g of 
bovine serum albumin powder in 100 mL of PBS with 0.001% Tween 20 (Sigma Aldrich). 
Membranes were probed with primary rabbit polyclonal antibody anti-cluster of 
differentiation (CD) 63 (1:1000; EXOAB-CD63A-1, System Biosciences, Palo Alto, 
California) and primary goat polyclonal antibody anti-tumor susceptibility gene (TSG) 101 
(1:500; sc-6037, Santa Cruz Biotechnology, Dallas, Texas), followed by secondary anti-
rabbit IgG (1:1000; A0545, Sigma–Aldrich) and secondary donkey anti-goat IgG-
horseradish peroxidase (1:1000; sc-2020, Santa Cruz Biotechnology). SuperSignal West 
Dura-Extended Duration Substrate (Thermo Fisher Scientific, Rockford, Illinois, USA) was 
used to visualise the proteins on X-ray film (Agfa, Mortsel, Belgium) and developed using a 
Konica Minolta SRX-101A processor (Konica Minolta Medical and Graphic Inc., Tokyo, 
Japan).  
 
Transmission electron microscopy 
For electron microscopy analysis, the samples were adsorbed on to a Formvar-coated 
copper grid (ProSciTech, Queensland, Australia) for 2 min, washed briefly in ultrapure water, 
and negatively stained with 1% uranyl acetate. The samples were then viewed using the 
JEOL 1010 transmission electron microscope (JEOL Ltd., Tokyo, Japan) operated at 80kV, 
and images were captured with Olympus Soft Imaging Veleta digital camera (Olympus Soft 
Imaging, Munster, Germany). 
 
Proteomic analysis of milk and plasma exosomes by mass spectrometry 
i) Sample preparation and desalting 
Exosomes (10 µg of protein) in PBS were sonicated to disrupt the exosome membrane and 
expose proteins for proteomic analyses by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). In brief, each of the exosome fractions was resuspended in 50 
mM ammonium bicarbonate and then resuspended with 20 mM dithiothreitol (DTT) in 25 
mM ammonium bicarbonate solution and reduced for 1 h at 65°C. The samples were then 
alkylated in 10 mM iodoacetamide at 37°C in darkness for 60 min. Samples were incubated 
with 1 μg/mL trypsin (Sigma–Aldrich) overnight at 37°C for 18 h and the reaction was 
stopped by the addition of 0.1% formic acid. The samples were combined and desalted 
according to a modified version of the stage tip protocol that we have published using a 3-
mm piece of an Empore C18 (Octadecyl) SPE Extraction Disk (Koh et al., 2016, Mitchell et 
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al., 2016). The eluted peptides were dried in a vacuum centrifuge prior to spectral 
acquisition. 
 
ii) Targeted mass spectrometry approach for the identification of exosome marker 
The digested protein samples were analyzed using an Eksigent 200 MicroLC 
chromatography system coupled with QTRAP® 5500 mass spectrometer (AB Sciex, 
Redwood City, CA). Peptide separation was performed on a HALO™ C18, 2.7µm 5.0 x 
50mm column from Eksigent (Redwood City, CA). The temperature of the column was 
maintained at 40ºC and flow rate was set to 15µL/min. The digested protein samples injected 
onto the column was separated with the following LC gradient; 5% Buffer B to 10% Buffer B 
in 1 min, to 50% Buffer B in 10 min, to 90% Buffer B in 2.5 min, where buffer A was 0.1% 
Formic acid/water and Buffer B was acetonitrile/0.1% formic acid. The column was flushed 
at 90% Buffer B for 2.5 min and brought to initial condition in 0.5 min and re-equilibrated for 
3 min. Analytes (LDQEVAVDKNIELLR, DEELSSALEK) were monitored using electrospray 
ionisation in positive-ion mode with multiple reaction monitoring (MRM) using characteristic 
precursor-product ion transitions of m/z 628.624 >1000.579Da, 855.552Da, 643.414Da and 
560.772 > 747.425Da, 661.268Da, 574.235Da. Parameters for the ion mentoring were set 
as follows:  Spray voltage, 5.5Kv; Curtain gas, 30; ion source gas 1 (GS1), 30; ion source 
gas 2 (GS2), 15; collision-activated dissociation (CAD) gas, medium; ion source 
temperature, 1500°C; entrance potential, 10; collision cell exit potential, 9. Declustering 
potential and collision energy were set to 76.9 and 31.8 Volts for LDQEVAVDKNIELLR, and 
for DEELSSALEK; declustering potential and collision energy were set to 72.0 and 28.0 
volts, respectively. Dwell time for both analytes was set 8 ms. Data processing was 
performed using Analyst software (version 1.6.2., AB Sciex). 
 
iii) Mass spectrometry for the identification of exosomal cargo 
The digested protein samples were analyzed using the TripleTOF® 5600 mass 
spectrometer (ABSciex) coupled to an Eksigent Nano 415 2D LC chromatography system. 
The ChromXP C18-CL TRAP (10 mm × 0.3 µm, 120 Å) and analytical ChromXP C18 
columns (2 µm × 150 mm; 3 µm, 120 Å; Eksigent) were used to separate the digested 
proteins. A 5 µL aliquot of digested material was injected onto the column and separated 
with a linear gradient of 2% to 40% Buffer B for 60 min (Buffer A: 0.1% Formic acid/water; 
Buffer B: acetonitrile/0.1% formic acid), 40 to 65% Buffer B (5 min), 65 to 95% Buffer B (5 
min), with a flow rate of 300 nL/min.  The column was flushed at 95% buffer B for 9 min and 
re-equilibrated with 2% Buffer B for 10 min. The in-depth proteomic analysis was performed 
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using the information-dependent acquisition experiments on the TripleTOF® 5600 System 
interfaced with a nanospray source.  The source parameters were as follows: Curtain gas 
value was 25 (arbitrary units).  A 250 ms accumulation time was set for the Time-of-flight 
mass spectrometry (TOFMS) survey scan, and from this scan, the 40 most intense precursor 
ions were selected automatically for the MS/MS analysis (accumulation time of 50 ms per 
MS/MS scan). 
 
Protein identification was determined using the ProteinPilot™ Software (version 4.5 beta, 
AB Sciex) with the Paragon algorithm and against UniProt, containing all proteins from Bos 
taurus. The search parameters were as follows: sample type, identification; cys alkylation, 
iodoacetamide; digestion, Trypsin; Instrument, TripleTOF 5600; special factors, none; and 
ID focus, biological modifications. False discovery rate (FDR) was selected in the processing 
method, which automatically sets the detected protein threshold to 0.05 (10%). The low 
protein threshold value allows a full range of identifications to be made, therefore providing 
a more comprehensive assessment of the quality of the data.  The data were processed and 
categorised based on the basis of the biological process and molecular function with the 
ontology and pathway analysis using the protein analysis through evolutionary relationships 
tool (PANTHER; http://www.pantherdb.org/) and gene ontology algorithms (Mi et al., 2016). 
 
Statistical analyses 
The statistical analyses were performed using a commercially available software package 
(Prism 6, GraphPad Inc, La Jolla, CA 92037 USA). The numbers of extracellular vesicles 
from milk, plasma, saliva and urine were compared using a nonparametric Kruskal-Wallis 
one-way ANOVA. A Mann-Whitney test was then further used to compare plasma and milk 
extracellular vesicles. The comparison between the numbers of milk and plasma exosomes 
between the pregnant dairy cows (n=6) was analyzed by a Mann-Whitney test. For all tests, 
values of P < 0.05 were considered to be statistically significant, and the data are presented 
as means ± SEM. 
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RESULTS 
 
Measurements of extracellular vesicles in body fluids. 
There were no significant differences observed in the mean size distribution of extracellular 
vesicles between the body fluids (milk (177 ± 4.2 nm) versus plasma (188 ± 5.3 nm) versus 
saliva (221 ± 14.3 nm) versus urine (164 ± 12.2 nm), Figure 3.1.1A). Using a nonparametric 
Kruskal-Wallis one-way ANOVA, the number of extracellular vesicles present in plasma and 
milk was significantly higher than saliva (P < 0.0001, P < 0.05 respectively) and urine (P < 
0.0001, P < 0.0001 respectively) (Figure 3.1.1B). Plasma and milk extracellular vesicles 
were further analyzed using Mann-Whitney test. The extracellular vesicles present in plasma 
were ~3.2 fold higher than the extracellular vesicles present in milk (P < 0.001) (Figure 
3.1.1B). The low level of extracellular vesicles in urine and saliva precluded them from 
further study since insufficient material would be available for subsequent analyses. 
 
Comparison of milk and plasma exosomes from pregnant dairy cows 
The exosomes isolated from the milk and plasma of pregnant dairy cows (n=6) were 
confirmed by Western blot for exosome markers TSG101 and CD63 (Figure 3.1.2A) and 
electron microscopy for a cup shaped morphology (Figure 3.1.2B). The mean size 
distribution (Figure 3.1.2C) of milk exosomes was 113 ± 26.8 nm and the size distribution of 
plasma exosomes was 94 ± 32.8 nm. No statistical differences were observed between the 
number of milk and plasma exosomes. 
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Figure 3.1.1. A relative comparison of extracellular vesicles present in milk, plasma, 
saliva and urine of pregnant dairy cows. (A) Representative measurement of particle-
size distribution (nm) of extracellular vesicles (milk (─), plasma ( ־־  ־ ), saliva (•••) and urine 
( ־·  ־ ). (B) The concentration of the extracellular vesicles present in the four biofluids. Data 
are presented as means ± SEM, n = 6. Differences of * P < 0.05, *** P < 0.001 and **** P < 
0.0001 were considered statistically significant. 
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Figure 3.1.2. Characterisation of milk and plasma exosomes from pregnant dairy 
cows. (A) Representative Western blot for exosome markers: Tumor susceptibility gene 
(TSG) 101 and cluster of differentiation (CD) 63. (B) Representative electron micrograph 
exosome fractions (scale bar = 50 nm). (C) Representative Nanosight (NanoSight Ltd., 
NanoSight NTA 3.0 Nanoparticle Tracking and Analysis Release Version Build 0064, 
Amesbury, United Kingdom) measurement of particle-size (nm) distribution of exosomes 
from milk (─), and plasma ( ־־  ־ ) from pregnant cows. Data are presented as means ± SEM, 
n = 6. 
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Targeted proteomic analysis of TSG101 peptides of milk and plasma exosomes 
In addition, a targeted proteomic approach using the triple quadrupole mass spectrometer 
was used to confirm the presence of TSG101 (Accession number: A3KN51, bovine) in both 
the milk and plasma exosomes. The triple quadrupole mass spectrometer identified two 
TSG101 peptide precursors with at least three transitions that correspond to the targeted 
peptide from both the milk and plasma exosomes. Peptide of TSG101 precursor 
LDQEVAVDKNIELLR (mass selected by the first quadrupole (Q1), 628.624 Da) was 
detected in both the milk and plasma exosomes (Figure 3.1.3A) with three transitions 
(1000.579 Da, 885.552 Da and 643.414 Da) that corresponded to the targeted peptide 
(relative retention time at 5.7 min), with peak area counts at 1.673 x 104, 2.501 x 104, 3.530 
x 104 respectively, from milk exosomes versus 2.409 x 104, 4.900 x 104 and 5.553 x 104, 
respectively from plasma exosomes. The peptide of TSG101 precursor DEELSSALEK 
(mass selected by Q1, 560.772 Da) was also detected in both the milk and plasma 
exosomes (Figure 3.1.3B) with three transitions (747.425 Da, 661.268 Da and 574.235 Da) 
that corresponded to the targeted peptide with peak area counts at 3.319 x 105, 3.935 x 104, 
7.796 x 104, respectively from milk exosomes versus 1.287 x 104, 4.965 x 104 and 6.656 x 
104, respectively from plasma exosomes. 
 
Mass spectrometric analysis of milk and plasma exosomes: proteomic profile. 
Mass spectrometric analysis, with a set false discovery rate (FDR) of 5% for proteins and at 
least two peptides above the 95% confidence area, identified 8 in common proteins present 
in both milk and plasma exosomes; 86 proteins were identified as unique to milk exosomes; 
and 37 proteins were identified as unique to plasma exosomes (Figure 3.1.4A). The data 
were subjected to ontology and pathway analysis using PANTHER and gene ontology 
algorithms and classified accordingly to biological process (Figure 3.1.4B) and molecular 
function (Figure 3.1.4C). In biological process, the clusters identified as unique to milk 
exosomes but not those in plasma exosomes were “developmental process” and 
“reproduction” (Figure 3.1.4B). In molecular functions, the cluster identified as unique to milk 
exosomes but not those in plasma exosomes was “signal transducer activity”. The proteins 
related to “binding” and “catalytic activity” were the greatest recognised in both milk and 
plasma exosomes (Figure 3.1.4C). 
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Figure 3.1.3. Identification of TSG101 in milk and plasma exosomes of pregnant dairy 
cows. (A) Representative spectra of triple quadrupole mass spectrometric detection of 
Tumor susceptibility gene (TSG) 101 precursor (LDQEVAVDKNIELLR, 628.624 Da) and the 
corresponding transitions (1000.579 Da, 885.552 Da and 643.414 Da) of milk and plasma 
exosomes. (B) Representative spectra of triple quadrupole mass spectrometric detection of 
TSG101 precursor (DEELSSALEK, 560.772 Da) and the corresponding transitions (661.268 
Da, 634.341 Da and 574.235 Da) of milk and plasma exosomes. 
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Figure 3.1.4. Proteomic analysis of milk and plasma exosomes of pregnant dairy 
cows. (A) Representative Venn diagram comparison between the common and unique 
proteins of milk and plasma exosomes. (B) Comparison of biological process and (C) 
molecular function using Panther (http://www.pantherdb.org) and Gene Ontology 
algorithms. 
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DISCUSSION 
Extracellular vesicles, particularly exosomes, have a recognised role in intercellular 
signalling through the transfer of bioactive molecules (e.g. proteins, miRNA and mRNA) to 
recipient cells. The transferred miRNA and mRNA may have regulatory roles in gene 
expression such as mediating post-transcriptional gene silencing, which can alter the 
recipient cell protein production and influence the phenotype of the recipient cell (Batagov 
and Kurochkin, 2013, Valadi et al., 2007, Zhang et al., 2015). Exosomes released into the 
extracellular space by various cell types are present in body fluids, including blood, milk, 
saliva and urine. Bioactive molecules in exosomes present in body fluids could provide novel 
potential targets for use as biomarkers for diagnostic and prognostic assessments. In clinical 
settings, plasma has been the most widely used source of body fluid that is used in 
diagnostics and clinical pathology. The reason is because plasma contains specific 
signatures in response to physiological, pathological, and environmental changes 
(Savelyeva et al., 2017, Liew et al., 2006). In an agricultural setting, milk can be used to 
identify certain conditions such as mastitis (Zhao et al., 2015, Verma and Ambatipudi, 2016). 
Milk is also evaluated in the dairy industry for quality and safety for human consumption 
(Vranjes et al., 2015, Oliver et al., 2009).  
 
By analyzing the exosomal content, we can then identify bioactive molecules (e.g. proteins, 
mRNA and miRNA) that are encapsulated within the exosome, and therefore, potential 
intercellular mediators can be measured. The potential benefit of proteomic analysis of 
exosomes from milk and plasma is that lower abundant proteins can be detected within the 
exosomes that in whole milk and blood may be masked by abundant proteins such as α-
lactalbumin in whole milk or apolipoprotein in whole plasma. By restricting the more 
abundant proteins and by analyzing the exosomal content, we can then identify bioactive 
molecules (e.g. proteins, mRNA and miRNA) encapsulated within the exosome, which could 
potentially be a novel biomarker.  
 
In our study, we describe the successful isolation of extracellular vesicles from bovine 
samples of plasma, milk, saliva and urine. Milk and plasma were found to contain sufficiently 
high concentrations of extracellular vesicles to warrant isolating exosomes and examining 
the proteins encapsulated within them. The protein content within the exosomes of these 
two fluids was found to be markedly different, logically reflecting the cellular functions that 
are unique to or have priority in the udder compared with those that may be represented 
within the general circulation. 
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We did not investigate further the saliva and urine exosomes because of the relatively low 
yield of extracellular vesicles obtained compared to those of milk and plasma. A larger 
volume of starting material may overcome some of these difficulties when using the 
differential ultracentrifugation method for exosome isolation from saliva and urine samples. 
However, the recovery for a larger amount of content (e.g. miRNA) may vary (Kim et al., 
2012) because of the inherent differences in biological samples as well as the approach 
used to collect and isolate them. Nevertheless, larger starting volumes are unlikely to be 
acceptable for routine and robust diagnostics. We believe that this precludes their utility in 
diagnostic approaches and thus did not merit further investigation. 
 
The milk and plasma exosomes were characterised by their morphology, size distribution 
and the presence of exosome markers, including TSG101 and CD63, which are described 
as the classical markers of exosomes in most of the published literature (Kalra et al., 2016, 
Villarroya-Beltri et al., 2016). In addition to the standard characterisation method, we applied 
a targeted screening approach by mass spectrometry. The triple quadrupole mass 
spectrometer was utilised to validate the presence of TSG101 in both milk and plasma 
exosomes. Two TSG101 peptide precursors with at least three transitions that correspond 
to the targeted peptide were identified by the triple quadrupole mass spectrometer, 
suggesting that targeted proteomics applications can be an alternative approach for 
screening exosome markers from body fluids (e.g. milk and blood plasma). 
 
Mass spectrometric analysis of the exosomal cargo revealed that only eight proteins were 
common in both milk and plasma exosomes. Immunoglobulin J chain and α2 macroglobulin 
were present in both milk and plasma exosomes, and are involved in immune system 
processes. Immunoglobulin J chain is one of the key proteins in immunologic defense 
(Johansen et al., 2000). The J chain is a highly conserved polypeptide (Zikan et al., 1985), 
which is essential structural requirement for polymeric immunoglobulins to provide secretory 
antibodies with high avidity (Della Corte and Parkhouse, 1973, Johansen et al., 2000). α2 
macroglobulin is induced during gestation by reproductive tissues including mammary 
gland, uterus, ovary and conceptus (He et al., 2005, Tayade et al., 2005). α2 macroglobulin 
is hypothesised to be involved in the endosomal pathways  and, depending on its 
conformation (native or transformed), can function as a protease inhibitor and as a molecular 
chaperone (Borth, 1994). Future studies of these proteins may be possible using either milk 
or plasma to further evaluate their conformation and regulatory functions.  
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In our studies, we identified 45 proteins in plasma exosomes, and PANTHER gene ontology 
analysis (Mi et al., 2016) reported that these proteins were mainly involved in biological 
processes (e.g. cellular process (22.5%), immune system process (20.0%) and response to 
stimulus (15.0%)), suggesting plasma exosomes in the circulation may be mainly derived 
from immune cells and have a possible role in modulating the immune system. 
 
Proteomic profile of milk exosomes revealed 94 proteins, most notably κ-casein, xanthine 
dehydrogenase/oxidase, lactadherin, butyrophilin subfamily 1, member A1 protein. These 
findings are in agreement with previous mass spectrometric analyses on bovine milk 
exosome proteome (Reinhardt et al., 2012). The protein diversity in milk exosomes could be 
derived from various cells in the milk compartment, such as immune cells and the secretory 
epithelia (Reinhardt et al., 2012). 
 
The κ-casein present was one of the most abundant proteins within milk exosomes. Through 
the PANTHER classification system (Mi et al., 2016), κ-casein was reported to be involved 
in a number of biological processes, including biological regulation, developmental 
processes, localisation, metabolic process, the multicellular organismal process, and 
reproduction. The genetic variants of κ-casein have been evaluated in several studies 
conducted in cows and sheep (Hallen et al., 2008, Djedovic et al., 2015, Yousefi et al., 2013) 
with significant effects described on the composition of milk components. Another study 
showed that deletion of the κ-casein gene in mice completely abrogates the ability for the 
females to lactate and suckle their pups because of blockage of the alveolar lumen and the 
mammary gland ducts by the protein aggregates, hence leading to perinatal death (Shekar 
et al., 2006). Similar studies have also reported the importance of κ-casein and its 
association with reproductive performance (Tsiaras et al., 2005, Lin et al., 1987, Bolet et al., 
2007, Bosze et al., 2000). 
 
In conclusion, our study highlights the potential benefits of using certain body fluids, in 
particular milk and plasma (from volumes as low as 6 mL) for use as a non-surgical biological 
source over saliva and urine, especially when higher volumes are difficult to obtain. Our data 
underscore that exosomes have a common group of proteins related to their biogenesis and 
they also harbor specific proteins that reflect the origin and biological functions of their 
parental cells. Moreover, these proteins are associated with different biological processes 
and molecular functions, suggesting the content (e.g. proteins) encapsulated within the 
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exosomal cargo may contain a snapshot of the condition of the parental cell. The findings 
could be expanded further to include detailed analyses of a full spectrum of molecular 
analytes (e.g. lipids and miRNAs profile) in exosomes from cow body fluid. Their utility for 
diagnostic and prognostic purposes to unravel important biological signals that reflect the 
cellular origin and organ type (e.g. mastitis of the udder) could aid a thorough and 
comprehensive assessment of the disease. 
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In Chapter 3.1, exosomes were isolated from the milk and plasma from dairy cows using 
differential and buoyant density ultracentrifugation. These technique were chosen because 
differential and buoyant density ultracentrifugation, using OptiprepTM or sucrose cushions to 
separate exosomes based on density, remain the gold standard and is most commonly used 
and reported techniques for exosome enrichment from EVs. However, there are limitations 
associated with these techniques including the amount of time required to perform these 
techniques, cost, and highly variable exosome yield (due to user variability and the 
successive washing and pelleting steps). Hence, there is a need to further optimise the 
techniques used to isolate and enrich exosome from different body fluids to ensure that 
exosome isolation will be suitable and applicable for routine and robust diagnostic and 
prognostic purposes. 
 
In chapter 3.2, Fatema B Almughlliq and I evaluated the following four methods for the 
enrichment of exosomes from dairy cow plasma: the direct use of size exclusion 
chromatography (SEC) for the isolation of exosomes (Method I); SEC coupled to 
ultracentrifugation (UC) (Method II); pre-processing of plasma with EDTA prior to UC 
coupled with SEC (Method III); and pre-processing of plasma with thrombin prior to UC 
coupled with SEC (Method IV). Exosomes were characterised using the following analyses: 
nanoparticle tracking analysis (NTA) was used to determine particle number; bicinchoninic 
acid assay (BCA) was used to estimate protein concentration; immunoblotting (Western blot) 
was used to indicate the presence of exosomal markers; and transmission electron 
microscopy (TEM) was employed to visualise morphology. These analyses were performed 
based on the requirements described by Witwer et al. and Lotvall et al. (Witwer et al., 2013, 
Lotvall et al., 2014). 
 
Chapter 3.2 is comprised of the article ‘Exosome enrichment by ultracentrifugation and size 
exclusion chromatography’ submitted to Frontiers in Bioscience and I am joint-first author 
on this publication with Fatema B Almughlliq: 
 
Koh, YQ, Almughlliq, FB, Vaswani, K, Peiris, HN & Mitchell, MD 2018, 'Exosome enrichment 
by ultracentrifugation and size exclusion chromatography', Front Biosci (Landmark Ed), vol. 
23, pp. 865-74. 
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Chapter 3.2: Exosome enrichment by ultracentrifugation and size 
exclusion chromatography 
Yong Qin Koh, Fatema B. Almughlliq, Kanchan Vaswani, Hassendrini N. Peiris, Murray D. 
Mitchell 
University of Queensland Centre for Clinical Research, The University of Queensland, 
Brisbane, Queensland, 4029, Australia. 
 
ABSTRACT 
Exosomes are a subset of extracellular vesicles (EVs) that have important roles in 
intercellular communication. They contain and carry bioactive molecules within their 
membranes which are delivered to target cells. Reproducible isolation and enrichment of 
these exosomes will aid in evaluation of cellular communication. We present an approach 
that involved the pre-processing of plasma, combined with ultracentrifugation (UC) and size 
exclusion chromatography (SEC) to isolate EVs and subsequently enrich exosomes. Four 
variations of this approach (denoted methods I to IV) were compared. Coupling an 
ultracentrifugation method with size exclusion chromatography (Method II) provided the best 
yield by nanoparticle tracking analyses (NTA), the presence of the exosomal markers CD63, 
Flotillin-1 and TSG101 (immunoblotting) and showed exosome morphology using 
transmission electron microscopy (TEM). This method provides an efficient way to enrich 
the exosomes from blood (plasma), which could be potentially employed for clinical 
diagnostic assessment and therapeutic intervention. 
 
Keywords: Extracellular vesicles, Plasma, Exosomes, Ultracentrifugation, Size exclusion 
chromatography, Bovine 
 
INTRODUCTION 
Over the last two decades, extracellular vesicles (EVs) have been studied intensely due to 
their functional roles in intercellular communication, such as the shuttling of nucleic acids 
between cells and regulation of information carried to target cells (Pegtel et al., 2014). EVs 
constitute a group of vesicles including microvesicles, ectosomes, exosomes, shedding 
vesicles and microparticles (Raposo and Stoorvogel, 2013). 
 
Exosomes, are secreted vesicles of endocytic origin in the size range of 30-120 nm 
(Camussi et al., 2010, Thery et al., 2002) that encapsulate bioactive molecules (e.g. 
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proteins, nucleic acids and lipids) and are released into body fluids including blood by 
different cell types (e.g. tumor cells, placental cells and immune cells) (Bard et al., 2004, 
Toth et al., 2007, Skokos et al., 2003). Numerous studies have demonstrated the dynamic 
cell-cell communication mediated by exosomes (Chen et al., 2016, Huang et al., 2015, 
Kosaka et al., 2013). The uptake of exosomes by target cells may dynamically modulate 
cellular activities of recipient cells. The discovery of exosome mediated intercellular 
communication has spurred further research interest on exosomes for diagnostic and 
prognostic assessment of disease states as well as their potential for therapeutic 
intervention, such as targeted drug delivery systems (Lenassi et al., 2010, Alvarez-Erviti et 
al., 2011b, Fevrier et al., 2004). 
 
Several methodologies exist to isolate and analyse EVs and the definition of an EV varies 
across different research groups (Witwer et al., 2013).The current methods for exosome or 
EV isolation include ultracentrifugation or commercial vesicle precipitation kits (Lotvall et al., 
2014). A major concern in the clinical utilisation of exosomes is that the separation of 
exosomes from EVs and other non-vesicular entities (e.g. apoptotic bodies), cannot be fully 
achieved by these commonly used isolation techniques (Livshits et al., 2015, Lotvall et al., 
2014). The composition of recovered EVs also varies vastly according to the isolation 
protocol being used. Ultracentrifugation alone, cannot achieve absolute separation of 
exosomes due to co-sedimentation of vesicles and other macromolecules (Livshits et al., 
2015, Witwer et al., 2013). Ultracentrifugation followed by differential gradient centrifugation, 
which separates vesicles based on density (e.g. OptiprepTM or sucrose cushions) is the 
current gold standard for exosome enrichment from EVs (Thery et al., 2006, Momen-Heravi 
et al., 2013). This approach, is time consuming, costly and exosome yields are highly 
variable (due to user variability). Moreover, the successive washing and pelleting steps 
result in a reduction in exosome yield. 
 
In this study, we compared the (Method I) direct use of size exclusion chromatography (SEC) 
for the isolation of exosomes with (Method II) using ultracentrifugation (UC) coupled to the 
enrichment of exosomes using size exclusion chromatography (SEC) and (Methods III and 
IV) the pre-processing of plasma prior to UC for the isolation of EVs coupled with SEC. The 
exosomes are characterised by nanoparticle tracking analysis (NTA) for particle number, 
bicinchoninic acid assay (BCA) for protein concentration, immunoblotting (Western blot) for 
presence of exosomal markers and transmission electron microscopy (TEM) for morphology 
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based on the requirement described by Witwer et al. and Lotvall et al. (Witwer et al., 2013, 
Lotvall et al., 2014). 
 
MATERIALS AND METHODS 
Animal samples (blood plasma) 
Blood from dairy cows was obtained and pooled. The procedures for plasma collection were 
managed by DairyNZ with the approval by the Ruakura Animal Ethics Committee (AEC 
13927). The plasma collected was pooled. 10mL of the pooled plasma was utilised for each 
exosome enrichment method II, III and IV (Figure 3.2.1), except for method I, which utilised 
500µL of pooled plasma, as per manufacturer’s instruction. 
 
 
Figure 3.2.1. Comparison of the four exosome enrichment methods. Method I: qEV 
column to enrich exosomes from bovine plasma using size exclusion chromatography (SEC) 
only. Method II: ultracentrifugation (UC) to isolate bovine plasma extracellular vesicles (EVs) 
followed by the enrichment of exosomes through SEC. Method III: 
ethylenediaminetetraacetic acid (EDTA) pre-treated bovine plasma processed by UC and 
followed by SEC. Method IV: thrombin pre-treated bovine plasma processed by UC and 
followed by SEC. 
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Plasma processing 
Method I: Plasma preparation for size exclusion chromatography (plasma + SEC) 
The pooled plasma (500µL) was centrifuged at 2,000 × rcf for 30 min at 4 °C to remove 
debris. The enrichment of exosomes continued using size exclusion chromatography (refer 
to the next section on Exosome enrichment using size exclusion chromatography (SEC)). 
 
Method II: Plasma preparation for extracellular vesicles isolation by ultracentrifugation 
(plasma + UC + SEC) 
Extracellular vesicles were isolated from 10mL pooled plasma by successive differential 
centrifugation steps at 2,000 × rcf for 30 min and 12,000 × rcf for 30 min at 4 °C. The 
supernatant was filtered through a 0.22-μm filter (Corning Costar) and ultracentrifuged at 
100,000 × rcf for 2 h at 4 °C (Beckman, Type 70.1 Ti, Fixed angle ultracentrifuge rotor). The 
pellet was reconstituted in 500µL phosphate-buffered saline (PBS; Gibco) and the 
enrichment of exosome continued using size exclusion chromatography (refer to the next 
section on Exosome enrichment using size exclusion chromatography (SEC)). 
 
Method III: EDTA treated plasma preparation for extracellular vesicles isolation by 
ultracentrifugation (EDTA treated plasma + UC + SEC) 
The pooled plasma (10mL) was centrifuged at 2,000 × rcf for 15 min at 4°C to remove debris. 
An equal volume of 0.25M ethylenediaminetetraacetic acid (EDTA; Sigma–Aldrich) at pH 7 
was added to the samples and incubated for 15 min on ice. The sample was further 
centrifuged at 12,000 × rcf for 60 min, 35,000 × rcf for 60 min and then 70,000 × rcf for 60 
min at 4°C (Beckman, Type 70.1 Ti Fixed angle ultracentrifuge rotor) the pellet was 
discarded at each step. The supernatant was filtered through a 0.22-μm filter (Corning 
Costar) and centrifuged at 100,000 × rcf for 2 h at 4 °C (Beckman, Type 70.1 Ti, Fixed angle 
ultracentrifuge rotor). The pellet was reconstituted in 500µL PBS and the enrichment of 
exosome continued using size exclusion chromatography (refer to the next section on 
Exosome enrichment using size exclusion chromatography (SEC)). 
 
Method IV: Thrombin treated plasma preparation for extracellular vesicles isolation by 
ultracentrifugation (thrombin treated plasma + UC + SEC) 
10 mL pooled plasma was centrifuged at 2,000 × rcf for 30 min and 12,000 × rcf for 30 min 
at 4 °C. Bovine thrombin (T7153, Sigma–Aldrich) was added to the supernatant (1:100) and 
incubated for 5 min at room temperature. The sample was centrifuged 12,000 × rcf for 30 
min at 4 °C, filtered through a 0.22-μm filter (Corning Costar) and centrifuged at 100,000 × 
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rcf for 2 h at 4 °C (Beckman, Type 70.1. Ti, Fixed angle ultracentrifuge rotor). The pellet was 
reconstituted in 500µL PBS and the enrichment of exosome continued using size exclusion 
chromatography (refer to the next section on Exosome enrichment using size exclusion 
chromatography (SEC)). 
 
Exosome enrichment using size exclusion chromatography (SEC) 
The processed plasma (method I) and EVs obtained from method II, III and IV were loaded 
on top of qEV size exclusion columns (Izon Science, Christchurch, New Zealand) followed 
by elution with PBS. 500µL fractions were collected in separate tubes (a total of 16 tubes), 
as per manufacturer’s instructions. The 16 fractions were concentrated using a vacuum 
concentrator (Eppendorf Concentrator Plus) for 1.5 h at room temperature and stored at -
80ÂºC until further analyses. 
 
Nanoparticle tracking analysis (NTA) 
NTA measurements were performed using a NanoSight NS500 instrument (NanoSight NTA 
3.0. Nanoparticle Tracking and Analysis Release Version Build 0064). This was used to 
determine the concentrations of particles. 
 
Protein quantification 
Protein concentration of each exosomal fractions (method I-IV) was determined by a 
bicinchoninic acid (BCA) assay using the bicinchoninic acid reagent kit from Sigma–Aldrich 
and bovine serum albumin standards (Peiris et al., 2014). 
 
Immunoblotting (Western blot) 
10 µg of exosomes (as determined by BCA) were incubated for 10 min at 70°C in reducing 
agent (NuPAGE Sample Reducing Agent, Life Technologies Australia Pty Ltd) and loading 
buffer (NuPAGE LDS sample buffer, Life Technologies Australia Pty Ltd). The reduced 
proteins were electrophoresed on NuPAGE Novex 4–12% Bis-Tris Gels (Life Technologies 
Australia Pty Ltd). The gel was transferred onto a polyvinylidene fluoride (PVDF) membrane 
(Bio-Rad Laboratories Pty Ltd, Australia) using the Trans-Blot Turbo system. Membranes 
were blocked for 1 hour in 2% BSA blocking solution and probed overnight with primary 
antibody; anti-Flotillin-1 (ab13493, Abcam), anti-CD63 (ab213092, Abcam) and, anti-
TSG101 (sc7964, Santa Cruz Biotechnology) at 4°C, followed by secondary antibody; anti-
rabbit IgG (A0545, Sigma–Aldrich), anti-mouse IgG (18765, Sigma–Aldrich) and anti-goat 
(sc-2020, Santa Cruz Biotechnology). The targeted proteins were visualised with 
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SuperSignal West Dura-Extended Duration Substrate (Thermo Fisher Scientific) on X-ray 
films using Konica SRX101A processor (Konica Minolta medical and graphic INC, Japan). 
 
Transmission electron microscopy (TEM) 
5uL of enriched exosomes were added onto formvar coated copper grids for 2 min, then 
briefly washed in ultrapure water and negatively stained with 1% uranyl acetate. The 
samples were than visualised using the JEOL 1010 transmission electron microscope 
operated at 80kV, and images were captured using an Olympus Soft Imaging Veleta digital 
camera. 
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RESULTS 
Nanoparticle tracking analysis (NTA) 
Fractions 1-16 from each enrichment method (I–IV) were analysed using a Nanosight NS-
300 system to determine particle density and size range. Particle numbers were negligible 
in fraction 1 to 6 for all the methods (method I-IV, Figure 3.2.2A-D), corresponding with the 
column void volume as described in the manufacturer’s instructions. Fractions 7-16 for 
each method showed variable number of exosomes (method I-IV, Figure 3.2.2A-D). 
Method II had the highest yield of 8.2.5 x 1011 particles per mL (Table 3.2.1). 
 
 
Figure 3.2.2. Concentration (particles per mL) of fractions 1–16 following the 
isolation and enrichment of bovine plasma exosomes using (A) methods I (○) size 
exclusion chromatography only, (B) method II (●) coupling ultracentrifugation (UC) 
followed by size exclusion chromatography (SEC), (C) method III (Δ) 
ethylenediaminetetraacetic acid (EDTA) pre-treated bovine plasma processed by UC and 
followed by SEC and (D) method IV (□) thrombin pre-treated bovine plasma processed by 
UC and followed by SEC. 
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Table 3.2.1. Particle yields (method I-IV) from nanoparticle tracking analysis (NTA) 
Methods for exosome enrichment Particle yields obtained from 
NTA (particles per mL) 
Method I: plasma + size exclusion chromatography 4.73. x 1011 
Method II: plasma + ultracentrifugation + size 
exclusion chromatography 
8.25 x 1011 
Method III: EDTA treated plasma + 
ultracentrifugation + size exclusion 
chromatography 
4.04 x 1011 
Method IV: thrombin treated plasma + 
ultracentrifugation + size exclusion 
chromatography 
6.24 x 1011 
 
Protein quantification 
The protein concentration were determined for all fractions (method I-IV) using BCA assay 
(Figure 3.2.3A-D). An increase in protein concentration was observed from fraction 9 
through to fraction 16 across all the methods. This trend was similar across methods II-IV, 
while method I showed a greater increase in protein concentration from fraction 14-16. 
 
Figure 3.2.3. Protein concentration (μg/ml) of the 16 fractions by bicinchoninic acid 
(BCA) assay following the isolation and enrichment of bovine plasma exosomes using (A) 
methods I (○) size exclusion chromatography only, (B) method II (●) coupling 
ultracentrifugation (UC) followed by size exclusion chromatography (SEC), (C) method III (
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Δ) ethylenediaminetetraacetic acid (EDTA) pre-treated bovine plasma processed by UC 
and followed by SEC and (D) method IV (□) thrombin pre-treated bovine plasma 
processed by UC and followed by SEC. 
Immunoblotting (Western blot) 
Flotillin-1 was consistently identified in the fractions 12-16 (method I-IV, Figure 3.2.4A-D). 
Further immunoblotting analyses for exosomal markers CD63 and TSG101 were carried 
out for method II. Both CD63 (Figure 3.2.5A) and TSG101 (Figure 3.2.5B) were detected 
in the fractions 11-16. 
 
 
Figure 3.2.4. Immunoblots for exosomal marker Flotillin-1 (49kDa) for SEC fractions 
5–16 for methods (I-IV); each lane depicts a separate fraction. “+” represents a positive 
control. Each gel includes a protein size ladder. (A) method I: size exclusion 
chromatography only (SEC), (B) method II: ultracentrifugation (UC) followed by size 
exclusion chromatography (SEC), (C) method III: ethylenediaminetetraacetic acid (EDTA) 
pre-treated bovine plasma processed by UC and followed by SEC. (D) method IV: 
thrombin pre-treated bovine plasma processed by UC and followed by SEC. 
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Figure 3.2.5. Immunoblots for exosomal markers (A) CD63 (26kDa) and (B) TSG101 
(45kDa) on fractions 4–16 obtained after size exclusion chromatography following Method 
II. Exosomal fractions 11–16 display a bands specific (in size) for both markers. Each gel 
includes a protein size ladder. 
 
Transmission electron microscope (TEM) analyses 
The enriched exosomes (method II) displayed a cup-shaped morphology by TEM (Figure 
3.2.6). 
 
Figure 3.2.6. Representative transmission electron microscopy of exosome 
morphology. Scale bar 100 nm. 
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DISCUSSION 
Exosomes are specific subset of extracellular vesicles that originate from the endosomal 
membrane cell compartment. They encapsulate selectively sorted bioactive molecules (e.g. 
proteins, lipids, and nucleic acids), and are released into the extracellular environment 
through fusion of multivesicular bodies with the cell plasma membrane. Exosomes can be 
transported through body fluids (e.g. blood) and mediate communication between 
neighbouring and/or distant cells by delivering encapsulated bioactive molecules to recipient 
cells. Owing to their vital role in cell-to-cell communication, exosomes are known to be 
involved in physiological and pathological processes such as tumor development (Yu et al., 
2007), pregnancy (Jessica et al., 2010) and immunomodulation (Li et al., 2006). Exosomes 
have the potential to be used in diagnostic and prognostic tests for disease and to be used 
in therapeutic interventions. A challenge for clinical application is the inability to efficiently 
and reproducibly isolate exosomes, due in part to a lack of a well-defined rigorous isolation 
protocol. 
 
There are many different techniques and commercial kits available for exosome isolation, 
and one has to take into account the additional workload, time, cost and most importantly 
reproducibility when considering which approach is suitable. No existing exosome isolation 
method has been accepted as universally appropriate, and the advantages and 
disadvantages of the most widespread methods have previously been discussed (Li et al., 
2017). The choice of approach for exosomes isolation is also dependent on the source 
matrix, due to the inherent differences in composition and complexity of body fluids (Witwer 
et al., 2013). Furthermore, species differences may exist in the composition of body fluids, 
including blood plasma (Yu and Ledeen, 1972, Poor et al., 2014) and milk (Yang et al., 
2017). Therefore, careful consideration of EV/exosome isolation methods must be taken into 
account, as this may have the potential to affect downstream experimentation. 
Ultracentrifugation followed by differential gradient centrifugation using OptiprepTM or 
sucrose cushions, which separates vesicles based on density remains the gold standard for 
exosome enrichment from EVs (Thery et al., 2006, Momen-Heravi et al., 2013). The 
limitations of using this approach, however, is that it is time consuming, and expensive. 
Moreover, there exists tremendous user variation in the quantity and quality of exosomes 
isolated, making the reproducibility of exosome isolation for this method poor. Importantly 
there is a reduction in exosome particle yield after several washing and pelleting steps. 
In this study, we evaluated four methods for the enrichment of exosomes. The best approach 
as determined by the requirements for exosome isolation as described by Witwer et al. and 
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Lotvall et al. (Witwer et al., 2013, Lotvall et al., 2014) coupled ultracentrifugation (to first 
isolate the EVs) with the subsequent enrichment of exosomes by size exclusion 
chromatography (Method II). The approach provided the most consistent yield of blood 
plasma exosomes based upon the particle yield, presence of exosome markers and 
exosome morphology. The initial step for ultracentrifugation discussed by Thery et al. (Thery 
et al., 2006), enables the removal of dead cells, some proteins and macromolecules and 
other contaminating debris. However, ultracentrifugation alone will not remove all soluble 
proteins (Muller et al., 2014). The direct isolation of exosomes through size exclusion 
chromatography (e.g. qEV column) have been demonstrated to separate exosomes from 
soluble contaminants with high efficiency (Boing et al., 2014, Lobb et al., 2015). However, 
the design of the qEV column only allows loading of a 500µL maximum sample size. The 
maximum capacity of the size exclusion chromatography column limits its scalability for high 
throughput applications. The use of an initial ultracentrifugation-based step for the 
enrichment of EVs also allows the ability to process a higher volume of the starting material, 
and therefore to achieve greater exosome yield. The subsequent use of the size exclusion 
chromatography column enables efficient removal of soluble proteins and other 
contaminants, hence enriching specifically for exosomes. This approach demonstrated 
decreased user variability and the time required for exosome enrichment as well as 
improved yield and reproducibility. This approach may also be useful for the enrichment of 
exosomes from other types of body fluids such as milk, saliva and urine. 
 
We further investigated the pre-treatment of the bovine plasma with anticoagulants to 
evaluate if the addition of an anticoagulant step would provide a better yield and/or purity of 
exosomes. To date, the choice of which anticoagulant is most effective for utility in 
EVs/exosomes study is unclear (Baek et al., 2016). In this study, bovine plasma was either 
treated with EDTA which chelate calcium (Wisgrill et al., 2016, Stewart et al., 2016), an 
important co-factor for blood clot or thrombin which can facilitate the removal of fibrinogen 
(Lobb et al., 2015) prior to EVs/exosomes isolation. No differences in yield were observed 
with the addition of an anticoagulant pre-treatment step. This may be due to the loss 
attributed to the additional ultracentrifugation steps required for the processing of the 
anticoagulant treated plasma. 
Clinical exosome based applications especially for clinical diagnostics requires a time-
efficient, reproducible and robust method. Our approach (method II) which couples 
ultracentrifugation with size exclusion chromatography enables the use of a greater starting 
volume for exosome isolation, is highly reproducible, time-efficient and can provide a greater 
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yield. This method provides an efficient way to enrich the exosomes from blood (plasma), 
which could be employed in clinical diagnostic assessment and potentially therapeutic 
intervention. 
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Chapter 3.2 focused on the development of a robust and reproducible method for the 
isolation and enrichment of exosomes from plasma. Coupling UC with SEC (Method II) 
provided a faster way to isolate exosomes from plasma. This method was also highly 
reproducible and produced the best exosomal yield (as determined by NTA). 
 
Chapter 3.3 focuses on the development of a robust and reproducible method for the 
isolation and enrichment of exosomes from bovine milk. It must be noted that due to the 
differences in composition of body fluids, the sample preparation methodology used to 
achieve optimum isolation and enrichment of exosomes from bovine milk was different to 
the method developed for the isolation and enrichment of exosomes from plasma. 
 
Chapter 3.3 is comprised of the article ‘A method for the isolation and enrichment of purified 
bovine milk exosomes’ submitted to Reproductive Biology and I am joint-first author on this 
publication with Kanchan Vaswani: 
 
Vaswani, K, Koh, YQ, Almughlliq, FB, Peiris, HN & Mitchell, MD 2017, 'A method for the 
isolation and enrichment of purified bovine milk exosomes', Reprod Biol, vol. 17, no. 4, pp. 
341-8. 
 
As per the University of Queensland requirements, the submitted version of the manuscript 
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original tables and figures were changed accordingly. The referencing citation numbering 
has also been updated to continue the citation sequence of the previous chapter. 
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ABSTRACT 
Exosomes are nanovesicles that play important roles in intercellular communication as they 
carry information to target cells. Isolation of high purity exosomes will aid in studying the 
exosomal cargo and quantity as well as how cell-specific messages are carried. We describe 
a new method incorporating size exclusion chromatography (SEC) to enrich milk-derived 
exosomes from extracellular vesicles (EVs). This involved the initial isolation of EVs from 
bovine milk via milk processing and ultracentrifugation; followed by a new method to enrich 
exosomes using SEC. This method was compared to buoyant density gradient 
centrifugation, a widely used method of enrichment. Exosomes were characterised by 
particle concentration and size (nanoparticle tracking analysis, NTA), morphology 
(transmission electron microscopy, TEM), presence of exosomal markers (immunoblotting) 
and protein concentration (bicinchoninic acid assay, BCA). Proteomic profiles of exosomal 
fractions were analyzed by mass spectrometry using Information Dependant Acquisition. 
Milk exosomal fractions were shown to contain exosomal markers Flotillin-1 and tumor 
susceptibility gene 101 (TSG101). The new method produced a higher yield of exosomes 
compared to buoyant density gradient centrifugation. Pooled exosomal fractions exhibited 
intact morphology by TEM. The use of SEC confirmed the fractionation of exosomes based 
on size while minimizing the interference with proteins. Tetraspanins CD9 and CD81 were 
observed via mass spectrometry in exosomal fractions. This new and efficient method 
confirmed the signatures for exosomes derived from unpasteurised bovine milk. Purification 
of exosomes is a foundational technique in the study of biomarkers for pathological 
conditions and effective drug delivery systems. 
 
Keywords: Extracellular Vesicles, Milk, Exosomes, Biomarker, Delivery System, Bovine 
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INTRODUCTION 
Exosomes, a subtype of extracellular vesicles (EVs), are currently being studied in different 
biological fluids such as plasma, saliva and milk (Foster et al., 2016). These studies aim to 
understand the roles of exosomes in the mechanisms underlying many diseases and identify 
potential candidate biomarkers for early detection of disease. Improving the purity of the 
exosomes isolated is essential for the integrity of biomarker and miRNA analysis and 
furthering the use of exosomes as drug delivery systems (Rekker et al., 2014). A number of 
laboratories are trying to isolate exosomes reproducibly, using diverse published techniques 
(Yamada et al., 2012, Munagala et al., 2016, Lobb et al., 2015, Van Deun et al., 2014, 
Welton et al., 2015, Yamada et al., 2013). However, the purity of the exosomes isolated is 
highly variable due to the presence of contaminating particles, vesicles and molecules such 
as proteins and/or nucleic acids and other cellular components (Baranyai et al., 2015, 
Welton et al., 2015, Ni-Ting and Ansel, 2016). Minimizing contamination in the isolation of 
exosomes is vital in providing reliable information upon which to base new paradigms. 
Hence, there is a need for an efficient and robust method by which enriched populations of 
exosomes can be obtained. The enriched exosomes need to be well characterised and 
validated prior to subsequent studies (Witwer et al., 2013, Lotvall et al., 2014). 
 
There are several commercial exosomal isolation methods available that utilise exosome 
precipitation (e.g. ExoQuick precipitation (Baek et al., 2016)), ultrafiltration, or immunoaffinity 
capture based techniques. Exosome precipitation commercial kits have limitations that 
include the co-precipitation of other non-exosomal contaminants such as proteins and 
macromolecules, and cannot discriminate between exosomes and other EVs (Li et al., 
2017).  Buoyant density gradient centrifugation is a method that generates higher purity 
exosomes than the commercial kits, however it is time consuming, labour intensive and 
limited in the yields obtained (Van Deun et al., 2014). Furthermore, most of these methods 
have been tested primarily on plasma samples. 
 
Exosomes, derived from a range of bodily fluids, including milk, are being used to identify 
cows with poor fertility, and issues related to the health of the transition cow (Crookenden 
et al., 2016). In dairy cows, the transition to lactation has been linked to physiological and 
metabolic stress as well as sub-optimal immune function (Sordillo and Raphael, 2013, 
Crookenden et al., 2016). During this transition period there is a high rate of infection and 
susceptibility to inflammatory disorders, such as mastitis and endometritis. These disorders 
result in a decrease in milk production and reproductive function (Halasa et al., 2007, 
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LeBlanc et al., 2002a, LeBlanc et al., 2002b). Milk exosomes may hold promise for early 
diagnosis of these problems and other reproductive disorders in mammals. Bovine milk is 
easy to obtain in large quantities, can remain fresh for long periods of time, is stable under 
long-term storage conditions and is a good source of exosomes (Munagala et al., 2016). 
 
The objective of this study was to develop a efficient and robust method for the enrichment 
of exosomes derived from bovine milk. This method is based on a combination of recent 
approaches for the initial preparation of milk for extracellular vesicle isolation (Yamada et 
al., 2013, Munagala et al., 2016, Kusuma et al., 2016) and the incorporation of size exclusion 
chromatography (SEC) for enrichment of exosomes. SEC columns are packed with porous 
polymeric beads, and have been used previously for the separation of EVs derived from 
biological fluids such as plasma and urine (Lozano-Ramos et al., 2015, Welton et al., 2015). 
Moreover, SEC has better separation (based on size) compared to buoyant density gradient 
centrifugation (based on density) and helps to eliminate contaminants with more confidence 
(Nordin et al., 2015).   
 
METHODS AND MATERIALS 
Milk collection 
Two litres of fresh unpasteurised milk was collected from a Holstein-Friesian dairy herd 
located at Gatton, The University of Queensland. The collected milk was aliquoted (15 mL) 
and stored at -80°C. 
 
Extracellular vesicle isolation 
EVs were isolated from milk by differential centrifugation. Briefly, milk aliquots (15 mL) were 
added to 25 mL PBS (Gibco, Life Technologies Australia), centrifuged at 3,000 rcf for 15 
min at 4°C to remove milk fat globules, cellular debris and somatic cells. The supernatant 
was divided into two groups, of a total of 20 mL each (i.e. equivalent of 7.5 mL milk each) 
and these were used for subsequent isolation and enrichment processes. An equal volume 
of 0.25M EDTA (Sigma Aldrich, Castle Hill, New South Wales, Australia; pH 7) was added 
to the samples and incubated for 15 min on ice to precipitate casein and exosomes coated 
with casein as  described by Kusuma et al. 2016 (Kusuma et al., 2016). The 50mL tubes 
were centrifuged at 12,000 rcf for 60 min at 4°C.  The supernatants were transferred to 
OptiSeal tubes (Beckman Coulter, Gladesville, Australia), and subjected to successive 
ultracentrifugation steps at 35,000 rcf for 60 min, and then at 70,000 rcf for 60 min at 4°C 
(Beckman, Type 70.1 Ti Fixed angle ultracentrifuge rotor). The supernatant was filtered 
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through 0.22 µm syringe filters and centrifuged at 100,000 rcf for 120 min at 4°C to pellet 
the extracellular vesicles. The extracellular vesicles were resuspended in 500 µL PBS 
(Gibco, Life Technologies Australia) as shown in Figure 3.3.1. Thereafter we evaluated our 
new method of exosome enrichment and compared it with the most widely used current 
method (Figure 3.3.2), employing buoyant density gradient centrifugation (Method A). 
 
Figure 3.3.1. Flowchart for the isolation of extracellular vesicles (EVs) from milk. EVs 
were isolated from milk by differential ultracentrifugation. Unpasteurised milk was 
centrifuged at 3,000 rcf followed by 0.25M EDTA treatment (1:1; v/v) and supernatants (S/N) 
subsequently centrifuged at 12,000, 35,000, 70,000 and 100,000 rcf respectively.  The pellet 
obtained after the sequential centrifugation process contains EVs. After reconstitution in 
PBS, the EV suspension was used for exosome enrichment. 
Exosome harvesting and enrichment 
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Method A 
Briefly, EVs in 500 µL of PBS, from the previous step, was loaded onto a discontinuous 
iodixanol gradient (OptiPrep™ gradient, Sigma-Aldrich) in ultracentrifuge tubes (Koh et al., 
2017). The tubes were centrifuged at 100,000 rcf for 20 h at 4°C (Beckman, Sw41Ti, 
Swinging-bucket ultracentrifuge rotor). Twelve individual fractions were obtained. Each 
fraction was transferred to separate ultracentrifuge tubes, diluted with PBS (Gibco, Life 
Technologies Australia) and ultracentrifuged again at 100,000 rcf for 2 h at 4°C, to wash the 
exosomes. The pellets were resuspended in 100 µL PBS and used for further analysis. This 
procedure is described in the flowchart in Figure 3.3.2. 
 
Method B 
Briefly, EVs in 500 µL of PBS were loaded on a qEV column (Izon Science Ltd, New 
Zealand) and eluted with further PBS in 500 µL fractions to a total of 16 fractions, as per 
manufacturer’s instructions (Figure 3.3.2, Method B).  The individual fractions were then 
used for further analysis. This procedure is described in detail in Figure 3.3.2. 
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Figure 3.3.2. Flowchart for the comparison of two exosome enrichment methods; 
buoyant density gradient centrifugation (Method A) and size exclusion 
chromatography (Method B). (A) 500 µL of EV suspension was loaded on top of the 
OptiPrep™ gradient and ultracentrifuged for 20 h to obtain 12 fractions as described in the 
flowchart. (B)  500 µL of EV suspension was introduced on top of a SEC column (qEV 
column) and processed via size exclusion chromatography to obtain 16 fractions as 
described in the flowchart. 
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Nanoparticle Tracking Analysis  
The nanoparticle tracking analysis was conducted using a Malvern NanoSight™ NS500 
instrument (NanoSight™, NTA 3.0 Nanoparticle Tracking and Analysis Release Version 
Build 0064; Amesbury, United Kingdom) as per manufacturer’s instructions as we have 
described (Koh et al., 2017). Briefly samples of each fraction (1-12; Method A) and (1-16; 
Method B) were characterised (including 3 technical replicates for each fraction) to 
determine the particle concentration (particles/mL) 
 
BCA Protein Quantitation 
Protein concentration was quantified using a Bicinchoninic acid (BCA) reagent kit (Sigma 
Aldrich, Castle Hill, New South Wales, Australia). All 12 fractions of Method A and 16 
fractions of Method B were quantified against a bovine serum albumin (BSA) standard (0-
2,000 µg/mL) (Sigma Aldrich, Castle Hill, New South Wales, Australia) to determine protein 
concentration. 
 
Immunoblotting  
Exosomal proteins (10 µg) were incubated for 10 min at 70°C in reducing agent (NuPAGE 
Sample Reducing Agent, Life Technologies Australia, Mulgrave, Victoria, Australia) and 
loading buffer (NuPAGE LDS sample buffer, Life Technologies Australia Pty Ltd). Reduced 
proteins were electrophoresed (SDS-PAGE) on NuPAGE Novex 4–12% Bis-Tris Gels, and 
transferred to a polyvinyl difluoride (PVDF; Bio-Rad Laboratories, Australia) membrane 
using the Trans-Blot Turbo system with pre-packed transfer packs and the 7-min protocol 
(Bio-Rad Laboratories, Australia). Membranes were blocked for 1 h in blocking solution and 
probed overnight with primary rabbit polyclonal antibody anti-Flotilin-1 (ab13493 Abcam, 
Boston, MA, USA) and, anti-TSG101 (sc-7964; Santa Cruz Biotechnology, California, USA 
) at 4°C, followed by secondary anti-rabbit IgG (1:1000; A0545, Sigma–Aldrich) and 
secondary donkey anti-goat IgG-HRP (1:1000; sc-2020, Santa Cruz Biotechnology, 
California, USA). SuperSignal West Dura-Extended Duration Substrate (Thermo Fisher 
Scientific Life Technologies, Australia) was used for development of the blot, and the signal 
visualised on X-ray film (Agfa, Mortsel, Belgium) and developed using a Konica Minolta 
SRX-101A processor (Konica Minolta medical and graphic INC, Japan). 
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Proteomic Profiling using Information Dependent Acquisition (IDA) Mass 
Spectrometry 
Exosomal fractions determined by our immunoblotting results which confirmed 
manufacturer’s instruction were pooled. The pooled exosomal fractions (Method A: fractions 
6-8; Method B: fractions 7-10) were analyzed by mass spectrometry. DTT/ bicarbonate (10 
µL of 20 mM) was added to each sample and incubated for 1 h at 60°C. Iodoacetamide (10 
µL of 1 M in 100 mM bicarbonate) was added to each tube and incubated for 1h at 37ºC in 
the dark. Parallel incubations were performed using BSA as a quality control for 
reduction/alkylation and digestion reactions. Samples were digested with Trypsin Gold (1 
µg) for 18 h at 37ºC. Post digestion, formic acid (100 µL, 0.1%) was added. Peptides were 
desalted using stage tips; a 3-mm piece of an Empore C18 (Octadecyl) SPE Extraction Disk 
was excised and placed in a gel loader tip and POROS slurry was added to form a 
microcolumn. Trifluoroacetic acid (1 volume, 0.1% in water) was added to the sample and 
loaded onto the microcolumn. The microcolumn was washed with trifluoroacetic acid (20 µL, 
0.1% in water). Peptides were eluted from the microcolumn by three washes of acetonitrile 
(20 µL x 3, 0.1% formic acid). Eluates were pooled and samples were evaporated at room 
temperature in a vacuum evaporator for 45 min. Samples were reconstituted in 30 µL formic 
acid. 
 
The digested protein samples were analyzed using the TripleTOF® 5600 mass 
spectrometer (ABSciex, Redwood City, California, USA) and Eksigent 1D+ NanoLC system 
to obtain initial high mass accuracy. MS/MS data were screened to identify the peptides 
present in the samples. A 10 μL aliquot of digested material was injected onto the column 
and separated with a linear gradient of 5 to 10 % Buffer B for 2 min (Buffer A: 0.1 % Formic 
acid/water; Buffer B: acetonitrile/0.1 % formic acid), 10 to 40 % Buffer B (58 min), 40 to 50 
% Buffer B (10 min), 50 to 95 % (10 min) with a flow rate of 500 nL/min. The column was 
flushed at 95 % buffer B for 15 min and re-equilibrated with 5 % Buffer B for 6 min. The in-
depth proteomic analysis was conducted using Information Dependant Acquisition (IDA) on 
the TripleTOF® 5600 System interfaced with a nanospray source. Results were analyzed 
using ProteinPilot™ (ABSciex, Redwood City, California, USA). 
 
Transmission Electron Microscopy (TEM) 
Exosomal fractions determined by our immunoblotting results which confirmed 
manufacturer’s instruction were pooled. 5 µL of the pooled exosomal fractions (Method A: 
fractions 6- 8; Method B: fractions 7-10) were analyzed by TEM.  Samples were placed on 
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formvar coated copper grids for 2 min, washed briefly in ultrapure water and negatively 
stained with 1% uranyl acetate. The samples were than viewed using the JEOL 1010 
transmission electron microscope operated at 80 kV, and images were captured with an 
Olympus Soft Imaging Veleta digital camera. Individual fractions 6-8 from Method A, and 7-
10 from Method B were also analyzed by TEM (Supplemental Figure S3.3.1 (see 
APPENDICES)). 
 
Statistical Analyses 
The number of exosomes from the bovine milk for each method are presented as number 
of particles per mL (means ± SEM, n = 3). Exosomal yield for each method was evaluated 
by Student’s T tests (two-tailed) using a commercially-available software package (Prism 6, 
GraphPad Inc, La Jolla, CA 92037 USA). Significance was defined as P < 0.05. 
 
RESULTS  
Nanoparticle Tracking Analysis  
The yield of exosomes obtained after Method A was approximately 3 x 1010 ± 1.08 x 1010 
particles/mL (n=3). In comparison Method B yielded  approximately 7 x 1011 ± 2.21 x 1011 
particles/mL (n=3) (Figure 3.3.3).  The pattern of particle number across the SEC fractions 
showed low particle numbers in fraction 1-6 (void volume) and an increase in particle 
number in exosomal fraction 7 through to fraction 9 and dropping slightly at fraction 10, with 
numbers declining from fraction 11 onwards. 
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Figure 3.3.3. A comparison of particle concentration between buoyant density 
gradient centrifugation (Method A) and size exclusion chromatography (Method B). 
Nanoparticle tracking analysis (NTA) was utilised to determine the particle 
concentration (particles/mL) of exosomes obtained after isolation and enrichment 
using; (A) Buoyant density gradient centrifugation enrichment of 12 fractions (n = 3 
experimental replicates) and; (B) SEC enrichment of 16 fractions (n = 3 experimental 
replicates). (C) Comparison of exosome yields obtained from Method A and Method B. Each 
fraction was evaluated in technical triplicate (n = 3) on NTA. Data are presented as 
means ± SEM and P < 0.05 defined as significant. 
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Protein concentration 
Method A fraction 7 had the highest protein concentration determined by BCA assay. In 
comparison, protein concentration in Method B showed an increasing trend with increasing 
fraction number (Figure 3.3.4). 
 
Figure 3.3.4. A comparison of protein concentration between buoyant density 
gradient centrifugation (Method A) and size exclusion chromatography (Method B). A 
representative graph of protein concentration (µg/mL) of all fractions obtained after 
isolation and enrichment following (A) buoyant density gradient centrifugation, fractions 1-
12 and (B) SEC, fractions 1-16 as determined by BCA assay.  
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Immunoblotting 
SDS-PAGE showed the presence of exosomal markers in fraction 7 for Method A (with faint 
detection in fractions adjacent to fraction 7) (Figure 3.3.5). Flotillin-1(49kDa) and TSG101 
(47 kDa) were clearly observed in the exosomal fractions 7-10.  Coomassie staining of SDS-
PAGE for Method B revealed a distinct protein profile for exosomal fractions 7-10 compared 
to non exosomal fractions 11-16. Moreover, exosomal markers TSG101 (47 kDa) and 
Flotillin-1 (49kDa) were detected in fractions 7-10 in Method B (Figure 3.3.6). 
 
Figure 3.3.5. Immunoblotting for the presence of exosomal markers, using Method A. 
SDS-PAGE (A) showing differences in protein profiles between all 12 fractions. Immunoblots 
indicating the presence of TSG101 (B) and Flotillin-1(C) in fractions (6-8) containing the 
exosomes. 
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Figure 3.3.6. Immunoblotting for the presence of exosomal markers, using Method B. 
SDS-PAGE (A) showing differences in protein profiles between all 16 fractions. Immunoblots 
indicating the presence of TSG101 (B) and Flotillin-1 (C) in fractions (7-10) containing the 
exosomes. 
 
Proteomic Analyses by Mass Spectrometry. 
Using Protein Pilot™, tetraspanin proteins CD9 and CD81 were detected in pooled 
exosomal fractions from both Methods A and B, but not in non-exosomal fractions. Method 
B detected more peptides (3 peptides of CD9 and 2 peptides of CD81) with greater than 
95% confidence, compared to Method A (1 peptide each) (see Table 3.3.1 for peptide 
information). 
 
Table 3.3.1. Peptides unique to Tetraspanins CD9 and CD81 detected in exosomal fractions 
from Methods A and B. More peptides of CD9 and CD81 were detected in Method B 
compared to Method A. 
Method A Method B 
CD9 CD81 CD9 CD81 
NLIDSLK QFYDQALQQAIVDDDANNAK NLIDSLK QFYDQALQQAIVDDDANNAK 
  FYEDTYNK NSLCPSSGNVITNLFK 
  AIHIALDCCGLTGVPEQFLTDTCPPK  
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Transmission Electron Microscopy (TEM) 
TEM confirmed the intact cup shaped/spherical morphology of exosomal vesicles that are 
concave in the middle, by both buoyant density gradient centrifugation (Method A) and size 
exclusion chromatography (Method B) (Figure 3.3.7). The vesicles observed ranged in size 
from 30-200 nm. Exosomes were also observed in the individual fractions 6-8 (Method A) 
and 7-10 (Method B), (Supplemental Figure S3.3.1. (see APPENDICES)). Although 
comparable morphology was observed in both methods, observed abundance, within a field 
of view, was lower in samples from Method A. 
 
Figure 3.3.7. Transmission electron microscopy displaying exosomal morphology 
and size. Representative electron micrographs of pooled exosome isolations from (A) and 
(B): buoyant density gradient centrifugation (Method A); and (C) and (D): size exclusion 
chromatography (Method B). A and C show relatively smaller particles, while B and D show 
relatively larger particles from each population. Scale bar 200 nm. 
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DISCUSSION 
Extracellular vesicle (EVs) pellets obtained after ultracentrifugation contain exosomes as 
well as other vesicles, macromolecules and protein aggregates. Our study evaluated the 
isolation of EVs using a series of ultracentrifugation steps (Figure 3.3.1) and thereafter the 
enrichment of exosomes from the isolated EVs. We compared two methods for exosome 
enrichment from bovine milk: buoyant density gradient centrifugation (Method A) and; size 
exclusion chromatography (SEC) utilising a commercially available column (Method B) 
(Figure 3.3.2). The new method (Method B) described in our study differs from other milk 
exosome isolation methods that use only SEC without an initial EV isolation step  (Blans et 
al., 2017). In our method (Method B), we first remove soluble proteins, fats, casein and other 
contaminants, by differential centrifugation during the EV isolation step. The SEC method is 
cost-effective, as the columns can be regenerated (by washing them with NaOH and PBS) 
and reused.  SEC of plasma has proven to be time-efficient, and demonstrates a narrow 
elution profile of exosomes (Welton et al., 2015, Baranyai et al., 2015, Boing et al., 2014).  
Using our new method of exosome enrichment (as described in this paper) a sample can be 
processed in approximately 30 mins (including washing and regeneration of the column). 
Moreover, multiple columns (2 to 4) can be run in tandem by a single operator to increase 
workflow productivity. In comparison, exosome isolation via buoyant density gradient 
centrifugation (Method A) requires a 16 or 20 h centrifugation step and multiple wash steps 
(at least one) to remove the sucrose and/or OptiPrep™ (See Figure 3.3.2, Method A). 
Therefore, processing 6 samples in tandem using Method A would take approximately 4.5h 
per sample. In addition, the washing steps result in incomplete recovery of exosomes, 
reducing yield (Momen-Heravi et al., 2013). This poor recovery helps explain why the new 
method presented in this paper, obtained significantly higher particle yield (approximately 3 
x 1012 particles/mL, P < 0.05) of approximately two orders of magnitude higher than the 
benchmark method (approximately 7 x 1010 particles/mL), using NTA. SEC, unlike buoyant 
density gradient centrifugation, also removes the need to make gradients, which is labour 
intensive and subject to significant user variability (Macdonald and Pike, 2005). 
 
Many definitions for EVs exist in the literature. EVs include (but are not limited to) 
microvesicles, ectosomes and shedding vesicles (Raposo and Stoorvogel, 2013). 
Microvesicles are EVs that are secreted into the extracellular space, and on average tend 
to be larger in size (i.e. 100-1000 nm) compared to exosomes (30-120 nm) (Pocsfalvi et al., 
2016). The size overlap between the two vesicle types makes it difficult to separate the two 
groups using existing techniques. In our study SEC fraction 7 most likely contained the larger 
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nanovesicles and some small microvesicles. Smaller microvesicles of about 100 nm may 
have been eluted in fraction 7, together with the larger exosomes and the extent of 
microvesicle contamination was difficult to determine. SEC fractions 8 and 9 contained the 
majority of nanoparticles (mainly exosomes), while fraction 10 contained the smaller 
exosomes (Method B). This suggests that when these four fractions were pooled, an 
enriched exosomal preparation was produced that was relatively free from contaminants 
such as soluble proteins, but may still contain a low concentration of smaller microvesicles.  
Buoyant density gradient centrifugation also has the same issue of contaminating 
microvesicles present in exosomal fractions 6-8, due to these vesicles possessing similar 
densities. 
 
A peak in protein concentration (Figure 3.3.4B) overlapped with particle concentration 
(particles/ mL) (Figure 3.3.3) for the exosomal fractions 7-10, while the later fractions had a 
continual increase in protein concentration that corresponded with elution of residual 
aggregated proteins. As protein aggregates are smaller than exosomes, they were retained 
longer on the Izon™ nano-beads compared to the larger particles that eluted earlier in the 
process (Szatanek et al., 2015, Lobb et al., 2015). This increasing trend in protein 
concentration in the later fractions (11-16, Method B) did not correspond with increased 
particle densities, since the majority of exosomes had eluted earlier in the chromatography 
process. 
 
TEM on pooled fractions 7-10 (Method B) clearly showed that most of the exosomal 
structures had been preserved and the corresponded to classical exosome morphology (i.e. 
spherical morphology) of approximately 30-120 nm in diameter (Willms et al., 2016). These 
results are similar to those from a study by Gamez-Valero et al. 2016, that described that 
SEC minimally alters the morphologic characteristics of isolated vesicles  (Gamez-Valero et 
al., 2016). In our study both methods (Methods A and B) had some larger vesicles, over 120 
nm diameter, by TEM. These vesicles could be the larger EVs that may not necessarily be 
exosomes (e.g. microvesicles), which have co-eluted in the SEC in fraction 7 (Method B). 
 
The exosomal markers Flotillin-1 and TSG101 (protein markers that meet ISEV guidelines) 
were clearly observed by immunoblotting to be enriched in the exosomal fractions 7-10 
(Method B), as expected.  Aggregated proteins were eluted after fraction 10, confirming that 
the SEC enrichment method has a narrow elution profile for exosomes. However, Flotillin-1 
and TSG101 may also be present in the contaminating small microvesicles that co-elute in 
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fraction 7. Flotillin-1 and TSG101 were not detectable by mass spectrometry-IDA (in both 
methods), possibly due to being in low abundance. Comparative analyses by mass 
spectrometry of the exosomal versus non-exosomal fractions detected CD9 and CD81 in 
the exosomal fractions (6-8, Method A and 7-10, Method B) only, making these potentially 
useful indicators (markers) for milk exosomes. 
 
As we demonstrated in this study, there are many overlapping characteristics between the 
distinct populations of exosomes and other EVs (Willms et al., 2016) and so far none of the 
techniques available are able to sufficiently discriminate and isolate a highly purified 
population of exosomes (Schorey et al., 2015, Kalra et al., 2016, Borges et al., 2013, 
Pocsfalvi et al., 2016). This is one limitation of the SEC and buoyant density gradient 
enrichment methods. Careful consideration must be given to the defining characteristics for 
“exosomes” and “extracellular vesicle” populations as well as other vesicles, as this has the 
potential to affect downstream experimentation. 
 
There are several benefits of using milk exosomes as a diagnostic tool. Under real life 
conditions where sample volumes may be limited (i.e. tissue biopsies), large volumes of milk 
can be obtained through a non-invasive procedure.  Milk exosomes can be isolated with 
high yield and quality making milk exosomes an ideal candidate in early diagnostic tests.  In 
addition, milk exosomes are an ideal candidate vehicle for delivering therapeutic agents and 
are tolerated across species, with bovine milk exosomes known to be taken up by human 
phagocytes (Izumi et al., 2015) with no adverse immune or inflammatory responses 
observed (Kusuma et al., 2016). The bi-lipid membrane and aqueous internal core of milk 
exosomes means they are able to carry both hydrophilic and lipophilic drugs (Munagala et 
al., 2016). Coupled with good physical and biological stability, this versatility makes milk 
exosomes a potential biocompatible and cost-effective vector for therapeutic delivery. 
 
In conclusion, the new method we have described enables the isolation of exosomes with 
increased yield, reduced contamination and co-precipitation of other macromolecules. This 
method is also time efficient allowing for higher throughput and is less labour intensive than 
other widely used methods such as buoyant density gradient centrifugation. With increasing 
interest into the roles of exosomes in cellular communication (i.e. packaging and delivering 
biologically active cargo) we believe the reliability of the new method will enable researchers 
to further investigate the potential utility of exosomes in diagnostics and therapeutics. In the 
dairy cow, the isolation and evaluation of bovine milk exosomes could enable earlier 
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identification of conditions such as mastitis and metabolic disorders which commonly occur 
in the transition period. 
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Summary for Chapter 3 
In chapter 3.1 exosomes were isolated from plasma and milk from dairy cows using 
differential and buoyant density ultracentrifugation, the gold standard and most commonly 
used approach for exosome enrichment from extracellular vesicles. The exosomes isolated 
from plasma and milk showed different proteomic profiles and contained proteins associated 
with specific biological processes and molecular functions. These findings highlight the 
potential benefits of using milk and plasma as sources of biomarkers for diagnostic and 
prognostic purposes. The isolation of exosomes from plasma and milk may represent an 
alternative to using tissue biopsies as they contain a snapshot of the condition of the parental 
cell and are easy to obtain without the need for invasive procedures. 
 
However, there are some major concerns regarding the clinical utilisation of exosomes. As 
discussed in chapter 3.1, current isolation techniques are time consuming, costly, and 
produce variable exosome yields (due to user variability and the successive washing and 
pelleting steps involved in the method). Therefore, there is a need to develop a more 
efficient, robust, and reproducible methods for the isolation and enrichment of exosomes 
from the body fluids of dairy cows (e.g. plasma and milk). Alternative exosome isolation 
methods were explored in Chapter 3. The composition of plasma is different to the 
composition of milk, subsequently different methods were developed for the optimum 
isolation of exosomes from these body fluids. A method for exosomal isolation and 
enrichment from plasma is described in chapter 3.2, whilst the optimised method for the 
isolation and enrichment of exosomes from milk is presented in chapter 3.3. 
 
Overall, I have demonstrated a new method for the enrichment of exosomes from plasma 
and milk by coupling differential centrifugation with size exclusion chromatography (SEC). 
This method is superior to other enrichment methods because it is robust with less variation, 
faster, and has improved yields compared to other currently used techniques like buoyant 
density ultracentrifugation. By using a pre-isolation step (differential centrifugation), 
contaminants such as soluble proteins, nucleic acids, cell debris, and other macromolecules 
are removed prior to SEC. The application of SEC further enriches the exosomes by 
removing other vesicles that are different sizes to the exosome (e.g. microvesicles and 
apoptotic bodies). We confirmed exosome enrichment by immunoblotting for exosomal 
markers as well as visualising the morphology of and confirming the correct size range of 
the isolated exosomes by electron microscopy. Comparative proteomic analysis of 
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exosomal fractions with non-exosomal fractions further confirmed the presence of exosomes 
in the isolated fractions by detecting tetraspanins CD9 and CD81. 
 
Based on the fact that exosomes harbour content important for cell-to-cell communication, 
the purification of exosomes from dairy cow milk and plasma is imperative for research into 
the use of exosomes as biomarkers for diagnostic and prognostic purposes by the dairy 
industry. 
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Chapter 4: A method development using a mass spectrometric 
targeted approach for the detection of exosomal markers. 
 
Overview 
 
In chapter 3, I developed a robust and reproducible method for the isolation and enrichment 
of exosomes from plasma and milk from dairy cows by coupling ultracentrifugation with size 
exclusion chromatography. However, the presence of exosomes in the isolated fractions 
must be confirmed in order to distinguish them from other confounding extracellular vesicles. 
The current techniques commonly used to validate, characterise, and distinguish exosomes 
from other confounding extracellular vesicles, as described by Witwer et al. (Witwer et al., 
2013) and Lotvall et al. (Lotvall et al., 2014) are based on particle size distribution (via 
nanoparticle tracking analyses), the presence of the exosomal markers TSG101, Flotillin-1, 
and CD63 (immunoblotting), and exosome morphology observed by transmission electron 
microscopy. 
 
Previous techniques for the detection of exosomal markers (e.g. TSG101, Flotillin-1 and 
CD63) in isolated fractions involve immunoblotting. It must be noted that characterisation of 
the proteomic profiles in the plasma and milk from dairy cows was attempted using the 
information-dependent acquisition-mediated LC-MS/MS, however, few exosomal markers 
(e.g. CD9 and CD81) were identified. Other classical exosomal markers (e.g. CD63, Flotillin-
1 and TSG101) were also not detectable by information-dependent acquisition-mediated 
LC-MS/MS, possibly due to the markers being in low abundance or masked by other 
abundant proteins (e.g. apolipoprotein in plasma or α-lactalbumin in milk).  
 
Subsequently, I attempted to screen and detect an exosomal marker, TSG101 from bovine 
plasma and milk (in Chapter 3) using a targeted proteomic approach with the triple 
quadrupole mass spectrometer. In this chapter, I aimed to develop a mass spectrometric-
targeted approach to detect a panel of exosomal markers (e.g. TSG101, Flotillin-1, and 
CD63) from bovine body fluids (e.g. plasma and milk). 
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ABSTRACT 
Exosomes, membrane-bound vesicles of endocytic origin, encapsulate bioactive molecules 
and are released by multiple cell types into body fluids that can be easily sampled. All 
exosomes share some common characteristics such as a spherical morphology, of sizes 
ranging between 30-120 nm, buoyant densities of 1.13-1.19 g/mL on sucrose gradient, and 
enrichment with exosomal protein markers (e.g. TSG101, Flotillin-1, and CD63). Exosomes 
were isolated from plasma (chapter 3.2) and milk (chapter 3.3) from dairy cows and were 
characterised by nanoparticle tracking analyses (NTA), exosomal markers CD63, Flotillin-1 
and TSG101 (immunoblotting), and transmission electron microscopy (TEM). A targeted 
proteomic approach using the quadrupole-ion trap (Q-TRAP) mass spectrometer was 
developed to detect [1] TSG101 peptide precursors (LDQEVAVDKNIELLR and 
DEELSSALEK), [2] Flotillin-1 peptide precursors (LTGVSISQVNHKPLR and 
ISLNTLTLNVK), and [3] CD63 peptide precursors (DFECCGAANYTDWEK and 
DNQTASILDK) from bovine plasma and milk exosomes. In the current study, the mass 
spectrometric targeted approach detected two peptide precursors with at least three 
transitions per peptide target for exosomal markers TSG101, Flotillin-1, and CD63 in bovine 
plasma exosomes. Conversely, in the milk exosomes, TSG101 was the only exosomal 
marker that was detected to have two peptide precursors with at least three transitions per 
peptide target. This method requires further optimisation to include recombinant exosomal 
protein markers as reference standards, and to increase the number of peptide targets for 
analyses. Nevertheless, this targeted mass spectrometry approach can provide an 
alternative approach for screening and confirming the presence of exosomal protein marker 
(i.e. TSG101) that are common to all exosomes from bovine plasma and milk. This proteomic 
approach is robust, has the potential to identify specific peptide sequences (at least for 
bovine plasma exosomes from this study), and can detect lower levels of protein (1.6 µg 
protein loaded onto column) compared to the amounts required for immunoblotting (10 µg 
protein). Furthermore, this method avoids the dependence on antibody specificity required 
for immunoblotting. The ability to efficiently detect exosomes from different body fluids 
through targeted proteomic applications will aid in the development of exosomes as novel 
diagnostics and prognostics for specific pathologies. 
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INTRODUCTION 
Exosomes are membrane-bound vesicles secreted by multiple cell types into body fluids 
that act as intercellular messengers (Corrado et al., 2013) via transfer of a diverse array of 
signalling molecules (e.g. proteins and nucleic acids). Moreover, the release of vesicles is 
regulated by physiological and pathological conditions such as tumor development (Yu et 
al., 2007), pregnancy (Jessica et al., 2010), and immunomodulation (Li et al., 2006). Hence, 
there is growing interest in the clinical applications of exosomes (Conlan et al., 2017) with 
research focused on investigating exosome function and potential use for the development 
of minimally invasive approaches (such as using blood, milk, urine, saliva or other biological 
fluids) for diagnostics and prognostics, and exosome-based therapeutics (e.g. exosome-
mediated drug delivery). 
 
In current literature there are several techniques and methodologies available for the 
isolation and enrichment of exosomes such as ultracentrifugation, size-based isolation, 
immunoaffinity capture, microfluidics, and other exosome isolation techniques (Li et al., 
2017, Konoshenko et al., 2018). Even though each techniques has advantages and 
shortcomings, all exosomes enriched from different biological fluids share certain common 
characteristics (Simons and Raposo, 2009, Konoshenko et al., 2018) including a spherical 
morphology, sizes ranging between 30-120 nm, buoyant densities of 1.13-1.19 g/mL on 
sucrose gradient, and enrichment with exosomal protein markers (e.g. TSG101, Flotillin-1, 
and CD63). A combination of several methods (e.g. transmission electron microscopy, 
nanoparticle tracking analysis, and/or immunoblotting) can be employed to characterise the 
morphology, size, biochemical compositions, and receptor proteins present on exosomes. 
 
Immunoblot (Western blot) is a common and well-established technique mostly employed 
for the characterisation of exosomal protein markers (e.g. TSG101, Flotillin-1, and CD63) 
(Witwer et al., 2013, Lotvall et al., 2014). However, this technique is dependent on specific 
antibodies against the exosomal protein markers. In the current study, the objective is to 
develop an alternative method to immunoblotting through a targeted proteomic approach 
using the quadrupole-ion trap (Q-TRAP) mass spectrometer to screen and detect exosomal 
protein markers that are common to all exosomes present in different body fluids. 
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METHODS AND MATERIALS 
Exosomes from bovine body fluids 
Exosomes isolated from bovine plasma (from Chapter 3.2) and milk (from Chapter 3.3) were 
used in this study. Briefly, exosomes were isolated and enriched using the ultracentrifugation 
and size exclusion chromatography method and were characterised based on size (using 
the NanoSight), the presence of the exosomal markers TSG101 and Flotillin-1 (determined 
by immunoblot), and an intact spherical morphology (visualised by transmission electron 
microscopy). 
 
Sample preparation through reduction, alkylation, tryptic digestion and desalting 
Plasma and milk exosomes (10 µg protein) in PBS were sonicated for 5 min to disrupt the 
exosome membrane and expose proteins. Plasma and milk exosomes, as well as BSA (10 
µg, quality control) were treated with 50 mM ammonium bicarbonate and reduced with 20 
mM dithiothreitol (DTT) for 1 h at 65°C. The samples were then alkylated in 100 mM 
iodoacetamide at 37°C in the dark for 60 min before being incubated with trypsin (Sigma–
Aldrich Castle Hill, NSW, Australia) at a 1:50 ratio overnight at 37°C for 18 h with the reaction 
stopped by the addition of 0.1%v/v formic acid. The samples were combined and desalted 
according to a modified version of the stage tip protocol using a 3-mm piece of an Empore 
C18 (Octadecyl) SPE Extraction Disk (Vaswani et al., 2015, Rappsilber et al., 2003). The 
eluted peptides were dried in a vacuum centrifuge prior to spectral acquisition. 
 
Targeted mass spectrometry approach for identification of exosome markers 
The digested protein samples were analyzed using an Eksigent 200 Micro-Liquid 
chromatography system coupled with a triple quadrupole (QTRAP), 5500 mass 
spectrometer (AB Sciex, Redwood City, CA) as described previously (Koh et al., 2017). The 
TSG101 analytes (LDQEVAVDKNIELLR and DEELSSALEK) were monitored using 
electrospray ionisation in positive-ion mode with multiple reaction monitoring (MRM) using 
characteristic precursor-product ion transitions of m/z for TSG101 (628.674 > 1,000.579, 
855.552, 643.414 Da and 560.772 > 747.425, 661.268, 574.235 Da respectively). The 
Flotillin-1 (LTGVSISQVNHKPLR and ISLNTLTLNVK) analytes were monitored using 
electrospray ionisation in positive-ion mode with MRM using characteristic precursor-
product ion transitions of m/z for Flotillin-1 (550.321 > 764.453, 658.377, 650.410, 571.345, 
385.256 Da and 608.369 > 902.531, 788.488, 743.430, 642.382 Da respectively). The CD63 
(DFECCGAANYTDWEK and DNQTASILDK) analytes were monitored using electrospray 
ionisation in positive-ion mode with multiple reaction monitoring (MRM) using characteristic 
125 
 
precursor-product ion transitions of m/z for CD63 (622.575 >  841.372, 678.310, 712.207, 
840.265 Da and 552.780 > 875.483, 747.425, 730.337 Da respectively). Data processing 
was performed using Analyst software (version 1.6.2. AB Sciex). 
 
RESULTS 
Targeted proteomic analysis of TSG101 peptides in plasma exosomes 
Triple quadrupole mass spectrometry identified two TSG101 peptide precursors with at least 
three transitions that correspond to the targeted peptide from plasma exosomes. A peptide 
from the TSG101 precursor, LDQEVAVDKNIELLR (mass selected by the first quadrupole 
(Q1), 628.674 Da), was detected in the plasma exosomes (Figure 4.1A) with three 
transitions (1000.579 Da, 885.552 Da and 643.414 Da) that corresponded to the targeted 
peptide (relative retention time at 5.5 min). Another peptide from the TSG101 precursor, 
DEELSSALEK (mass selected by Q1, 560.772 Da), was also detected in plasma exosomes 
(Figure 4.1B) with three transitions (747.425 Da, 661.268 Da and 574.235 Da) that 
corresponded to the targeted peptide (relative retention time at 5.5 min). 
 
Targeted proteomic analysis of Flotillin-1 peptides in plasma exosomes 
Triple quadrupole mass spectrometry identified two Flotillin-1 peptide precursors with at 
least three transitions that correspond to the targeted peptide from plasma exosomes. A 
peptide from the Flotillin-1 precursor, LTGVSISQVNHKPLR (mass selected by the first 
quadrupole (Q1), 550.321 Da), was detected in the plasma exosomes (Figure 4.2A) with 
four transitions (658.377, 650.410, 571.345, and 385.256 Da) that corresponded to the 
targeted peptide (relative retention time at 5.3 min). Another peptide from the Flotillin-1 
precursor, ISLNTLTLNVK (mass selected by Q1, 608.369 Da), was also detected in plasma 
exosomes (Figure 4.2B) with three transitions (788.488, 743.430, and 642.382 Da) that 
corresponded to the targeted peptide (relative retention time at 5.5 min). 
 
Targeted proteomic analysis of CD63 peptides in plasma exosomes 
Triple quadrupole mass spectrometry identified two CD63 peptide precursors with at least 
three transitions that correspond to the targeted peptide from plasma exosomes. A peptide 
from the CD63 precursor, DFECCGAANYTDWEK (mass selected by Q1, 622.575 Da), was 
detected in the plasma exosomes (Figure 4.3A) with four transitions (841.372, 678.310, 
712.207, and 840.265 Da) that corresponded to the targeted peptide (relative retention time 
at 6.2 min). Another peptide from the CD63 precursor, DNQTASILDK (mass selected by the 
first quadrupole (Q1), 552.780 Da), was also detected in plasma exosomes (Figure 4.3B) 
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with three transitions (875.483, 747.425, and 730.337 Da) that corresponded to the targeted 
peptide (relative retention time at 5.8 min). 
 
 
 
 
 
 
 
 
Figure 4.1. Mass spectrometric detection of TSG101 peptides in plasma exosomes. 
(A) Representative chromatogram of TSG101 precursor (LTGVSISQVNHKPLR, 628.674 
Da) and the corresponding transitions (1000.579 Da, 885.552 Da, and 643.414 Da) in 
plasma exosomes (relative retention time at 5.5 min). (B) Representative chromatogram of 
TSG101 precursor (DEELSSALEK, 560.772 Da) and the corresponding transitions (747.425 
Da, 661.268 Da, and 574.235 Da) in plasma exosomes (relative retention time at 5.5 min). 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Figure 4.2. Mass spectrometric detection of Flotillin-1 peptides in plasma exosomes. 
(A) Representative chromatogram of Flotillin-1 precursor (LTGVSISQVNHKPLR, 550.321 
Da) and the corresponding transitions (658.377, 650.410, 571.345, and 385.256 Da) in 
plasma exosomes (relative retention time at 5.3 min). (B) Representative chromatogram of 
Flotillin-1 precursor (ISLNTLTLNVK, 608.369 Da) and the corresponding transitions 
(788.488, 743.430, and 642.382 Da) in plasma exosomes (relative retention time at 5.5 min). 
A 
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Figure 4.3. Mass spectrometric detection of CD63 peptides in plasma exosomes. (A) 
Representative chromatogram of CD63 precursor (DFECCGAANYTDWEK, 622.575 Da) 
and the corresponding transitions (841.372, 678.310, 712.207, and 840.265 Da) in plasma 
exosomes (relative retention time at 6.2 min). (B) Representative chromatogram of CD63 
precursor (DNQTASILDK, 552.780 Da) and the corresponding transitions (875.483, 
747.425, and 730.337 Da) in plasma exosomes (relative retention time at 5.8 min). 
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Targeted proteomic analysis of TSG101 peptides in milk exosomes 
Triple quadrupole mass spectrometry identified two TSG101 peptide precursors with at least 
three transitions that correspond to the targeted peptide from milk exosomes. A peptide from 
TSG101 precursor, LDQEVAVDKNIELLR (mass selected by the first quadrupole (Q1), 
628.674 Da), was detected in milk exosomes (Figure 4.4A) with three transitions (1000.579 
Da, 885.552 Da and 643.414 Da) that corresponded to the targeted peptide (relative 
retention time at 5.7 min). Another peptide from TSG101 precursor, DEELSSALEK (mass 
selected by Q1, 560.772 Da), was also detected in milk exosomes (Figure 4.4B) with three 
transitions (747.425 Da, 661.268 Da and 574.235 Da) that corresponded to the targeted 
peptide (relative retention time at 5.8 min). 
 
Targeted proteomic analysis of Flotillin-1 peptides in milk exosomes 
Triple quadrupole mass spectrometry identified only one Flotillin-1 peptide precursor 
(LTGVSISQVNHKPLR) with at least three transitions that correspond to the targeted peptide 
from milk exosomes. A peptide from Flotillin-1 precursor, LTGVSISQVNHKPLR (mass 
selected by the first quadrupole (Q1), 550.321 Da), was detected in milk exosomes (Figure 
4.5A) with three transitions (764.453, 650.410, and 385.256 Da) that corresponded to the 
targeted peptide (relative retention time at 5.5 min). Another peptide from Flotillin-1 
precursor, ISLNTLTLNVK (mass selected by Q1, 608.369 Da), detected in milk exosomes 
(Figure 4.5B) identified two transitions (902.531 and 743.430 Da) that corresponded to the 
targeted peptide (relative retention time at 5.6 min). 
 
Targeted proteomic analysis of CD63 peptides in milk exosomes 
Triple quadrupole mass spectrometry identified only one CD63 peptide precursor 
(DFECCGAANYTDWEK) with at least three transitions that correspond to the targeted 
peptide from milk exosomes. A peptide from the CD63 precursor, DFECCGAANYTDWEK 
(mass selected by Q1, 622.575 Da), was detected in the milk exosomes (Figure 4.6A) with 
three transitions (841.372, 678.310, and 840.265 Da) that corresponded to the targeted 
peptide (relative retention time at 6.0 min). Another peptide from the CD63 precursor, 
DNQTASILDK (mass selected by Q1, 552.780 Da), detected in milk exosomes (Figure 4.6B) 
identified two transitions (747.425, and 730.337 Da) that corresponded to the targeted 
peptide (relative retention time at 5.9 min). 
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Figure 4.4. Mass spectrometric detection of TSG101 peptides in milk exosomes. (A) 
Representative chromatogram of TSG101 precursor (LDQEVAVDKNIELLR, 628.674 Da) 
and the corresponding transitions (1000.579 Da, 885.552 Da, and 643.414 Da) in milk 
exosomes (relative retention time at 5.7 min). (B) Representative chromatogram of TSG101 
precursor (DEELSSALEK, 560.772 Da) and the corresponding transitions (747.425 Da, 
661.268 Da, and 574.235 Da) in milk exosomes (relative retention time at 5.8 min). 
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Figure 4.5. Mass spectrometric detection of Flotillin-1 peptides in milk exosomes. (A) 
Representative chromatogram of Flotillin-1 precursor (LTGVSISQVNHKPLR, 550.321 Da) 
and the corresponding transitions (764.453, 650.410, and 385.256 Da) in milk exosomes 
(relative retention time at 5.5 min). (B) Representative chromatogram of Flotillin-1 precursor 
(ISLNTLTLNVK, 608.369 Da) and the corresponding transitions (902.531 and 743.430 Da) 
in milk exosomes (relative retention time at 5.6 min). 
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Figure 4.6. Mass spectrometric detection of CD63 peptides in milk exosomes. (A) 
Representative chromatogram of CD63 precursor (DFECCGAANYTDWEK, 622.575 Da) 
and the corresponding transitions (841.372, 678.310, and 840.265 Da) in milk exosomes 
(relative retention time at 6.0 min). (B) Representative chromatogram of CD63 precursor 
(DNQTASILDK, 552.780 Da) and the corresponding transitions (747.425, and 730.337 Da) 
in milk exosomes (relative retention time at 5.9 min). 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
B 
133 
 
DISCUSSION 
There is a growing research interest in exosomes due to the potential applications of 
exosomes as biomarkers and diagnostics, therapeutics, and drug delivery systems. 
However, there are currently no unique protein markers that validate exosomes as 
biomarkers. Subsequently several methods, like transmission electron microscopy, 
nanoparticle tracking analysis, and/or immunoblotting, are used to characterise exosomes. 
In this study, a targeted mass spectrometric approach was employed to validate a panel of 
exosomal markers (i.e. TSG101, Flotillin-1, and CD63) from bovine plasma and milk. 
 
Using a targeted mass spectrometric approach, the exosomal markers TSG101, Flotillin-1, 
and CD63 were detected in plasma exosomes revealing at least two peptide precursors with 
at least three transitions per peptide target. However, TSG101 was the only exosomal 
marker in milk exosomes detected to have two peptide precursors with at least three 
transitions per peptide target. The exosomal markers Flotillin-1 and CD63 detected in milk 
exosomes only revealed one peptide precursor with at least three transitions, while the other 
peptide precursor only detected two transitions of the peptide targets. In order to determine 
the level of confidence in assay specificity, as well as avoid false positive results, the 
detection of exosomal markers in plasma and milk exosomes by mass spectrometry requires 
at least two peptide precursors with at least three transitions per peptide target (Liebler and 
Zimmerman, 2013, Yocum and Chinnaiyan, 2009). 
 
Our results also showed that detection of a Flotillin-1 peptide, LTGVSISQVNHKPLR (Figure 
4.2A, mass selected by the first quadrupole (Q1) 550.321 Da with three transitions at 
658.377, 650.410, 571.345, and 385.256 Da), in plasma exosomes corresponded to the 
peptide sequence of the Flotillin-1 antibody (ab13493, epitope (SISQVNHKPLRTA), Abcam) 
that was used to detect Flotillin-1 by immunoblotting in our previous study (Koh et al., 
2018a). This further increased the level of confidence in assay specificity and also supported 
MRM of proteotypic peptides as an alternative approach to immunoblotting (Aebersold et 
al., 2013, Schoenherr et al., 2015). 
 
In our targeted mass spectrometric approach for the detection of exosomal markers (e.g. 
Flotillin-1 and CD63) in milk exosomes, the inability to detect MRM transitions leading to 
poor data quality could be due to matrix effects that can arise from different biological 
matrices and vary with sample preparation and ionisation type (Panuwet et al., 2016, Dams 
et al., 2003). Further optimisation of a targeted mass spectrometric experimental method to 
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improve the detection of exosomal markers in body fluids could include recombinant 
exosomal protein markers as reference standards and an increase in the number of peptide 
targets. 
 
In conclusion, a targeted mass spectrometry approach can be applied to detect and quantify 
multiple target proteins (e.g. exosomal markers) in complex protein mixtures such as 
plasma. The targeted proteomic approach employed in this study is robust, has the potential 
to identify specific peptide sequences, as well as the capacity to detect low amounts (e.g. 
1.6 µg protein loaded onto column) of plasma and milk exosomal proteins compared with 
immunoblotting (e.g.10 µg exosomal proteins). Mass spectrometry also provides greater 
specificity by detecting more than one peptide region in a protein of interest, whereas 
immunoblotting can only detect one epitope of the protein of interest. A targeted proteomic 
approach is useful when there is a limited availability of antibodies for the investigation of 
novel proteins. This approach can also be optimised to analyze a broader range of analytes 
from complex biological samples that can assist with the development of novel diagnostics 
and prognostics for specific pathologies (e.g. reproductive health and fertility). 
 
135 
 
Summary for chapter 4 
In chapter 4 a targeted mass spectrometric approach was developed as an alternative 
method to the common techniques, like immunoblotting, used to detect and screen 
exosomal markers in different body fluids. Compared to immunoblotting, targeted mass 
spectrometry avoids the dependence on antibody specificity and can also provide greater 
specificity to detect more than one peptide region in a protein of interest. 
 
In this study a targeted proteomic approach, using the quadrupole-ion trap (Q-TRAP) mass 
spectrometer, was able to detect [1] TSG101 peptide precursors (LDQEVAVDKNIELLR and 
DEELSSALEK), [2] Flotillin-1 peptide precursors (LTGVSISQVNHKPLR and 
ISLNTLTLNVK), and [3] CD63 peptide precursors (DFECCGAANYTDWEK and 
DNQTASILDK), with at least three transitions per peptide target for exosomal markers 
TSG101, Flotillin-1, and CD63 in bovine plasma exosomes. However, TSG101 was the only 
exosomal marker that was detected in milk exosomes to have two peptide precursors with 
at least three transitions per peptide target. 
 
I believe this targeted approach can be further improved to include a broader range of 
analytes (e.g. pregnancy-associated proteins and/or novel proteins associated with bovine 
reproduction) from a complex biological sample that could assist in the development of novel 
diagnostics and prognostics for the dairy industry (e.g. fertility, metabolic disorder, mastitis, 
milk quality and safety for human consumption). 
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Chapter 5: To evaluate exosomes isolated from high and low 
fertility dairy cows and investigate their effects on the functions 
of bovine endometrial cells. 
 
Overview 
 
The decline in dairy cow pregnancy rates is common in dairy-producing countries, therefore 
the development of markers such as SNP, proteins, miRNA, and exosomes, to identify 
higher fertility heifers is crucial for improving the productivity of dairy industries. This study 
focused on the potential role of exosomes in dairy cow fertility and produced results that 
suggests exosomes are a promising target for the development of new and innovative 
methodologies that could reverse the declining fertility in dairy cows. 
 
It is hypothesised that differences in fertility of dairy cows could be assessed by monitoring 
exosomal cargo differences and that the differences in cargo content could be manifested 
and reflected by changes in endometrial function when bovine endometrial cells are co-
incubated with exosomes from the two herds. 
 
Chapter 5 is a study of dairy cow herds that have been generated to have higher or lower 
fertility through developing extreme diversity in fertility breeding values but being very similar 
in other key animal traits (e.g. live-weight, milk production and percentage of North American 
genetics). The research investigated: 
Chapter 5.1. Proteome profiling of exosomes derived from plasma of heifers with divergent 
genetic merit for fertility. 
 
Chapter 5.2. Inflammatory mediator regulation in bovine endometrial stromal and epithelial 
cells by plasma exosomes from heifers with divergent genetic merit for fertility. 
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INTERPRETIVE SUMMARY 
Evaluation of exosomal content may lead to the development of prognostic tools to 
differentiate dairy cow fertility and subsequently lead to interventions in dairy cow 
reproduction. In this study, we examined the protein profile in plasma exosomes of heifers 
that were bred to have high or low fertility as demonstrated by extreme diversity in fertility 
breeding values. Exosomes of low fertility heifers demonstrated a lower number of 
exosomes, but a greater protein content within the exosomes as compared with high fertility 
heifers. Our results suggest that proteins identified in plasma exosomes could be indicative 
of the fertility status of heifers. 
 
ABSTRACT 
The current study evaluated exosomes isolated from plasma of heifers bred to have high or 
low fertility through developing extreme diversity in fertility breeding values, however, key 
animal traits (e.g. body weight, milk production, and percentage of North American genetics) 
remained similar between the two groups. The exosomes were isolated by a combined 
ultracentrifugation and size exclusion chromatography approach and characterised by their 
size distribution (nanoparticle tracking analysis), morphology (transmission electron 
microscopy), and presence of exosomal markers (immunoblotting). In addition, a targeted 
mass spectrometry approach was utilised to confirm the presence of two exosomal markers, 
tumor susceptibility gene 101 and Flotillin-1. The number of exosomes from plasma of high 
fertility heifers was greater compared with low fertility heifers. Interestingly, the exosomal 
proteomic profile, evaluated using mass spectrometry, identified 89 and 116 proteins in the 
high and low fertility heifers respectively, of which 4 and 31 were unique, respectively. These 
include proteins associated with specific biological processes and molecular functions of 
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fertility. Most notably, the tetratricopeptide repeat protein 41-related, glycodelin, and kelch-
like protein 8 were identified in plasma exosomes unique to the low fertility heifers. These 
proteins are suggested to play a role in reproduction; however, the role of these proteins in 
dairy cow reproduction remains to be elucidated. Their identification underscores the 
potential for proteins within exosomes to provide information on the fertility status and 
physiological condition of the cow. This may potentially lead to the development of 
prognostic tools and interventions to improving dairy cow fertility. 
 
Keywords: bovine, plasma, fertility, reproduction, exosomes  
 
INTRODUCTION 
Dairy cows with good fertility and reproductive performance are vital for the profitability and 
sustainability of dairy farms, especially in seasonal-calving pasture-based systems (Burke 
and Verkerk, 2010). Consequent with the increased metabolic pressure for milk production 
in the past decades, fertility of the dairy cow has decreased (Roche et al., 2011). 
Furthermore, an inflammation through immune (Formigoni and Trevisi, 2003, Piccinini et al., 
2004) or infectious (McDougall et al., 2007) challenge can have long-term consequences 
for the fertility of dairy cows. This peripartum inflammatory state, likely, contributes to the 
decline in fertility and reproductive success by disrupting endocrine signalling, negatively 
impacting uterine homeostasis, and invoking perturbations in ovarian function and oocyte 
development (Bromfield et al., 2015, Karsch et al., 2002). 
 
It has recently been established that exosomes can mediate inter- and intracellular signalling 
under normal and pathological conditions, through the transfer of bioactive molecules (e.g. 
proteins and miRNAs) that can modulate the biological function of the recipient cells (e.g. 
immune response, cellular adhesion, development, proliferation, and metabolism) (Corrado 
et al., 2013, McGough and Vincent, 2016, Crookenden et al., 2017). A number of studies 
have identified the involvement of exosomes in providing autocrine (i.e. local signals 
between the same cell type, such as cancer cells) (Weaver, 2017), paracrine (i.e. local 
signals between different cell types, such as between epithelial cancer cells and stromal 
cells) (Heneberg, 2016), and endocrine (i.e. distant signals between many types of cells 
usually carried in bodily fluids, such as blood) (Zduriencikova et al., 2015). Exosomes are 
membranous nanovesicles of endocytic origin that are defined by characteristics such as 
size, density, and morphology as well as the presence of exosomal markers (e.g. Tumor 
susceptibility gene (TSG) 101 and Flotillin-1) (Lotvall et al., 2014). Concomitant changes in 
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the concentration or the content of exosomes may provide informative details of the overall 
health condition of the animal, including the possible physiological status underlying fertility. 
 
To improve our knowledge in key areas of dairy cow reproductive physiology, a long-term 
project was initiated using cows with similar key animal traits (e.g. body weight, milk 
production, and percentage of North American genetics), but with extreme diversity in their 
estimated breeding values (EBV) for fertility. It was envisaged that the underlying 
physiological basis of low fertility heifers could be elucidated through the investigation of the 
content (e.g. proteins) encapsulated by exosomes isolated from the plasma of two cohorts 
of heifers that were identified to be either of low or high fertility. We hypothesised that heifers 
selected on the basis of differential fertility EBV would have exosomal signatures in plasma 
representative of their fertility genotype. 
 
MATERIALS AND METHODS 
Animals and Management 
Heifers used in this study were part of a larger experiment (n = 60 Holstein-Friesian heifers) 
from a recently established fertility animal model described by (Meier et al., 2017). From this 
larger group, 24 heifers were identified as being either high fertility (n = 12) or low fertility (n 
= 12) based on the extreme diversity in their EBV for fertility but being similar in genetic 
character for other key traits (e.g. body weight, milk production, and percentage of North 
American genetics). The EBV for fertility is measured using eight predictor traits. The 
predictor traits used to estimate the fertility breeding values includes whether cows are 
mated within 21 days of the planned start of mating (PM21) in first, second and third parity 
cows (expressed as a binomial trait); calved in the first 42 days after the planned start of 
calving (CR42) in second, third and fourth parity cows (as a binomial trait); milk volume in a 
cows’ first lactation and body condition score (BCS) in a cows’ first lactation at 60 days in 
milk. The details of the genetic merit of the 24 heifers are presented in Table 5.1.1. All heifers 
used in the current study were post-pubertal, and have expressed a minimum of 1 
spontaneous oestrus (Meier et al., 2017). To minimise interventions as well as to aligned 
with other studies to better understand the underlying drivers of fertility in dairy cattle, the 
timing of sampling was aligned with an oestrus event stimulated with prostaglandin (500 µg 
cloprostenol (Ovuprost, Bayer, New Zealand Ltd))_ as described by (Reed et al., 2017). The 
animals and their management, as well as the procedures for samples collection were 
managed by DairyNZ Ltd with approval by the Ruakura Animal Ethics Committee (AEC 
13574 and 13934). 
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Table 5.1.1. Genetic indices of the animal model (group means and standard error (SEM) 
of these means) 
 Animal model  
 High Fertility (n = 12) Low Fertility (n = 12)  
Parameters Mean SEM Mean SEM T-test 
Age (days) 402.17 3.91 394.67 4.93 0.246 
Breeding worth 1 154.00 7.59 69.25 4.43 < 0.0001 
Production worth 2 94.87 8.31 115.78 5.75 0.0504 
Fertility BV 3 6.17 0.10 -4.89 0.21 < 0.0001 
Milk volume BV 4 791.67 40.76 744.33 28.72 0.3528 
Milk fat BV 4 17.09 1.42 22.75 1.32 0.0079 
Protein BV 4 25.67 0.91 25.91 1.22 0.8732 
Body weight BV 40.10 2.64 37.08 2.79 0.4399 
Body condition score BV 5 0.08 0.01 -0.09 0.02 < 0.0001 
Gestation length BV 6 -3.13 0.68 -1.73 0.60 0.1394 
North American Holstein-
Friesian genes (%) 
56.64 1.28 60.43 1.87 0.1089 
Residual survival BV 7 55.00 11.00 38.75 27.39 0.5875 
Total longevity BV 8 386.92 9.17 124.92 28.22 < 0.0001 
Somatic cell count BV 9 -0.10 0.04 0.18 0.04 < 0.0001 
1 Breeding worth is the NZ$ net farm income/5 tonne of dry matter which is assumed to be fed per cow per 
year. 
2 Production worth measures the ability of the cow to convert feed into profit over her lifetime. 
https://www.dairynz.co.nz/animal/animal-evaluation/animal-and-herd-averages/, accessed 17-1-2018 
3 Fertility BV is a percentage value consisting of the lactating cow's ability to start cycling (- a binary trait 
called PM21, representing success/failure at being presented for mating in the first 21 days of the herd's 
mating period, from 1st, 2nd and 3rd parity cows) and a lactating cow's ability to conceive (- a binary trait called 
CR42, representing success/failure for re-calving in the first 42 days of the herd's calving period, from 1st, 2nd 
and 3rd parity cows), and a lactating cow's interval calving-conception (- calving interval (CI), in days, from 
Parity 1 to Parity 2) (NZAEL, 2017; https://www.dairynz.co.nz/animal/animal-evaluation/interpreting-the-
info/breeding-values/ accessed 4 Aug 2017). 
4 The mating plan aimed to confine the BV for milk volume, fat, protein, body weight and ancestry (% North 
American Holstein-Friesian) to be within 1 SD, and produce calves of 15/16th or 16/16th Holstein-Friesian 
breeding. 
5 Body condition unit is a measure of subcutaneous fat deposits (Roche et al., 2004), calculated using 
records collected on two year old heifers. 
6 Ancestry data based on Animal Evaluation run following parentage checks (Feb 2016). 
7 Residual survival BV represents 'residual' or 'uncounted' genetic merit for survival. 
https://www.dairynz.co.nz/animal/animal-evaluation/interpreting-the-info/breeding-values/, accessed 17-1-
2018 
8 Total longevity BV is calculated from information derived from herd testing, herd recording software. Four 
direct and nine predictor traits are currently used to estimate the longevity BV: Direct: Survival from 1st to 2nd, 
1st to 3rd, 1st to 4th, 1st to 5th lactation. Nine predictor traits are; Protein yield in lactation 1, Somatic cell score 
in lactation 1, Body condition score in lactation 1, Calving rate in the first 42 days after the planned start of 
calving (CR42) in lactation 2, Owner opinion in lactation 1, Milking speed in lactation 1, Leg conformation in 
lactation 1, Dairy conformation in lactation 1, Udder overall in lactation 1. 
https://www.dairynz.co.nz/animal/animal-evaluation/interpreting-the-info/breeding-values/, accessed 17-1-
2018 
9 Somatic cell score is the log transformed of the Somatic cell count which is derived from herd testing (NZAEL, 
2017; https://www.dairynz.co.nz/animal/animal-evaluation/interpreting-the-info/breeding-values/, accessed 4 
Aug 2017). 
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Blood Collection 
Blood was drawn from a jugular vein into EDTA Vacutainer tubes (Greiner Bio-one, 
Kremsmunster, Austria). The tubes were then centrifuged at 1,120 × g for 12 min at 4°C, 
and the plasma aspirated was stored at -80°C. 
 
Exosome Isolation from EDTA Plasma  
Exosomes were isolated by coupling ultracentrifugation and size exclusion chromatography 
as described by (Almughlliq et al., 2017).  In brief, plasma (10 mL) of high (n = 12) and low 
(n = 12) fertility heifers was diluted with an equal volume of phosphate-buffered saline (PBS; 
Gibco, Life Technologies Australia Pty Ltd, Mulgrave, Victoria, Australia) and centrifuged at 
2,000 × g for 30 min at 4°C, 12,000 × g for 30 min at 4°C and at 100,000 × g for 75 min at 
4°C, filtered through a 0.22 μm polyethersulfone (PES) membrane filter (Corning, New York, 
USA) and then ultracentrifuged at 100,000 × g for 120 min. The pellet was reconstituted in 
500 µL PBS and layered on a qEV size exclusion column (Izon Science, Christchurch, New 
Zealand). Fractions of 500 µL were collected in separate tubes (a total of 16 tubes), as per 
manufacturer’s instructions. The 16 fractions were concentrated using a vacuum 
concentrator (Eppendorf Concentrator Plus) for 1.5 h at room temperature and stored at -
80ºC until further analyses. 
 
Nanoparticle Tracking Analysis  
The nanoparticle tracking analysis (NTA) was conducted using a NanoSight NS500 
instrument (NanoSight NTA 3.0 Nanoparticle Tracking and Analysis Release Version Build 
0064) as previously described (Kobayashi et al., 2014, Salomon et al., 2014). This method 
was utilised to determine the size distribution and total exosome particle number of the 
EDTA plasma. 
 
Western Blot Analysis  
The proteins were extracted from the isolated exosomes using radioimmunoprecipitation 
assay buffer (RIPA; Sigma–Aldrich Castle Hill, NSW, Australia) and were incubated for 10 
min at 70°C in a reducing agent (NuPAGE Sample Reducing Agent, Life Technologies 
Australia Pty Ltd, Mulgrave, Victoria, Australia) and a loading buffer (NuPAGE lithium 
dodecyl sulfate sample buffer, Life Technologies Australia Pty Ltd). Electrophoresis was 
performed on the reduced proteins loaded and separated in NuPAGE Novex 4–12% Bis-
Tris Gels. Proteins were transferred to a polyvinyl difluoride (PVDF) membrane using the 
Trans-Blot Turbo system (Bio-Rad Laboratories Pty., Ltd, Australia). Membranes were 
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blocked for 1 h in blocking solution (2% of bovine serum albumin in PBST (0.001% Tween 
20 in PBS (Sigma–Aldrich Castle Hill, NSW, Australia)). Membranes were probed with 
primary antibody anti-Flotillin-1 (1:500; goat polyclonal, ab13493, epitope 
(SISQVNHKPLRTA), Abcam), primary antibody anti-TSG101 (1:500; rabbit polyclonal, 
ab50582, Abcam) and primary antibody anti-CD63 (1:1000; rabbit polyclonal, EXOAB-
CD63A-1, System Biosciences), followed by secondary donkey anti-goat IgG-HRP (1:1000; 
sc-2020, Santa Cruz Biotechnology) and anti-rabbit IgG (1:1000; A0545, Sigma–Aldrich 
Castle Hill, NSW, Australia). SuperSignal West Dura-Extended Duration Substrate (Thermo 
Fisher Scientific) was used to visualise the proteins on X-ray film (Agfa, Mortsel, Belgium) 
and developed using a Konica Minolta SRX-101A processor (Konica Minolta medical and 
graphic INC, Japan). 
 
Transmission Electron Microscopy 
For electron microscopy analysis, the samples were adsorbed on to a formvar coated copper 
grid for 2 min, washed briefly in ultrapure water (Invitrogen, Life Technologies Australia Pty 
Ltd, Mulgrave, Victoria, Australia), and negatively stained with 1% uranyl acetate. The 
samples were then viewed using a JEOL 1010 transmission electron microscope operating 
at 80kV and images captured with a Olympus Soft Imaging Veleta digital camera. 
 
Proteomic Analysis of High and Low Fertility Plasma Exosomes by Mass 
Spectrometry (MS) 
i) Sample Preparation and Desalting. 
Exosomes (10 µg of protein) in PBS were sonicated for 5 mins to disrupt the exosome 
membrane and expose proteins for proteomic analyses by liquid chromatography tandem-
mass spectrometry (LC-MS/MS). In brief, each of the exosome fractions was treated with 
50 mM ammonium bicarbonate, and then with 20 mM dithiothreitol (DTT) and reduced for 1 
h at 65°C. The samples were then alkylated in 100 mM iodoacetamide at 37°C in the dark 
for 60 min. Samples were incubated with trypsin (Sigma–Aldrich Castle Hill, NSW, Australia) 
at a 1:50 ratio overnight at 37°C for 18 h and the reaction was stopped by the addition of 
0.1% formic acid. The samples were combined and desalted according to a modified version 
of the stage tip protocol using a 3-mm piece of an Empore C18 (Octadecyl) SPE Extraction 
Disk (Rappsilber et al., 2003, Vaswani et al., 2015). The eluted peptides were dried in a 
vacuum centrifuge prior to spectral acquisition. 
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ii) Targeted Mass Spectrometry Approach for the Identification of Exosome Marker. 
The digested protein samples were analyzed using an Eksigent 200 Micro-Liquid 
chromatography system coupled with a triple quadrupole (QTRAP), 5500 mass 
spectrometer (AB Sciex, Redwood City, CA) as described previously (Koh et al., 2017). The 
TSG101 analytes (LDQEVAVDKNIELLR and DEELSSALEK) were monitored using 
electrospray ionisation in positive-ion mode with multiple reaction monitoring using 
characteristic precursor-product ion transitions of m/z for TSG101 (628.624 > 1,000.579, 
855.552, 643.414 Da and 560.772 > 747.425, 661.268, 574.235 Da respectively). Whereas, 
Flotillin-1 (LTGVSISQVNHKPLR and ISLNTLTLNVK) analytes were monitored using 
electrospray ionisation in positive-ion mode with multiple reaction monitoring (MRM) using 
characteristic precursor-product ion transitions of m/z for Flotillin-1 (824.978 > 1078.612, 
999.547, 385.256 Da and 608.369 > 788.48, 743.430, 642.382 Da respectively). Data 
processing was performed using Analyst software (version 1.6.2., AB Sciex). 
 
iii) Mass Spectrometry for the Identification of Exosomal Cargo. 
The digested protein samples were analyzed using the TripleTOF® 5600 mass 
spectrometer (ABSciex, Redwood City, CA) coupled to an Eksigent nano ultra 1D+ HPLC 
system. The ChromXP C18-CL TRAP (10 mm × 0.3 µm, 120 Å) and analytical ChromXP 
C18 columns (0.075 µm x 150 mm; 3 µm, 120 Å) (Eksigent, Redwood City, CA) were used 
to separate the digested proteins. A 5 µL aliquot of digested material was injected onto the 
column and separated with a linear gradient of 5% to 40% Buffer B for 58 min (Buffer A: 
0.1% Formic acid/water; Buffer B: acetonitrile/0.1% formic acid), 40 to 50% Buffer B (5 min), 
50 to 95% Buffer B (10 min), with a flow rate of 250 nL/min.  The column was flushed with 
95% buffer B for 15 min and re-equilibrated with 2% Buffer B for 6 min.  The in-depth 
proteomic analysis was performed using Information Dependent Acquisition (IDA) on the 
TripleTOF® 5600 System interfaced with a nanospray ion source.  The source parameters 
were: curtain gas value was 25, ion source gas (GAS1) 10 and declustering potential (DP) 
70 (arbitrary units).  A 250 msec accumulation time was set for the TOFMS survey scan 
and, from this scan, the 12 most intense precursor ions were selected automatically for the 
MS/MS analysis (accumulation time of 150 msecs per MS/MS scan). 
 
Protein identification was determined using the ProteinPilot™ Software (v4.5 beta, AB Sciex, 
Redwood City, CA) with the Paragon algorithm and against UniProt (Bos taurus protein 
database).  The search parameters were: sample type, identification; cys alkylation, 
iodoacetamide; digestion, Trypsin; Instrument, TripleTOF 5600; special factors, none; and 
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ID focus, biological modifications. False discovery rate (FDR) was selected in the processing 
method which automatically sets the detected protein threshold to 0.05 (10%). The low 
protein threshold value allows a full range of identifications to be made, therefore providing 
a more comprehensive assessment of the quality of the data.  The data were processed and 
categorised based on biological process (defined as the function of a particular protein in 
the context of a larger network of proteins that interact to accomplish a process at the level 
of the cell or organism) and molecular function (defined as the function of the protein by itself 
or with directly interacting proteins at a biochemical level) with the ontology and pathway 
analysis using the protein analysis through evolutionary relationships tool (PANTHER; 
http://www.pantherdb.org/) and gene ontology (GO) algorithms (Mi et al., 2016). 
 
Statistical Analyses 
The statistical analyses were performed using a commercially-available software package 
(Prism 6, GraphPad Inc, La Jolla, CA 92037, USA). A Mann-Whitney test was used to 
analyze and compare the total exosome particle number between the high and low fertility 
treatment groups. P < 0.05 was considered to be statistically significant and the data are 
presented as means ± SEM. 
 
RESULTS 
Characterisation of Exosomes Isolated from Plasma of High and Low Fertility Heifers 
Plasma exosomes derived from high and low fertility heifers were characterised using 
immunoblotting for the presence of exosomal markers, Flotillin-1, TSG101, and CD63 
proteins (representative immunoblot shown in Figure 5.1.1A). The spherical and intact 
morphology of the exosomes (representative vesicle shown in Figure 5.1.1B) was confirmed 
with transmission electron microscopy. Figure 5.1.1C and 5.1.1D demonstrates size 
distribution and particle number for both high (n = 12) and low (n = 12) fertility groups through 
NTA (Figure 5.1.1D). The total exosome particle number (particles per mL) was 23% greater 
(P < 0.05) in the high fertility heifers (2.64 × 1010 ± 0.11 × 1010 particles/mL; means ± SEM) 
compared with the low fertility heifers (2.04 ×1010 ± 0.18 ×1010 particles/mL; means ± SEM). 
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Figure 5.1.1. Characterisation of exosomes isolated from plasma of high and low 
fertility heifers. (A) Representative immunoblot of exosome markers: Flotillin-1, TSG101, 
and CD63. (B) Representative electron micrograph of exosomes, Scale bar 100 nm. (C) 
Nanosight measurement of particle-size (nm) distribution of plasma exosomes from high 
fertility (─), and low fertility ( ־־  ־ ) heifers. (D) The total exosome particle number (particles 
per mL) isolated from plasma of high and low fertility heifers were compared. Symbols 
represent individual animals and the data are presented as means ± SEM, n = 12. 
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Targeted Proteomic Analysis of TSG101 Peptides of High and Low Fertility Plasma 
Exosomes 
To validate the detection of TSG101 by immunoblot (Figure 5.1.1A), we identified two 
TSG101 peptide precursors (Accession number: A3KN51, bovine) with at least three 
transitions that correspond to the targeted peptide in both the high and low fertility plasma 
exosomes by a targeted proteomic approach using the triple quadrupole (QTRAP) mass 
spectrometer to facilitate confident peptide identification (Yocum and Chinnaiyan, 2009). A 
peptide of TSG101, LDQEVAVDKNIELLR (mass selected by the first quadrupole (Q1), 
628.624 Da) was detected in both the high and low fertility plasma exosomes (Table 5.1.2A) 
with three transitions (1000.579 Da, 885.552 Da and 643.414 Da); it corresponded with the 
targeted peptide (relative retention time at 5.6 min). The peptide of TSG101, DEELSSALEK 
(mass selected by the first quadrupole (Q1), 560.772 Da) was also detected in both the high 
and low fertility plasma exosomes (Table 5.1.2B) with three transitions (747.425 Da, 661.268 
Da, and 574.235 Da) corresponding to the targeted peptide (relative retention time at 5.7 
min). 
 
Targeted Proteomic Analysis of Flotillin-1 Peptides of High and Low Fertility Plasma 
Exosomes 
The exosome marker, Flotillin-1 (Accession number: Q08DN8, bovine) in both the exosomes 
from plasma of high and low fertility groups was also confirmed by the targeted proteomic 
approach using the triple quadrupole mass spectrometer. The triple quadrupole mass 
spectrometer identified two Flotillin-1 peptide precursors with at least three transitions that 
correspond to the targeted peptide from both the high and low fertility plasma exosomes. A 
peptide of Flotillin-1, LTGVSISQVNHKPLR (mass selected by the first quadrupole (Q1), 
824.978 Da) was detected in both the high and low fertility plasma exosomes (Table 5.1.2C) 
with three transitions (1078.612 Da, 999.547 Da, and 385.256 Da) that corresponded to the 
peptide (relative retention time at 5.6 min). The Flotillin-1 precursor peptide 
(LTGVSISQVNHKPLR) identified by mass spectrometry is consistent will the peptide 
sequence of the Flotillin-1 antibody (SISQVNHKPLRTA) used for immunoblotting (Figure 
5.1.1A). The peptide of Flotillin-1, ISLNTLTLNVK (mass selected by the first quadrupole 
(Q1), 608.369 Da) was also detected in both the high and low fertility plasma exosomes 
(Table 5.1.2D) with three transitions (788.488 Da, 743.430 Da, and 642.382 Da) 
corresponded to the peptide (relative retention time at 5.5 min). 
 
 
148 
 
Table 5.1.2. Triple quadrupole mass spectrometric detection of TSG101 and 
Flotillin-1 precursor and its corresponding transitions. 
A. A3KN51_TSG101_LDQEVAVDKNIELLR 
Q1 
Mass (Da) 
Q3 
Mass (Da) 
Charge 
Retention time 
(min) 
628.674 1000.58 +3y8 5.6 
628.674 885.552 +3y7 5.6 
628.674 643.414 +3y5 5.6 
    
B. A3KN51_TSG101_DEELSSALEK 
Q1 
Mass (Da) 
Q3 
Mass (Da) 
Charge 
Retention time 
(min) 
560.772 747.425 +2y7 5.7 
560.772 661.268 +2b6 5.7 
560.772 574.235 +2b5 5.7 
    
C. Q08DN8_Flotillin-1_LTGVSISQVNHKPLR 
Q1 
Mass (Da) 
Q3 
Mass (Da) 
Charge 
Retention time 
(min) 
824.978 1078.61 +3y9 5.6 
824.978 999.547 +1b10 5.6 
824.978 385.256 +2y3 5.6 
    
D. Q08DN8_Flotillin-1_ISLNTLTLNVK 
Q1 
Mass (Da) 
Q3 
Mass (Da) 
Charge 
Retention time 
(min) 
608.369 788.488 +2y7 5.5 
608.369 743.43 +1b7 5.5 
608.369 642.382 +3b6 5.5 
 
Mass Spectrometric Analysis of High and Low Fertility Plasma Exosomes: Proteomic 
Profile. 
Mass spectrometric analysis, with a set false discovery rate (FDR) of 5% for proteins and at 
least two peptides above the 95% confidence area, identified a total of 120 proteins in the 
exosomes isolated from plasma of high and low fertility heifers (Figure 5.1.2, Table 5.1.3 
and Supplemental Table S5.1.1 (see APPENDICES)). The total spectra and peptide number 
for each protein of 12 individual cows from each group is presented in Supplemental Table 
S5.1.2 (see APPENDICES). There were 85 in common proteins between the two groups 
(Figure 5.1.2).  Four proteins were unique to the exosomes isolated from plasma from high 
fertility heifers, while 31 proteins were unique to the exosomes isolated from plasma from 
low fertility heifers. 
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The proteins identified by mass spectrometry were further clustered into biological 
processes and molecular function, as defined by the PANTHER classification system and 
GO algorithms (Table 5.1.3 and Supplemental Table S5.1.1 (see APPENDICES)). CD5L 
(accession number F1N514) is identified as common to both the plasma exosomes from 
high and low fertility heifers (Supplemental Table S5.1.1 (see APPENDICES)). This protein 
was reported by de Menezes-Neto et al., 2015 to be a suitable exosomal marker for the 
identification of plasma-derived exosomes by mass spectrometry (de Menezes-Neto et al., 
2015). Through the PANTHER classification system and GO algorithms, CD5L is revealed 
to have roles in biological processes (i.e. cellular process, localisation and metabolic 
process) and molecular functions (i.e. catalytic activity and receptor activity). 
 
Keratin, type II cytoskeletal 6A (accession number M0QVY0) and keratin, type II cytoskeletal 
1 (accession number G3N0V2) were proteins identified unique to plasma exosomes from 
high fertility heifers (Table 5.1.3A). Through PANTHER and GO algorithms classification, 
keratin, type II cytoskeletal 6A (accession number M0QVY0) and keratin, type II cytoskeletal 
1 (accession number G3N0V2) were found to have structural molecular activity and is mainly 
associated with cellular component organisation or biogenesis, and cellular processes. The 
PANTHER and GO algorithms also attempts to predict an uncharacterised protein 
(accession number G5E5V1) identified unique to plasma exosomes from high fertility heifers 
and assigned to have a role for stimulus-response (Table 5.1.3A). 
 
Glycodelin (accession number G5E5H7), and kelch-like protein 8 (accession number 
E1BPB7) were unique proteins identified in plasma exosomes from low fertility heifers (Table 
5.1.3B) and were mainly associated with a role for cellular and metabolic processes and has 
catalytic activity. Whereas, the tetratricopeptide repeat protein 41-related (accession 
number F1MRZ1), a unique protein identified in plasma exosomes from low fertility heifers 
was not assigned with a role for biological process and molecular function that was covered 
by PANTHER classification system and GO algorithms. 
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Figure 5.1.2. Proteomic analysis of exosomes isolated from the plasma of high and 
low fertility heifers. The Venn diagram comparison between the common and unique 
proteins identified by liquid chromatography tandem-mass spectrometry in exosomes 
isolated from plasma of the high and low fertility heifers. 
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Table 5.1.3. List of unique proteins identified in plasma exosomes of high and low fertility heifers. 
A. List of the unique proteins identified in plasma exosomes of high fertility heifers 
Accession 
number Name Gene name Biological Process Molecular Function 
M0QVY0 
Uncharacterised protein (Keratin, 
type II cytoskeletal 6A) KRT6A  
Cellular component 
organisation or biogenesis 
/ Cellular process 
Structural molecule 
activity 
G5E5V1 
Uncharacterised protein 
(SUBFAMILY NOT NAMED)  Response to stimulus  
Q2KIV9 
Complement C1q subcomponent 
subunit B  C1QB    
G3N0V2 
Uncharacterised protein (Keratin, 
type II cytoskeletal 1) KRT1  
Cellular component 
organisation or biogenesis 
/ Cellular process 
Structural molecule 
activity 
 
B. List of the unique proteins identified in plasma exosomes of low fertility heifers 
Accession 
number Name Gene name Biological Process Molecular Function 
K4JDR8 Alpha-2-macroglobulin variant 5  A2M    
Q2HJF3 Origin recognition complex subunit 6  ORC6  
Cellular process / 
Metabolic process Binding 
Q95121 Pigment epithelium-derived factor  SERPINF1  Biological regulation Catalytic activity 
G5E5H2 
Uncharacterised protein 
(SUBFAMILY NOT NAMED)  Response to stimulus  
A5PJT7 ECM1 protein  ECM1    
F1MJ31 
Uncharacterised protein (Adenylate 
kinase 9) AK9  Metabolic process Catalytic activity 
A7MB82 C1QTNF3 protein  C1QTNF3  
Multicellular organismal 
process  
E1BFW7 
Uncharacterised protein (DNA-
binding protein RFX7) RFX7  
Cellular process / 
Metabolic process Binding 
Q56JW3 
Nucleoside-diphosphate kinase 
NBR-A  LOC574091    
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G3MWT1 Uncharacterised protein     
F1MH61 
Uncharacterised protein (Protein 
FAM98B) FAM98B    
B0JYQ0 ALB protein  ALB    
Q9BGU1 Histidine-rich glycoprotein  BTHRG    
F1MM86 Complement component C6  C6    
F1MZ96 Uncharacterised protein     
F1MRZ1 
Uncharacterised protein 
(tetratricopeptide repeat protein 41-
related)    
E1BKU2 Septin-2  SEPT2   
E1BNR0 
Uncharacterised protein 
(Apolipoprotein B-100) APOB  Metabolic process Transporter activity 
Q58DG7 
TBP-associated factor 6 isoform 
alpha  TAF6  
Cellular component 
organisation or biogenesis 
/ Cellular process / 
Metabolic process Binding 
A5PKL1 Oxidation resistance protein 1  OXR1    
G5E5H7 
Uncharacterised protein 
(Glycodelin) PAEP  
Cellular process / 
Localisation / Metabolic 
process Binding / Catalytic activity 
O46375 Transthyretin  TTR  
Cellular process / 
Metabolic process Binding 
F1MD73 
Uncharacterised protein (Deleted in 
malignant brain tumors 1 protein)  
Cellular process / 
Localisation / Metabolic 
process 
Catalytic activity / 
Receptor activity 
P01030 Complement C4 (Fragments)  C4  
Cellular process / 
Metabolic process / 
Response to stimulus Binding / Catalytic activity 
E1BMJ0 
Uncharacterised protein (Plasma 
protease C1 inhibitor) SERPING1  Biological regulation Catalytic activity 
F1MIW8 Desmoglein-1  DSG1    
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E1BDK9 
Uncharacterised protein (All-trans-
retinol 13,14-reductase) RETSAT  
Biological regulation / 
Cellular process / 
Metabolic process Catalytic activity 
F1MKE9 Spectrin beta chain  SPTB  
Cellular process / 
Developmental process 
Binding / Structural 
molecule activity 
F5XVA9 von Willebrand factor  VWF    
P02663 Alpha-S2-casein  CSN1S2    
E1BPB7 
Uncharacterised protein (Kelch-like 
protein 8) KLHL8  
Cellular process / 
Metabolic process Catalytic activity 
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DISCUSSION 
Dairy cow fertility is important for the profitability and sustainability of dairy farms, especially 
in strict seasonal-calving pasture-based systems to ensure that the cows are able to calve 
within the seasonal production system (Burke and Verkerk, 2010). We hypothesised that 
heifers selected on the basis of differential fertility EBV would have exosomal signatures in 
plasma representative of their fertility genotype. A greater number of exosomes were 
observed in the high fertility group as compared with the low fertility group. Interestingly, the 
exosomes from plasma of the low fertility group revealed greater protein abundance when 
compared with the high fertility group. The differences in the numbers and protein content 
of exosomes in the plasma may be associated with the differences in fertility breeding value. 
It is also plausible that differences in the body condition score, total longevity as well as 
somatic cell count score (Table 5.1.1) of the high and low fertility heifers could also contribute 
to differences in the numbers and protein content of exosomes in the plasma. 
 
A recent study (Mitchell et al., 2016) compared the exosomes from plasma of dairy cows 
with divergent fertility phenotypes (fertile and subfertile). These cows differed in their genetic 
ancestry, with subfertile being a North American Holstein-Friesian strain (>92% North 
American genetics) and fertile being a New Zealand Holstein-Friesian strain (<23% North 
American genetics). In the study by Mitchell et al., the subfertile dairy cows also had fewer 
exosomes and a greater protein abundance encapsulated within the plasma exosomes. This 
finding is similar to the current study, which compared exosomes from plasma of heifers with 
similar genetic ancestry, but generated to only have higher or lower fertility through 
developing extreme diversity in fertility breeding values. 
 
Koch et al. evaluated differences in proteomic content in uterine lumen of non-pregnant and 
early pregnant ewes by LC MS/MS and identified a unique proteomic signature in early 
pregnant ewes compared to non-pregnant (Koch et al., 2010).  Exosomal differences 
(exosomal content - i.e. miRNAs, RNAs, and proteins) from exosomes isolated from uterine 
fluid of pregnant and cyclic ewes was investigated by Burns et al. (Burns et al., 2014). 
Importantly, the differences in the exosomal profiles between the two groups may be 
dependent on the cell type from which they originate (e.g. conceptus and/or maternal 
endometrium) and could serve to reflect the physiological and/or pregnancy status of ewes 
(Burns et al., 2014). In addition, Nakamura et al. reported that conceptus-derived exosomes 
from the uterine flushings of day 15 and 17 pregnant ewes contained functional proteins, 
including macrophage-capping protein (CAPG), aldo-keto reductase family 1, member B1 
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protein (AKR1B1), and interferon-tau (IFNτ). This study demonstrated that these exosomes 
upregulated the expression of several interferon stimulated genes of endometrial epithelial 
cells, suggesting that exosomes released from the conceptus may be important during the 
attachment of the conceptus to the maternal endometrium and establishment of pregnancy 
(Nakamura et al., 2016). 
 
It is well recognised that exosomes released into the extracellular space and/or into the 
circulation are an important signalling system that transfers biomolecules between different 
cells under normal as well as pathological conditions (Koniusz et al., 2016). The proteomic 
profiling by Reinhardt et al. revealed that protein diversity in milk exosomes may be 
contributed by the different types of cells present in the milk compartment, including immune 
cells and the secretory epithelia (Reinhardt et al., 2012). Furthermore, the same group also 
evidenced that the milk exosome proteome changes during physiological (e.g. mid lactation) 
and pathological conditions (e.g. mastitis) (Reinhardt et al., 2013). Due to the nature of their 
formation, exosomes provide important functional information of the propagating cell. 
Hence, elucidating the biomolecules encapsulated within these exosomes can provide 
details to the overall health status of dairy cows, including the fertility status of dairy cows 
(Pohler et al., 2017, Mitchell et al., 2016). 
 
Our mass spectrometric analysis revealed a total of 120 distinct proteins (both high and low 
fertility groups), of which 85 proteins (70%) were common to plasma exosomes of both high 
and low fertility heifers.  Interestingly, 31 proteins were identified unique to the plasma 
exosomes of the low fertility heifers, and 4 unique proteins in high fertility heifers. 
 
Notably, the tetratricopeptide repeat protein 41-related (accession number F1MRZ1), 
glycodelin (accession number G5E5H7), and kelch-like protein 8 (accession number 
E1BPB7) were identified as unique to low fertility heifers and, therefore, may have vital roles 
in fertility. The tetratricopeptide repeat protein 41-related is a protein-protein interaction 
module that consists of the tetratricopeptide repeat motifs which serve as scaffolds for the 
assembly of different multiprotein complexes (Zeytuni and Zarivach, 2012). Increasingly, 
studies have indicated the association of tetratricopeptide repeat motif and its role in the 
regulation of reproductive development (Tranguch et al., 2005, Yang et al., 2006, Yu et al., 
2016, Xu et al., 2015, Gray et al., 2006). Tsukahara et al. (1996) identified a Down syndrome 
critical region of chromosome 21q22.2, which encodes a protein possessing the 
tetratricopeptide repeat motif. An overexpression of the gene was found to cause several 
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morphological anomalies in the brain of a Down syndrome fetus (Tsukahara et al., 1996). 
To date, no specific studies are available on the role of tetratricopeptide repeat protein 41-
related in the formation of multi-protein complexes. Tetratricopeptide repeat protein 41-
related was also not assigned with a role for biological process and molecular function that 
was covered by PANTHER classification system and GO algorithms. However, identifying 
and elucidating the protein(s) in which tetratricopeptide repeat protein 41-related interacts 
may improve our knowledge on protein-protein interaction that are important in bovine 
fertility and reproduction. 
 
Glycodelin, identified uniquely to the low fertility heifers, is a progesterone-regulated 
glycoprotein that can have different functions depending on progesterone concentration at 
different phases of the reproductive cycle (Uchida et al., 2013). Through PANTHER 
classification system and GO, glycodelin was identified to have catalytic activity and is 
associated with a role for cellular and metabolic processes. Studies have shown that 
glycodelin is synthesised in the endometrium (Spencer et al., 2004, Seppala et al., 2002) as 
well as the luteinised granulosa cells of the ovary and is present in follicular fluid (Glister et 
al., 2014, Rizos et al., 2016). The timely expression of glycodelin during reproduction, in 
particular fertilisation and implantation, is regulated by the endocrine system (Taheripanah 
et al., 2017, Seppala et al., 1997). The increased expression of glycodelin during the period 
of endometrial receptivity, is essential for the immunologic (Alok and Karande, 2009) and 
hormonal (Uchida et al., 2005) regulation of reproduction. However, the presence of 
glycodelin during the fertilisation period can cause fertilisation to fail by suppressing sperm 
capitation and inhibit the binding of spermatozoa to the zona pellucida (Koistinen et al., 
2003), thus not favoring sperm-egg fertilisation and ovum formation. 
 
Kelch-like protein 8 (KLHL8) was also identified in exosomes from plasma of low fertility 
heifers. Through the PANTHER classification system and GO, KLHL8 was identified to have 
catalytic activity and is associated with a role for cellular and metabolic processes. 
Expression of the KLHL8 gene was initially identified as preferentially expressed in the 
female gonads of fish (zebrafish and carbiomedaka) where it may play a role in oogenesis 
(Gautier et al., 2011). Strucken et al. (2012) demonstrated that KLHL8 could affect the non-
return rate (defined as the percentage of inseminated cows that are pregnant at 56 days 
after service) in heifers by regulating the ovulation process and suggested the use of KLHL8 
as a candidate ovary-specific gene marker for the detection of the non-return rate in heifers 
(Strucken et al., 2012). 
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In conclusion, our study has demonstrated that exosomes carry important messages that 
could reveal the fertility status and physiological condition of the cow. The current study 
examined the proteome of plasma exosomes from high and low fertility heifers using a high 
throughput mass spectrometric discovery approach to unravel new information and potential 
candidate proteins for fertility. However, further validation of potential candidate proteins 
through a targeted quantification approach will further strengthen the development of those 
proteins as markers for fertility. A thorough investigation into the functions of exosomal 
protein cargo (e.g. biological processes and molecular functions) and how these 
biomolecules (e.g. proteins) are regulated, particularly those that affect dairy cow fertility, 
may reveal key biological signals that could aid the assessment of the fertility status of dairy 
cows. This may potentially lead to the development of prognostic tools and interventions to 
improve dairy cow fertility. 
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In chapter 5.1 I examined the plasma exosomal content from heifers that were bred to have 
high or low fertility. The number of exosomes isolated from the plasma of low fertility heifers 
was lower compared with high fertility heifers, although a greater protein content was 
estimated in the exosomes from low fertility heifers. The exosomal proteomic profile, 
evaluated using information-dependent acquisition on TripleTOF 5600 system mass 
spectrometry, revealed proteins (notably the tetratricopeptide repeat protein 41-related, 
glycodelin, and kelch-like protein 8) associated with specific biological processes and 
molecular functions of fertility. These findings highlight the potential for exosomal proteomic 
profiles to provide information on the fertility and physiological status of heifers. 
 
Based on the different exosomal proteomic profiles observed in heifers that were bred to 
have high or low fertility, I further investigated (Chapter 5.2) the effects of exosomes from 
high and low fertility heifers on inflammatory mediator gene expression and cytokine 
production by endometrial stromal and epithelial cells. 
 
Chapter 5.2 is comprised of a paper ‘Inflammatory mediator regulation in bovine endometrial 
stromal and epithelial cells by plasma exosomes from heifers with divergent genetic merit 
for fertility’ submitted to Reproduction, Fertility and Development: 
 
Koh, YQ, Peiris, HN, Vaswani, K, Almughlliq, FB, Meier, S, Burke, CR, Roche, JR, Reed, 
CB & Mitchell, MD 2018, 'Inflammatory mediator regulation in bovine endometrial stromal 
and epithelial cells by plasma exosomes from heifers with divergent genetic merit for fertility 
',  Reprod Fertil Dev (Under review) 
 
As per the University of Queensland requirements, the submitted version of the manuscript 
is presented herein. However, in order to suit the thesis structure, the formatting of the 
original tables and figures were changed accordingly. The referencing citation numbering 
has also been updated to continue the citation sequence of the previous chapter. 
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ABSTRACT 
Abnormalities in endometrial function contribute to poor fertility and reproductive failure. 
Exosomes are small lipid vesicles that contain transferable bioactive substances; they 
participate in intercellular signalling and may have critical roles in reproductive mechanisms, 
including endometrial remodeling in preparation for pregnancy. In this study, we evaluated 
the effects of plasma exosomes from heifers with high and low genetic merit for fertility on 
bovine endometrial epithelial and stromal cell functions that included inflammatory mediator 
gene expression and cytokine production. Co-incubation of exosomes from low, compared 
with high, fertility heifers upregulated the gene expression of pro-inflammatory IL-1α and IL-
8 (CXCL8) but downregulation of IL-4 gene expression in epithelial cells. In contrast, stromal 
cells co-incubated with plasma exosomes from low, when compared with high, fertility 
heifers resulted in downregulation of gene expression of pro-inflammatory chemokines 
CXCL9, CXCL10, and CX3CL1. Our findings demonstrate that exosomes modulate 
endometrial cell function. It is likely that the low fertility heifers, when compared with high 
fertility heifers, have an activated pro-inflammatory uterine microenvironment that can have 
an impact on uterine receptivity. However, an in-depth investigation is required to elucidate 
the role of exosomes in regulating endometrial remodeling events required for enhanced 
reproductive performance and fertility in dairy cows. 
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INTRODUCTION 
Many physiological events that occur within the microenvironment of the uterus are driven 
by immunological and endocrinological processes, which are recognised as important 
regulators of uterine function (Critchley et al., 2001, King and Critchley, 2010, Shynlova et 
al., 2013). Exosomes have emerged as important regulators of molecular processes, 
reflected in their ability to shuttle bioactive molecules (e.g. proteins, miRNAs, and 
eicosanoids (Zaborowski et al., 2015, Peiris et al., 2017)) between cells, leading to the 
reprogramming of the recipient cells; hence their association with intercellular 
communication (Nazimek et al., 2015, Corrado et al., 2013). 
 
Exosomes are small membrane-bound vesicles ranging from 30-120 nm (as measured by 
electron microscopy) and are released into the extracellular environment by most cell types. 
Due to their endocytic origins, exosomes are characterised and identified by the abundance 
of endosome-associated proteins (e.g. flotillin and annexins), which are endosomal sorting 
complexes required for transport (ESCRT) machinery proteins (e.g. TSG101) and 
tetraspanins (e.g. CD63) (Akers et al., 2013, Raposo and Stoorvogel, 2013). 
 
An increasing number of studies have reported that exosomes display immunomodulatory 
properties (Williams et al., 2013, McCracken et al., 2016, Robbins and Morelli, 2014) and 
may act as paracrine/endocrine effectors for the establishment and maintenance of 
pregnancy (Machtinger et al., 2016, Nakamura et al., 2016). McCracken et al. (McCracken 
et al., 2016) reported that FasL positive exosomes can induce p65 suppression by activating 
Fas on maternal T-cells, while TRAIL positive exosomes induced T-cell apoptosis but did 
not suppress p65 expression during pregnancy, indicating that FasL positive and TRAIL 
positive exosomes from plasma of pregnant women can alter T-cell function and have an 
immunomodulatory role during pregnancy. Bai et al. (Bai et al., 2018) reported that seminal 
exosomes from boars can induce the expression of immune-related genes in the porcine 
uterus, while downregulating genes associated with steroid biosynthetic process and 
metabolic pathways. Nakamura et al. (Nakamura et al., 2016) demonstrated that IFNT-
containing exosomes derived from the conceptuses from sheep can upregulate several 
interferon stimulated genes in uterine cells, suggesting paracrine actions of conceptus-
derived exosomes on maternal endometrium. 
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Few studies have evaluated the link between exosomes and maternal physiology (e.g. 
fertility status), and the reproductive system (e.g. uterus). Aberrant inflammation of the 
endometrium can negatively impact fertility and uterine health (McDougall et al., 2011, 
Sheldon et al., 2014, Sheldon et al., 2006).  Therefore, in the present study, we investigated 
the effects of plasma exosomes from heifers with divergent genetic merit for fertility on the 
epithelial and stromal cells of bovine endometrium focusing on the alterations of 
inflammatory mediator gene expression (e.g. cytokines and chemokines) and cytokine 
production. We hypothesised that plasma exosomes from heifers with high and low genetic 
merit for fertility will differentially modulate inflammatory mediator gene expression (e.g. 
cytokines and chemokines) and cytokine production by bovine endometrial cells. 
 
MATERIALS AND METHODS 
Animals, management and blood collection 
The animals and their management, as well as the procedures for sample collections were 
approved by the Ruakura Animal Ethics Committee (AEC 13574 and 13934). The animals 
used in this study were part of a larger experiment (n = 60 Holstein-Friesian heifers) from a 
recently established fertility animal model described by Meier et al. (Meier et al., 2017). From 
this larger group, 24 heifers were identified as being either high fertility (HighFert, n = 12) or 
low fertility (LowFert, n = 12) based on the extreme diversity in their estimated breeding 
value (EBV) for fertility, but being similar in genetic character for other key traits (e.g. body 
weight, milk production, and percentage of North American genetics). The details of the 
genetic merit of the 24 heifers are presented in Table 5.1.1. All heifers used in the current 
study were post-pubertal, and have expressed a minimum of one spontaneous oestrus 
(Meier et al., 2017). To minimise interventions and better understand the underlying drivers 
of fertility in dairy cattle, the timing of sampling was aligned with an oestrus event stimulated 
by prostaglandin (500 µg cloprostenol (Ovuprost, Bayer, New Zealand Ltd)) as described in 
Reed et al. (Reed et al., 2017). Blood samples were collected into EDTA Vacutainer tubes 
(Greiner Bio-one, Kremsmunster, Austria) from a jugular vein during the preovulatory phase 
of the oestrous cycle. The blood samples were centrifuged at 1,120 × g for 12 min at 4°C, 
and the plasma aspirated and stored at -80°C.  
 
Plasma exosome isolation and characterisation from high and low fertility heifers 
Exosomes were isolated by coupling ultracentrifugation and size exclusion chromatography. 
This methodology was characterised and validated in detail in publication (Koh et al., 2018a, 
Koh et al., 2018c). In brief, the extracellular vesicles (i.e. 100,000 × g pellet) were obtained 
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following differential ultracentrifugation of EDTA plasma (10mL plasma from HighFert (n=12) 
and LowFert (n=12) heifers). The 100,000 × g pellet was then reconstituted in 500 µL PBS 
and layered on a size exclusion column. Our validation studies using immunoblotting and 
transmission electron microscope confirmed the presence of exosomal markers and 
exosomes respectively. 
 
Bovine endometrial epithelial and stromal cell culture experiments 
Well characterised bovine endometrial epithelial (bEEL) and stromal (bCSC) cells 
(Krishnaswamy et al., 2009, Fortier et al., 1988) were a generous gift from Professor Michel 
A. Fortier (Université Laval, Québec). bEEL epithelial cells and bCSC stromal cells were 
also previously investigated and characterised under conditions that mimic physiological 
stress associated with reduced fertility (e.g. infection and inflammation) (Koh et al., 2018b). 
In this study, bEEL epithelial cells (seeded at 35,000 cells per well) and bCSC stromal cells 
(seeded at 8,000 cells per well) were cultured in a 24-well culture plates (Corning Costar) 
supplemented with RPMI media (Gibco, Thermo Fisher Scientific Australia Pty Ltd, 
Scoresby Vic) containing exosome depleted 10% fetal bovine serum (Bovorgen, Interpath 
Services Pty. Ltd.) and 1,000 U/mL antibiotic-antimycotic solution (Gibco, Thermo Fisher 
Scientific Australia Pty. Ltd.) in a humidified cell culture incubator at 37°C under an 
atmosphere of 5% CO2-balanced N2.  For the coculture experiment (treatment with 
exosomes), fetal bovine serum–free RPMI media, containing 1,000 U/mL antibiotic-
antimycotic solution (Gibco, Thermo Fisher Scientific Australia Pty Ltd.), was used. We 
evaluated the effects of plasma exosomes from HighFert (n = 12) and LowFert heifers (n = 
12) on inflammatory mediator gene expression and cytokine production of endometrial cells. 
Treatments were 1) with no addition of exosomes (no exosomes control, for baseline 
measurements), 2) plasma exosomes from HighFert heifers (1 x 108 particles per mL), 3) 
plasma exosomes from LowFert heifers (1 x 108 particles per mL), 4) sonicated pooled 
plasma exosomes from HighFert heifers (sonicated 1 x 108 particles per mL) or 5) sonicated 
pooled plasma exosomes from LowFert heifers (sonicated 1 x 108 particles per mL). 
Exosomal dosage was chosen based on our previous study (Almughlliq et al., 2017) and to 
abolish the effect of exosomes on endometrial cells, plasma exosomes from HighFert and 
LowFert heifers were sonicated for 30 min (sonication bath) as previously validated 
(Salomon et al., 2016). The time of 24 h was chosen for gene expression analyses based 
on a time-course study in endometrium which had previously demonstrated induced gene 
expression associated with pro-inflammatory pathways, including nuclear factor kappa B 
(NF-kB) signalling and chemokine signalling pathways when co-incubated with exosomes 
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for 24 h (Srinivasan et al., 2017). Conditioned media samples were collected at 36 h for IL-
6 and IL-10 production analyzed by Enzyme-Linked Immunosorbent Assays (ELISA details 
given below) (Srinivasan et al., 2017). Well and assay incubations were in duplicate per cow. 
Cells and conditioned media collected were stored at -80°C until further analyses. 
 
RNA Extraction and cDNA Synthesis 
The isolation of total RNA from the samples (bEEL and bCSC cells) followed the 
manufacturer’s protocol using a RNeasy Mini kit (Qiagen, Victoria, Australia) and RNase-
free DNase (Qiagen, Victoria, Australia) was used to remove any contaminating DNA. The 
concentration and purity of RNA was further determined using a Nanodrop ND-1000 
(Nanodrop Technologies, Wilmington, Delaware). 500 ng of RNA was reverse transcribed 
into complementary DNA (cDNA) using the RT2 First Strand Kit (Qiagen, Victoria, Australia). 
The cDNA samples were kept at –20°C until further analyses. 
 
Inflammatory Mediator Gene Expression Analyses 
Real-time PCR (RT-PCR) quantification of inflammatory mediator gene expression was 
performed using a customised bovine cytokine and chemokine RT2 Profiler PCR Array 
(CAPB13849; Qiagen, Victoria, Australia). The reaction mixture was prepared using the RT2 
Real-Timer SyBR Green/ROX PCR Mix kit (Qiagen, Victoria, Australia) following the 
manufacturer’s instructions. Briefly, RT-PCR was performed using the QuantStudio ™ 3 
Real-Time PCR System (Applied Biosystems ™, Foster City, California) with an initial 10 
min incubation at 95°C followed by 40 cycles at 95°C for 15 seconds and 60°C for 60 
seconds. The specificity of the RT-PCR products was confirmed by analysis of melting 
curves. Gene expression data which met the cycle threshold cut-offs (<35) were analyzed. 
PCR reproducibility, reverse transcription efficiency and the presence of genomic DNA 
contamination was verified prior to further data analyses using the SABiosciences web 
portal, (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). The data collected 
for inflammatory mediator gene expression were normalised against the expression of the 
endogenous reference genes, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
hypoxanthine phosphoribosyltransferase 1 (HPRT1), and TATA box binding protein (TBP) 
which had showed no significant differences in the gene expression between the treatment 
groups (HighFert and LowFert heifers) and media control (no exosomes control) of bEEL 
and bCSC cells. 
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Enzyme-Linked Immunosorbent Assays (ELISA) 
The concentrations of IL-6 in the supernatant of cell cultures were measured using ELISA 
kits following the manufacturer’s instructions (Bovine IL-6 ELISA reagent kit ESS0029; 
Thermo Scientific; Frederick, MD, USA). The IL-6 ELISA plate was prepared by coating the 
wells with 100 μL per well of capture antibody diluted in 0.2 M sodium carbonate-bicarbonate 
buffer (pH9.4), sealed with a plate sealer and incubated overnight at room temperature. The 
coating antibody solutions were aspirated and blocked in assay diluents at room 
temperature for 1 h. 100 μL of standard or sample was added to the wells and incubated at 
room temperature for 1 h with moderate shaking. The wells were then washed three times 
with wash buffer to remove non-specifically bound materials and added with 100 μL of 
detecting antibody. After 1 h of incubation at room temperature in 100 μL of detecting 
antibody, the liquid was aspirated and the wells were washed three times with wash buffer. 
100 μL of streptavidin-HRP diluted in reagent diluent were added to the well and incubated 
at room temperature for 30 min. Liquid was aspirated and the wells were washed three times 
with wash buffer to ensure any dried-on conjugate is re-solubilised and washed away. 100 
μL of stop solution was added to each well after wells were incubated in the dark for 20 min 
in 100 μL of substrate solution. The absorbance (absorbance at 450 nm minus absorbance 
at 550 nm) was measured by the SPECTROstar Nano microplate reader (BMG LABTECH, 
Offenburg, Germany). The detection range for IL-6 is 78-5000 pg/mL. 
 
The concentrations of IL-10 in the supernatant of cell cultures were measured by ELISA kits 
following the manufacturer’s instructions (Bovine IL-10 ELISA reagent kit MBS008726; San 
Diego; California, USA). In brief, 50 μL of standard or sample was added to the wells and 
incubated at 37ºC for 1 h. The wells were then washed four times with wash buffer and 
added with 50 μL of Chromogen Solution A and 50 μL of Chromogen Solution B to each well 
successively. The plate was incubated in the dark at 37ºC for 15 min and the reaction was 
stopped with 50μL stop solution. The absorbance was measured at 450 nm by the 
SPECTROstar Nano microplate reader (BMG LABTECH). The detection range for IL-10 is 
15.6-500 pg/mL. 
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Statistical Analyses 
The data for the inflammatory mediator gene expression were analyzed through the 
SABiosciences web portal, 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php) as discussed previously. 
Statistical analyses were performed using a commercially-available software package 
(Prism 6, GraphPad Inc, La Jolla, CA 92037 USA). A non-parametric Kruskal-Wallis one-
way ANOVA was performed to compare the inflammatory mediator gene expression in bEEL 
and bCSC cells between all treatment groups. And the student’s t-tests (two-tailed) were 
utilised to compare the inflammatory mediator gene expression in bEEL and bCSC cells 
between the treatment groups (plasma exosomes from HighFert and LowFert heifers). The 
comparison of IL-6 and IL-10 production between the treatment groups (plasma exosomes 
from HighFert and LowFert heifers) and the media control (no exosomes control) were 
analyzed using a non-parametric Kruskal-Wallis one-way ANOVA. For all statistical 
analyses, a P-value of <0.05 was considered statistically significant. The results are 
presented as means ± SEM. 
 
RESULTS 
Characterisation of plasma exosomes from high and low fertility heifers 
The characterisation of plasma exosomes from LowFert and HighFert heifers used in this 
study was presented previously in Koh et al (Koh et al., 2018c). The exosomes were 
characterised accordingly to the requirements described by Witwer et al. (Witwer et al., 
2013) and Lotvall et al. (Lotvall et al., 2014). Exosomal markers (i.e. Flotillin-1, TSG101, and 
CD63) and morphology were confirmed in the plasma exosomes of LowFert and HighFert 
heifers (Koh et al., 2018c). 
 
The effect of plasma exosomes from high and low fertility heifers on inflammatory 
mediator gene expression of bovine endometrial epithelial cells (bEEL) 
The RT-PCR array data for inflammatory mediator gene expression in bovine endometrial 
epithelial cells (bEEL) co-incubated with plasma exosomes from HighFert and LowFert 
heifers are presented in Figure 5.2.1 and in Supplemental Table S5.2.1 (see 
APPENDICES). From a total of 29 genes analyzed, three inflammatory mediator genes were 
significantly altered in bEEL cells by plasma exosomes from HighFert and LowFert heifers 
(Figure 5.2.1, Supplemental Table S5.2.1 (see APPENDICES)). Gene expression data that 
did not meet the cycle threshold cut-offs (<35) or were not altered by plasma exosomes 
treatment on bEEL cells are in Supplemental Table S5.2.1 (see APPENDICES). The gene 
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expression of IL-1α (P < 0.05) and CXCL8 (P < 0.01) were upregulated, whereas gene 
expression of IL-4 (Figure 5.2.1C, P < 0.01) was downregulated in bEEL cells when co-
incubated with plasma exosomes from LowFert heifers compared with plasma exosomes 
from HighFert heifers and when compared with media control (no exosomes control) (Figure 
5.2.1A-C). No significant differences in the gene expression of inflammatory mediators were 
observed when bEEL cells were co-incubated with plasma exosomes from HighFert heifers 
in comparison with media control (no exosomes control) (Figure 5.2.1A-C). The sonicated 
plasma exosomes from HighFert and LowFert heifers did not alter the inflammatory mediator 
gene expression in bEEL cells (Figure 5.2.1A-C). 
 
The effect of plasma exosomes from high and low fertility heifers on inflammatory 
mediator gene expression of bovine endometrial stromal cells (bCSC) 
From a total of 29 genes analyzed, four inflammatory mediator genes were significantly 
altered in bCSC cells by plasma exosomes from HighFert and LowFert heifers (Figure 5.2.2, 
Supplemental Table S5.2.2 (see APPENDICES)). The gene expression data that did not 
meet the cycle threshold cut-offs (<35) or were not altered by plasma exosomes treatment 
on bCSC cells are in Supplemental Table S5.2.1 (see APPENDICES). The co-incubation of 
bCSC cells with plasma exosomes from LowFert heifers downregulated the gene expression 
of CXCL9 (P < 0.01), CXCL10 (P < 0.05) and CX3CL1 (P < 0.05) when compared with bCSC 
cells co-incubated with plasma exosomes from HighFert heifers and when compared with 
media control (no exosomes control) (Figure 5.2.2A-D). No differences were found in 
inflammatory gene expression when bCSC cells were co-incubated with plasma exosomes 
from HighFert heifers, compared with media control (no exosomes control) (Figure 5.2.2A-
D). The sonicated plasma exosomes from HighFert and LowFert heifers did not alter the 
inflammatory mediator gene expression in bCSC cells (Figure 5.2.2A-D). 
 
The effects of plasma exosomes from high and low fertility heifers on IL-6 and IL-10 
production by bovine endometrial epithelial (bEEL) and stromal (bCSC) cells 
No significant differences were found in IL-6 and IL-10 production by bEEL cells co-
incubated with exosomes from HighFert versus LowFert heifers (Figure 5.2.3 and 5.2.4). 
bCSC cells co-incubated with exosomes from both high and low fertility heifers stimulated 
IL-6 production by bCSC cells (Figure 5.2.3B, P < 0.05) but not IL-10 production (Figure 
5.2.4B). 
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Figure 5.2.1. The effect of plasma exosomes from high and low fertility heifers on 
inflammatory mediator gene expression of bovine endometrial epithelial cells (bEEL). 
(A) IL-1α, (B) CXCL8 (IL-8), and (C) IL-4 are their relative fold gene expression in bEEL cells 
when co-incubated for 24 h with plasma exosomes from HighFert and LowFert heifers, 
media control (no exosome control) and sonicated exosomes from HighFert and LowFert 
heifers. Data are means ± SEM (n=12), and the gene expression was normalised against 
the expression of the endogenous reference genes (GAPDH, HPRT1, and TBP). 
Differences of P < 0.05 are considered statistically significant with comparisons between 
bEEL cells co-incubated with media control (no exosomes control) denoted by (a) and bEEL 
cells co-incubated with exosomes from HighFert heifers (b). 
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Figure 5.2.2. The effect of plasma exosomes from high and low fertility heifers on 
inflammatory mediator gene expression of bovine endometrial stromal cells (bCSC). 
(A) CXCL9, (B) CXCL10, (C) CCL5, and (D) CX3CL1 are their relative fold change in gene 
expression in bCSC cells when co-incubated for 24 h with plasma exosomes from HighFert 
and LowFert heifers, media control (no exosome control) and sonicated exosomes from 
HighFert and LowFert heifers. Data are means ± SEM (n = 12). The gene expression was 
normalised against the expression of the endogenous reference genes (GAPDH, HPRT1, 
and TBP). Differences of P < 0.05 are considered statistically significant with comparisons 
between bCSC cells co-incubated with exosomes from LowFert heifers and media control 
(no exosomes control) denoted by (a) and bCSC cells co-incubated with exosomes from 
HighFert heifers (b).  
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Figure 5.2.3. The effects of plasma exosomes from high and low fertility heifers on IL-
6 production by bovine endometrial epithelial (bEEL) and stromal (bCSC) cells. (A) 
bEEL and (B) bCSC are cellular IL-6 production when co-incubated for 36 h with plasma 
exosomes from HighFert and LowFert heifers, media control (no exosome control) and 
sonicated exosomes from HighFert and LowFert heifers. Data are means ± SEM (n=12). A 
difference of P < 0.05 is considered statistically significant. Comparisons against bCSC cells 
co-incubated with media control (no exosomes control) are denoted by (a). 
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Figure 5.2.4. IL-10 production by bovine endometrial epithelial (bEEL) and stromal 
(bCSC) cells was not affected by plasma exosomes from high and low fertility heifers 
(A) bEEL and (B) bCSC are cellular IL-10 production when co-incubated for 36 h with plasma 
exosomes from LowFert and HighFert heifers, media control (no exosome control) and 
sonicated exosomes from HighFert and LowFert heifers. Data are means ± SEM (n=12). 
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DISCUSSION 
A major factor in poor reproductive performance of dairy cows is an overactive or aberrant 
inflammatory response in the endometrium, i.e. increased chemokine and cytokine 
production resulting in a pro-inflammatory state (Sheldon et al., 2006, Sheldon et al., 2014, 
McDougall, 2001). This pro-inflammatory state can result in abnormalities in endometrial 
function compromising endometrial receptivity that in turn negatively affects fertility and 
pregnancy success. In the present study, we evaluated the gene expression of 29 
inflammatory mediators in bovine endometrial epithelial cells (bEEL) and stromal (bCSC) 
when co-incubated with plasma exosomes from LowFert and HighFert heifers. A pro-
inflammatory cytokine IL-6 (Brodzki et al., 2015a) and an anti-inflammatory cytokine IL-10 
(Mohammed et al., 2017) were also measured in the media collected at 36 h by ELISA but 
no differences in production rate were found. 
 
Plasma exosomes from LowFert, but not from HighFert heifers, induced the expression of 
IL-1α and IL-8 (CXCL8) but downregulated the gene expression of IL-4 in endometrial 
epithelial cells. Several studies have indicated that IL-1α, IL-1β, and IL-1 receptors are 
expressed in the corpus luteum as well as in the endometrium throughout the oestrous cycle 
(Tanikawa et al., 2005) and during early pregnancy (Schaefer et al., 2005, Leung et al., 
2000). An in vitro study by Majewska et al. (Majewska et al., 2010) demonstrated that IL-1α 
stimulates luteolytic PGF2α by the bovine corpus luteum and endometrium. A comparative 
study of postpartum fertile and infertile cattle revealed that the expression of pro-
inflammatory mediators (i.e. IL-1α, IL-1β, and IL-6) in the endometrium was greater in 
infertile postpartum cattle than those that were fertile (Herath et al., 2009). IL-1α and IL-1β 
are major pro-inflammatory cytokines that have broader functions not limited to regulating 
inflammatory processes (Bergqvist et al., 2001); they may also participate in local regulation 
of endometrial and reproductive functions (Tabibzadeh et al., 1990, Simon et al., 1993, 
Geisert et al., 2012). Schaefer et al. (Schaefer et al., 2005) demonstrated that IL-1β 
expression in human endometrial epithelial cells can enhance the pro-inflammatory 
response by upregulating IL-8 (CXCL8) gene expression and production possibly inducing 
apoptosis of endometrial glandular and stromal cells (Selam et al., 2002, Kayisli et al., 2002). 
Treatment with estradiol can have an inhibitory effect on IL-1β-mediated inflammatory 
responses such as the expression and secretion of human β-defensin-2 and IL-8 (CXCL8) 
by endometrial epithelial cells (Schaefer et al., 2005). The inhibitory effect of estradiol on 
endometrial epithelial cells may indicate a link between the endocrine and immune system 
to ensure normal physiological processes during the time of ovulation or pregnancy. In our 
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study, an activated pro-inflammatory response was found when plasma exosomes from 
LowFert heifers are co-incubated with endometrial epithelial cells (Figure 2). This is reflected 
in an increase in IL-8 (CXCL8) expression which is likely induced by the upregulation of IL-
1α expression in the endometrial epithelial cells (Arici et al., 1993). 
 
IL-4 is an essential anti-inflammatory cytokine for T helper 2 differentiation. The 
downregulation of IL-4 gene expression in endometrial epithelial cells, when co-incubated 
with plasma exosomes of LowFert heifers, indicates a diminished T helper 2 response and 
may in turn trigger a T helper 1 bias in the endometrium of LowFert heifers. A strong T helper 
1 environment that predominates in the endometrium is associated with negative effects on 
pregnancy success (Makhseed et al., 2001, Sykes et al., 2012). Several studies (Piccinni et 
al., 1998, Chatterjee et al., 2014, Chatterjee et al., 2015) have reported that a dysregulated 
IL-4 can lead to gestational complications including preeclampsia and abortion (Piccinni et 
al., 1998). The upregulation in gene expression of pro-inflammatory IL-1α, IL-8 (CXCL8) and 
the downregulation of IL-4 gene expression when endometrial epithelial cells were co-
incubated with plasma exosomes from LowFert, when compared with HighFert heifers, 
strongly suggest that there is a shift towards a T helper 1 response that can promote a pro-
inflammatory uterine environment through cell mediated immunity and hence cause a the 
poorer reproductive performance in the LowFert heifers. 
 
CXCL9 and CXCL10 expression in endometrial stromal cells were downregulated by plasma 
exosomes from LowFert heifers but not from HighFert heifers. The decreased 
concentrations of CXCL10 has been found in serum and peritoneal fluid of women with 
advanced endometriosis compared with women without endometriosis, indicating a 
decreased natural killer cell activity to eliminate ectopic endometrial cells (Galleri et al., 
2009). CXCL9, CXCL10 and CXCL11 expression was reported to increase as the menstrual 
cycle progressed and is correlated with the increasing number of natural killer cells in the 
endometrium (Sentman et al., 2004, Kitaya et al., 2004). However, uterine natural killer cells 
do not produce CXCL9 and CXCL10 without activation by IL-15 (Sela et al., 2013, Manaster 
et al., 2008). It is suggested that these chemokines expressed by the endometrium are 
involved in the recruitment of natural killer cells (Sentman et al., 2004) into the human 
endometrium and are expressed in anticipation for the attraction and adhesion of blastocyst 
to the endometrium (Sela et al., 2013, Manaster et al., 2008). Indeed, the expression of 
CXCL9, CXCL10, CXCL11 and their receptor CXCR3 is reported to be greater during 
pregnancy than in the non-pregnant stage in the endometrium of humans (Gotsch et al., 
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2007) and other animals (Han et al., 2017, Imakawa et al., 2006, Imakawa et al., 2005). 
CXCR3 expression has also been reported on trophoblast as well as on endometrial 
epithelial and stromal cells, indicating that these chemokines may act in autocrine and 
paracrine manner in the uterus (Han et al., 2017, Imakawa et al., 2006). 
 
Our findings are consistent with those of our earlier study by Walker et al (Walker et al., 
2012), in which we demonstrated that the chemokines CXCL10 and CXCL11 were 
downregulated in the caruncular and intercaruncular endometrial tissue of subfertile cows 
when compared with fertile cows. The downregulation of CXCL9 and CXCL10 gene 
expression in endometrial stromal cells by plasma exosomes from LowFert heifers suggests 
that LowFert heifers have a poorer capability to mediate blastocyst attachment to the 
endometrium, which may potentially affect the establishment of a pregnancy. 
 
The gene expression of CX3CL1 in endometrial stromal cells was also downregulated by 
plasma exosomes from LowFert heifers but not from HighFert heifers. Several studies 
(Kervancioglu Demirci et al., 2016, Siwetz et al., 2015, Cammas et al., 2005, Hannan et al., 
2006)  have suggested that CX3CL1 has key roles in regulating trophoblast adhesion and 
migration processes in fetal-maternal interaction during gestation. The dysregulation of 
CX3CL1 expression is associated with pregnancy complications (Szukiewicz et al., 2013, 
Hou et al., 2016, Wang et al., 2014). However, in a mouse study by Cook et al. (Cook et al., 
2001) CX3CL1-deficient mice did not exhibit any developmental abnormalities or reduced 
fertility.  
 
Our findings are consistent with earlier reports (McDougall et al., 2011, Sheldon et al., 2009, 
McDougall et al., 2007) that infection/inflammation leads to reduced fertility. Interestingly, 
McDougall et al. (McDougall et al., 2016) reported that treatment with Meloxicam (a 
nonsteroidal anti-inflammatory drug) can result in enhanced fertility.  Our results suggest 
that the exosomes from LowFert but not from HighFert heifers will activate a pro-
inflammatory response in the uterine microenvironment and thus negatively affect uterine 
receptivity. It is possible that the differences in exosomes and their proteomic content, 
characterised in our previous study (Mitchell et al., 2016, Koh et al., 2018c), likely contribute 
to the change in endometrial cell function. Investigations on exosome-mediated maternal-
fetal communication will further elucidate the role of exosomes in uterine receptivity and the 
establishment of pregnancy. 
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Summary for Chapter 5 
In chapter 5, I tested the hypothesis that differences in fertility of dairy cows could be 
assessed by monitoring exosomal cargo differences and that the differences in cargo 
content could be manifested and reflected by changes in endometrial function when bovine 
endometrial cells are co-incubated with exosomes from the two herds. 
 
To investigate this hypothesis, two main aims were developed: (i) to evaluate and compare 
the plasma exosomal proteomic profiles of heifers bred to have high or low fertility (Chapter 
5.1); and (ii) to evaluate inflammatory mediator regulation and cytokine production by bovine 
endometrial stromal and epithelial cells co-incubated with plasma exosomes from high and 
low fertility heifers (Chapter 5.2). 
 
With respect to the first aim, I demonstrated that the exosomal proteomic profiles from low 
fertility heifers were different to those from high fertility heifers. Mass spectrometry analyses 
also showed that exosomes from low fertility heifers contained more proteins than the 
exosomes from high fertility heifers (116 compared with 89 proteins respectively). Three 
proteins including the tetratricopeptide repeat protein 41-related, glycodelin, and kelch-like 
protein 8 were identified in the exosomes from low fertility heifers suggesting possible roles 
in reproduction. The research presented here provides preliminary evidence for the potential 
of proteins from exosomes to inform the fertility and physiological status of dairy cows. 
 
With respect to the second aim, I showed that co-incubation of exosomes from low, 
compared with high, fertility heifers downregulated the gene expression of pro-inflammatory 
chemokines CXCL9, CXCL10, and CX3CL1 in stromal cells. In contrast, epithelial cells co-
incubated with plasma exosomes from low, when compared with high, fertility heifers 
resulted in upregulation of gene expression of pro-inflammatory IL-1α and IL-8 (CXCL8) and 
downregulation of IL-4 gene expression. Our findings demonstrate that exosomes modulate 
endometrial cell functions by modulating inflammatory mediator gene expression. 
 
In summary, the findings presented in this chapter support the hypothesis tested, however, 
to strengthen the hypothesis further validation (e.g. to investigate from a validation cohort) 
and a thorough investigation into the functions of these candidate protein markers for fertility 
are required. 
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Chapter 6: Discussion 
 
6.1 Overview 
In this chapter, a summary of the key findings from each study are presented, followed by a 
discussion of the research outcomes supported by current literature. Future research 
directions are also included. 
 
The aim of my study was to investigate the role of exosomes in dairy cow fertility and to 
investigate the possible utility of exosomal biomarkers from easily accessible body fluids 
that help the dairy industry. In my research, I aimed to test the hypothesis that differences 
in the fertility of dairy cows could be assessed by monitoring exosomal cargo differences 
and that these differences in cargo content could be manifested and reflected by changes 
in endometrial function when bovine endometrial cells are co-incubated with exosomes from 
the high and low fertility herds. 
 
To test my hypothesis, three aims were constructed (Figure 6.1.1). The first aim was an in 
vitro study to characterise bovine endometrial cells as a suitable in vitro model of the 
maternal cell component, a critical component of maternal-fetal communication during the 
establishment of pregnancy. The second aim was to develop, improve, and characterise a 
robust and reproducible method for the isolation and enrichment of exosomes from bovine 
plasma and milk. An alternative technique employing targeted mass spectrometry was also 
established to confirm the isolation of exosomes from bovine plasma and milk and to 
characterise and detect the presence of exosomal markers. 
 
Following the completion of the initial two aims of my thesis, I proceeded to my final and 
third aim to test my hypothesis using a fertility animal model herd that was established by 
Meier et al. (Meier et al., 2017). The fertility animal model herd was established to better 
understand the key drivers of cow fertility which can then be further utilised to improve the 
accuracy of predictions (i.e. fertility breeding value and biomarkers for fertility) in 
differentiating between the high from the low fertility heifers. In this study, I evaluated and 
compared the proteomic profile of exosomes isolated from the plasma of heifers that were 
bred to have higher or lower fertility. Other key animal traits (e.g. live-weight, milk production, 
and percentage of North American genetics) remained within similar ranges between the 
two herds. In my final study, I evaluated whether or not exosomes from low fertility heifers 
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can alter endometrial cell function by modulating inflammatory mediator expression in the 
endometrial cells. 
 
 
Figure 6.1.1. An overview of the aims of my study. The first aim was an in vitro study that 
aimed to characterise bovine endometrial cells as a suitable in vitro model of the maternal 
cell component. The second aim was to develop, improve, and characterise a robust and 
reproducible method for the isolation and enrichment of exosomes from bovine plasma and 
milk. And the final and third aim of my study was the clinical evaluation of a fertility animal 
model herd that was established by Meier et al, 2017. 
 
6.2 Key findings presented in this thesis 
 
6.2.1 Aim 1: Characterisation of bovine endometrial cells 
The first aim of my PhD involved the characterisation of endometrial cells and the study of 
the effect of stimuli and/or conditions that mimic physiologic stress associated with reduced 
fertility in dairy cows (i.e. infectious agent, inflammatory mediators (Aim 1.1) and hypoxia 
(Aim 1.2)). Understanding the mechanisms (e.g. inflammatory mediator gene expression 
and production) that regulate endometrial function can facilitate a better understanding of 
endometrial physiology. The responsiveness of the bovine endometrial cells also ensured 
their suitability as an in vitro model for my final and third aim. That investigated the effects 
of exosomes isolated from high and low fertility heifers on inflammatory mediator gene 
expression in bovine endometrial cells (Aim 3.2 and is described in detail in chapter 5.2).  
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6.2.1.1 Key findings from Aim 1.1. The infectious agent LPS and the pro-inflammatory 
cytokines IL-1β and TNFα, modulate inflammatory mediator gene expression and 
cytokine production in endometrial epithelial and stromal cells. As described in detail 
in chapter 2.1. 
 
In this study, bovine endometrial epithelial and stromal cell lines were treated with LPS (a 
widely accepted infectious agent (Hitchcock et al., 1986)) and IL-1β and TNFα (pro-
inflammatory stimuli (van Deuren, 1994)). Evaluating the ability of these cells to respond to 
stimuli is critical in understanding their role in early pregnancy/placentation. It has been 
proposed that these cells interact and communicate in a controlled manner as the first line 
of defense against infectious agents and/or inflammatory mediators in bovine and human 
studies (Chen et al., 2013, Srivastava et al., 2013, Borges et al., 2012, MacKintosh et al., 
2013). Inflammatory mediator gene expression and cytokine production were evaluated in 
bovine endometrial epithelial and stromal cells in response to the aforementioned stimuli. 
Previous studies (Cronin et al., 2012, Siemieniuch et al., 2016, Turner et al., 2014) reported 
that endometrial epithelial and stromal cells can be induced to produce a pro-inflammatory 
response in vitro in response to a stimulus (e.g. LPS), and that these cells increased the 
expression of mRNA transcripts in the endometrium that encodes molecules associated with 
inflammation, such as the cytokine IL-6 and the chemokine IL-8. A major strength of this 
study is the large number of genes analyzed. A total of 84 inflammatory mediator genes (i.e. 
chemokines, interleukins, interferons, growth factors, TNF receptor superfamily members, 
anti-inflammatory cytokines, and other cytokines) from two different bovine endometrial cell-
types (epithelial cells and stromal) treated with LPS, IL-1β, and TNFα were evaluated in this 
study. 
 
An immune response was elicited in both the bovine endometrial epithelial and stromal cells 
in response to LPS and IL-1β through an increased gene expression of CXCL8/IL-8, IL-1α, 
IL-1β, and IL-6 cytokine genes. Interestingly, bovine endometrial epithelial and stromal cells 
treated with IL-1β increased IL-1β gene expression, suggesting that IL-1β can act unusually 
in an autocrine positive feedback (Tanaka et al., 2000, Correia-Alvarez et al., 2015). When 
treated with TNFα, bovine endometrial stromal cells showed enhanced chemokine CCL2, 
CCL20, CCL5, CX3CL1, and CXCL5 expression. The changes in pro-inflammatory IL-6 and 
anti-inflammatory IL-10 cytokine production elicited by LPS and IL‐1β on bovine endometrial 
epithelial and stromal cells were also observed. LPS and IL-1β induced a greater IL-6 
production by bovine endometrial epithelial and stromal cells when compared with untreated 
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cells. The anti-inflammatory IL-10 production was only significantly increased when bovine 
endometrial epithelial cells were treated with IL-1β. Bovine endometrial stromal cell 
production of IL-10 was significantly greater when treated with LPS and with IL-1β when 
compared with the untreated cells. This differential gene expression and cytokine production 
may be indicative of a signalling interaction between the cells to support individual cellular 
response (Goffin et al., 2002, MacKintosh et al., 2013). In other words, stromal cells produce 
molecules to support epithelial cell functions. 
 
The responses of these cells are consistent with those of Ibrahim et al (Ibrahim et al., 2017) 
who reported that higher mRNA expressions of pro-inflammatory factors (i.e. PTGS2, 
CXCL3, IL-1α, IL-6, and IL-8) in bovine endometrial cells were observed when these cells 
were stimulated with a T. pyogenes strain that had higher growth rate and expressed more 
virulence factors. Gärtner et al (Gartner et al., 2016) and Ghasemi et al (Ghasemi et al., 
2012) also reported the higher expression of inflammatory cytokine gene expression and/or 
production in endometrial cytobrush samples of cows with endometritis when compared with 
healthy cows. Moreover, these events have been described in the endometrium of dairy 
cows with postpartum uterine disease that can negatively impact female reproductive 
function and fertility (Sheldon et al., 2009). 
 
Collectively, the data presented confirm the responsiveness of these cells (i.e. bovine 
endometrial stromal cells and bovine endometrial epithelial cell) to pro-inflammatory stimuli 
and their suitability as in vitro models of the maternal compartment for studying the uterine 
environment. 
 
Future studies should further interrogate these cells by manipulating the response of the 
cells through treatment with antagonists to block signalling pathways involved in immune 
modulation (e.g. TLR4 inhibitors), as well as treatment with anti-inflammatory agents to 
provide a screening platform for measuring cellular responses to treatments against 
inflammation (e.g. nonsteroidal anti-inflammatory drugs). These new areas of investigation 
may help uncover the mechanisms involved or help in the development of potential therapies 
to reverse the detrimental effects of infection and inflammation. 
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6.2.1.2 Key findings from Aim 1.2. Hypoxia, a known stimulus of exosomal release, 
altered the cellular function (i.e. migration, proliferation, and apoptosis), exosomal 
content, and release of exosomes from bovine endometrial cells. As described in 
detail in chapter 2.2. 
 
High environmental temperature and humidity (previously described in the Chapter 1) can 
cause heat stress in dairy cows. In the literature, it has been reported that heat stress in 
dairy cows is associated with reduced fertility (Dash et al., 2016). During heat stress, the 
intrauterine environment of the cow is compromised. Heat stress can result in elevated 
uterine temperature, alteration to reproductive hormones (Khodaei-Motlagh et al., 2011, 
Hansen, 2009) and decreased blood flow (Roman-Ponce et al., 1978, De Rensis and 
Scaramuzzi, 2003) and oxygen delivery to the uterus (Tao and Dahl, 2013). Heat stress can 
also expose the fetus to a hypoxic state due to changes in utero-placental oxygen uptake 
(Reynolds et al., 1985). 
 
A study by Gahlenbeck et al (Gahlenbeck et al., 1968) measured the placental gas 
exchange of pregnant cows during the fifth until the ninth month of pregnancy and found 
that the mean oxygen half-saturation tension was 33 mm Hg (calculated to be 8% oxygen 
tension) in the uterine blood. Evidence from studies has demonstrated that a lower-than-
normal oxygen tension in utero can influence many developmental events with potentially 
lifelong consequences (Dufty and Sloss, 1977, Anthony et al., 2003, Swift and Paumer, 
1978). Hypoxia is also a known stimulus of exosome release (Salomon et al., 2013a, Truong 
et al., 2017). In this study hypoxia (1% O2), when compared with normal oxygen tension (8% 
O2 identified as physiological oxygen tension in utero (Gahlenbeck et al., 1968)) altered the 
cellular function of bovine endometrial cells (ICAR) by decreasing cell migration and 
proliferation but increasing the activation of apoptotic caspase 3. The protein content of 
exosomes, and the release of exosomes, was altered in ICAR cells following hypoxic 
stimulus. Mass spectrometry analyses revealed that more proteins were detected in ICAR-
derived exosomes when cultured at 1% O2 compared with culturing at 8% O2 (i.e. 241 
compared with 159 proteins respectively). Two proteins of interest identified were: (1) 
Pantetheinase which was identified as unique to exosomes released by ICAR cells cultured 
at 8% O2, and (2) ADAM10 which was identified as unique to exosomes released by ICAR 
cells cultured at 1% O2. 
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Pantetheinase is an enzyme encoded by the VNN1 gene that regulates a variety of 
responses to stress (Rommelaere et al., 2015, Pitari et al., 2000). Pantetheinase is important 
for maintaining normal cell function (Kaskow et al., 2012, Roisin-Bouffay et al., 2008) and 
may also be involved in regulating uterine receptivity for attachment/implantation and 
trophoblast invasion (Smits et al., 2017, Mullen et al., 2012, Hayes et al., 2012).  
 
Whereas, ADAM10 is associated with specific biological processes for reproduction (Latifi 
et al., 2018, Greening et al., 2016). Increased ADAM10 expression was previously reported 
in preeclamptic placentas compared with normal placentas (Zhao et al., 2010). The up-
regulation of ADAM10 induced placental release of soluble vascular endothelial growth 
factor receptor-1 (sFlt-1) that is associated with endothelial dysfunction (Zhao et al., 2010). 
This evidence suggests a significant role of oxidative stress in preeclamptic placentas (Zhao 
et al., 2010). 
 
Although these proteins are poorly described in bovine studies, they are known to be 
involved in human reproduction. Taken together, the main findings from this study suggest 
that a lower than normal oxygen tension in vitro can influence endometrial cell function (cell 
proliferation, migration, and apoptosis), exosome release, and exosome proteomic content 
in response to adverse stimuli. The stimulated differential release and altered content of 
exosomes may reflect the physiological/pathological cell status, suggesting that exosomes 
and their cargo content have tremendous potential as biomarkers that may serve to inform 
us of the reproductive health of dairy cows. 
 
6.2.2 Aim 2: Method development for the isolation and characterisation of exosomes 
from bovine body fluids 
The second aim of my PhD was to isolate and evaluate exosomes from body fluids (i.e. 
plasma, milk, saliva and urine) of dairy cows. The ability to detect exosomal biomarkers (e.g. 
fertility traits) in body fluids means a minimally-invasive or non-invasive technique can be 
utilised for monitoring the effectiveness of intervention and management strategies to aid 
the improvement of dairy cow fertility. In this study (Aim 2.1), a differential and buoyant 
density ultracentrifugation was applied to isolate and enrich exosomes from body fluids of 
dairy cows, as described in chapter 3.1. As there were many disadvantages to the 
methodologies available for exosome isolation at the start of my PhD (e.g. time consuming 
and poor recovery of exosomes due to multiple washing steps), I evaluated and developed 
a method using ultracentrifugation and size exclusion chromatography for the optimum 
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isolation and enrichment of exosomes from plasma (Aim 2.2) and milk (Aim 2.3). In addition 
the need to develop a robust strategy to detect exosomal markers was imperative. In Aim 
2.4 a new targeted mass spectrometry approach was developed to improve sensitivity and 
specificity of detection and decrease the time taken to detect multiple exosomal markers in 
a single sample.  
 
6.2.2.1 Key findings from Aim 2.1. The proteomic content in plasma and milk 
exosomes was found to be markedly different reflecting cellular functions that are 
unique to, or have priority in, the udder compared with those may be present in the 
circulation. As described in detail in chapter 3.1. 
 
In this study, exosomes were isolated from concurrently collected body fluids (i.e. plasma, 
milk, saliva and urine) from dairy cows using differential and buoyant density 
ultracentrifugation. Due to the low levels of extracellular vesicles in saliva and urine, further 
detailed evaluation on the exosomal proteomic profile was only investigated in the enriched 
exosomes isolated from bovine plasma and milk. The proteomic profiles of plasma and milk 
exosomes were evaluated using information-dependent acquisition-mediated liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). The plasma exosomes contain 
proteins that differed greatly from the milk exosomes. The findings suggest that the cargo 
content encapsulated within the exosomes contain molecules that reflect the cellular origin 
and organ type. A major strength from this study is that exosomes were isolated from body 
fluids that were concurrently collected at the same time point and from the same group of 
six pregnant Holstein-Friesian dairy cows. This coordinated sampling further strengthened 
the comparative study of exosomal content in plasma and milk exosomes. The finding also 
highlights the potential benefits of using plasma and milk as a source that is least invasive 
and easy to obtain for sample collection and can be useful for diagnostics and prognostic 
purposes for the dairy industries. However, because the exosome isolation techniques used 
in this study were time consuming and could result in poor exosome recovery due to multiple 
washing steps, there was a need to improve the method of exosome isolation and 
enrichment. 
 
6.2.2.2 Key findings from Aim 2.2 and Aim 2.3. A robust and reproducible method 
through coupling ultracentrifugation and size exclusion chromatography was 
established for the isolation and enrichment of exosomes from bovine plasma and 
milk. As described in detail in chapter 3.2 and chapter 3.3 respectively. 
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Effective methodology for the isolation and enrichment of exosomes is crucial for exosome 
research because the production of a pure population of exosomes with a high yield is 
essential for the integrity of exosomes as biomarkers for diagnostic and prognostic 
purposes, as well as for future use of exosomes as drug delivery systems. 
 
There are still a number of different techniques used for the isolation and enrichment of 
exosomes including ultracentrifugation, size-based isolation, and other exosome isolation 
techniques (Konoshenko et al., 2018, Li et al., 2017). The differences in the composition of 
body fluids will also dictate different procedures for sample preparation prior to exosome 
isolation and enrichment. In this study, the techniques utilised for the isolation and 
enrichment of exosomes from bovine body fluids was the coupling of ultracentrifugation and 
size exclusion chromatography. 
 
The isolation and enrichment of exosomes from plasma and milk using differential and 
buoyant density ultracentrifugation (as discussed previously) requires the user to make 
gradients. Furthermore, multiple washing steps are required to remove sucrose and/or 
OptiPrepTM from the enriched exosomes. This approach can result in greater user variability 
and poor recovery of exosomes. The ultracentrifugation and size exclusion chromatography 
method enables exosomes to be enriched and separated from soluble contaminants without 
the need for additional washing steps. Exosomes were confirmed by detecting exosomal 
markers (by immunoblotting) and observing exosome morphology (using transmission 
electron microscopy) based on the requirements described by Witwer et al. (Witwer et al., 
2013) and Lotvall et al. (Lotvall et al., 2014). Coupling ultracentrifugation and size exclusion 
chromatography provided a more robust, less variable, and faster method for the isolation 
and enrichment of exosomes from plasma and milk compared with differential and buoyant 
density ultracentrifugation. Importantly, this method also improved exosome yield compared 
with differential and buoyant density ultracentrifugation.  
 
With a robust and reproducible method for the isolation and enrichment of exosomes, an 
accurate evaluation of the exosomal content may help provide more information (e.g. 
physiological or pathological conditions) relevant to the development of biomarkers for 
diagnostic and prognostic purposes for the dairy industry (e.g. fertility, metabolic disorder, 
mastitis, and milk quality). This study also highlights the potential benefits of using certain 
body fluids, in particular milk and plasma, as non-invasive biological sources for a thorough 
and comprehensive assessment of dairy cow health and disease. 
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Future studies should include the isolation of exosomes from other biological fluids such as 
cerebrospinal fluid, uterine flushing, follicular fluids, amniotic, and allantoic fluids to uncover 
novel exosomal biomarkers (e.g. fertility). Also, by applying this robust and reproducible 
methodology for the isolation and enrichment of exosomes from other body fluids, a more 
in-depth investigation can be made into the biological role of exosomes in physiology and 
pathology (e.g. maternal-fetal communication, gestation, and pregnancy complications). 
This would expand our current knowledge and provide a more complete understanding of 
exosome biology in the area of bovine reproduction. 
 
6.2.2.3 Key findings from Aim 2.4. A targeted mass spectrometric approach was 
developed as an alternative technique for the detection of exosomal markers 
(TSG101, Flotillin-1, and CD63) from bovine plasma and milk. As described in detail 
in chapter 4. 
 
Regardless of the method used, the presence of exosomes must be confirmed with analyses 
based on the requirements described by Witwer et al. (Witwer et al., 2013) and Lotvall et al. 
(Lotvall et al., 2014). Exosomes share several common characteristics including morphology 
(spherical), size (30-120 nm), and exosomal protein markers (e.g. TSG101, Flotillin-1, and 
CD63). The objective of this study was to develop a targeted mass spectrometric approach 
to screen and detect exosomal markers in exosomes isolated from bovine plasma and milk. 
 
Immunoblotting is a common technique employed by many investigators to characterise the 
protein markers of exosomes (e.g. TSG101, Flotillin-1, and CD630). However, several 
drawbacks for using immunoblotting include but are not limited to, having issues with the 
cross-reactivity and specificity of an antibody, having an unknown or similar molecular 
weight of protein targets as well as the lack of positive and negative control lysates (Bass et 
al., 2017). Hence, to improve the efficiency of marker detection in exosomes from bovine 
plasma and milk, an alternative targeted mass spectrometric approach, using a quadrupole-
ion trap (QTRAP) mass spectrometer, was developed. This targeted approach detected [1] 
TSG101 peptide precursors (LDQEVAVDKNIELLR and DEELSSALEK), [2] Flotillin-1 
peptide precursors (LTGVSISQVNHKPLR and ISLNTLTLNVK), and [3] CD63 peptide 
precursors (DFECCGAANYTDWEK and DNQTASILDK), with at least three transitions per 
peptide target for exosomal markers TSG101, Flotillin-1, and CD63 in bovine plasma 
exosomes. However, TSG101 was the only exosomal marker detected in milk exosomes to 
have two peptide precursors with at least three transitions per peptide target. 
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The major strength of this study was that the targeted mass spectrometric approach used a 
QTRAP mass spectrometer which was capable of screening and detecting multiple 
exosomal markers from a single sample. This targeted approach provides a more robust 
assessment of protein markers than the commonly used immunoblotting that detects only 
one epitope of an exosomal protein marker. Therefore, using a targeted mass spectrometric 
approach with multiple protein markers avoids the restricted antibody specificity associated 
with immunoblotting. 
 
Future studies should further investigate the targeted mass spectrometric approach to 
determine the specificity and sensitivity of exosomal marker detection in different biological 
fluids. The specificity of a targeted mass spectrometric approach in different sample 
matrices can be interrogated by including several recombinant exosomal protein markers 
(e.g. TSG101 recombinant protein, Flotillin-1 recombinant protein, and CD63 recombinant 
protein) as reference standards. Furthermore, future studies should also test the sensitivity 
and limits of detection prescribed by targeted mass spectrometric approach compared to 
immunoblotting. This could be achieved using serial dilutions of the recombinant proteins 
(detailed above) and by comparing the results produced by the two different detection 
methods. 
 
Once a robust and reproducible targeted mass spectrometric approach is established, a 
broader range of analytes (e.g. pregnancy-associated proteins and/or novel proteins 
associated with fertility and reproduction) from more complex biological samples can be 
investigated potentially aiding in the development of novel diagnostics and prognostics for 
specific pathologies (e.g. reproductive health and fertility). 
 
6.2.3 Aim 3: Clinical evaluation of the fertility animal model herd 
The finding of aims one and two were utilised for the experimental approach taken in aim 3. 
Aim 3 was further divided into aim 3.1 the identification of exosomal proteomic cargo of 
heifers with divergent fertility and aim 3.2 the effects of these exosomes on cellular function 
(i.e. inflammatory mediator gene expression and cytokine production form endometrial 
cells). 
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6.2.3.1 Key findings from Aim 3.1. Plasma exosomal content from low fertility heifers 
differs from plasma exosomal content of high fertility heifers identifying potential 
candidate proteins for fertility. As described in detail in chapter 5.1. 
 
In aim 3.1, I characterised the proteomic profiles of exosomes isolated from plasma of high 
and low fertility heifers. The heifers used in this study were part of a larger experiment from 
a recently established fertility animal model described by Meier et al. (Meier et al., 2017). 
From this larger group, 24 heifers were identified as being either high fertility (n = 12) or low 
fertility (n = 12) based on extreme diversity in their estimated breeding value for fertility whilst 
being similar in other key traits (e.g. body weight, milk production, and percentage of North 
American genetics). The predictor traits used to estimate the fertility breeding values 
includes whether cows are mated within 21 days of the planned start of mating (PM21) in 
first, second and third parity cows (expressed as a binomial trait); calved in the first 42 days 
after the planned start of calving (CR42) in second, third and fourth parity cows (as a 
binomial trait); milk volume in a cows’ first lactation and body condition score (BCS) in a 
cows’ first lactation at 60 days in milk. All heifers were post-pubertal and had expressed a 
minimum of one spontaneous oestrus. The fertility animal model herd was established to 
better understand the key drivers of cow fertility which can then be further utilised to improve 
the accuracy of predictions (i.e. fertility breeding value and biomarkers for fertility) 
differentiating between the high and low fertility heifers. 
 
Exosomes were isolated from plasma collected from high and low fertility heifers using 
ultracentrifugation and size exclusion chromatography (as described in the previous aim and 
Chapter 3.2). The presence of exosomes in the isolated fractions was confirmed by size 
distribution (nanoparticle tracking analysis), morphology (transmission electron 
microscopy), and exosomal markers (immunoblotting and a targeted mass spectrometric 
approach). 
 
Following the confirmation of exosomes in the isolated fractions, an in-depth proteomic 
analysis was performed using information dependent acquisition on a TripleTOF 5600 mass 
spectrometer. These results showed differences in the exosomal proteomic profile in high 
and low fertility heifers. Most notably, the tetratricopeptide repeat protein 41-related, 
glycodelin, and kelch-like protein 8 were identified in plasma exosomes from low fertility 
heifers. The tetratricopeptide repeat protein 41-related was reported to be involved in the 
regulation of reproductive development (Tranguch et al., 2005, Yang et al., 2006, Yu et al., 
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2016, Xu et al., 2015, Gray et al., 2006). Tsukahara et al. (1996) identified a Down syndrome 
critical region of chromosome 21q22.2, which encodes a protein possessing the 
tetratricopeptide repeat motif. An overexpression of the gene can lead to morphological 
anomalies in the brain of a Down syndrome fetus (Tsukahara et al., 1996). 
 
Glycodelin, identified as unique to low fertility heifers, is a progesterone-regulated 
glycoprotein that has different functions depending on the progesterone concentration at 
different phases of the reproductive cycle (Uchida et al., 2013). The timely expression of 
glycodelin during reproduction, in particular fertilisation and implantation, is regulated by the 
endocrine system (Taheripanah et al., 2017, Seppala et al., 1997). The increased 
expression of glycodelin during the period of endometrial receptivity, is essential for the 
immunologic (Alok and Karande, 2009) and hormonal (Uchida et al., 2005) regulation of 
reproduction. However, the presence of glycodelin during the fertilisation period can cause 
fertilisation to fail by suppressing sperm capitation and inhibit the binding of spermatozoa to 
the zona pellucida (Koistinen et al., 2003), thus not favoring sperm-egg fertilisation and 
ovum formation. 
 
Kelch-like protein 8 (KLHL8) was also identified in exosomes from plasma of low fertility 
heifers. The KLHL8 gene was preferentially expressed in the female gonads of fish 
(zebrafish and carbiomedaka) and was identified to play a role in oogenesis (Gautier et al., 
2011). Strucken et al. (2012) demonstrated that KLHL8 could affect the non-return rate 
(defined as the percentage of inseminated cows that are pregnant at 56 days after service) 
in heifers by regulating the ovulation process and suggested the use of KLHL8 as a 
candidate ovary-specific gene marker for the detection of the non-return rate in heifers 
(Strucken et al., 2012). 
 
These proteins are thought to play a role in reproduction although the precise role of these 
proteins in dairy cow reproduction remains unknown. However, their identification highlights 
the potential of these exosomal proteins to inform us of the fertility status and physiological 
condition of a dairy cow. Previous results published by my group underscored that the 
proteomic investigation of the exosomal cargo content contains potential indicators of fertility 
(Mitchell et al., 2016), disease (Almughlliq et al., 2018), and metabolic health status 
(Crookenden et al., 2016) of dairy cows. While in a human study, Melo et al (2015) provided 
evidence that gypican-1 was a candidate protein marker in serum exosomes that 
distinguishes patients with pancreatic cancer from healthy individuals (Melo et al., 2015). 
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Several published papers in the literature in humans (Mei et al., 2017, Jia et al., 2015, Meng 
et al., 2018) and animals (Sun et al., 2015, da Silveira et al., 2012, Berrone et al., 2015) 
studies also supported that exosomes carry biomolecules that have potential diagnostic and 
prognostic value. A comprehensive analysis of the exosomal cargo content holds 
tremendous potential for biomarker discovery. The proteins identified in my current findings 
should further be validated on a larger cohort study and if consistent, can also be aligned 
with other activities in this study to better understand what influences fertility in dairy cows. 
Therefore, this study can also provide a starting point from which further investigations can 
be made into future cohorts. 
 
Future studies should also include the validation of potential candidate proteins as well as 
other molecular analytes for fertility (e.g. lipids and miRNAs) encapsulated in these 
exosomes for the development of novel biomarkers for fertility. Investigations into these 
potential candidate analytes (e.g. proteins, lipids, and miRNAs) and their roles in female 
reproduction will further strengthen these candidate analytes as biomarkers for fertility that 
may serve to accurately predict fertility status or reproductive health and possibly help 
determine appropriate treatment strategies. 
 
6.2.3.2 Key findings from Aim 3.2. Changes in inflammatory mediator gene expression 
and cytokine production in bovine endometrial stromal and epithelial cells were 
observed when cells were co-incubated with plasma exosomes from high and low 
fertility heifers. As described in detail in chapter 5.2. 
 
In aim 3.2, I investigated whether or not differences in the exosomal cargo of heifers bred to 
have high or low fertility will differentially modulate inflammatory mediator gene expression 
(e.g. cytokines and chemokines) and cytokine production by bovine endometrial cells when 
co-incubated with exosomes from the two herds. The bovine endometrial epithelial and 
stromal cells characterised (as described in previous aim and Chapter 2.1) were utilised for 
this study. 
 
In my study, endometrial epithelial cells co-incubated with plasma exosomes from low, 
compared with high fertility heifers upregulated the gene expression of pro-inflammatory IL-
1α and IL-8 (CXCL8) but downregulated IL-4 gene expression in these cells. In contrast, the 
gene expression of pro-inflammatory chemokines CXCL9, CXCL10, and CX3CL1 were 
downregulated in endometrial stromal cells when co-incubated with plasma exosomes from 
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low, when compared with high fertility heifers. These findings suggest that an activated pro-
inflammatory uterine microenviroment in the low fertility heifers, compared with high fertility 
heifers, can negatively affect uterine receptivity in low fertility heifers (Galleri et al., 2009, 
Herath et al., 2009). The decreased CXCL9 and CXCL10 may be indicative of reduced 
ability for the attachment and adhesion of trophoblasts to the endometrium in the low fertility 
heifers as CXCL9 and CXCL10 are key factors involved in blastocyst-endometrium 
interaction (Imakawa et al., 2006, Imakawa et al., 2005, Sakumoto et al., 2017). However, 
an in-depth investigation is required to elucidate the role of exosomes in regulating 
endometrial remodeling events and maternal-fetal communication. They are also consistent 
with Walker et al (Walker et al., 2012) who reported a downregulation of chemokines 
CXCL10 and CXCL11 in the caruncular and intercaruncular endometrial tissue of subfertile 
cows when compared with fertile cows. Moreover, this study is also consistent with my 
earlier findings in Chapter 2.1, in which increased IL-1α and IL-8 (CXCL8) expression in 
bovine endometrial epithelial cells and decreased CXCL10 and CXCL11 expression in 
bovine endometrial stromal cells were also observed when the cells were treated with 1 
µg/mL LPS and 10 ng/mL IL-1β. 
 
The maternal immune system is recognised to have a profound impact on fertility of dairy 
cows (Fair, 2015). To improve the health, reproduction and productivity in livestock animals, 
the identification of immune traits through estimation of breeding values for selected immune 
traits or estimating the heritability of immune traits were previously reported in dairy cows 
(Banos et al., 2013, Thompson-Crispi et al., 2012) as well as in pigs (Flori et al., 2011, 
Clapperton et al., 2009). An emerging area of research is the study of the 
immunomodulatory role of exosomes that can contribute to successful reproductive function, 
fertility and pregnancy. Previous findings from my group showed that the co-incubation of 
exosomes isolated from plasma from dairy cows with uterine infection compared with those 
without uterine infection altered prostaglandin production in bovine endometrial epithelial 
cells by decreasing PGF2α production (Almughlliq et al., 2017). Another study by my group 
also reported that exosomes isolated from plasma from high risk of metabolic dysfunction 
compared to those from low risk of metabolic dysfunction increased the proliferation of 
Madin-Darby bovine kidney cells and also induced the expression of 3 pro-inflammatory 
genes (granulocyte colony-stimulating factor, ciliary neurotrophic factor, and CD27 ligand) 
which are involved in cellular growth and survival in Madin-Darby bovine kidney cells 
(Crookenden et al., 2017). In an ovine study, Nakamura et al (2016) demonstrated that 
conceptus-derived exosomes can upregulate several interferon stimulated genes in uterine 
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cells, suggesting that exosomes secreted from conceptuses are involved in conceptus-
endometrium interaction which is required for conceptus attachment to the uterine 
endometrium (Nakamura et al., 2016). Furthermore, the cross-talk and interactions between 
gametes, embryo, oviduct and female reproductive tract through exosomes to regulate 
fertility (Al-Dossary and Martin-Deleon, 2016, Sullivan et al., 2005), blastocyst formation, 
and embryo development (Lopera-Vasquez et al., 2017, Qu et al., 2017) were reported. 
Together these investigations demonstrated the potential role of exosomes in regulating 
uterine receptivity and maternal-fetal crosstalk, which are crucial for endometrial health and 
the establishment of pregnancy. 
 
The significance of this study is that it suggests that exosomal cargo can influence 
reproductive function by altering inflammatory mediator gene expression and cytokine 
production of endometrial cells and that exosomal cargo can also reflect the fertility status 
of dairy cows. It infers a link between exosomes, maternal physiology (e.g. fertility status), 
and the reproductive system (e.g. uterus). Furthermore, it demonstrates the potential role of 
exosomes in intercellular communication. Exosomes can be transported through the 
lymphatic system (Srinivasan et al., 2016) and blood vessels (Morishita et al., 2015), cross 
the basement membrane, blood brain barrier and can cross from the foetal to the maternal 
side of the uterine tissues through a systemic route during pregnancy, supporting the idea 
that foetal signals can be delivered via exosomes (Sheller-Miller et al., 2016). Recent 
publications have demonstrated the ability of exosomes to transport their bioactive cargo to 
distant sites with entry into the body via oral, intravenous, or subcutaneous routes 
(Wiklander et al., 2015, Munagala et al., 2016) as fluorescent-labelled exosomes were 
detected in the liver, lung, kidney, gastrointestinal tract, pancreas, spleen, colon, brain and 
the ovaries. 
 
Future studies should include the labelling of exosomes to visualise and confirm exosome 
uptake by endometrial cells. Similar experiments should also be performed on oviduct cells 
to uncover the consequential effect of exosomes from high and low fertility heifers on 
oviductal cell inflammatory mediator gene expression. Furthermore, investigating the 
intercellular signalling mediated by exosomes between reproductive cells (e.g. endometrial, 
oviduct, and trophoblast cells) will uncover important cellular processes and/or signalling 
pathways that can impact reproductive processes and fertility. 
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6.3. Implications of findings and future work 
The findings presented in this thesis address possible factors contributing to reduced fertility 
in dairy cows. This data provides a starting point from which further investigations should be 
made to uncover potential applications for this research. 
 
Future studies complementing the current findings could include: 
(i) Investigating the use of antagonists to block signalling pathways involved in immune 
modulation (e.g. TLR4 inhibitors (Chotimanukul et al., 2017)) as well as testing the effect of 
anti-inflammatory treatments (e.g. nonsteroidal anti-inflammatory drugs (MacLaren et al., 
2006, Erdem and Guzeloglu, 2010)) to reduce aberrant inflammation of the bovine 
endometrium will help provide further insights into the mechanisms involved in reduced 
fertility and aid in the development of potential therapies to reverse the detrimental effects 
of infection and/or inflammation. 
 
(ii) Investigating a broader range of analytes in exosomes (e.g. lipids, miRNAs, and/or 
mRNAs associated with fertility and reproduction) isolated from more complex biological 
samples (e.g. uterine flushing, follicular fluid and amniotic fluid) that will potentially assist 
with the development of novel clinical applications (e.g. diagnostics and prognostics) for 
reproductive health and diseases and possibly help to determine the most appropriate 
treatment strategies to achieve the best possible outcomes for dairy cows. This includes the 
validation of potential candidate proteins for fertility (i.e. the tetratricopeptide repeat protein 
41-related, glycodelin, and kelch-like protein 8) in a larger cohort study and if consistent, can 
also be aligned with other activities to better understand what influences fertility in dairy 
cows and the potential development of early diagnostic and prognostic of fertility in dairy 
cows. 
 
(iii) Establishing an in vitro model for maternal-fetal communication and to further investigate 
the role of exosomes in maternal-fetal crosstalk by co-culturing endometrial cells (maternal 
cell component) with trophoblast cells (fetal cell component) to evaluate the exosomal cargo, 
such as interferon-tau (a pregnancy recognition signal). Through this a greater 
understanding of the role of exosomes in maternal-fetal communication may be achieved. 
Thereby providing insights into the establishment of uterine receptivity for blastocyst 
attachment and the successful initiation of pregnancy. 
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(iv) Establishing a method that can label, as well as to load, exosomes with therapeutic 
proteins. This will enable the visualisation of exosomal uptake by targeted cells and the 
development of exosome-based drug delivery systems. The potential of exosome research 
to develop therapeutic interventions and effective drug delivery systems will help improve 
dairy cow outcomes (e.g. treating mastitis, enhancing ovulatory response as well as 
enhancing blastocyst formation and quality). 
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Chapter 7: Conclusions 
In summary the work presented in this thesis re-examined the risk factors (e.g. insults 
including LPS, inflammatory stimuli IL-1β and TNFα, and hypoxia) that can adversely affect 
fertility and reproductive performance of dairy cows and established a maternal cell 
component for the study of the intrauterine environment. Subsequently the research focused 
on the potential role of exosomes in dairy cow fertility and provided a promising new direction 
to address the critical problem of declining fertility in dairy cows. 
 
A method was developed that coupled ultracentrifugation and size exclusion 
chromatography for the isolation and enrichment of exosomes from bovine body fluids. A 
targeted mass spectrometric approach was also employed to screen and detect several 
exosomal markers from a single sample. Furthermore, an in-depth proteomic analysis was 
performed using information dependent acquisition mass spectrometry to unravel the 
proteomic profile of exosomes from bovine body fluids. A combination of these methods 
assisted our efforts aimed at the development of biomarkers for novel diagnostic and 
prognostic purposes (e.g. fertility, metabolic disorder, mastitis, and milk quality) for the dairy 
industry. 
 
The need for, and utility of, biomarkers for dairy cow fertility geared our investigations 
towards examining the exosomal proteomic content from an established fertility animal 
model that consisted of heifers bred to have high or low fertility. Indeed, a few candidate 
protein markers were identified. However, further study is required to determine their utility 
as markers of fertility. Bovine endometrial stromal and epithelial cells were further co-
incubated with these exosomes (from heifers bred to have high or low fertility) and the effect 
on inflammatory mediator gene expression and cytokine production by bovine endometrial 
cells were evaluated. This study suggested that exosomal cargo may affect reproductive 
function by altering the inflammatory mediator gene expression and cytokine production of 
endometrial cells and might also reflect the fertility status of dairy cows. 
 
Overall, the findings of this thesis suggest a link between exosomes, maternal physiology 
(e.g. fertility status), and the reproductive system (e.g. uterus) and also demonstrate the 
potential role of exosomes in intercellular communication. The work presented here can also 
be aligned to a larger study involving the established fertility animal model by Meier et al. 
(Meier et al., 2017) to not only better understand the factors influencing fertility in dairy cows 
but to also provide a starting point from which further investigations can be made in future 
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validation cohorts. These outcomes may assist in the selection of dairy cows with high 
fertility traits that would ensure a healthy uterine environment and enable optimal fertility in 
the dairy herd. 
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Chapter 1 
Supplemental Table S1.1: Summary of key publications on the potential role of exosomes 
in bovine studies. 
Source Isolation method Main finding Reference 
Milk Ultracentrifugation Exosome cargo changes in 
response to different cellular 
condition such as mastitis. bta-
miR-142-5p and −223 were 
upregulated and were suggested 
as potential biomarkers for the 
detection of inflammation of the 
bovine mammary glands. 
(Cai et al., 
2018) 
OptiPrep density 
gradient 
centrifugation 
Milk exosomes contain proteins 
that regulate immune response and 
growth. 
(Samuel et al., 
2017) 
Ultracentrifugation Colostrum vesicles contain 
immune-related miRNAs which are 
directly associated with several 
immune modulatory effects, 
including regulating the production 
of IL-1β and IL-10 and cell 
migration. 
(Sun et al., 
2013) 
Sucrose density 
gradient 
centrifugation 
Bovine leukemia virus proteins 
were released with bovine milk 
exosome suggesting: 
[1] an alternative route for 
transmission of viral proteins into 
recipient cells of calves without 
requiring virus infection  
[2] bovine milk exosomes 
participate to eliminate bovine 
leukemia virus proteins from 
infected cells. 
(Yamada et 
al., 2013) 
Ultracentrifugation Exosomes are resistant to acidic 
conditions. MicroRNAs 
encapsulated in exosomes have 
key roles in the development of 
calf’s gastrointestinal and immune 
system. 
(Hata et al., 
2010) 
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Plasma Ultracentrifugation 
coupled with size 
exclusion 
chromatography 
Involved in structural molecule 
activity and immune system 
processes. Have potential roles in 
early diagnosis of uterine infection 
in dairy cows. 
(Almughlliq et 
al., 2018) 
OptiPrep density 
gradient 
centrifugation 
Potential role in immune function in 
transition dairy cows and exosomal 
protein cargo as biomarkers of 
metabolic state. 
(Crookenden 
et al., 2016) 
OptiPrep density 
gradient 
centrifugation 
Exosomes profiles may reflect the 
fertility status of the cow. Proteins 
encapsulated in exosomes are 
involved in immunomodulatory 
processes and cellular 
communication. 
(Mitchell et al., 
2016) 
Ultracentrifugation Exosomes derived from grazing 
cows has higher miR-451 
expression, which is associated 
with skeletal muscle. It has 
potential roles in the secretion or 
intake of miRNAs between 
circulation and tissue cells in 
grazing cattle. 
(Muroya et al., 
2015) 
Follicular 
fluids 
Ultracentrifugation Support cumulus expansion (Hung et al., 
2015) 
Ultracentrifugation Oocyte developmental 
competence and cell-to-cell 
communication in the follicular 
microenvironment. 
(Sohel et al., 
2013) 
Blastocysts Ultracentrifugation Bovine embryo release exosomes 
and their composition varies 
dependent on the embryo 
competence. 
(Mellisho et 
al., 2017) 
Ultracentrifugation Essential for blastocyst formation, 
blastocyst quality, and following 
development to term. 
(Qu et al., 
2017) 
225 
 
Oviduct Ultracentrifugation Has key proteins involved in 
sperm-oocyte binding, fertilisation 
and embryo development. 
(Alminana et 
al., 2017, 
Alminana et 
al., 2018) 
Epididymal 
fluids 
Differential 
centrifugation 
Involved in cell-to-cell 
communication in bovine 
spermatozoa during epididymal 
maturation. 
(Caballero et 
al., 2013) 
Seminal 
plasma 
Sucrose-density 
gradient 
ultracentrifugation 
Are metabolically active and 
capable of producing extracellular 
adenosine triphosphate. 
(Ronquist et 
al., 2013) 
Cell culture Ultracentrifugation Granulosa cell culture exosomes 
carry antioxidant molecules by 
mediating defence mechanism 
against oxidative stress. 
(Saeed-
Zidane et al., 
2017) 
Ultracentrifugation Exosomes derived from bovine 
oviduct epithelial cells positively 
affect the quality of bovine embryo, 
the communication between the 
oviduct and the embryo in the early 
stages of development and induce 
cryoprotection. 
(Lopera-
Vasquez et al., 
2016) 
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Chapter 2.1 
Supplemental Table S2.1.1: The RT-PCR array data for inflammatory mediator gene 
expression in bovine endometrial epithelial cells (bEEL) treated with LPS, IL-1β, and 
TNFα. 
 
Mean SEM Mean SEM Mean SEM Mean SEM
ADIPOQ 0.000145475 1.33962E-05 0.000359565 0.000177544 0.000317233 0.000129892 UNDETERMINED UNDETERMINED
BMP2 0.475720277 0.032089516 0.457467016 0.025105248 0.219912674 0.048226302 0.418065304 0.024682743
BMP3 0.050962089 0.00481721 0.104221271 0.024929243 0.071664859 0.003537887 0.062854281 0.017955043
BMP6 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
BMP7 0.650433071 0.079104634 0.659763423 0.17631555 0.569453864 0.013496046 0.657916256 0.154055302
C5 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CCL1 0.000300007 8.62369E-05 0.000229184 5.15534E-05 0.000109798 2.74935E-05 0.000175469 2.13309E-05
CCL11 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CCL17 0.731314081 0.117848537 0.65996603 0.104477447 0.329294173 0.100019727 0.526117125 0.113291406
CCL19 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CCL2 0.000224618 7.07888E-05 0.001430215 0.000104298 0.000267627 4.58969E-05 0.000470725 0.000134564
CCL20 0.000949851 0.000462365 0.020226257 0.005083443 0.003750102 0.00120109 0.000286865 6.44621E-06
CCL21 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CCL22 0.000292194 UNDETERMINED 0.001782735 0.000424929 0.001529883 0.000543651 0.000124249 5.07817E-06
CCL24 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CCL3 5.36184E-05 1.67679E-05 UNDETERMINED UNDETERMINED 1.99544E-05 5.80801E-06 9.52803E-05 3.33958E-05
CCL4 UNDETERMINED UNDETERMINED 0.000217309 0.000109285 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CCL5 0.002313906 0.00114661 0.002258663 0.000377104 0.001656993 0.000386439 0.001419363 0.000334206
CCL8 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CD40LG UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CD70 0.001100936 0.000420689 0.001896826 0.000732719 0.00130442 0.000420175 0.001161076 0.000350193
CNTF 0.001577205 0.000216726 0.001712357 0.000324376 0.001185143 0.000233007 0.001848036 0.000584333
CSF1 0.018420969 0.001700958 0.048315702 0.019662003 0.036443209 0.012425872 0.029469635 0.007842722
CSF2 0.587067527 0.025904892 1.609367097 0.067106693 0.735719135 0.186231878 0.597381298 0.06402557
CSF3 0.000173287 0.000153473 6.69428E-05 6.643E-06 7.25028E-05 3.30742E-05 0.000121099 4.75995E-05
CTF1 0.01177656 0.001585376 0.013869797 0.004127903 0.013070912 0.001611494 0.012486385 0.001988622
CX3CL1 0.021526013 0.001390699 0.844603951 0.108500283 0.68911271 0.059108386 0.02265034 0.002875696
CXCL10 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CXCL11 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CXCL12 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CXCL13 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CXCL16 0.86206425 0.081417976 1.741644379 0.213701709 1.11829701 0.191694983 0.933905707 0.120541658
CXCL3 0.003895541 0.000681619 2.482796934 0.32869626 1.264546181 0.27253542 0.004121807 0.000792401
CXCL5 0.032951286 0.002898369 16.14554585 1.961258016 13.56995651 2.427060004 0.044171568 0.002117021
CXCL8 0.000339387 0.000154951 0.289314905 0.079188018 0.106282015 0.026300698 0.000232166 3.05724E-05
CXCL9 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
FASLG UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
GPI 0.711616383 0.052077957 0.961190003 0.314741226 1.011511111 0.163295826 0.761482151 0.095394427
GRO1 0.002795869 0.000595612 0.884426683 0.145984931 0.943161342 0.098578749 0.002674761 0.00094688
IFNG UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
IL10 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
IL12A 0.000313697 8.18389E-05 0.000139895 6.10899E-05 0.000132629 7.34669E-05 0.000311948 7.02792E-05
IL12B UNDETERMINED UNDETERMINED 0.000360692 5.25859E-05 7.62536E-05 4.89528E-05 0.000187386 9.16908E-05
IL13 0.00022021 4.82458E-05 0.000306635 6.59032E-05 0.000212337 0.000112642 0.000221541 8.61388E-05
IL15 0.148103641 0.009802576 0.144019341 0.029482414 0.078566571 0.01578471 0.140509584 0.024593463
IL16 0.00012901 1.93561E-05 0.000259054 0.000182689 0.000198625 4.54549E-05 0.000193725 4.28745E-05
IL17A 0.000151286 1.52807E-05 UNDETERMINED UNDETERMINED 7.78488E-05 6.46226E-05 0.000250374 0.000100016
IL17F UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
IL18 0.096956578 0.004391387 0.078956514 0.010282147 0.056883631 0.01567045 0.080561702 0.013724444
IL1A 0.000914331 8.34878E-05 0.197125453 0.053781942 0.086624528 0.00664088 0.001146309 0.000297219
IL1B 1.17583E-05 0.00019957 0.117457004 0.032489699 0.016442539 0.001973749 0.000242838 7.77149E-05
IL1RN 0.177337661 0.012782353 0.490456871 0.166194253 0.387602169 0.007558552 0.200886669 0.045176366
IL2 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
IL21 0.000373204 4.67767E-05 9.66892E-05 3.57619E-05 0.000193632 5.44628E-05 0.00029038 2.99082E-05
IL22 0.000112298 4.13619E-05 5.22906E-05 1.12232E-05 3.79554E-05 2.10871E-05 8.78349E-05 2.0177E-05
IL23A 0.002648016 0.000445237 0.005788964 0.001522896 0.002614074 0.000270957 0.002614478 0.00031207
IL24 0.000494582 2.73738E-05 0.00076398 0.000261587 0.000391162 5.72198E-05 0.000476279 3.15438E-05
IL27 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
IL3 0.00035958 0.000316866 9.69097E-05 UNDETERMINED 4.57836E-05 4.10273E-05 0.000109715 8.4958E-05
IL4 0.000524075 7.57503E-05 0.000652765 0.000172506 0.000336045 9.45324E-05 0.00060861 0.00017222
IL5 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
IL6 0.37363339 0.049019226 1.851550418 0.178600975 0.766841572 0.245714466 0.34846942 0.025024633
IL7 0.008886315 0.000425676 0.013076671 0.002711852 0.008412909 0.001106599 0.00944493 0.001258168
IL9 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED 1.02059E-05 2.92455E-06
LIF 0.106672276 0.010584201 0.34146307 0.133798736 0.218749497 0.031431875 0.122133696 0.015629373
LOC517108UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
LTA 0.001250388 9.55897E-05 0.000230941 0.000220017 0.000424985 6.44696E-05 0.000437147 0.00012006
LTB 0.000667302 0.000194872 0.066844413 0.016989827 0.021062847 0.005201192 0.002222579 0.000289386
MIF 0.124256646 0.02125956 0.126032292 0.048213292 0.097660531 0.025270161 0.151854626 0.025677858
MSTN 0.000729557 0.000229327 0.000429704 0.000197852 UNDETERMINED UNDETERMINED 0.001479854 0.000629076
NODAL 0.000275412 0.000116811 0.000186672 0.000119236 0.00021101 9.92402E-05 0.000428247 0.000155928
OSM 8.12657E-05 5.1185E-06 0.000177492 5.08027E-05 0.000125627 7.81659E-05 0.000204299 8.20959E-05
PF4 9.1248E-05 4.32512E-05 6.84874E-05 3.84035E-05 3.65133E-05 1.19276E-05 9.15677E-05 1.12107E-05
PPBP 2.46521E-05 1.22852E-05 0.000100436 5.96464E-05 UNDETERMINED UNDETERMINED 0.000182535 9.26277E-05
SPP1 50.0174112 1.646491169 63.09440206 12.46343238 41.92038232 2.140382865 44.30464473 7.592799798
TGFB2 0.611999991 0.038045734 0.555345681 0.132955702 0.479969082 0.019425125 0.631735427 0.137597723
THPO 0.023508631 0.00354074 0.014541657 0.000390285 0.008376159 0.000753475 0.015939407 0.001883974
TNF 6.36649E-05 1.25872E-05 0.005038743 0.00152482 0.001916563 0.000427495 0.000104006 4.37067E-05
TNFRSF11B 0.005808006 0.000172883 0.061577266 0.012604604 0.038870572 0.004252171 0.00818581 0.001100748
TNFSF10 0.031926896 0.001044879 0.067618909 0.012793953 0.034676068 0.001047248 0.038385103 0.00759961
TNFSF11 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
TNFSF13B 0.002620171 0.000297336 0.004135004 0.001347203 0.001950745 0.000597916 0.002527487 0.000731069
VEGFA 0.514664887 0.013993637 0.557071508 0.099386835 0.286602316 0.064543066 0.473413243 0.053758586
XCL1 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
IL-1β TNFα 
bEEL Gene Expression (2^-ΔΔCt)
Control LPS
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Supplemental Table S2.1.2: The RT-PCR array data for inflammatory mediator gene 
expression in bovine endometrial stromal cells (bCSC) treated with LPS, IL-1β, and TNFα. 
 
 
Mean SEM Mean SEM Mean SEM Mean SEM
ADIPOQ UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
BMP2 0.07159977 0.008990885 0.129769737 0.005494657 0.115353037 0.012639395 0.188116377 0.023616092
BMP3 UNDETERMINED UNDETERMINED 0.001064606 0.000367962 0.001918563 0.000974244 UNDETERMINED UNDETERMINED
BMP6 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
BMP7 0.001599136 0.000163919 0.003256648 0.000418379 0.004336386 0.000681762 0.002586842 5.11612E-05
C5 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CCL1 0.000191691 2.79747E-05 0.000156351 3.16072E-05 0.000125957 1.3675E-05 0.000269387 4.85006E-05
CCL11 0.000323471 0.000133376 0.001719457 0.000190721 0.001858242 0.000199313 0.001258881 8.34706E-05
CCL17 0.00235684 0.000707249 0.00234608 0.000439267 0.001151 0.000120278 0.006127787 0.001153626
CCL19 UNDETERMINED UNDETERMINED 0.000158874 3.18042E-05 UNDETERMINED UNDETERMINED 0.000296522 7.91972E-05
CCL2 0.159823608 0.080011816 2.202216375 0.637905436 1.414914332 0.34431177 2.815771427 0.844414061
CCL20 4.53058E-05 2.62118E-05 0.005757592 0.000983831 0.021822808 0.004560903 0.000252206 6.38558E-05
CCL21 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CCL22 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CCL24 UNDETERMINED UNDETERMINED 0.000210493 7.60511E-05 0.00018953 7.09467E-05 UNDETERMINED UNDETERMINED
CCL3 UNDETERMINED UNDETERMINED 0.000111573 7.83048E-05 0.000115644 3.15568E-05 7.29535E-05 2.27783E-05
CCL4 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CCL5 0.001471004 0.000239144 0.201392941 0.036851315 0.065345978 0.000943769 0.274082397 0.178353563
CCL8 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CD40LG UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CD70 0.003730108 0.000717498 0.003153502 0.000941975 0.001845338 0.000710735 0.004205627 0.000646295
CNTF 0.001792027 0.000489169 0.002183408 0.000977204 0.002053208 0.000697495 0.001453411 0.000528955
CSF1 0.296084583 0.089753954 0.551960501 0.02501741 0.322493485 0.036044142 0.573072746 0.091882441
CSF2 0.003532659 0.0003863 0.112156679 0.029160511 0.425903181 0.108521825 0.012595296 0.004285821
CSF3 5.9496E-05 2.20037E-05 0.001197291 0.001152195 0.047823276 0.121512702 7.80733E-05 9.53713E-06
CTF1 0.002591249 0.000760776 0.001368915 0.000346947 0.00109458 0.000362497 0.001181135 0.000236469
CX3CL1 0.04748838 0.011206301 0.403362643 0.00743726 0.1145377 0.001775184 0.764906354 0.073037208
CXCL10 0.002224791 0.000500304 0.000932425 0.000241042 0.000329633 0.000115367 0.002348714 0.000850273
CXCL11 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
CXCL12 0.60504464 0.091109744 0.262675931 0.024788166 0.152580001 0.031733983 0.44920209 0.019097435
CXCL13 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED 2.36014E-05 8.63998E-06 UNDETERMINED UNDETERMINED
CXCL16 0.79144016 0.242606587 1.426591144 0.124079342 1.21786846 0.121121315 2.05301276 0.293810646
CXCL3 0.072944158 0.023587189 1.24304147 0.252620312 3.568366111 1.256339277 0.171315068 0.034148613
CXCL5 0.882611029 0.353978586 28.92245216 2.212689945 68.26005433 14.08677837 3.762160246 0.807135074
CXCL8 0.005969007 0.003346021 0.548784118 0.141720803 0.964326296 0.849290021 0.040909294 0.022380849
CXCL9 0.001818322 0.000252481 9.98699E-05 4.16415E-05 8.24801E-05 4.98101E-05 0.000356152 0.000104211
FASLG UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED 0.000329922 5.87916E-05 UNDETERMINED UNDETERMINED
GPI 1.21505845 0.27621182 1.230939599 0.177883759 1.270720374 0.148948816 1.318174548 0.058603738
GRO1 0.025210158 0.008281907 1.009443073 0.171034941 2.230258618 1.662693658 0.128620669 0.047510576
IFNG UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
IL10 0.000645491 0.00023015 0.001166268 0.000210216 0.000773042 6.55479E-05 0.000698355 0.000351179
IL12A 0.002099207 0.000518203 0.003753147 0.000524421 0.002386552 0.00043845 0.003684184 0.001039915
IL12B UNDETERMINED UNDETERMINED 0.000117793 6.13775E-05 0.000104702 3.93351E-05 3.49285E-05 2.08536E-05
IL13 0.000103808 4.04463E-05 UNDETERMINED UNDETERMINED 0.000277102 0.000132873 5.15304E-05 3.89644E-05
IL15 0.000736015 0.000180284 0.003164678 0.00071589 0.001381488 0.000268109 0.003584505 0.000829263
IL16 0.00462594 0.001525306 0.008793562 0.00115954 0.004960302 0.000307402 0.011315076 0.002238165
IL17A 5.20517E-05 2.37733E-05 0.00020842 0.000151393 0.000177362 7.81511E-05 0.000145072 6.75724E-05
IL17F UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
IL18 0.319519874 0.059634685 0.356469635 0.027485936 0.261809936 0.029298503 0.429021752 0.078650831
IL1A 0.044423 0.015477145 0.686440637 0.07999296 0.751919858 0.386724403 0.152712865 0.027272111
IL1B 0.000582917 0.000384366 0.034443683 0.006527751 0.132560602 0.018548949 0.002265229 0.000355511
IL1RN 0.018173926 0.003225153 0.011591002 0.001503407 0.005856222 0.001423059 0.01781259 0.002039875
IL2 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
IL21 0.000124952 5.61661E-05 0.000292325 0.000140871 0.000313154 9.21214E-05 0.000240106 2.83485E-05
IL22 6.44259E-05 2.28791E-05 0.000121014 6.48672E-05 0.000168187 7.16227E-05 5.08648E-05 1.6508E-05
IL23A 0.000932113 0.000243317 0.001723773 0.000393054 0.001796925 0.000406958 0.001508246 0.000520934
IL24 0.000906121 0.000311367 0.000638151 0.000359831 0.000495148 0.000115242 0.000754544 0.000224565
IL27 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED 0.00016524 5.43107E-05 UNDETERMINED UNDETERMINED
IL3 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED 0.000120457 0.00010543 UNDETERMINED UNDETERMINED
IL4 0.00025986 5.91097E-05 0.000117347 8.36118E-05 UNDETERMINED UNDETERMINED 0.000228565 0.000120279
IL5 UNDETERMINED UNDETERMINED 7.00874E-05 3.64155E-05 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
IL6 0.050588167 0.019386611 2.267629699 0.772064596 4.57367832 3.380182144 0.369530043 0.093768725
IL7 0.054585522 0.015907234 0.083752644 0.005846687 0.082342627 0.011772666 0.084180105 0.020734978
IL9 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED 0.000109279 8.69859E-05 UNDETERMINED UNDETERMINED
LIF 0.006783404 0.00216983 0.030558524 0.006218173 0.054623411 0.02016179 0.011397089 0.002683653
LOC517108UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
LTA 0.000861687 0.00014843 0.00092758 0.000516155 0.001135872 0.000318429 0.000707936 9.75017E-05
LTB UNDETERMINED UNDETERMINED 0.000143567 5.55789E-05 0.000127772 5.99611E-05 6.14218E-05 1.9849E-05
MIF 0.144620093 0.044522585 0.131582529 0.009887912 0.095355966 0.01090344 0.142545708 0.01848212
MSTN UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
NODAL 0.001366238 0.00057026 0.000576304 9.71088E-05 0.0007993 0.000267778 0.000700087 0.000128424
OSM 3.16445E-05 1.24783E-05 8.84683E-05 5.5978E-05 9.55974E-05 4.73767E-05 6.43653E-05 3.72488E-05
PF4 0.000687074 0.000269698 0.003655661 0.00022672 0.005593414 0.000509081 0.001609765 0.000434314
PPBP 0.000369523 0.000119044 0.000607259 0.000162566 0.001112187 8.80802E-05 0.000725076 0.000278076
SPP1 11.83599555 2.425030157 4.750056862 0.618997377 2.820963269 0.221060914 5.8098942 0.681708383
TGFB2 0.064925652 0.015087217 0.046985184 0.003834334 0.037888479 0.001418089 0.075389978 0.007595246
THPO 0.002939928 0.000593064 0.001350119 0.000436164 0.001630439 0.000622211 0.001482197 0.000339617
TNF UNDETERMINED UNDETERMINED 0.000163399 6.11284E-05 0.000165883 4.36159E-05 0.000109565 4.6938E-06
TNFRSF11B 0.000401035 0.000130083 0.00145332 0.00078621 0.002824673 0.000132012 0.001739229 0.000189906
TNFSF10 0.001098207 0.000300135 0.003462653 0.000602411 0.001864891 0.000515114 0.006155028 0.002384991
TNFSF11 UNDETERMINED UNDETERMINED 0.000435586 0.000116937 0.000701179 0.000487237 UNDETERMINED UNDETERMINED
TNFSF13B 0.00458552 0.000734781 0.01543581 0.001956431 0.023802243 0.006805534 0.010750837 0.002811282
VEGFA 0.457058254 0.108611003 0.691081529 0.14454832 0.839372395 0.100586627 0.871151502 0.060188195
XCL1 UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED UNDETERMINED
Control LPS IL-1β TNFα 
bCSC Gene Expression  (2^-ΔΔCt)
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Supplemental Table 2.2.1. List of the proteins identified in exosomes of ICAR cultured at 1% O2 and at 8% O2  
A. List of 113 common proteins identified in exosomes of ICAR cultured at 1% O2 and at 8% O2 
Protein ID 
 
Name 
 
Gene Name 
 
Biological Process (Total # 
Gene 69; Total #Function 146) 
 
Molecular function (Total # 
Gene 69; Total #Function 
81) 
A1L523_BOVIN 
 
Copine II (Fragment)  
 
CPNE2  
    
A3KN51_BOVIN 
 
TSG101 protein  
 
TSG101  
 
Metabolic process 
 
Catalytic activity 
A5D7L1_BOVIN 
 
CLEC11A protein  
 
CLEC11A  
 
Cellular process / 
Developmental process 
 
Binding / Structural molecule 
activity 
A5D9D2_BOVIN 
 
Complement 
component 4 binding 
protein, alpha chain  
 
C4BPA  
    
A5PJ69_BOVIN 
 
SERPINA10 protein  
 
SERPINA10  
 
Biological regulation / Metabolic 
process 
 
Catalytic activity / Enzyme 
regulator activity 
A5PJE3_BOVIN 
 
Fibrinogen alpha 
chain  
 
FGA  
    
A5PK77_BOVIN 
 
SERPINA11 protein  
 
SERPINA11  
 
Biological regulation / Metabolic 
process 
 
Catalytic activity / Enzyme 
regulator activity 
A6QLB7_BOVIN 
 
Adenylyl cyclase-
associated protein 
 
CAP1  
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A6QLL8_BOVIN 
 
Fructose-
bisphosphate 
aldolase 
 
ALDOA  
    
A6QNZ7_BOVIN 
 
Keratin 10 
(Epidermolytic 
hyperkeratosis; 
keratosis palmaris et 
plantaris) 
 
KRT10  
    
A6QPP2_BOVIN 
 
SERPIND1 protein  
 
SERPIND1  
 
Biological regulation / Metabolic 
process 
 
Catalytic activity / Enzyme 
regulator activity 
A6QPR1_BOVIN 
 
PCYOX1 protein  
 
PCYOX1  
    
LG3BP_BOVIN 
 
Galectin-3-binding 
protein  
 
LGALS3BP  
 
Apoptotic process / Biological 
adhesion / Biological regulation 
/ Cellular process / 
Developmental process / 
Immune system process / 
localisation / Metabolic process 
 
Catalytic activity / Receptor 
activity 
A7MB82_BOVIN 
 
C1QTNF3 protein  
 
C1QTNF3  
    
A7YWB6_BOVIN 
 
LOC539596 protein  
 
LOC539596  
    
B0JYM4_BOVIN 
 
Tetraspanin  
 
CD63  
    
B0JYN6_BOVIN 
 
Alpha-2-HS-
glycoprotein  
 
AHSG  
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B0JYQ0_BOVIN 
 
ALB protein  
 
ALB  
    
B5B3R8_BOVIN 
 
Alpha S1 casein  
 
CSN1S1  
    
E1BDG5_BOVIN 
 
Protein Wnt 
 
WNT5A  
 
Biological regulation / Cellular 
process / Developmental 
process / Multicellular 
organismal process / Response 
to stimulus 
 
Binding 
CBG_BOVIN 
 
Corticosteroid-binding 
globulin 
 
SERPINA6  
 
Biological regulation / Metabolic 
process 
 
Catalytic activity / Enzyme 
regulator activity 
F1MAV0_BOVIN 
 
Fibrinogen beta chain  
 
FGB  
    
F1MB08_BOVIN 
 
Alpha-enolase  
 
ENO1  
    
F1MC11_BOVIN 
 
Keratin, type I 
cytoskeletal 14 
 
KRT14  
    
F1MM32_BOVIN 
 
Sulfhydryl oxidase  
 
QSOX1  
   
Catalytic activity 
F1MMK9_BOVIN 
 
Protein AMBP  
 
AMBP  
    
F1MMP5_BOVIN 
 
Inter-alpha-trypsin 
inhibitor heavy chain 
H1  
 
ITIH1  
    
ITA3_BOVIN 
 
Integrin alpha-3  
 
ITGA3  
    
F1MNW4_BOVIN 
 
Inter-alpha-trypsin 
inhibitor heavy chain 
H2  
 
ITIH2  
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F1MSZ6_BOVIN 
 
Antithrombin-III  
 
SERPINC1  
    
F1MTV5_BOVIN 
 
Amino acid 
transporter  
 
SLC1A5  
    
F1MW44_BOVIN 
 
Coagulation factor XIII 
A chain  
 
F13A1  
    
F1MXJ5_BOVIN 
 
IST1 homolog  
 
IST1  
    
F1MXX6_BOVIN 
 
Lactadherin  
 
MFGE8  
    
F1MY85_BOVIN 
 
Complement C5a 
anaphylatoxin  
 
C5  
    
F1N045_BOVIN 
 
Complement 
component C7  
 
C7  
    
HTRA1_BOVIN 
 
Serine protease 
HTRA1  
 
HTRA1  
 
Cellular process / Metabolic 
process 
 
Catalytic activity 
F1N1I6_BOVIN 
 
Gelsolin  
 
GSN  
    
F6QVC9_BOVIN 
 
Annexin  
 
ANXA5  
    
G3X6N3_BOVIN 
 
Serotransferrin  
 
TF  
    
G5E5A9_BOVIN 
 
Fibronectin  
 
FN1  
    
G5E5V0_BOVIN 
 
Carboxypeptidase N 
catalytic chain  
 
CPN1  
    
G8JKX6_BOVIN 
 
Tetraspanin 
(Fragment)  
 
CD9  
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I7CT57_BOVIN 
 
Vitamin D binding 
protein  
      
M0QVZ6_BOVIN 
 
Keratin, type II 
cytoskeletal 5 
 
KRT5  
    
THRB_BOVIN 
 
Prothrombin  
 
F2  
 
Immune system process / 
Metabolic process / Response 
to stimulus 
 
Catalytic activity 
PROC_BOVIN 
 
Vitamin K-dependent 
protein C (Fragment)  
 
PROC  
 
Response to stimulus 
 
Binding 
KNG2_BOVIN 
 
Kininogen-2  
 
KNG2  
    
THYG_BOVIN 
 
Thyroglobulin  
 
TG  
 
Metabolic process 
 
Catalytic activity 
HBA_BOVIN 
 
Hemoglobin subunit 
alpha  
 
HBA  
 
localisation / Multicellular 
organismal process 
  
HBBF_BOVIN 
 
Hemoglobin fetal 
subunit beta  
   
localisation / Multicellular 
organismal process 
  
ALBU_BOVIN 
 
Serum albumin  
 
ALB  
 
localisation 
  
ANXA2_BOVIN 
 
Annexin A2  
 
ANXA2  
 
Developmental process / 
Metabolic process 
  
ASSY_BOVIN 
 
Argininosuccinate 
synthase 
 
ASS1  
 
Cellular process / Metabolic 
process 
 
Catalytic activity 
APOH_BOVIN 
 
Beta-2-glycoprotein 1  
 
APOH  
 
Cellular process / Immune 
system process / localisation / 
 
Catalytic activity / Receptor 
activity / Transporter activity 
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Metabolic process / Response 
to stimulus 
CLUS_BOVIN 
 
Clusterin  
 
CLU  
    
HSP7C_BOVIN 
 
Heat shock cognate 
71 kDa protein  
 
HSPA8  
 
Cellular component 
organisation or biogenesis / 
Immune system process / 
Metabolic process / Response 
to stimulus 
  
ANXA7_BOVIN 
 
Annexin A7  
 
ANXA7  
 
Metabolic process 
  
ANX11_BOVIN 
 
Annexin A11  
 
ANXA11  
 
Metabolic process 
  
A2AP_BOVIN 
 
Alpha-2-antiplasmin  
 
SERPINF2  
 
Biological regulation / Metabolic 
process 
 
Catalytic activity / Enzyme 
regulator activity 
A1AT_BOVIN 
 
Alpha-1-
antiproteinase  
 
SERPINA1  
 
Biological regulation / Metabolic 
process 
 
Catalytic activity / Enzyme 
regulator activity 
GDIB_BOVIN 
 
Rab GDP dissociation 
inhibitor beta  
 
GDI2  
 
Biological regulation / Cellular 
process / localisation / 
Metabolic process / Multicellular 
organismal process 
 
Binding / Catalytic activity / 
Enzyme regulator activity 
F12AI_BOVIN 
 
Factor XIIa inhibitor  
      
ITB1_BOVIN 
 
Integrin beta-1  
 
ITGB1  
 
Biological adhesion / Cellular 
process / Response to stimulus 
 
Receptor activity 
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ITIH3_BOVIN 
 
Inter-alpha-trypsin 
inhibitor heavy chain 
H3  
 
ITIH3  
 
Biological regulation / Metabolic 
process 
 
Binding / Catalytic activity / 
Enzyme regulator activity 
ACTB_BOVIN 
 
Actin, cytoplasmic 1  
 
ACTB  
 
Cellular component 
organisation or biogenesis / 
Cellular process / 
Developmental process / 
localisation 
 
Structural molecule activity 
ANXA6_BOVIN 
 
Annexin A6  
 
ANXA6  
 
Metabolic process 
  
CFAB_BOVIN 
 
Complement factor B  
 
CFB  
 
Biological adhesion / Cellular 
process / Immune system 
process / localisation / 
Metabolic process / Response 
to stimulus 
 
Catalytic activity / Receptor 
activity / Transporter activity 
TBA1B_BOVIN 
 
Tubulin alpha-1B 
chain  
   
Cellular process / 
Developmental process / 
localisation 
 
Structural molecule activity 
LUM_BOVIN 
 
Lumican  
 
LUM  
 
Biological adhesion / Biological 
regulation / Cellular process / 
Developmental process / 
Immune system process / 
 
Receptor activity 
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Metabolic process / Multicellular 
organismal process 
UPAR_BOVIN 
 
Urokinase 
plasminogen activator 
surface receptor  
 
PLAUR  
    
5NTD_BOVIN 
 
5'-nucleotidase  
 
NT5E  
 
Metabolic process 
 
Catalytic activity 
PGM1_BOVIN 
 
Phosphoglucomutase
-1 
 
PGM1  
 
Cellular process / Metabolic 
process 
 
Catalytic activity 
Q09TE3_BOVIN 
 
Insulin-like growth 
factor binding protein 
acid labile subunit 
      
Q17R18_BOVIN 
 
Adenosine kinase 
 
ADK  
    
FA5_BOVIN 
 
Coagulation factor V 
 
F5  
 
Biological adhesion / Biological 
regulation / Cellular process / 
Developmental process / 
Immune system process / 
localisation / Metabolic process 
/ Multicellular organismal 
process / Response to stimulus 
 
Binding / Catalytic activity / 
Enzyme regulator activity / 
Receptor activity / 
Transporter activity 
Q2KIF2_BOVIN 
 
Leucine-rich alpha-2-
glycoprotein 1 
 
LRG1  
 
Cellular process / Multicellular 
organismal process 
 
Receptor activity 
CBPB2_BOVIN 
 
Carboxypeptidase B2 
 
CPB2  
 
Metabolic process 
 
Catalytic activity 
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Q2KJ47_BOVIN 
 
EH-domain containing 
2 
 
EHD2  
 
Biological regulation / Cellular 
process / localisation / 
Metabolic process / Multicellular 
organismal process 
 
Binding / Catalytic activity / 
Enzyme regulator activity 
TBB5_BOVIN 
 
Tubulin beta-5 chain 
 
TUBB5  
 
Cellular process / 
Developmental process / 
localisation 
 
Structural molecule activity 
A1BG_BOVIN 
 
Alpha-1B-glycoprotein 
 
A1BG  
 
Cellular process / Immune 
system process / Response to 
stimulus 
 
Binding / Receptor activity 
HPT_BOVIN 
 
Haptoglobin 
 
HP  
 
Biological regulation / Immune 
system process / localisation / 
Metabolic process / 
Multicellular organismal process 
/ Reproduction / Response to 
stimulus 
 
Binding / Catalytic activity / 
Enzyme regulator activity / 
Receptor activity 
CO3_BOVIN 
 
Complement C3 
 
C3  
 
Biological regulation / Cellular 
process / Metabolic process / 
Response to stimulus 
 
Binding / Catalytic activity / 
Enzyme regulator activity 
Q3MHH8_BOVIN 
 
Alpha-amylase 
 
AMY2A  
    
SAHH_BOVIN 
 
Adenosylhomocystein
ase 
 
AHCY  
 
Cellular process / Metabolic 
process 
 
Catalytic activity 
237 
 
CO9_BOVIN 
 
Complement 
component C9 
 
C9  
 
Cellular process / localisation / 
Metabolic process / Response 
to stimulus 
 
Catalytic activity / Receptor 
activity / Transporter activity 
Q3MHW2_BOVIN 
 
F10 protein 
(Fragment) 
 
F10  
    
Q3MHZ0_BOVIN 
 
FLOT1 protein 
(Fragment) 
 
FLOT1  
    
Q3SYR0_BOVIN 
 
Serpin peptidase 
inhibitor, clade A 
(Alpha-1 
antiproteinase, 
antitrypsin), member 
7 
 
SERPINA7  
    
FETA_BOVIN 
 
Alpha-fetoprotein 
 
AFP  
 
Developmental process / 
localisation 
  
Q3SZH5_BOVIN 
 
Angiotensinogen 
 
AGT  
    
HEMO_BOVIN 
 
Hemopexin 
 
HPX  
 
localisation 
  
Q3SZZ9_BOVIN 
 
FGG protein 
 
FGG  
    
PGK1_BOVIN 
 
Phosphoglycerate 
kinase 1 
 
PGK1  
 
Metabolic process 
 
Catalytic activity 
Q3T101_BOVIN 
 
IGL@ protein 
 
IGL@  
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G6PI_BOVIN 
 
Glucose-6-phosphate 
isomerase 
 
GPI  
 
Metabolic process 
 
Catalytic activity 
Q3ZBX0_BOVIN 
 
Basigin 
 
BSG  
    
Q3ZC87_BOVIN 
 
Pyruvate kinase 
(Fragment) 
 
PKM2  
    
Q3ZCI4_BOVIN 
 
6-phosphogluconate 
dehydrogenase, 
decarboxylating 
 
PGD  
 
Metabolic process 
 
Catalytic activity 
FETUB_BOVIN 
 
Fetuin-B 
 
FETUB  
    
EHD1_BOVIN 
 
EH domain-containing 
protein 1 
 
EHD1  
 
Biological regulation / Cellular 
process / localisation / 
Metabolic process / Multicellular 
organismal process 
 
Binding / Catalytic activity / 
Enzyme regulator activity 
HPPD_BOVIN 
 
4-
hydroxyphenylpyruvat
e dioxygenase 
 
HPD  
 
Metabolic process 
 
Catalytic activity 
Q5EA67_BOVIN 
 
Inter-alpha (Globulin) 
inhibitor H4 (Plasma 
Kallikrein-sensitive 
glycoprotein) 
 
ITIH4  
    
Q5GN72_BOVIN 
 
Alpha-1-acid 
glycoprotein 
 
agp  
    
239 
 
BHMT1_BOVIN 
 
Betaine--
homocysteine S-
methyltransferase 1 
 
BHMT  
 
Cellular process / Metabolic 
process 
 
Catalytic activity 
Q5J801_BOVIN 
 
Endopin 2B 
      
Q6T182_BOVIN 
 
Sex hormone-binding 
globulin (Fragment) 
 
SHBG  
    
A2MG_BOVIN 
 
Alpha-2-
macroglobulin 
 
A2M  
 
Biological regulation / Cellular 
process / Immune system 
process / Metabolic process / 
Response to stimulus 
 
Binding / Catalytic activity / 
Enzyme regulator activity 
PEDF_BOVIN 
 
Pigment epithelium-
derived factor 
 
SERPINF1  
 
Biological regulation / Metabolic 
process 
 
Catalytic activity / Enzyme 
regulator activity 
CHIA_BOVIN 
 
Acidic mammalian 
chitinase 
 
CHIA  
 
Immune system process / 
Metabolic process / Response 
to stimulus 
 
Binding / Catalytic activity 
IPSP_BOVIN 
 
Plasma serine 
protease inhibitor 
 
SERPINA5  
 
Biological regulation / Metabolic 
process 
 
Catalytic activity / Enzyme 
regulator activity 
SPA31_BOVIN 
 
Serpin A3-1 
 
SERPINA3-
1  
 
Biological regulation / Metabolic 
process 
 
Catalytic activity / Enzyme 
regulator activity 
V6F9A2_BOVIN 
 
Apolipoprotein A-I 
preproprotein 
 
APOA1  
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B. List of 128 unique proteins identified in exosomes of ICAR cultured at 1% O2  
Protein ID 
 
Name 
 
Gene 
Name 
 
Biological Process (Total # 
Gene 22; Total #Function 49) 
 
Molecular function (Total # 
Gene 22; Total #Function 
28) 
G3X6T9_BOVIN 
 
Flotillin-2 (Fragment) 
 
FLOT2 
    
TSP1_BOVIN 
 
Thrombospondin-1 
 
THBS1 
    
F1N2L9_BOVIN 
 
4-
trimethylaminobutyrald
ehyde dehydrogenase 
 
ALDH9A1 
    
E1B9F6_BOVIN 
 
Elongation factor 1-
alpha 
 
EEF1A1 
    
APOE_BOVIN 
 
Apolipoprotein E 
 
APOE 
 
Apoptotic process / Biological 
regulation / Cellular component 
organisation or biogenesis / 
Cellular process / 
Developmental process / Growth 
/ 
localisation / Metabolic process / 
 
Binding / Catalytic activity / 
Enzyme regulator activity / 
Transporter activity 
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Multicellular organismal process 
/ Response to stimulus 
G1K1R6_BOVIN 
 
Galactokinase 
 
GALK1 
    
G3P_BOVIN 
 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
 
GAPDH 
 
Metabolic process 
 
Catalytic activity 
Q0P5B0_BOVIN 
 
Arrestin domain 
containing 1 
 
ARRDC1 
    
RL40_BOVIN 
 
Ubiquitin-60S 
ribosomal protein L40 
 
UBA52 
 
Metabolic process 
 
Binding / Structural 
molecule activity 
A5D9B6_BOVIN 
 
Syntenin 
 
SDCBP 
    
Q8HZY1_BOVIN 
 
Serine protease 
inhibitor clade E 
member 2 
 
SERPINE
2 
    
Q5E962_BOVIN 
 
Aldo-keto reductase 
family 1, member B1 
 
AKR1B1 
    
A7MBH9_BOVIN 
 
GNAI2 protein 
 
GNAI2 
 
Biological regulation / Cellular 
process / Metabolic process / 
Response to stimulus 
 
Binding / Catalytic activity 
GBB2_BOVIN 
 
Guanine nucleotide-
binding protein 
 
GNB2 
 
Cellular process / Metabolic 
process / Multicellular 
organismal process 
 
Binding / Catalytic activity 
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G(I)/G(S)/G(T) subunit 
beta-2 
I6YIV1_BOVIN 
 
Annexin 
      
F16P1_BOVIN 
 
Fructose-1,6-
bisphosphatase 1 
 
FBP1 
 
Metabolic process 
  
F1N3Q7_BOVIN 
 
Apolipoprotein A-IV 
 
APOA4 
    
AK1A1_BOVIN 
 
Alcohol dehydrogenase 
[NADP(+)] 
 
AKR1A1 
 
localisation / Metabolic process 
 
Catalytic activity / 
Transporter activity 
A5D784_BOVIN 
 
CPNE8 protein 
 
CPNE8 
 
localisation 
  
HS90A_BOVIN 
 
Heat shock protein 
HSP 90-alpha 
 
HSP90AA
1 
 
Immune system process / 
Metabolic process / Response to 
stimulus 
  
Q1JPA2_BOVIN 
 
Eukaryotic translation 
elongation factor 1 
gamma (Fragment) 
 
EEF1G 
    
SERA_BOVIN 
 
D-3-phosphoglycerate 
dehydrogenase 
 
PHGDH 
 
Metabolic process 
 
Catalytic activity 
Q3T085_BOVIN 
 
OGN protein 
 
OGN 
    
A8DBT6_BOVIN 
 
Monocyte 
differentiation antigen 
CD14 
 
CD14 
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A5PK73_BOVIN 
 
Fructose-bisphosphate 
aldolase 
 
ALDOB 
    
G5E5U7_BOVIN 
 
S-adenosylmethionine 
synthase 
 
MAT1A 
    
F1N2W0_BOVIN 
 
Prostaglandin 
reductase 1 
 
PTGR1 
    
IF4A1_BOVIN 
 
Eukaryotic initiation 
factor 4A-I 
 
EIF4A1 
 
Biological regulation / Metabolic 
process 
 
Binding / Catalytic activity / 
Translation regulator 
activity 
Q05B55_BOVIN 
 
IGK protein 
 
IGK 
    
F1N1D4_BOVIN 
 
Protein tweety homolog 
 
TTYH3 
 
localisation 
 
Transporter activity 
A4FV94_BOVIN 
 
KRT6A protein 
 
KRT6A 
    
RGN_BOVIN 
 
Regucalcin 
 
RGN 
 
Cellular process / localisation / 
Metabolic process 
 
Binding / Catalytic activity 
1433E_BOVIN 
 
14-3-3 protein epsilon 
 
YWHAE 
 
Cellular process 
  
Q2HJB6_BOVIN 
 
Procollagen C-
endopeptidase 
enhancer 
 
PCOLCE 
 
Biological adhesion / Biological 
regulation / Cellular process / 
Developmental process / 
Immune system process / 
localisation / Metabolic process / 
Multicellular organismal process 
/ Response to stimulus 
 
Binding / Catalytic activity / 
Enzyme regulator activity / 
Receptor activity / 
Transporter activity 
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B8YB76_BOVIN 
 
Homogentisate 1,2-
dioxygenase 
 
HGD 
    
DHSO_BOVIN 
 
Sorbitol dehydrogenase 
 
SORD 
 
Metabolic process 
 
Catalytic activity 
HS71A_BOVIN 
 
Heat shock 70 kDa 
protein 1A 
 
HSPA1A 
 
Cellular component organisation 
or biogenesis / Immune system 
process / Metabolic process / 
Response to stimulus 
  
Q3ZBQ9_BOVIN 
 
APOM protein 
 
APOM 
    
PYGL_BOVIN 
 
Glycogen 
phosphorylase, liver 
form 
 
PYGL 
 
Metabolic process 
 
Catalytic activity 
A6QP30_BOVIN 
 
CPN2 protein 
 
CPN2 
 
Cellular process / Multicellular 
organismal process 
 
Receptor activity 
ARF3_BOVIN 
 
ADP-ribosylation factor 
3 
 
ARF3 
 
Cellular process / localisation / 
Metabolic process 
 
Binding / Catalytic activity 
G3MYH4_BOVIN 
 
Tetraspanin (Fragment) 
 
CD81 
    
ACTC_BOVIN 
 
Actin, alpha cardiac 
muscle 1 
 
ACTC1 
 
Cellular component organisation 
or biogenesis / Cellular process / 
Developmental process / 
localisation 
 
Structural molecule activity 
GALM_BOVIN 
 
Aldose 1-epimerase 
 
GALM 
 
Metabolic process 
 
Catalytic activity 
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TSN6_BOVIN 
 
Tetraspanin-6 
 
TSPAN6 
 
Biological adhesion / Cellular 
process / Immune system 
process / Multicellular 
organismal process / 
Reproduction / Response to 
stimulus 
 
Binding / Receptor activity 
Q3ZC83_BOVIN 
 
Solute carrier family 29 
(Nucleoside 
transporters), member 
1 
 
SLC29A1 
 
localisation / Metabolic process 
 
Transporter activity 
B4GA1_BOVIN 
 
Beta-1,4-
glucuronyltransferase 1 
 
B4GAT1 
 
Metabolic process 
 
Catalytic activity 
ADA10_BOVIN 
 
Disintegrin and 
metalloproteinase 
domain-containing 
protein 10 
 
ADAM10 
 
Apoptotic process / 
Developmental process / 
Reproduction 
  
A6QR28_BOVIN 
 
Phosphoserine 
aminotransferase 
 
PSAT1 
 
Metabolic process 
 
Catalytic activity 
Q1JPB6_BOVIN 
 
Acetyl-Coenzyme A 
acetyltransferase 2 
 
ACAT2 
    
DDBX_BOVIN 
 
Dihydrodiol 
dehydrogenase 3 
   
localisation  / Metabolic process 
 
Catalytic activity / 
Transporter activity 
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A2VE11_BOVIN 
 
IGSF8 protein 
 
IGSF8 
    
F1MS32_BOVIN 
 
Apolipoprotein D 
 
APOD 
    
A6QP64_BOVIN 
 
VPS37B protein 
(Fragment) 
 
VPS37B 
    
Q2KIW4_BOVIN 
 
Lecithin-cholesterol 
acyltransferase 
 
LCAT 
 
Metabolic process 
 
Catalytic activity 
GBB1_BOVIN 
 
Guanine nucleotide-
binding protein 
G(I)/G(S)/G(T) subunit 
beta-1 
 
GNB1 
 
Cellular process / Metabolic 
process 
 
Binding / Catalytic activity 
GNA11_BOVIN 
 
Guanine nucleotide-
binding protein subunit 
alpha-11 
 
GNA11 
 
Biological regulation / Cellular 
process / Metabolic process / 
Response to stimulus 
 
Catalytic activity 
Q17QK4_BOVIN 
 
Epoxide hydrolase 2, 
cytoplasmic 
 
EPHX2 
    
K2C7_BOVIN 
 
Keratin, type II 
cytoskeletal 7 
 
KRT7 
 
Cellular component organisation 
or biogenesis / Cellular process / 
Developmental process 
 
Structural molecule activity 
CLIC1_BOVIN 
 
Chloride intracellular 
channel protein 1 
 
CLIC1 
 
Biological regulation / Cellular 
process / Metabolic process / 
Response to stimulus 
 
Binding / Catalytic activity 
/Structural molecule activity 
/ Translation regulator 
activity 
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Q08DW4_BOVIN 
 
Mannan-binding lectin 
serine peptidase 1 
(C4/C2 activating 
component of Ra-
reactive factor) 
 
MASP1 
    
B4GT1_BOVIN 
 
Beta-1,4-
galactosyltransferase 1 
 
B4GALT1 
    
A5D7E6_BOVIN 
 
Tetraspanin 
 
CD82 
 
Cellular process / Response to 
stimulus 
 
Binding / Receptor activity 
A5D973_BOVIN 
 
Alpha isoform of 
regulatory subunit A, 
protein phosphatase 2 
 
PPP2R1A 
    
E1B726_BOVIN 
 
Plasminogen 
 
PLG 
    
G5E6I9_BOVIN 
 
Histone H2B 
 
LOC1019
04777 
 
Cellular component organisation 
or biogenesis / Cellular process / 
Metabolic process 
 
Binding 
ADIPO_BOVIN 
 
Adiponectin 
 
ADIPOQ 
    
F1MBC5_BOVIN 
 
Coagulation factor IX 
 
F9 
    
A2VDL2_BOVIN 
 
Solute carrier family 2 
(Facilitated glucose 
transporter), member 3 
 
SLC2A3 
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VPS4B_BOVIN 
 
Vacuolar protein 
sorting-associated 
protein 4B 
 
VPS4B 
    
G3X8B1_BOVIN 
 
Peptidyl-prolyl cis-trans 
isomerase 
 
LOC6134
01 
    
K4JB97_BOVIN 
 
Alpha-2-macroglobulin 
variant 4 
 
A2M 
    
ACTG_BOVIN 
 
Actin, cytoplasmic 2 
 
ACTG1 
 
Cellular component organisation 
or biogenesis / Cellular process / 
localisation 
 
Structural molecule activity 
Q1JPG7_BOVIN 
 
Pyruvate kinase 
 
PKLR 
    
GTR1_BOVIN 
 
Solute carrier family 2, 
facilitated glucose 
transporter member 1 
 
SLC2A1 
    
F1N342_BOVIN 
 
Protein tweety homolog 
 
TTYH2 
 
localisation 
 
Transporter activity 
ADHX_BOVIN 
 
Alcohol dehydrogenase 
class-3 
 
ADH5 
 
Metabolic process 
 
Catalytic activity 
URP2_BOVIN 
 
Fermitin family 
homolog 3 
 
FERMT3 
    
E1B7N2_BOVIN 
 
Histone H4 
 
HIST1H4I 
 
Cellular component organisation 
or biogenesis / Cellular process / 
Metabolic process 
 
Binding 
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EF2_BOVIN 
 
Elongation factor 2 
 
EEF2 
 
Biological regulation / Metabolic 
process 
 
Binding / Translation 
regulator activity 
KLKB1_BOVIN 
 
Plasma kallikrein 
 
KLKB1 
 
Biological regulation / 
localisation / Metabolic process / 
Response to stimulus 
 
Binding / Catalytic activity / 
Enzyme regulator activity / 
Receptor activity 
ESTD_BOVIN 
 
S-formylglutathione 
hydrolase 
 
ESD 
 
Metabolic process 
 
Catalytic activity 
SEPR_BOVIN 
 
Prolyl endopeptidase 
FAP 
 
FAP 
 
Cellular process / Immune 
system process / localisation / 
Metabolic process / Multicellular 
organismal process / Response 
to stimulus 
 
Binding / Catalytic activity 
Q5EA54_BOVIN 
 
Solute carrier family 3 
(Activators of dibasic 
and neutral amino acid 
transport), member 2 
 
SLC3A2 
    
Q1JPD9_BOVIN 
 
G protein-coupled 
receptor, family C, 
group 5, member B 
 
GPRC5B 
 
Cellular process 
 
Receptor activity 
F1MS05_BOVIN 
 
Aconitate hydratase 
 
ACO1 
    
F1MJ12_BOVIN 
 
Complement C1s 
subcomponent 
 
C1S 
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CNDP2_BOVIN 
 
Cytosolic non-specific 
dipeptidase 
 
CNDP2 
 
Metabolic process 
 
Catalytic activity 
Q2TBQ1_BOVIN 
 
Coagulation factor XIII, 
B polypeptide 
 
F13B 
 
Biological adhesion / Cellular 
process / Immune system 
process / localisation / Metabolic 
process / Response to stimulus 
 
Catalytic activity / Receptor 
activity / Transporter 
activity 
Q1JP72_BOVIN 
 
Colony stimulating 
factor 1 receptor 
 
CSF1R 
    
Q0VD03_BOVIN 
 
CD44 antigen 
 
CD44 
    
G3X6Y4_BOVIN 
 
Osteomodulin 
 
OMD 
    
GAMT_BOVIN 
 
Guanidinoacetate N-
methyltransferase 
 
GAMT 
    
VWA1_BOVIN 
 
von Willebrand factor A 
domain-containing 
protein 1 
 
VWA1 
    
SERC3_BOVIN 
 
Serine incorporator 3 
 
SERINC3 
    
Q862H8_BOVIN 
 
Similar to 40S 
ribosomal protein SA 
(P40) (Fragment) 
      
A8E4P3_BOVIN 
 
STOM protein 
 
STOM 
    
F1MHP6_BOVIN 
 
Adenylosuccinate lyase 
 
ADSL 
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E1BMG9_BOVIN 
 
10-
formyltetrahydrofolate 
dehydrogenase 
 
ALDH1L1 
 
Metabolic process 
 
Catalytic activity 
Q705V4_BOVIN 
 
Kappa-casein 
(Fragment) 
 
csn3 
    
G3X6Q8_BOVIN 
 
Pentraxin-related 
protein PTX3 
 
PTX3 
    
K7QEL2_BOVIN 
 
MHC class I antigen 
 
BoLA 
    
TCPQ_BOVIN 
 
T-complex protein 1 
subunit theta 
 
CCT8 
 
Cellular component organisation 
or biogenesis / Metabolic 
process 
  
F1N6Z0_BOVIN 
 
26S proteasome non-
ATPase regulatory 
subunit 5 
 
PSMD5 
    
ARLY_BOVIN 
 
Argininosuccinate lyase 
 
ASL 
 
Metabolic process 
 
Catalytic activity 
E1BNG2_BOVIN 
 
alpha-1,2-Mannosidase 
 
MAN1A1 
 
Metabolic process 
  
F1MU79_BOVIN 
 
Peptidyl-prolyl cis-trans 
isomerase FKBP4 
 
FKBP4 
    
DPYL2_BOVIN 
 
Dihydropyrimidinase-
related protein 2 
 
DPYSL2 
 
Metabolic process 
 
Catalytic activity 
PRS23_BOVIN 
 
Serine protease 23 
 
PRSS23 
    
B0JYN1_BOVIN 
 
Cathepsin L2 
 
CTSL2 
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A4FV99_BOVIN 
 
FCNB protein 
 
FCNB 
    
A7YW37_BOVIN 
 
CD58 protein 
(Fragment) 
 
CD58 
 
Immune system process / 
Response to stimulus 
 
Binding 
F1MTP5_BOVIN 
 
WD repeat-containing 
protein 1 
 
WDR1 
    
A7E3D0_BOVIN 
 
CCDC45 protein 
(Fragment) 
 
CCDC45 
    
Q0VCK1_BOVIN 
 
Myeloid-associated 
differentiation marker 
 
MYADM 
    
A1L570_BOVIN 
 
Ephrin-B1 
 
EFNB1 
 
Biological regulation / Cellular 
component organisation or 
biogenesis / Cellular process / 
Developmental process / 
locomotion / Multicellular 
organismal process / Response 
to stimulus 
 
Binding 
F1N049_BOVIN 
 
Actin-related protein 3 
(Fragment) 
 
ACTR3 
    
PAI1_BOVIN 
 
Plasminogen activator 
inhibitor 1 
 
SERPINE
1 
 
Biological regulation / Metabolic 
process 
 
Catalytic activity / Enzyme 
regulator activity 
Q3ZC30_BOVIN 
 
Sulfotransferase 
 
SULT1E1 
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COL11_BOVIN 
 
Collectin-11 
 
COLEC11 
 
Biological regulation / Immune 
system process / Multicellular 
organismal process 
  
MPZL1_BOVIN 
 
Myelin protein zero-like 
protein 1 
 
MPZL1 
 
Cellular process / localisation 
 
Transporter activity 
G5E595_BOVIN 
 
Lys-63-specific 
deubiquitinase 
BRCC36 
 
BRCC3 
    
O18977_BOVIN 
 
Tenascin-X 
 
TN-X 
    
A6H7D3_BOVIN 
 
KRT18 protein 
(Fragment) 
 
KRT18 
    
J9ZXG5_BOVIN 
 
Integrin alpha V subunit 
      
B0JYN3_BOVIN 
 
L-lactate 
dehydrogenase 
 
LDHB 
    
MB211_BOVIN 
 
Protein mab-21-like 1 
 
MAB21L1 
    
E1B7R4_BOVIN 
 
Eukaryotic translation 
initiation factor 3 
subunit A 
 
EIF3A 
 
Biological regulation / Metabolic 
process 
 
Binding  / Translation 
regulator activity 
 
C. List of 46 unique proteins identified in exosomes of ICAR cultured at 8 % O2 
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Protein ID 
 
Name 
 
Gene 
Name 
 
Biological Process (Total # Gene 
22; Total #Function 49) 
 
Molecular function (Total # 
Gene 22; Total #Function 
28) 
F1MMD7_BOVIN 
 
Inter-alpha-trypsin 
inhibitor heavy chain 
H4 
 
ITIH4 
    
F1N3A1_BOVIN 
 
Thrombospondin-1 
 
THBS1 
    
PLMN_BOVIN 
 
Plasminogen 
 
PLG 
 
Biological regulation / localisation 
/ Metabolic process / Response to 
stimulus 
 
Binding / Catalytic activity / 
Enzyme regulator activity / 
Receptor activity 
F1MYN5_BOVIN 
 
Fibulin-1 
 
FBLN1 
 
Cellular process / Developmental 
process 
 
Binding 
F1MNV5_BOVIN 
 
Kininogen-1 
 
KNG1 
    
EF1A1_BOVIN 
 
Elongation factor 1-
alpha 1 
 
EEF1A1 
 
Biological regulation / Metabolic 
process 
 
Binding / Catalytic activity / 
Translation regulator 
activity 
ITAV_BOVIN 
 
Integrin alpha-V 
 
ITGAV 
 
Biological adhesion 
  
F1MK44_BOVIN 
 
Integrin alpha-5 
 
ITGA5 
    
TTHY_BOVIN 
 
Transthyretin 
 
TTR 
 
localisation 
 
Transporter activity 
F1MC45_BOVIN 
 
Complement factor H 
(Fragment) 
 
CFH 
    
J9QD97_BOVIN 
 
Periostin variant 9 
      
255 
 
ACTS_BOVIN 
 
Actin, alpha skeletal 
muscle 
 
ACTA1 
 
Cellular component organisation or 
biogenesis / Cellular process / 
Developmental process / 
localisation 
Structural molecule activity 
E1B9K1_BOVIN 
 
Polyubiquitin-C 
 
UBC 
    
A7YWR0_BOVIN 
 
Apolipoprotein E 
 
APOE 
    
FA9_BOVIN 
 
Coagulation factor IX 
 
F9 
 
Apoptotic process / 
Biological regulation / 
Developmental process 
/ Immune system 
process / 
localisation / Metabolic 
process / Multicellular 
organismal process / 
Response to stimulus 
 
Binding / Catalytic activity / 
Enzyme regulator activity / 
Receptor activity 
COMP_BOVIN 
 
Cartilage oligomeric 
matrix protein 
 
COMP 
    
K2C80_BOVIN 
 
Keratin, type II 
cytoskeletal 80 
 
KRT80 
 
Cellular component 
organisation or 
biogenesis / Cellular 
process / 
Developmental process 
 
Structural molecule activity 
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TRFE_BOVIN 
 
Serotransferrin 
 
TF 
 
localisation / Metabolic 
process 
 
Catalytic activity 
K4JDR8_BOVIN 
 
Alpha-2-
macroglobulin variant 
5 
 
A2M 
    
Q32P72_BOVIN 
 
CP protein 
(Fragment) 
 
CP 
    
J9ZW47_BOVIN 
 
Integrin beta 
      
F1MM86_BOVIN 
 
Complement 
component C6 
 
C6 
    
E1BI02_BOVIN 
 
Fibromodulin 
 
FMOD 
    
VNN1_BOVIN 
 
Pantetheinase 
 
VNN1 
 
Biological adhesion / 
Cellular process / 
Metabolic process 
 
Catalytic activity 
G3X807_BOVIN 
 
Histone H4 
(Fragment) 
   
Cellular component 
organisation or 
biogenesis / Cellular 
process / Metabolic 
process 
 
Binding 
MOT1_BOVIN 
 
Monocarboxylate 
transporter 1 
 
SLC16A1 
 
Cellular process / 
localisation 
 
Transporter activity 
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TF_BOVIN 
 
Tissue factor 
 
F3 
 
Biological regulation / 
Cellular process / 
Response to stimulus 
 
Binding / Receptor activity 
HS71L_BOVIN 
 
Heat shock 70 kDa 
protein 1-like 
 
HSPA1L 
 
Metabolic process / 
Response to stimulus 
  
Q3ZCA7_BOVIN 
 
Guanine nucleotide 
binding protein (G 
protein), alpha 
inhibiting activity 
polypeptide 3 
GNAI3 
 
Biological regulation / 
Cellular process / 
Metabolic process / 
Response to stimulus 
 
Binding / Catalytic activity 
IDHC_BOVIN 
 
Isocitrate 
dehydrogenase 
[NADP] cytoplasmic 
 
IDH1 
    
Q1PBC8_BOVIN 
 
CD14 (Fragment) 
      
F1MJJ8_BOVIN 
 
Radixin (Fragment) 
 
RDX 
    
IF4A2_BOVIN 
 
Eukaryotic initiation 
factor 4A-II 
 
EIF4A2 
 
Biological regulation / 
Metabolic process 
 
Binding / Catalytic activity / 
Translation regulator 
activity 
C1QB_BOVIN 
 
Complement C1q 
subcomponent 
subunit B 
 
C1QB 
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A6QPD4_BOVIN 
 
LOC790886 protein 
 
LOC79088
6 
    
CTL2_BOVIN 
 
Choline transporter-
like protein 2 
 
SLC44A2 
 
localisation 
 
Transporter activity 
HPCL1_BOVIN 
 
Hippocalcin-like 
protein 1 
 
HPCAL1 
 
Cellular process / 
Multicellular organismal 
process 
  
Q24K07_BOVIN 
 
Vacuolar protein 
sorting 11 homolog 
(S. cerevisiae) 
 
VPS11 
    
Q5H9M6_BOVIN 
 
Dynein heavy chain 
(Fragment) 
 
Bv2 
    
Q864S1_BOVIN 
 
Cathepsin C 
(Fragment) 
      
Q4ZJS0_BOVIN 
 
MHC class I antigen 
(Fragment) 
 
BoLA-N 
    
Q58CZ4_BOVIN 
 
Flotillin 2 
 
FLOT2 
    
MBL2_BOVIN 
 
Mannose-binding 
protein C 
 
MBL 
   
Binding 
TM214_BOVIN 
 
Transmembrane 
protein 214 
 
TMEM214 
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Q8MIR1_BOVIN 
 
Nicotinic 
acetylcholine 
receptor beta 2 
subunit (Fragment) 
 
CHRNB2 
    
Q5E9W1_BOVIN 
 
CDC45-like 
 
CDC45L 
    
260 
 
Chapter 3.3 
Method A (Buoyant density gradient centrifugation) 
  
 
 
Method B (Size exclusion chromatography) 
  
  
 
Supplemental Figure S3.3.1. Transmission electron microscopy displaying 
exosomal morphology of individual exosomal fractions. Representative electron 
micrographs of exosomes from fraction 6 (A), fraction 7 (B) and fraction 8 (C) after buoyant 
density gradient centrifugation (Method A). Representative electron micrographs of 
exosomes of fraction 7 (D), fraction 8 (E), fraction 9 (F) and fraction 10 (G) following size 
exclusion chromatography (Method B).
A B 
C 
D E 
F G 
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Chapter 5.1 
Supplemental Table S5.1.1. List of 85 common proteins identified in plasma exosomes of high and low fertility heifers 
Accession 
number Name Gene name Biological Process Molecular Function 
Q3T101 IGL@ protein  IGL@  
  
Q1RMN8 
Immunoglobulin light chain, 
lambda gene cluster  IGL@  
  
Q5E9E3 
Complement C1q 
subcomponent subunit A  C1QA  
  
A6QPP2 SERPIND1 protein  SERPIND1  Biological regulation Catalytic activity 
A5D7Q2 Putative uncharacterised protein  
   
A6QM09 Putative uncharacterised protein  
   
Q29437 
Primary amine oxidase, liver 
isozyme  
   
F1MH40 
Uncharacterised protein 
(Protein Gm20730) 
 
Response to stimulus 
 
F1MAV0 Fibrinogen beta chain  FGB  
  
D4QBB4 Globin A1  HBB  
  
Q1RMH5 C1QC protein (Fragment)  C1QC  
  
G5E604 
Uncharacterised protein 
(SUBFAMILY NOT NAMED) 
 
Response to stimulus 
 
A4IFI0 IGLL1 protein  IGLL1  
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Q9TTE1 Serpin A3-1  SERPINA3-1  Biological regulation Catalytic activity 
P81644 Apolipoprotein A-II  APOA2  
Biological regulation / Cellular 
component organisation or 
biogenesis / Metabolic process / 
Multicellular organismal process 
Binding / Catalytic activity 
/ Transporter activity 
Q68RU0 
Ovarian and testicular 
apolipoprotein N  ApoN  
  
A5PJE3 Fibrinogen alpha chain  FGA  
  
A0A140T897 Serum albumin  ALB  
  
Q5GN72 Alpha-1-acid glycoprotein  agp  Response to stimulus 
 
Q2KIU3 Protein HP-25 homolog 2  
   
I7CT57 Vitamin D binding protein  
   
Q7SIH1 Alpha-2-macroglobulin  A2M  
Cellular process / Metabolic 
process / Response to stimulus Binding / Catalytic activity 
E1BH06 
Uncharacterised protein 
(Complement C4-B) LOC617696  
Cellular process / Metabolic 
process / Response to stimulus Binding / Catalytic activity 
G3MZH0 Uncharacterised protein  
 
Response to stimulus 
 
F1N076 
Uncharacterised protein 
(Ceruloplasmin) CP  
Developmental process / 
Response to stimulus 
 
F1N514 
Uncharacterised protein (CD5 
antigen-like) CD5L  
Cellular process / Localisation / 
Metabolic process 
Catalytic activity / 
Receptor activity 
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G5E513 
Uncharacterised protein (Ig mu 
chain C region) 
 
Biological regulation / Cellular 
component organisation or 
biogenesis / Cellular process / 
Localisation / Metabolic process 
/ Multicellular organismal 
process / Response to stimulus 
 
Q3SYR8 Immunoglobulin J chain  IGJ  Response to stimulus Binding 
Q58D62 Fetuin-B  FETUB  Biological regulation Catalytic activity 
P23805 Conglutinin  CGN1  Biological regulation 
 
A5D9D2 
Complement component 4 
binding protein, alpha chain  C4BPA  
  
Q3MHN2 Complement component C9  C9  
Biological adhesion / Cellular 
process / Immune system 
process 
 
A7E3W2 Galectin-3-binding protein  LGALS3BP  
  
F1MLW8 
Uncharacterised protein 
(SUBFAMILY NOT NAMED) 
 
Response to stimulus 
 
P02662 Alpha-S1-casein  CSN1S1  Localisation 
 
V6F9A2 Apolipoprotein A-I preproprotein  APOA1  
  
G3X6N3 Serotransferrin  TF  
  
B0JYP6 IGK protein  IGK  
  
A0A1K0FUD3 Globin C1  GLNC1  
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G3MXG6 
Uncharacterised protein (Ig 
heavy chain V region MC101) 
 
Biological regulation / Cellular 
component organisation or 
biogenesis / Cellular process / 
Localisation / Metabolic process 
/ Multicellular organismal 
process / Response to stimulus Binding 
G3N0V0 
Uncharacterised protein (Ig 
gamma-1 chain C region-
related) 
 
Biological regulation / Cellular 
component organisation or 
biogenesis / Cellular process / 
Localisation / Metabolic process 
/ Multicellular organismal 
process / Response to stimulus Binding 
Q2KJF1 Alpha-1B-glycoprotein  A1BG  
Cellular process / Response to 
stimulus Receptor activity 
Q2KIT0 Protein HP-20 homolog  
   
B0JYN6 Alpha-2-HS-glycoprotein  AHSG  
  
F1MMP5 
Inter-alpha-trypsin inhibitor 
heavy chain H1  ITIH1  
  
G3N1R1 
Uncharacterised protein (Ig 
heavy chain V-II region COR-
related) 
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F1MJK3 
Uncharacterised protein 
(Pregnancy zone protein) 
 
Cellular process / Metabolic 
process / Response to stimulus Binding / Catalytic activity 
Q2KIF2 
Leucine-rich alpha-2-
glycoprotein 1  LRG1  
  
P00735 Prothrombin  F2  
Metabolic process / Response to 
stimulus Catalytic activity 
Q3ZBS7 Vitronectin  VTN  Cellular process 
 
Q3SZZ9 FGG protein  FGG  
  
O02659 Mannose-binding protein C  MBL  
Biological regulation / Metabolic 
process / Response to stimulus Binding 
P81187 Complement factor B  CFB  
Biological adhesion / Cellular 
process / Response to stimulus 
 
F1N3Q7 Apolipoprotein A-IV  APOA4  
  
G3N0S9 
Uncharacterised protein (C4b-
binding protein alpha chain) LOC515150  
Biological adhesion / Cellular 
process / Response to stimulus 
 
A5D9E9 
Complement component 1, r 
subcomponent  C1R  
  
G5E5T5 
Uncharacterised protein (Ig mu 
chain C region) 
  
Binding 
Q2UVX4 Complement C3  C3  
Cellular process / Metabolic 
process / Response to stimulus Binding / Catalytic activity 
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K4JF16 
Alpha-2-macroglobulin variant 
23  A2M  
  
P28800 Alpha-2-antiplasmin  SERPINF2  Biological regulation Catalytic activity 
Q2KIX7 Protein HP-25 homolog 1  
   
P02666 Beta-casein  CSN2  
Biological regulation / 
Localisation Binding / Catalytic activity 
Q6T182 
Sex hormone-binding globulin 
(Fragment)  SHBG  
  
F1MNW4 
Inter-alpha-trypsin inhibitor 
heavy chain H2  ITIH2  
  
F1MLW7 Uncharacterised protein  LOC100297192  
  
Q28085 Complement factor H  CFH  
Biological adhesion / Cellular 
process / Immune system 
process 
 
V6F9A3 Apolipoprotein C-III  ApoC3  
  
F1MVK1 
Uncharacterised protein 
(Complement C4-B) 
 
Cellular process / Metabolic 
process / Response to stimulus Binding / Catalytic activity 
G3MZE0 
Uncharacterised protein 
(SUBFAMILY NOT NAMED) 
   
P34955 Alpha-1-antiproteinase  SERPINA1  Biological regulation Catalytic activity 
Q3SZV7 Hemopexin  HPX  Localisation 
 
Q3Y5Z3 Adiponectin  ADIPOQ  
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A0A140T8A9 Kappa-casein (Fragment)  csn3  
  
G3MXL3 Keratin, type II cytoskeletal 3  KRT3  
Cellular component organisation 
or biogenesis / Cellular process 
Structural molecule 
activity 
F1MMK9 Protein AMBP  AMBP  
  
A0A140T8C8 Beta-2-glycoprotein 1  APOH  
  
A0A140T843 Kininogen-1  KNG1  
  
P06868 Plasminogen  PLG  
  
B8Y9S9 
Embryo-specific fibronectin 1 
transcript variant  FN1  
  
Q3T052 
Inter-alpha (Globulin) inhibitor 
H4 (Plasma Kallikrein-sensitive 
glycoprotein)  ITIH4  Metabolic process Binding / Catalytic activity 
Q3SZQ8 Endopin 2  SERPINA3-7  
  
F1N1I6 Gelsolin  GSN  
  
F1MY85 Complement C5a anaphylatoxin  C5  
  
G3X6K8 Haptoglobin  HP  
  
P41361 Antithrombin-III  SERPINC1  Biological regulation Catalytic activity 
 
 
 
268 
 
Supplemental Table S5.1.2. Mass spectrometric analysis of high (n=12) and 
low (n=12) fertility heifers. The total spectra and peptide number for each 
protein of individual heifers were presented. 
 
Protein N Representative Accession Name Confident Peptides Confident Sequences Confident Spectra %Seq Cov - peptides >95% conf
1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 321 128 1767 77.28
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 405 132 6066 92.09
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 204 109 658 63.58
4 tr|G3X6N3|G3X6N3_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=1 SV=1 88 44 263 67.47
5 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 95 34 1360 71.37
6 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 86 34 289 60.00
7 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 56 32 155 33.45
8 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 75 34 290 49.92
9 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 74 27 807 69.67
10 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 61 30 217 75.47
11 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 81 27 290 60.46
12 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 39 26 91 18.84
13 tr|G5E5A9|G5E5A9_BOVIN Fibronectin OS=Bos taurus GN=FN1 PE=1 SV=1 26 20 44 11.34
14 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 49 23 212 66.87
15 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 23 15 48 19.45
16 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 23 14 70 34.64
17 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 15 10 41 29.62
18 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 15 11 32 17.14
19 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 21 13 31 12.54
20 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 16 11 28 26.71
21 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 16 10 32 10.97
22 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 24 10 107 62.58
23 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 27 8 92 66.00
24 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 9 7 16 12.75
25 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 16 11 47 25.32
26 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 17 9 67 36.49
27 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 16 8 32 13.36
28 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 12 9 25 60.00
29 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 9 8 13 9.85
30 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 14 8 36 19.96
31 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 7 6 10 20.00
32 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 14 7 61 40.42
33 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 13 7 33 44.53
34 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 6 6 12 12.16
35 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 12 8 22 16.80
36 tr|F1MNV5|F1MNV5_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=2 12 8 27 18.81
37 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 7 6 12 19.14
38 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 8 4 19 19.17
39 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 11 8 15 23.37
40 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 8 5 15 18.06
41 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 5 4 6 11.09
42 tr|F1N1I6|F1N1I6_BOVIN Gelsolin OS=Bos taurus GN=GSN PE=1 SV=1 3 3 3 4.35
43 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 6 3 17 11.93
44 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 4 3 27 30.47
45 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 5 3 8 16.74
46 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 9 5 12 17.86
47 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 6 4 15 27.75
48 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 9 4 19 77.02
49 tr|Q32T06|Q32T06_BOVIN Endopin 2C OS=Bos taurus PE=2 SV=1 3 3 7 6.28
50 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 3 2 10 13.37
51 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 3 3 5 10.40
52 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 5 2 10 71.24
53 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 3 2 6 74.36
54 tr|A6QM09|A6QM09_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 4 3 6 63.36
55 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 5 2 16 43.93
56 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 4 2 14 15.92
57 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 3 2 7 5.66
58 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 3 2 6 12.22
59 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 3 2 6 23.96
60 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 4 2 8 25.90
61 tr|A0A140T843|A0A140T843_BOVIN Beta-2-glycoprotein 1 OS=Bos taurus GN=APOH PE=4 SV=1 2 2 2 6.96
62 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 4 2 13 88.30
63 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 2 1 11 72.30
64 sp|P01030|CO4_BOVIN Complement C4 (Fragments) OS=Bos taurus GN=C4 PE=1 SV=2 1 1 3 24.89
65 tr|G3MZH0|G3MZH0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 1 2 40.15
66 sp|P01045|KNG2_BOVIN Kininogen-2 OS=Bos taurus GN=KNG2 PE=1 SV=1 1 1 1 9.69
67 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=1 SV=2 1 1 1 1.01
68 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 1 1 1 1.56
69 tr|Q3SZH5|Q3SZH5_BOVIN Angiotensinogen OS=Bos taurus GN=AGT PE=1 SV=1 1 1 1 3.54
70 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 2 1 4 3.77
71 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 1 1 1 3.29
72 tr|F1MM86|F1MM86_BOVIN Complement component C6 OS=Bos taurus GN=C6 PE=4 SV=1 1 1 3 1.93
73 sp|Q95121|PEDF_BOVIN Pigment epithelium-derived factor OS=Bos taurus GN=SERPINF1 PE=1 SV=1 1 1 1 7.21
74 tr|E1BMJ0|E1BMJ0_BOVIN Uncharacterized protein OS=Bos taurus GN=SERPING1 PE=3 SV=2 2 1 4 3.42
75 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 2 1 6 8.20
76 sp|Q58D62|FETUB_BOVIN Fetuin-B OS=Bos taurus GN=FETUB PE=1 SV=1 1 1 1 6.46
77 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 1 0.61
78 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 1 1 4 1.31
79 tr|A5PK72|A5PK72_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 1 1 1 59.75
80 tr|B5B3R8|B5B3R8_BOVIN Alpha S1 casein OS=Bos taurus GN=CSN1S1 PE=2 SV=1 1 1 1 0.00
81 tr|A4IFI0|A4IFI0_BOVIN IGLL1 protein OS=Bos taurus GN=IGLL1 PE=2 SV=1 4 2 9 67.23
82 tr|A5D9D2|A5D9D2_BOVIN Complement component 4 binding protein, alpha chain OS=Bos taurus GN=C4BPA PE=2 SV=1 0 0 0 0.00
83 sp|A0JN39|COPB_BOVIN Coatomer subunit beta OS=Bos taurus GN=COPB1 PE=1 SV=1 0 0 0 0.00
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1 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 437 138 6480 92.42
2 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 337 125 1790 76.69
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 189 101 572 62.07
4 sp|Q29443|TRFE_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=2 SV=1 78 39 230 63.78
5 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 78 38 271 53.50
6 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 84 36 285 60.81
7 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 87 33 1294 70.09
8 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 75 30 282 76.23
9 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 82 28 263 62.30
10 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 84 33 992 68.71
11 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 42 25 116 27.84
12 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 31 22 58 14.93
13 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 52 23 222 68.71
14 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 22 17 43 28.82
15 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 21 14 38 16.17
16 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 20 12 45 32.01
17 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 17 12 25 11.00
18 tr|G5E5A9|G5E5A9_BOVIN Fibronectin OS=Bos taurus GN=FN1 PE=1 SV=1 16 11 29 5.45
19 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 15 11 33 32.41
20 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 20 12 55 28.32
21 tr|G3X6K8|G3X6K8_BOVIN Haptoglobin OS=Bos taurus GN=HP PE=3 SV=1 13 10 20 25.94
22 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 14 10 30 12.17
23 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 30 11 735 69.92
24 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 11 9 19 14.24
25 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 16 11 50 28.48
26 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 10 8 11 12.88
27 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 13 10 23 28.95
28 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 15 7 55 25.35
29 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 15 7 64 40.42
30 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 11 7 22 51.03
31 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 15 7 39 66.00
32 tr|A0A140T8C8|A0A140T8C8_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=1 9 5 15 6.92
33 tr|G3N0S9|G3N0S9_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC515150 PE=4 SV=1 6 5 8 26.13
34 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 6 5 6 6.03
35 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 7 5 16 13.03
36 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 4 4 8 10.78
37 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 10 4 29 44.53
38 tr|A0A0A0MPA0|A0A0A0MPA0_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC784932 PE=1 SV=1 4 4 9 9.35
39 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 4 4 7 7.68
40 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 6 4 13 27.75
41 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 10 7 19 13.52
42 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 6 4 16 19.17
43 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 4 4 5 8.67
44 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 4 4 5 12.59
45 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 6 4 10 13.62
46 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 4 3 10 11.93
47 tr|A6QM09|A6QM09_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 3 3 5 61.64
48 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 5 3 28 29.61
49 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 8 3 17 45.32
50 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 7 3 11 9.25
51 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 6 3 16 21.02
52 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 4 3 7 15.81
53 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 4 3 12 17.82
54 tr|A5D9D2|A5D9D2_BOVIN Complement component 4 binding protein, alpha chain OS=Bos taurus GN=C4BPA PE=2 SV=1 3 2 3 5.25
55 tr|A0A1K0FUD3|A0A1K0FUD3_BOVIN Globin C1 OS=Bos taurus GN=GLNC1 PE=3 SV=1 4 3 6 18.31
56 sp|P34955|A1AT_BOVIN Alpha-1-antiproteinase OS=Bos taurus GN=SERPINA1 PE=1 SV=1 2 2 2 6.49
57 tr|A5PK72|A5PK72_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 2 2 2 60.17
58 tr|G8JKW7|G8JKW7_BOVIN Uncharacterized protein OS=Bos taurus GN=SERPINA3 PE=3 SV=1 4 2 15 13.11
59 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 2 2 4 7.51
60 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 3 2 4 30.22
61 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 3 2 4 9.16
62 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 2 2 2 6.58
63 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=1 SV=2 3 3 3 3.94
64 tr|G3MZH0|G3MZH0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 3 3 4 56.06
65 tr|E1BGA4|E1BGA4_BOVIN Histone-lysine N-methyltransferase OS=Bos taurus GN=ASH1L PE=4 SV=1 1 1 1 0.24
66 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 2 1 12 86.33
67 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 5 2 9 73.93
68 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 3 1 8 63.40
69 tr|A0A0M4MD57|A0A0M4MD57_BOVIN Haptoglobin OS=Bos taurus GN=HP PE=2 SV=1 2 1 2 25.94
70 tr|D4QBB3|D4QBB3_BOVIN Hemoglobin beta OS=Bos taurus GN=HBB PE=3 SV=1 1 1 1 51.03
71 tr|G3MWT1|G3MWT1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 5 36.50
72 tr|F1N1I6|F1N1I6_BOVIN Gelsolin OS=Bos taurus GN=GSN PE=1 SV=1 1 1 1 1.41
73 tr|G3N309|G3N309_BOVIN Uncharacterized protein OS=Bos taurus GN=DNAH8 PE=4 SV=1 0 0 0 0.15
74 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 2 0.61
75 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 1 1 1 1.28
76 tr|F1MM86|F1MM86_BOVIN Complement component C6 OS=Bos taurus GN=C6 PE=4 SV=1 1 1 2 1.93
77 tr|G5E6P7|G5E6P7_BOVIN Uncharacterized protein OS=Bos taurus GN=FAM98B PE=4 SV=1 0 0 0 3.65
78 tr|E1BMJ0|E1BMJ0_BOVIN Uncharacterized protein OS=Bos taurus GN=SERPING1 PE=3 SV=2 1 1 1 3.42
79 tr|E1BKU2|E1BKU2_BOVIN Septin-2 OS=Bos taurus GN=SEPT2 PE=3 SV=2 0 0 0 1.94
80 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 2 1 4 1.31
81 sp|Q2KIX7|HP251_BOVIN Protein HP-25 homolog 1 OS=Bos taurus PE=1 SV=1 1 1 1 7.07
82 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 2 1 4 16.67
83 tr|F1MT59|F1MT59_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 0 0 0 5.47
84 tr|E1BJF9|E1BJF9_BOVIN Serum amyloid A protein OS=Bos taurus PE=3 SV=1 1 1 1 5.38
85 tr|F1MLH1|F1MLH1_BOVIN Uncharacterized protein OS=Bos taurus GN=MSH3 PE=4 SV=2 0 0 0 0.89
86 tr|E1BK21|E1BK21_BOVIN Uncharacterized protein OS=Bos taurus GN=C20orf144 PE=4 SV=1 0 0 0 0.00
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1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 412 153 3439 77.88
2 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 216 116 672 65.56
3 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 369 127 5165 92.42
4 tr|G3X6N3|G3X6N3_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=1 SV=1 78 39 199 61.36
5 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 77 44 217 40.68
6 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 89 36 1546 77.35
7 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 72 37 263 50.73
8 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 78 30 266 60.92
9 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 80 34 276 54.75
10 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 78 29 1562 69.41
11 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 48 25 159 65.66
12 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 39 28 88 18.09
13 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 53 23 311 60.43
14 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 23 14 49 32.01
15 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 18 13 33 14.19
16 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 14 11 24 12.26
17 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 9 8 13 16.03
18 tr|G5E5A9|G5E5A9_BOVIN Fibronectin OS=Bos taurus GN=FN1 PE=1 SV=1 11 9 17 4.40
19 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 19 11 39 16.60
20 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 16 11 27 8.25
21 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 10 7 22 46.90
22 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 13 8 41 23.68
23 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 26 11 134 59.08
24 tr|F1MZ96|F1MZ96_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 15 6 83 33.75
25 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 8 6 17 15.13
26 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 11 9 23 22.27
27 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 8 8 11 9.85
28 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 21 14 57 25.49
29 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 14 6 38 61.00
30 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 11 11 20 27.31
31 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 15 10 33 24.26
32 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 7 6 8 10.08
33 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 5 4 11 14.20
34 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 10 5 24 27.87
35 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 11 7 17 8.83
36 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 14 10 25 19.29
37 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 7 4 24 19.17
38 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 4 4 7 12.97
39 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 6 3 31 30.47
40 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 5 5 8 6.67
41 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 7 6 10 25.81
42 tr|A0A140T8C8|A0A140T8C8_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=1 4 3 6 4.03
43 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 6 3 12 11.68
44 tr|Q32T06|Q32T06_BOVIN Endopin 2C OS=Bos taurus PE=2 SV=1 3 3 8 6.28
45 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 4 3 6 9.25
46 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 6 3 8 23.56
47 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 3 2 10 10.40
48 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 4 2 18 74.23
49 tr|G3N0S9|G3N0S9_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC515150 PE=4 SV=1 5 5 8 15.58
50 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 6 3 17 40.29
51 tr|F1N1I6|F1N1I6_BOVIN Gelsolin OS=Bos taurus GN=GSN PE=1 SV=1 3 2 3 2.43
52 tr|A5D9D2|A5D9D2_BOVIN Complement component 4 binding protein, alpha chain OS=Bos taurus GN=C4BPA PE=2 SV=1 5 4 8 7.21
53 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 4 2 15 15.92
54 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=1 SV=2 2 2 2 1.97
55 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 3 2 9 68.09
56 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 6 3 12 30.22
57 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 3 3 4 3.83
58 tr|B7FEK7|B7FEK7_BOVIN 43kDa collectin OS=Bos taurus GN=CL43 PE=4 SV=1 2 2 4 7.16
59 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 2 2 3 5.05
60 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 2 1 11 87.31
61 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 3 1 48 79.17
62 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 5 2 9 73.93
63 sp|P01030|CO4_BOVIN Complement C4 (Fragments) OS=Bos taurus GN=C4 PE=1 SV=2 1 1 2 23.59
64 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 3 1 7 37.38
65 tr|F1N5R7|F1N5R7_BOVIN Uncharacterized protein OS=Bos taurus GN=DNAH7 PE=4 SV=2 1 1 1 0.25
66 sp|O02659|MBL2_BOVIN Mannose-binding protein C OS=Bos taurus GN=MBL PE=2 SV=1 1 1 1 3.61
67 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 2 1 3 2.01
68 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 2 1 4 3.47
69 tr|A0A140T843|A0A140T843_BOVIN Beta-2-glycoprotein 1 OS=Bos taurus GN=APOH PE=4 SV=1 2 1 3 4.35
70 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 3 2 6 6.05
71 tr|F1MM86|F1MM86_BOVIN Complement component C6 OS=Bos taurus GN=C6 PE=4 SV=1 1 1 2 1.93
72 tr|C4T8B4|C4T8B4_BOVIN Pentaxin OS=Bos taurus GN=CRP PE=2 SV=1 0 0 0 4.46
73 tr|B5B3R8|B5B3R8_BOVIN Alpha S1 casein OS=Bos taurus GN=CSN1S1 PE=2 SV=1 1 1 2 5.61
74 tr|A7MB82|A7MB82_BOVIN C1QTNF3 protein OS=Bos taurus GN=C1QTNF3 PE=2 SV=1 1 1 1 5.29
75 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 1 1 2 16.67
76 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 2 1 2 3.77
77 tr|A0A1K0FUD3|A0A1K0FUD3_BOVIN Globin C1 OS=Bos taurus GN=GLNC1 PE=3 SV=1 4 3 7 16.20
78 tr|F1MH22|F1MH22_BOVIN Oncoprotein-induced transcript 3 protein OS=Bos taurus GN=OIT3 PE=4 SV=2 0 0 0 2.60
79 tr|F1N045|F1N045_BOVIN Complement component C7 OS=Bos taurus GN=C7 PE=4 SV=1 1 1 1 1.42
80 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 1 1 2 1.31
81 tr|G3MZE0|G3MZE0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 2 2 22.22
82 tr|E1BB73|E1BB73_BOVIN Uncharacterized protein OS=Bos taurus GN=INPP5B PE=4 SV=2 0 0 0 0.90
83 tr|F1MCW9|F1MCW9_BOVIN Uncharacterized protein OS=Bos taurus GN=ZC3H6 PE=4 SV=2 1 1 1 1.28
84 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 1 1 1 36.25
85 tr|F1MYE9|F1MYE9_BOVIN Uncharacterized protein OS=Bos taurus GN=IQSEC1 PE=4 SV=2 1 1 1 0.00
86 tr|F1MRJ5|F1MRJ5_BOVIN Uncharacterized protein OS=Bos taurus GN=AMER3 PE=4 SV=2 0 0 0 0.00
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Protein N Representative Accession Name Confident Peptides Confident Sequences Confident Spectra %Seq Cov - peptides >95% conf
1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 368 143 2128 76.75
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 395 128 5129 92.42
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 174 98 512 57.98
4 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 105 40 1281 72.65
5 tr|G3X6N3|G3X6N3_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=1 SV=1 57 34 164 52.41
6 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 88 35 1308 71.37
7 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 52 32 144 31.22
8 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 68 32 234 46.50
9 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 61 28 202 74.34
10 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 75 28 228 64.60
11 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 73 30 222 53.94
12 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 32 23 73 16.66
13 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 48 24 182 69.94
14 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 36 13 947 69.92
15 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 16 11 28 19.32
16 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 28 14 65 29.58
17 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 15 11 35 13.27
18 tr|G5E5A9|G5E5A9_BOVIN Fibronectin OS=Bos taurus GN=FN1 PE=1 SV=1 17 11 27 5.37
19 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 13 10 26 34.39
20 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 13 10 19 17.88
21 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 10 7 23 18.28
22 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 10 8 12 20.12
23 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 17 8 62 42.08
24 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 20 12 52 28.10
25 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 18 6 69 61.00
26 tr|A7E350|A7E350_BOVIN PLG protein OS=Bos taurus GN=PLG PE=1 SV=1 8 7 10 9.53
27 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 11 9 18 7.12
28 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 12 7 28 10.57
29 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 13 9 24 73.10
30 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 12 7 33 20.68
31 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 13 7 35 23.68
32 tr|A0A0M4MD57|A0A0M4MD57_BOVIN Haptoglobin OS=Bos taurus GN=HP PE=2 SV=1 11 8 17 21.95
33 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 7 6 10 9.99
34 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 11 9 18 17.85
35 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 6 6 7 12.16
36 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 9 5 24 25.42
37 tr|A0A140T8C8|A0A140T8C8_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=1 10 6 20 8.05
38 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 5 4 7 8.29
39 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 6 4 11 11.93
40 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 9 4 30 38.69
41 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 5 3 13 17.82
42 tr|T1T0C1|T1T0C1_BOVIN Beta-casein OS=Bos taurus GN=csn2 PE=2 SV=1 3 3 7 17.86
43 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 7 5 13 15.90
44 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 3 3 3 5.96
45 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 5 3 9 16.74
46 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 3 3 5 8.68
47 tr|Q5J801|Q5J801_BOVIN Endopin 2B OS=Bos taurus PE=2 SV=1 3 3 6 7.19
48 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 7 4 14 27.75
49 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 5 2 22 70.69
50 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 5 3 12 74.79
51 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 6 3 36 30.47
52 tr|B5B3R8|B5B3R8_BOVIN Alpha S1 casein OS=Bos taurus GN=CSN1S1 PE=2 SV=1 1 1 3 10.28
53 tr|G3N0V2|G3N0V2_BOVIN Uncharacterized protein OS=Bos taurus GN=KRT1 PE=1 SV=1 2 2 2 4.29
54 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 3 2 7 13.52
55 tr|Q68RU0|Q68RU0_BOVIN Ovarian and testicular apolipoprotein N OS=Bos taurus GN=ApoN PE=2 SV=1 2 2 3 10.42
56 tr|F1N1I6|F1N1I6_BOVIN Gelsolin OS=Bos taurus GN=GSN PE=1 SV=1 3 3 3 7.81
57 sp|Q9TTE1|SPA31_BOVIN Serpin A3-1 OS=Bos taurus GN=SERPINA3-1 PE=1 SV=3 3 3 6 9.25
58 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 5 3 7 9.89
59 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 3 2 6 23.96
60 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 6 3 20 21.02
61 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 3 2 3 5.66
62 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 6 3 12 77.02
63 sp|Q2KIX7|HP251_BOVIN Protein HP-25 homolog 1 OS=Bos taurus PE=1 SV=1 4 2 6 11.79
64 tr|A0A1K0FUD3|A0A1K0FUD3_BOVIN Globin C1 OS=Bos taurus GN=GLNC1 PE=3 SV=1 3 2 5 15.49
65 tr|G3MXL3|G3MXL3_BOVIN Uncharacterized protein OS=Bos taurus GN=KRT3 PE=1 SV=1 1 1 6 1.95
66 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=1 SV=2 2 2 4 0.95
67 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 1 1 1 1.81
68 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 4 2 13 86.33
69 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 2 1 17 79.17
70 sp|P01030|CO4_BOVIN Complement C4 (Fragments) OS=Bos taurus GN=C4 PE=1 SV=2 1 1 1 23.48
71 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 1 9.05
72 tr|G3MWT1|G3MWT1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 3 36.50
73 tr|G3MZH0|G3MZH0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 1 40.15
74 tr|G5E5V1|G5E5V1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 1 3 44.29
75 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 7 2 22 43.93
76 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 1 4 45.32
77 tr|M0QVY0|M0QVY0_BOVIN Uncharacterized protein OS=Bos taurus GN=KRT6C PE=3 SV=1 2 2 2 3.85
78 tr|G3MY87|G3MY87_BOVIN Uncharacterized protein OS=Bos taurus GN=MGAM PE=3 SV=1 1 1 1 0.55
79 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 1 1 1 3.47
80 tr|A0A140T843|A0A140T843_BOVIN Beta-2-glycoprotein 1 OS=Bos taurus GN=APOH PE=4 SV=1 2 1 2 4.35
81 sp|O46375|TTHY_BOVIN Transthyretin OS=Bos taurus GN=TTR PE=1 SV=1 1 1 1 15.65
82 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 2 1 3 3.77
83 sp|Q58D62|FETUB_BOVIN Fetuin-B OS=Bos taurus GN=FETUB PE=1 SV=1 1 1 1 2.58
84 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 1 1 2 1.31
85 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 3 2 3 3.29
86 tr|E1BJF9|E1BJF9_BOVIN Serum amyloid A protein OS=Bos taurus PE=3 SV=1 1 1 1 5.38
87 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 3 2 3 6.10
88 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 1 18.71
89 tr|E1BKZ5|E1BKZ5_BOVIN Uncharacterized protein OS=Bos taurus GN=GOLGB1 PE=4 SV=2 0 0 0 0.00
90 tr|G3X7I5|G3X7I5_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 1 18.35
91 sp|A0JN39|COPB_BOVIN Coatomer subunit beta OS=Bos taurus GN=COPB1 PE=1 SV=1 0 0 0 0.00
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1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 383 150 2598 77.88
2 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 174 98 514 59.84
3 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 326 110 4144 92.42
4 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 104 39 1993 71.79
5 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 104 40 1785 72.87
6 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 79 37 315 51.38
7 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 64 33 173 35.14
8 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 91 36 339 57.98
9 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 87 32 320 62.30
10 tr|G5E5A9|G5E5A9_BOVIN Fibronectin OS=Bos taurus GN=FN1 PE=1 SV=1 42 28 87 12.91
11 tr|G3X6N3|G3X6N3_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=1 SV=1 42 27 109 40.48
12 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 52 26 163 70.94
13 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 78 29 546 73.93
14 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 36 23 73 17.00
15 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 30 16 70 36.34
16 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 29 15 73 33.55
17 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 18 13 33 19.76
18 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 40 14 1541 69.67
19 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 13 9 27 13.42
20 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 14 9 22 6.96
21 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 11 7 18 19.68
22 tr|F1MZ96|F1MZ96_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 15 7 72 35.42
23 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 12 7 32 18.08
24 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 8 6 16 16.18
25 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 11 7 19 60.00
26 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 12 7 32 20.89
27 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 15 6 46 61.00
28 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 11 8 28 17.72
29 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 13 9 24 18.37
30 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 7 6 13 8.28
31 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 7 5 11 6.73
32 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 8 4 27 19.17
33 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 9 4 41 33.91
34 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 9 5 37 40.29
35 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 4 4 7 6.67
36 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 4 4 9 11.05
37 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 8 4 17 22.13
38 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 4 4 4 6.03
39 tr|G3MZH0|G3MZH0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 11 5 27 48.48
40 sp|P00978|AMBP_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=1 SV=2 3 3 6 11.93
41 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 4 3 7 11.68
42 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 7 3 24 21.02
43 tr|Q32T06|Q32T06_BOVIN Endopin 2C OS=Bos taurus PE=2 SV=1 3 3 7 6.28
44 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 5 3 14 23.56
45 tr|F1MNV5|F1MNV5_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=2 6 4 8 5.73
46 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 3 3 8 6.04
47 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 2 2 2 3.83
48 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 2 3 30.22
49 tr|F1N1I6|F1N1I6_BOVIN Gelsolin OS=Bos taurus GN=GSN PE=1 SV=1 2 2 2 2.43
50 tr|A0A1K0FUD3|A0A1K0FUD3_BOVIN Globin C1 OS=Bos taurus GN=GLNC1 PE=3 SV=1 4 3 6 21.13
51 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 2 2 2 3.68
52 tr|G3N148|G3N148_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 4 2 9 35.97
53 tr|A6QM09|A6QM09_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 9 5 13 68.53
54 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 3 3 3 15.81
55 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 4 2 11 68.09
56 tr|G3MZE0|G3MZE0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 3 3 6 34.92
57 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 2 2 4 5.05
58 sp|Q2KIX7|HP251_BOVIN Protein HP-25 homolog 1 OS=Bos taurus PE=1 SV=1 3 3 4 11.32
59 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 2 2 3 6.10
60 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 3 1 10 68.25
61 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 2 1 37 80.64
62 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 4 1 10 73.93
63 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 5 1 10 37.38
64 tr|E1BNR0|E1BNR0_BOVIN Uncharacterized protein OS=Bos taurus GN=APOB PE=1 SV=2 1 1 1 0.33
65 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 2 2 3 5.38
66 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 2 0.61
67 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 2 1 3 3.47
68 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 1 1 1 3.77
69 tr|F1MM86|F1MM86_BOVIN Complement component C6 OS=Bos taurus GN=C6 PE=4 SV=1 1 1 1 1.93
70 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 2 1 2 1.31
71 sp|O02659|MBL2_BOVIN Mannose-binding protein C OS=Bos taurus GN=MBL PE=2 SV=1 2 1 2 4.42
72 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 2 1 3 16.67
73 tr|Q862Q3|Q862Q3_BOVIN Beta-2-microglobulin (Fragment) OS=Bos taurus PE=2 SV=1 1 1 1 8.60
74 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 2 1 5 5.94
75 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 1 1 1 2.19
76 tr|E1BCX3|E1BCX3_BOVIN Zinc f inger SWIM domain-containing protein 8 OS=Bos taurus GN=ZSWIM8 PE=4 SV=1 1 1 1 0.82
77 tr|Q56JW3|Q56JW3_BOVIN Nucleoside-diphosphate kinase NBR-A OS=Bos taurus GN=LOC574091 PE=2 SV=1 1 1 1 6.78
78 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 1 1 1 2.11
79 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 1 1 1 37.92
80 sp|A5PKL1|OXR1_BOVIN Oxidation resistance protein 1 OS=Bos taurus GN=OXR1 PE=2 SV=2 0 0 0 1.15
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1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 388 132 2508 74.04
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 349 111 3772 92.42
3 tr|A0A0F6QNP7|A0A0F6QNP7_BOVIN Complement component 3 OS=Bos taurus GN=C3 PE=2 SV=1 197 98 498 56.89
4 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 93 40 478 52.52
5 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 99 34 336 56.57
6 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 90 32 1099 67.52
7 tr|F1MI18|F1MI18_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 64 40 173 30.04
8 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 98 32 1284 73.96
9 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 97 33 345 62.76
10 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 66 28 206 70.94
11 tr|G5E5A9|G5E5A9_BOVIN Fibronectin OS=Bos taurus GN=FN1 PE=1 SV=1 33 20 65 10.37
12 sp|Q29443|TRFE_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=2 SV=1 32 19 77 27.98
13 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 41 19 183 57.06
14 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 24 19 59 13.04
15 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 40 13 1287 68.38
16 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 21 12 46 25.39
17 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 25 9 94 43.33
18 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 18 10 29 13.42
19 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 15 10 29 11.03
20 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 11 8 18 11.48
21 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 10 8 17 6.80
22 sp|P02662|CASA1_BOVIN Alpha-S1-casein OS=Bos taurus GN=CSN1S1 PE=1 SV=2 10 8 30 44.39
23 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 13 8 32 25.35
24 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 12 8 35 17.09
25 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 13 6 37 61.00
26 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 12 9 34 17.86
27 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 9 6 13 20.12
28 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 10 7 19 15.11
29 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 9 5 23 13.48
30 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 7 5 15 27.87
31 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 8 4 37 33.91
32 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 9 4 28 19.17
33 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 8 7 15 8.14
34 tr|A0A140T8C8|A0A140T8C8_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=1 6 4 11 5.47
35 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 4 3 6 8.94
36 tr|A5D9D2|A5D9D2_BOVIN Complement component 4 binding protein, alpha chain OS=Bos taurus GN=C4BPA PE=2 SV=1 4 3 5 5.41
37 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 8 3 19 45.32
38 tr|G3N1H5|G3N1H5_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 10 3 23 40.15
39 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 7 3 18 21.02
40 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 4 3 7 15.71
41 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 6 5 11 6.54
42 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 5 4 9 23.45
43 tr|T1T0C1|T1T0C1_BOVIN Beta-casein OS=Bos taurus GN=csn2 PE=2 SV=1 3 2 8 11.61
44 sp|P00978|AMBP_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=1 SV=2 2 2 3 7.67
45 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 4 2 6 8.03
46 tr|G3MYU2|G3MYU2_BOVIN Uncharacterized protein OS=Bos taurus GN=KRT77 PE=1 SV=1 2 2 3 3.86
47 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 3 2 3 5.05
48 tr|Q705V4|Q705V4_BOVIN Kappa-casein (Fragment) OS=Bos taurus GN=csn3 PE=4 SV=1 2 2 5 17.61
49 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 4 3 11 7.35
50 tr|Q32T06|Q32T06_BOVIN Endopin 2C OS=Bos taurus PE=2 SV=1 4 4 7 8.45
51 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 5 2 10 67.23
52 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 2 1 8 5.94
53 tr|G3MXL3|G3MXL3_BOVIN Uncharacterized protein OS=Bos taurus GN=KRT3 PE=1 SV=1 1 1 3 1.95
54 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 4 1 12 89.29
55 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 4 1 14 64.82
56 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 6 2 10 70.09
57 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 4 1 31 73.53
58 sp|O02659|MBL2_BOVIN Mannose-binding protein C OS=Bos taurus GN=MBL PE=2 SV=1 2 1 2 4.42
59 tr|O77777|O77777_BOVIN Beta-lactoglobulin variant D (Fragment) OS=Bos taurus GN=LGB PE=4 SV=1 2 1 3 55.32
60 sp|Q148H7|K2C79_BOVIN Keratin, type II cytoskeletal 79 OS=Bos taurus GN=KRT79 PE=2 SV=1 1 1 1 3.55
61 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 2 1 3 3.47
62 sp|P02663|CASA2_BOVIN Alpha-S2-casein OS=Bos taurus GN=CSN1S2 PE=1 SV=2 3 3 4 18.92
63 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 2 0.61
64 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 2 6.48
65 tr|G3X690|G3X690_BOVIN Uncharacterized protein OS=Bos taurus GN=KIF16B PE=3 SV=1 0 0 0 0.00
66 tr|G3N148|G3N148_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 3 23.74
67 tr|A2VDN9|A2VDN9_BOVIN KIAA0020 protein OS=Bos taurus GN=KIAA0020 PE=2 SV=1 0 0 0 0.00
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1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 349 139 2277 77.15
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 358 119 4423 92.75
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 199 103 627 62.19
4 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 95 40 396 59.35
5 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 85 38 1583 71.37
6 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 73 44 188 41.96
7 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 92 34 373 56.36
8 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 89 31 343 66.44
9 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 68 30 1528 69.67
10 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 62 29 220 75.47
11 sp|Q29443|TRFE_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=2 SV=1 41 25 97 44.18
12 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 31 24 67 15.91
13 tr|G5E5A9|G5E5A9_BOVIN Fibronectin OS=Bos taurus GN=FN1 PE=1 SV=1 33 21 61 10.69
14 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 56 24 312 69.02
15 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 22 16 39 26.20
16 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 17 14 29 12.86
17 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 23 14 39 20.08
18 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 21 14 55 36.34
19 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 21 12 39 31.57
20 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 13 11 23 13.09
21 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 17 11 49 27.89
22 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 15 11 23 16.89
23 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 16 10 31 75.17
24 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 17 10 36 25.05
25 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 24 9 101 60.39
26 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 14 8 33 34.26
27 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 15 10 35 31.00
28 tr|F1MZ96|F1MZ96_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 16 7 67 35.42
29 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 14 6 46 61.00
30 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 6 6 7 12.00
31 tr|F1MNV5|F1MNV5_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=2 8 5 14 13.53
32 sp|Q3MHN5|VTDB_BOVIN Vitamin D-binding protein OS=Bos taurus GN=GC PE=2 SV=1 8 5 24 11.81
33 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 13 5 41 44.53
34 sp|P02662|CASA1_BOVIN Alpha-S1-casein OS=Bos taurus GN=CSN1S1 PE=1 SV=2 6 5 16 24.30
35 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 4 4 5 6.03
36 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 9 7 18 13.52
37 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 8 4 30 33.91
38 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 6 4 16 45.32
39 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 8 4 22 19.17
40 sp|Q2KIX7|HP251_BOVIN Protein HP-25 homolog 1 OS=Bos taurus PE=1 SV=1 5 4 7 17.45
41 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 5 4 9 22.13
42 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 8 4 25 17.82
43 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 7 4 10 28.27
44 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 7 5 14 13.45
45 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=1 SV=2 5 5 8 4.83
46 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 4 3 6 6.30
47 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 5 4 8 7.62
48 sp|Q9TTE1|SPA31_BOVIN Serpin A3-1 OS=Bos taurus GN=SERPINA3-1 PE=1 SV=3 4 3 12 6.81
49 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 4 3 11 11.93
50 tr|A6QM09|A6QM09_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 4 3 9 63.36
51 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 3 3 3 4.54
52 tr|A0A1K0FUD3|A0A1K0FUD3_BOVIN Globin C1 OS=Bos taurus GN=GLNC1 PE=3 SV=1 4 3 8 18.31
53 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 6 3 19 21.02
54 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 4 3 5 11.68
55 sp|Q58D62|FETUB_BOVIN Fetuin-B OS=Bos taurus GN=FETUB PE=1 SV=1 3 3 3 11.37
56 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 5 3 14 77.02
57 tr|A5D9D2|A5D9D2_BOVIN Complement component 4 binding protein, alpha chain OS=Bos taurus GN=C4BPA PE=2 SV=1 3 2 3 4.26
58 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 8 4 12 76.92
59 tr|G3MZE0|G3MZE0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 4 4 6 34.92
60 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 3 2 6 7.31
61 sp|P02666|CASB_BOVIN Beta-casein OS=Bos taurus GN=CSN2 PE=1 SV=2 2 2 8 11.61
62 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 6 2 21 73.89
63 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 2 4 30.22
64 tr|F1N1I6|F1N1I6_BOVIN Gelsolin OS=Bos taurus GN=GSN PE=1 SV=1 2 2 4 6.91
65 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 4 3 5 16.74
66 tr|Q705V4|Q705V4_BOVIN Kappa-casein (Fragment) OS=Bos taurus GN=csn3 PE=4 SV=1 2 2 3 17.61
67 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 3 3 6 9.18
68 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 3 2 4 7.51
69 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 1 1 2 1.81
70 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 2 1 8 87.64
71 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 2 1 28 80.64
72 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 4 1 8 43.93
73 tr|G3MZH0|G3MZH0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 3 3 3 56.06
74 tr|Q5J801|Q5J801_BOVIN Endopin 2B OS=Bos taurus PE=2 SV=1 2 2 4 7.19
75 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 1 0.61
76 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 1 1 1 2.11
77 sp|O02659|MBL2_BOVIN Mannose-binding protein C OS=Bos taurus GN=MBL PE=2 SV=1 1 1 1 4.42
78 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 1 1 1 16.67
79 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 2 1 3 3.77
80 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 2 1 4 1.31
81 tr|A5PJT7|A5PJT7_BOVIN ECM1 protein OS=Bos taurus GN=ECM1 PE=2 SV=1 1 1 1 1.93
82 tr|Q56JW3|Q56JW3_BOVIN Nucleoside-diphosphate kinase NBR-A OS=Bos taurus GN=LOC574091 PE=2 SV=1 1 1 1 6.78
83 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 1 1 1 3.06
84 sp|Q17R10|AF1L2_BOVIN Actin f ilament-associated protein 1-like 2 OS=Bos taurus GN=AFAP1L2 PE=2 SV=1 1 1 1 1.84
85 sp|O46375|TTHY_BOVIN Transthyretin OS=Bos taurus GN=TTR PE=1 SV=1 1 1 1 15.65
86 sp|Q32PA8|AAMDC_BOVIN Mth938 domain-containing protein OS=Bos taurus GN=AAMDC PE=2 SV=1 1 1 1 7.38
87 tr|A0A140T843|A0A140T843_BOVIN Beta-2-glycoprotein 1 OS=Bos taurus GN=APOH PE=4 SV=1 2 1 3 4.35
88 tr|E1BB73|E1BB73_BOVIN Uncharacterized protein OS=Bos taurus GN=INPP5B PE=4 SV=2 0 0 0 0.90
89 sp|P02663|CASA2_BOVIN Alpha-S2-casein OS=Bos taurus GN=CSN1S2 PE=1 SV=2 1 1 1 3.60
90 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 0 0 0 0.00
91 tr|E1B8J6|E1B8J6_BOVIN Uncharacterized protein OS=Bos taurus GN=FAM83H PE=4 SV=1 0 0 0 0.00
92 tr|F1MIU2|F1MIU2_BOVIN Uncharacterized protein OS=Bos taurus GN=BAG3 PE=1 SV=1 0 0 0 0.00
93 tr|G3MWT1|G3MWT1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 3 36.50
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1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 388 132 2508 77.02
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 349 111 3772 92.42
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 197 98 498 60.51
4 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 93 40 478 77.35
5 tr|F1MI18|F1MI18_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 99 34 336 34.84
6 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 90 32 1099 69.67
7 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 64 40 173 55.28
8 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 98 32 1284 56.36
9 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 97 33 345 59.31
10 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 66 28 206 69.06
11 sp|Q29443|TRFE_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=2 SV=1 33 20 65 43.75
12 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 32 19 77 22.63
13 sp|P07589|FINC_BOVIN Fibronectin OS=Bos taurus GN=FN1 PE=1 SV=4 41 19 183 9.56
14 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 24 19 59 17.23
15 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 40 13 1287 61.66
16 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 21 12 46 33.55
17 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 25 9 94 15.33
18 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 18 10 29 14.75
19 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 15 10 29 33.68
20 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 11 8 18 67.18
21 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 10 8 17 36.98
22 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 10 8 30 27.63
23 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 13 8 32 12.34
24 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 12 8 35 13.47
25 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 13 6 37 8.87
26 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 12 9 34 25.63
27 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 9 6 13 22.22
28 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 10 7 19 25.88
29 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 9 5 23 19.20
30 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 7 5 15 66.00
31 tr|F1MZ96|F1MZ96_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 8 4 37 35.42
32 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 9 4 28 18.64
33 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 8 7 15 12.16
34 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 6 4 11 10.25
35 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 4 3 6 16.18
36 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 4 3 5 19.17
37 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 8 3 19 22.13
38 tr|A0A0A0MPA0|A0A0A0MPA0_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC784932 PE=1 SV=1 10 3 23 11.03
39 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 7 3 18 28.27
40 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 4 3 7 15.24
41 tr|Q3SYT3|Q3SYT3_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 6 5 11 11.17
42 tr|F1MNV5|F1MNV5_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=2 5 4 9 9.40
43 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 3 2 8 15.32
44 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 2 2 3 30.47
45 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 4 2 6 9.25
46 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 2 2 3 21.02
47 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 3 2 3 23.45
48 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 2 2 5 11.68
49 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=1 SV=2 4 3 11 4.23
50 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 4 4 7 76.92
51 tr|G3N1H5|G3N1H5_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 5 2 10 46.21
52 tr|G3MZE0|G3MZE0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 1 8 34.92
53 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 3 40.29
54 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 4 1 12 10.40
55 sp|P00978|AMBP_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=1 SV=2 4 1 14 7.67
56 tr|A5D9D2|A5D9D2_BOVIN Complement component 4 binding protein, alpha chain OS=Bos taurus GN=C4BPA PE=2 SV=1 6 2 10 5.25
57 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 4 1 31 68.09
58 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 2 1 2 1.81
59 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 2 1 3 3.47
60 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 1 1 1 16.67
61 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 2 1 3 67.59
62 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 3 3 4 77.70
63 sp|P01030|CO4_BOVIN Complement C4 (Fragments) OS=Bos taurus GN=C4 PE=1 SV=2 1 1 1 31.85
64 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 1 1 2 37.38
65 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 2 25.90
66 tr|Q32T06|Q32T06_BOVIN Endopin 2C OS=Bos taurus PE=2 SV=1 1 1 1 7.97
67 tr|F1N1I6|F1N1I6_BOVIN Gelsolin OS=Bos taurus GN=GSN PE=1 SV=1 0 0 0 1.02
68 tr|A8YXZ2|A8YXZ2_BOVIN C8G protein OS=Bos taurus GN=C8G PE=2 SV=1 1 1 3 3.80
69 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 0 0 0 3.06
70 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 0 0 0 3.47
71 tr|G3N2Z6|G3N2Z6_BOVIN Oncoprotein-induced transcript 3 protein OS=Bos taurus GN=OIT3 PE=4 SV=1 0 0 0 2.55
72 sp|O02659|MBL2_BOVIN Mannose-binding protein C OS=Bos taurus GN=MBL PE=2 SV=1 0 0 0 4.42
73 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 0 0 0 3.77
74 tr|G3N0S9|G3N0S9_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC515150 PE=4 SV=1 0 0 0 6.03
75 sp|Q95121|PEDF_BOVIN Pigment epithelium-derived factor OS=Bos taurus GN=SERPINF1 PE=1 SV=1 0 0 0 7.21
76 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 0 0 0 0.61
77 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 0 0 0 2.79
78 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 0 0 0 1.31
79 sp|Q58D62|FETUB_BOVIN Fetuin-B OS=Bos taurus GN=FETUB PE=1 SV=1 0 0 0 6.46
80 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 0 0 0 41.67
81 tr|G3N148|G3N148_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 0 0 0 35.97
82 tr|A4IFI0|A4IFI0_BOVIN IGLL1 protein OS=Bos taurus GN=IGLL1 PE=2 SV=1 0 0 0 67.23
83 tr|G5E5V1|G5E5V1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 0 0 0 39.29
84 sp|Q1RMU5|RBM5_BOVIN RNA-binding protein 5 OS=Bos taurus GN=RBM5 PE=2 SV=1 0 0 0 1.72
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1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 377 139 2419 75.50
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 363 118 4508 92.42
3 tr|A0A0F6QNP7|A0A0F6QNP7_BOVIN Complement component 3 OS=Bos taurus GN=C3 PE=2 SV=1 181 102 533 58.76
4 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 99 35 1566 70.02
5 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 109 37 1972 67.95
6 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 86 38 288 51.22
7 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 57 32 149 31.82
8 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 87 35 290 57.78
9 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 59 29 187 73.58
10 tr|G3X6N3|G3X6N3_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=1 SV=1 47 29 110 46.02
11 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 78 30 280 64.37
12 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 27 20 60 13.61
13 tr|G5E5A9|G5E5A9_BOVIN Fibronectin OS=Bos taurus GN=FN1 PE=1 SV=1 26 17 45 8.35
14 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 51 22 187 62.88
15 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 18 12 36 14.84
16 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 22 16 37 16.18
17 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 17 15 39 35.73
18 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 19 15 37 21.18
19 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 33 11 1319 69.67
20 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 23 15 58 30.24
21 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 13 9 29 26.44
22 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 14 7 47 66.00
23 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 17 10 29 12.05
24 tr|F1MZ96|F1MZ96_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 19 8 92 37.50
25 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 14 9 24 14.46
26 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 14 9 37 23.84
27 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 10 7 23 25.35
28 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 18 10 43 22.88
29 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 7 6 12 12.18
30 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 7 5 13 27.87
31 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 6 5 8 7.75
32 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 12 9 19 19.82
33 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 17 7 49 52.34
34 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 5 5 5 7.68
35 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 4 3 9 11.93
36 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 10 5 19 36.65
37 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 4 4 7 13.75
38 sp|P06868|PLMN_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 5 5 6 6.03
39 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 6 4 8 15.24
40 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 4 3 6 23.45
41 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=1 SV=2 5 4 6 3.76
42 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 5 4 6 23.72
43 tr|Q5J801|Q5J801_BOVIN Endopin 2B OS=Bos taurus PE=2 SV=1 3 3 5 7.19
44 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 8 3 24 21.02
45 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 3 2 25 26.18
46 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 5 3 7 11.68
47 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 3 2 4 10.40
48 sp|Q2KIX7|HP251_BOVIN Protein HP-25 homolog 1 OS=Bos taurus PE=1 SV=1 5 3 6 16.51
49 tr|A6QM09|A6QM09_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 5 4 12 62.93
50 tr|G3X6K8|G3X6K8_BOVIN Haptoglobin OS=Bos taurus GN=HP PE=3 SV=1 2 2 2 4.24
51 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 2 2 2 3.87
52 tr|G5E5V1|G5E5V1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 5 2 9 30.71
53 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 6 2 13 25.90
54 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 3 1 10 87.31
55 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 9 4 15 72.22
56 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 3 3 3 10.00
57 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 1 4 40.29
58 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 2 1 2 16.67
59 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 2 1 4 3.47
60 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 1 1 1 3.06
61 tr|F1MNV5|F1MNV5_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=2 4 3 7 7.57
62 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 3 2 5 5.66
63 tr|A5PK72|A5PK72_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 3 2 4 56.78
64 tr|F1MH40|F1MH40_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 1 1 1 38.33
65 sp|A5PKL1|OXR1_BOVIN Oxidation resistance protein 1 OS=Bos taurus GN=OXR1 PE=2 SV=2 0 0 0 1.15
66 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 1 1 1 2.90
67 tr|Q3SYT3|Q3SYT3_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 1 1 1 2.79
68 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 2 0.61
69 tr|Q2KIV6|Q2KIV6_BOVIN GTPase, IMAP family member 7 OS=Bos taurus GN=GIMAP7 PE=2 SV=1 1 1 1 2.36
70 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 1 1 3 1.31
71 tr|A4IFI0|A4IFI0_BOVIN IGLL1 protein OS=Bos taurus GN=IGLL1 PE=2 SV=1 4 2 9 63.83
72 tr|F1MYE9|F1MYE9_BOVIN Uncharacterized protein OS=Bos taurus GN=IQSEC1 PE=4 SV=2 1 1 1 0.00
73 tr|Q9BGU3|Q9BGU3_BOVIN Integrin alpha-4 subunit OS=Bos taurus GN=ITGA4 PE=2 SV=1 1 1 1 0.00
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1 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 403 129 5578 92.09
2 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 373 136 2356 74.44
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 227 119 694 68.09
4 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 91 36 1880 67.95
5 sp|Q29443|TRFE_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=2 SV=1 75 40 195 56.11
6 tr|F1MI18|F1MI18_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 57 35 142 34.10
7 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 70 33 222 57.37
8 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 86 31 2058 69.67
9 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 68 33 181 45.85
10 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 66 26 182 60.23
11 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 48 24 144 63.40
12 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 66 27 306 66.87
13 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 35 26 74 17.46
14 tr|G5E5A9|G5E5A9_BOVIN Fibronectin OS=Bos taurus GN=FN1 PE=1 SV=1 22 16 42 7.95
15 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 15 12 26 10.60
16 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 16 13 30 14.19
17 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 16 11 46 32.41
18 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 29 10 178 60.61
19 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 20 11 47 32.01
20 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 21 14 46 34.70
21 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 21 13 34 17.65
22 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 13 10 34 22.15
23 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 12 9 27 36.21
24 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 15 10 24 16.27
25 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 15 9 34 21.57
26 tr|A7E350|A7E350_BOVIN PLG protein OS=Bos taurus GN=PLG PE=1 SV=1 8 8 12 10.91
27 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 13 9 26 15.49
28 tr|F1MZ96|F1MZ96_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 21 8 99 35.42
29 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 7 6 11 9.99
30 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 13 8 28 20.75
31 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 10 5 33 25.74
32 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 7 6 17 16.18
33 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 9 7 16 37.93
34 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 11 6 38 61.00
35 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 6 4 10 6.62
36 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 7 4 19 19.17
37 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 5 5 7 8.96
38 tr|G5E5V1|G5E5V1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 10 6 19 39.29
39 tr|F1MNV5|F1MNV5_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=2 5 4 7 7.57
40 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 5 4 7 23.72
41 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 6 4 12 24.59
42 tr|Q32T06|Q32T06_BOVIN Endopin 2C OS=Bos taurus PE=2 SV=1 3 3 8 6.28
43 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 3 3 6 11.68
44 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 13 5 34 44.53
45 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=1 SV=2 8 7 10 3.28
46 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 7 3 12 23.56
47 sp|P00978|AMBP_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=1 SV=2 4 3 7 7.67
48 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 7 5 14 33.91
49 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 7 3 20 21.02
50 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 5 2 20 40.29
51 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 5 3 8 7.31
52 tr|A0A1K0FUD3|A0A1K0FUD3_BOVIN Globin C1 OS=Bos taurus GN=GLNC1 PE=3 SV=1 3 2 4 13.38
53 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 2 3 30.22
54 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 6 4 9 8.54
55 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 1 1 1 1.81
56 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 3 1 7 64.93
57 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 5 2 13 70.51
58 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 1 1 1 70.64
59 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 3 1 26 73.53
60 sp|P01030|CO4_BOVIN Complement C4 (Fragments) OS=Bos taurus GN=C4 PE=1 SV=2 1 1 2 25.00
61 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 2 2 4 10.82
62 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 4 1 8 45.79
63 tr|G3N148|G3N148_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 3 35.97
64 tr|G3MZH0|G3MZH0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 3 3 3 48.48
65 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 1 1 3 2.11
66 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 1 1 1 3.47
67 tr|F1MM86|F1MM86_BOVIN Complement component C6 OS=Bos taurus GN=C6 PE=4 SV=1 1 1 2 1.93
68 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 2 1 2 16.67
69 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 1 1 1 3.77
70 tr|G3N0S9|G3N0S9_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC515150 PE=4 SV=1 1 1 1 6.03
71 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 1 1 1 3.06
72 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 2 0.61
73 tr|F1N101|F1N101_BOVIN Uveal autoantigen w ith coiled-coil domains and ankyrin repeats protein OS=Bos taurus GN=UACA PE=4 SV=2 1 1 2 0.77
74 tr|A5PK72|A5PK72_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 2 2 5 56.78
75 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 1 1 2 1.31
76 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 2 2 3 41.67
77 tr|E1BB73|E1BB73_BOVIN Uncharacterized protein OS=Bos taurus GN=INPP5B PE=4 SV=2 0 0 0 0.90
78 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 3 2 3 3.47
79 tr|A1L565|A1L565_BOVIN CD1D antigen, d polypeptide (Fragment) OS=Bos taurus GN=CD1D PE=1 SV=1 0 0 0 2.25
80 tr|F1MUD4|F1MUD4_BOVIN Uncharacterized protein OS=Bos taurus GN=USP19 PE=4 SV=2 1 1 1 0.70
81 tr|F1MH40|F1MH40_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 2 2 2 40.42
82 tr|Q2KJH7|Q2KJH7_BOVIN Aldehyde dehydrogenase 18 family, member A1 OS=Bos taurus GN=ALDH18A1 PE=2 SV=1 1 1 1 0.00
83 tr|A7MBJ7|A7MBJ7_BOVIN KLHL18 protein OS=Bos taurus GN=KLHL18 PE=2 SV=1 0 0 0 0.00
84 sp|A5PKL1|OXR1_BOVIN Oxidation resistance protein 1 OS=Bos taurus GN=OXR1 PE=2 SV=2 0 0 0 1.15
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1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 377 139 2419 75.50
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 363 118 4508 92.42
3 tr|A0A0F6QNP7|A0A0F6QNP7_BOVIN Complement component 3 OS=Bos taurus GN=C3 PE=2 SV=1 181 102 533 58.76
4 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 99 35 1566 70.02
5 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 109 37 1972 67.95
6 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 86 38 288 51.22
7 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 57 32 149 31.82
8 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 87 35 290 57.78
9 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 59 29 187 73.58
10 tr|G3X6N3|G3X6N3_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=1 SV=1 47 29 110 46.02
11 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 78 30 280 64.37
12 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 27 20 60 13.61
13 tr|G5E5A9|G5E5A9_BOVIN Fibronectin OS=Bos taurus GN=FN1 PE=1 SV=1 26 17 45 8.35
14 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 51 22 187 62.88
15 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 18 12 36 14.84
16 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 22 16 37 16.18
17 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 17 15 39 35.73
18 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 19 15 37 21.18
19 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 33 11 1319 69.67
20 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 23 15 58 30.24
21 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 13 9 29 26.44
22 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 14 7 47 66.00
23 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 17 10 29 12.05
24 tr|F1MZ96|F1MZ96_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 19 8 92 37.50
25 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 14 9 24 14.46
26 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 14 9 37 23.84
27 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 10 7 23 25.35
28 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 18 10 43 22.88
29 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 7 6 12 12.18
30 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 7 5 13 27.87
31 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 6 5 8 7.75
32 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 12 9 19 19.82
33 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 17 7 49 52.34
34 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 5 5 5 7.68
35 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 4 3 9 11.93
36 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 10 5 19 36.65
37 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 4 4 7 13.75
38 sp|P06868|PLMN_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 5 5 6 6.03
39 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 6 4 8 15.24
40 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 4 3 6 23.45
41 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=1 SV=2 5 4 6 3.76
42 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 5 4 6 23.72
43 tr|Q5J801|Q5J801_BOVIN Endopin 2B OS=Bos taurus PE=2 SV=1 3 3 5 7.19
44 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 8 3 24 21.02
45 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 3 2 25 26.18
46 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 5 3 7 11.68
47 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 3 2 4 10.40
48 sp|Q2KIX7|HP251_BOVIN Protein HP-25 homolog 1 OS=Bos taurus PE=1 SV=1 5 3 6 16.51
49 tr|A6QM09|A6QM09_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 5 4 12 62.93
50 tr|G3X6K8|G3X6K8_BOVIN Haptoglobin OS=Bos taurus GN=HP PE=3 SV=1 2 2 2 4.24
51 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 2 2 2 3.87
52 tr|G5E5V1|G5E5V1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 5 2 9 30.71
53 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 6 2 13 25.90
54 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 3 1 10 87.31
55 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 9 4 15 72.22
56 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 3 3 3 10.00
57 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 1 4 40.29
58 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 2 1 2 16.67
59 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 2 1 4 3.47
60 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 1 1 1 3.06
61 tr|F1MNV5|F1MNV5_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=2 4 3 7 7.57
62 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 3 2 5 5.66
63 tr|A5PK72|A5PK72_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 3 2 4 56.78
64 tr|F1MH40|F1MH40_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 1 1 1 38.33
65 sp|A5PKL1|OXR1_BOVIN Oxidation resistance protein 1 OS=Bos taurus GN=OXR1 PE=2 SV=2 0 0 0 1.15
66 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 1 1 1 2.90
67 tr|Q3SYT3|Q3SYT3_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 1 1 1 2.79
68 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 2 0.61
69 tr|Q2KIV6|Q2KIV6_BOVIN GTPase, IMAP family member 7 OS=Bos taurus GN=GIMAP7 PE=2 SV=1 1 1 1 2.36
70 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 1 1 3 1.31
71 tr|A4IFI0|A4IFI0_BOVIN IGLL1 protein OS=Bos taurus GN=IGLL1 PE=2 SV=1 4 2 9 63.83
72 tr|F1MYE9|F1MYE9_BOVIN Uncharacterized protein OS=Bos taurus GN=IQSEC1 PE=4 SV=2 1 1 1 0.00
73 tr|Q9BGU3|Q9BGU3_BOVIN Integrin alpha-4 subunit OS=Bos taurus GN=ITGA4 PE=2 SV=1 1 1 1 0.00
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Protein N Representative Accession Name Confident Peptides Confident Sequences Confident Spectra %Seq Cov - peptides >95% conf
1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 378 144 2492 77.68
2 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 212 115 669 64.24
3 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 326 116 3699 91.76
4 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 101 37 2937 69.92
5 tr|F1MI18|F1MI18_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 62 37 170 36.81
6 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 97 35 1626 71.37
7 tr|G3X6N3|G3X6N3_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=1 SV=1 55 32 146 47.30
8 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 86 36 315 57.98
9 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 86 30 301 60.92
10 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 58 28 210 70.94
11 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 81 38 299 55.77
12 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 40 26 85 16.20
13 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 58 27 336 73.31
14 tr|G5E5A9|G5E5A9_BOVIN Fibronectin OS=Bos taurus GN=FN1 PE=1 SV=1 21 14 37 7.30
15 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 16 12 35 20.09
16 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 33 14 175 65.21
17 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 17 12 33 14.19
18 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 27 15 64 32.01
19 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 21 13 39 32.03
20 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 13 10 29 25.05
21 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 16 14 25 11.25
22 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 16 11 33 12.37
23 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 18 9 98 44.17
24 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 10 6 23 18.60
25 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 14 10 38 21.94
26 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 22 12 66 23.75
27 tr|A5D9D2|A5D9D2_BOVIN Complement component 4 binding protein, alpha chain OS=Bos taurus GN=C4BPA PE=2 SV=1 18 12 30 19.02
28 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 8 5 21 12.18
29 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 8 5 19 30.20
30 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 8 5 18 27.87
31 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 11 6 37 61.00
32 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 11 7 15 10.04
33 sp|P06868|PLMN_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 7 7 9 8.50
34 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 5 4 10 7.75
35 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 8 4 22 19.17
36 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 9 8 17 17.06
37 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 10 6 27 20.61
38 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 7 4 17 33.91
39 tr|G3N0S9|G3N0S9_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC515150 PE=4 SV=1 14 9 23 31.16
40 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 5 3 9 11.93
41 tr|A0A0A0MPA0|A0A0A0MPA0_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC784932 PE=1 SV=1 5 5 8 11.03
42 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 5 5 7 9.92
43 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 9 5 19 40.29
44 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 6 3 12 74.04
45 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 4 3 6 10.77
46 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 13 5 39 44.53
47 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 9 5 14 76.92
48 sp|Q2KIV9|C1QB_BOVIN Complement C1q subcomponent subunit B OS=Bos taurus GN=C1QB PE=1 SV=1 2 2 4 15.79
49 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 5 3 9 11.68
50 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 3 2 4 5.05
51 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 8 3 25 21.02
52 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 3 2 5 3.40
53 tr|A0A140T8C8|A0A140T8C8_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=1 6 4 9 5.47
54 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 3 2 5 11.52
55 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 2 2 2 8.84
56 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 2 2 2 5.00
57 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 2 2 30.22
58 tr|A5PK72|A5PK72_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 2 2 3 60.17
59 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 3 2 5 7.31
60 tr|G3MXL3|G3MXL3_BOVIN Uncharacterized protein OS=Bos taurus GN=KRT3 PE=1 SV=1 1 1 2 1.95
61 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 1 1 2 1.81
62 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 3 1 6 85.67
63 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 1 1 13 79.17
64 sp|P01030|CO4_BOVIN Complement C4 (Fragments) OS=Bos taurus GN=C4 PE=1 SV=2 1 1 1 22.83
65 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 1 9.49
66 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 4 1 13 37.38
67 tr|G3N148|G3N148_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 3 35.97
68 tr|E1BNR0|E1BNR0_BOVIN Uncharacterized protein OS=Bos taurus GN=APOB PE=1 SV=2 1 1 1 0.33
69 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 2 1 3 3.47
70 tr|E1BEL8|E1BEL8_BOVIN Globin B1 OS=Bos taurus GN=HBE1 PE=3 SV=1 2 1 3 6.80
71 tr|A0A140T843|A0A140T843_BOVIN Beta-2-glycoprotein 1 OS=Bos taurus GN=APOH PE=4 SV=1 1 1 1 4.35
72 sp|O46375|TTHY_BOVIN Transthyretin OS=Bos taurus GN=TTR PE=1 SV=1 1 1 1 15.65
73 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 1 1 1 16.67
74 tr|G8JKW7|G8JKW7_BOVIN Uncharacterized protein OS=Bos taurus GN=SERPINA3 PE=3 SV=1 2 1 10 3.88
75 tr|E1BAI7|E1BAI7_BOVIN Uncharacterized protein OS=Bos taurus GN=TMOD2 PE=4 SV=2 2 1 2 1.99
76 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 3 1 10 68.36
77 sp|O02659|MBL2_BOVIN Mannose-binding protein C OS=Bos taurus GN=MBL PE=2 SV=1 2 1 2 4.42
78 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 2 1 2 2.01
79 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 1 1 2 1.31
80 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 1 0.61
81 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=1 SV=2 1 1 1 0.60
82 tr|F1N1I6|F1N1I6_BOVIN Gelsolin OS=Bos taurus GN=GSN PE=1 SV=1 1 1 1 0.00
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Protein N Representative Accession Name Confident Peptides Confident Sequences Confident Spectra %Seq Cov - peptides >95% conf
1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 392 150 2208 77.88
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 357 120 4910 92.42
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 196 101 606 59.66
4 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 78 44 222 43.51
5 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 105 37 2139 69.92
6 sp|Q29443|TRFE_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=2 SV=1 70 38 198 62.36
7 tr|B8Y9S9|B8Y9S9_BOVIN Embryo-specif ic f ibronectin 1 transcript variant OS=Bos taurus GN=FN1 PE=1 SV=1 56 38 119 21.74
8 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 109 39 458 59.80
9 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 102 45 488 52.85
10 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 105 36 411 67.36
11 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 91 33 1418 71.37
12 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 59 27 202 72.08
13 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 36 23 73 16.77
14 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 50 20 258 58.28
15 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 35 13 252 63.68
16 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 17 13 39 17.97
17 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 17 13 35 20.20
18 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 30 15 64 31.35
19 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 21 14 32 12.70
20 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 17 12 39 30.18
21 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 19 12 32 14.06
22 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 18 12 50 20.26
23 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 15 9 47 32.59
24 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 11 7 23 60.00
25 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 22 9 116 44.17
26 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 13 6 43 61.00
27 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 11 8 18 11.48
28 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 7 5 16 12.18
29 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 10 8 16 19.48
30 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 5 5 9 6.03
31 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 6 5 10 10.81
32 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 7 6 8 8.67
33 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 7 5 17 27.87
34 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 7 6 8 13.33
35 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 8 4 20 19.17
36 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 12 8 30 13.92
37 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 4 3 8 11.93
38 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=1 SV=2 7 7 8 6.20
39 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 11 8 22 15.35
40 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 5 3 13 17.82
41 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 7 4 14 28.27
42 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 12 5 28 44.53
43 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 4 3 15 30.47
44 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 6 4 8 8.48
45 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 21 6 64 52.34
46 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 6 4 8 9.76
47 sp|P34955|A1AT_BOVIN Alpha-1-antiproteinase OS=Bos taurus GN=SERPINA1 PE=1 SV=1 3 2 5 6.49
48 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 5 3 12 13.95
49 sp|O02659|MBL2_BOVIN Mannose-binding protein C OS=Bos taurus GN=MBL PE=2 SV=1 2 2 3 8.03
50 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 2 2 3 8.03
51 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 8 4 13 74.04
52 tr|G3N0S9|G3N0S9_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC515150 PE=4 SV=1 7 6 8 25.13
53 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 6 2 23 75.22
54 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 7 3 24 21.02
55 tr|Q32T06|Q32T06_BOVIN Endopin 2C OS=Bos taurus PE=2 SV=1 2 2 5 4.35
56 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 2 3 30.22
57 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 3 2 4 7.31
58 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 7 3 13 74.79
59 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 2 2 3 3.83
60 tr|A0A1K0FUD3|A0A1K0FUD3_BOVIN Globin C1 OS=Bos taurus GN=GLNC1 PE=3 SV=1 4 3 6 13.38
61 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 3 1 13 86.33
62 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 3 1 21 79.17
63 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 2 1 3 10.82
64 tr|G3N148|G3N148_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 3 35.97
65 tr|E1BDZ3|E1BDZ3_BOVIN Uncharacterized protein OS=Bos taurus GN=CHD9 PE=4 SV=1 1 1 1 0.38
66 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 2 1 2 2.01
67 tr|Q9BGU1|Q9BGU1_BOVIN Histidine-rich glycoprotein OS=Bos taurus GN=BTHRG PE=2 SV=1 1 1 1 1.83
68 tr|Q68RU0|Q68RU0_BOVIN Ovarian and testicular apolipoprotein N OS=Bos taurus GN=ApoN PE=2 SV=1 1 1 1 6.95
69 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 1 1 1 3.47
70 tr|F1MM86|F1MM86_BOVIN Complement component C6 OS=Bos taurus GN=C6 PE=4 SV=1 1 1 1 1.93
71 tr|A7MB82|A7MB82_BOVIN C1QTNF3 protein OS=Bos taurus GN=C1QTNF3 PE=2 SV=1 1 1 1 5.29
72 sp|Q2KIX7|HP251_BOVIN Protein HP-25 homolog 1 OS=Bos taurus PE=1 SV=1 2 1 4 7.07
73 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 2 1 3 16.67
74 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 2 1 4 3.77
75 tr|E1BMJ0|E1BMJ0_BOVIN Uncharacterized protein OS=Bos taurus GN=SERPING1 PE=3 SV=2 1 1 1 3.42
76 sp|Q9TTE1|SPA31_BOVIN Serpin A3-1 OS=Bos taurus GN=SERPINA3-1 PE=1 SV=3 1 1 1 4.87
77 tr|A5PJT7|A5PJT7_BOVIN ECM1 protein OS=Bos taurus GN=ECM1 PE=2 SV=1 1 1 2 1.93
78 tr|F1N1I6|F1N1I6_BOVIN Gelsolin OS=Bos taurus GN=GSN PE=1 SV=1 2 2 2 1.41
79 tr|A5D9D2|A5D9D2_BOVIN Complement component 4 binding protein, alpha chain OS=Bos taurus GN=C4BPA PE=2 SV=1 1 1 1 0.00
80 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 0 0 0 0.00
81 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 1 1 1 0.00
82 tr|Q56JW3|Q56JW3_BOVIN Nucleoside-diphosphate kinase NBR-A OS=Bos taurus GN=LOC574091 PE=2 SV=1 1 1 1 6.78
Low fertility heifer number 1
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Protein N Representative Accession Name Confident Peptides Confident Sequences Confident Spectra %Seq Cov - peptides >95% conf
1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 318 140 1579 77.68
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 371 137 4922 92.42
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 192 107 556 62.43
4 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 125 52 1243 66.02
5 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 131 48 807 79.80
6 tr|B8Y9S9|B8Y9S9_BOVIN Embryo-specif ic f ibronectin 1 transcript variant OS=Bos taurus GN=FN1 PE=1 SV=1 66 47 165 27.44
7 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 125 40 571 67.36
8 sp|Q29443|TRFE_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=2 SV=1 72 38 212 62.07
9 tr|F1MI18|F1MI18_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 62 36 168 39.11
10 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 86 34 1712 67.52
11 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 57 27 205 71.32
12 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 67 27 493 61.66
13 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 54 25 522 66.84
14 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 31 22 65 18.84
15 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 20 12 59 26.58
16 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 16 11 28 18.78
17 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 16 11 27 9.55
18 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 14 10 34 12.07
19 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 11 9 14 29.57
20 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 17 10 62 38.16
21 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 18 8 65 61.00
22 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 12 8 22 45.32
23 tr|Q05B55|Q05B55_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 16 7 98 43.33
24 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 11 8 26 26.24
25 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 12 8 21 12.26
26 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 12 7 24 19.43
27 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 12 8 36 22.57
28 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 19 7 78 59.96
29 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 8 6 16 14.70
30 sp|Q9TTE1|SPA31_BOVIN Serpin A3-1 OS=Bos taurus GN=SERPINA3-1 PE=1 SV=3 7 6 12 15.82
31 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 8 6 13 9.27
32 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 9 6 20 16.18
33 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 6 4 10 10.78
34 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 5 5 10 6.16
35 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 7 4 13 23.72
36 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 7 4 19 73.19
37 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 10 4 32 33.91
38 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 6 4 15 28.27
39 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 7 4 14 19.17
40 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 5 4 9 31.72
41 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 4 3 4 6.31
42 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 5 4 7 10.57
43 tr|F1MNV5|F1MNV5_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=2 4 3 5 5.73
44 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 3 3 5 3.84
45 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 4 3 7 17.82
46 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 5 3 10 18.85
47 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 6 3 13 30.22
48 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 3 3 7 13.54
49 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 4 2 11 15.92
50 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 6 2 10 70.09
51 tr|A4IFI0|A4IFI0_BOVIN IGLL1 protein OS=Bos taurus GN=IGLL1 PE=2 SV=1 2 2 5 63.40
52 tr|A5PK72|A5PK72_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 3 2 4 56.36
53 tr|B5B3R8|B5B3R8_BOVIN Alpha S1 casein OS=Bos taurus GN=CSN1S1 PE=2 SV=1 1 1 3 10.28
54 tr|A0A1K0FUD3|A0A1K0FUD3_BOVIN Globin C1 OS=Bos taurus GN=GLNC1 PE=3 SV=1 2 2 2 9.86
55 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 1 1 1 1.81
56 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 3 2 10 87.31
57 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 3 1 11 71.90
58 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 2 1 10 75.74
59 tr|A6H7J7|A6H7J7_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 1 1 1 62.55
60 tr|G3MZE0|G3MZE0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 1 33.33
61 tr|Q32T06|Q32T06_BOVIN Endopin 2C OS=Bos taurus PE=2 SV=1 0 0 0 7.97
62 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 3 2 5 2.92
63 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 1 1 3 2.11
64 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 1 1 4 3.47
65 tr|G3X6K8|G3X6K8_BOVIN Haptoglobin OS=Bos taurus GN=HP PE=3 SV=1 1 1 1 2.24
66 tr|F1MM86|F1MM86_BOVIN Complement component C6 OS=Bos taurus GN=C6 PE=4 SV=1 1 1 1 1.93
67 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 2 1 2 1.31
68 tr|A5PJT7|A5PJT7_BOVIN ECM1 protein OS=Bos taurus GN=ECM1 PE=2 SV=1 1 1 1 1.93
69 sp|O02659|MBL2_BOVIN Mannose-binding protein C OS=Bos taurus GN=MBL PE=2 SV=1 1 1 1 3.61
70 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 2 1 6 3.77
71 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 1 1 2 3.65
72 tr|E1BKU2|E1BKU2_BOVIN Septin-2 OS=Bos taurus GN=SEPT2 PE=3 SV=2 1 1 1 1.94
73 sp|Q95121|PEDF_BOVIN Pigment epithelium-derived factor OS=Bos taurus GN=SERPINF1 PE=1 SV=1 1 1 1 7.21
74 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 1 1 1 16.67
75 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 1 1 3 3.41
76 sp|O46375|TTHY_BOVIN Transthyretin OS=Bos taurus GN=TTR PE=1 SV=1 1 1 1 15.65
77 tr|F1MJ31|F1MJ31_BOVIN Uncharacterized protein OS=Bos taurus GN=AK9 PE=4 SV=2 1 1 1 0.42
78 sp|Q2HJF3|ORC6_BOVIN Origin recognition complex subunit 6 OS=Bos taurus GN=ORC6 PE=2 SV=1 1 1 1 5.56
79 tr|F1MJB0|F1MJB0_BOVIN Uncharacterized protein OS=Bos taurus GN=FILIP1L PE=4 SV=2 0 0 0 0.00
80 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 0 0 0 0.00
Low fertility heifer number 2
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Protein N Representative Accession Name Confident Peptides Confident Sequences Confident Spectra %Seq Cov - peptides >95% conf
1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 357 130 1946 74.83
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 362 118 4630 92.42
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 225 113 702 66.53
4 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 102 43 402 55.93
5 tr|G5E5A9|G5E5A9_BOVIN Fibronectin OS=Bos taurus GN=FN1 PE=1 SV=1 57 39 108 20.98
6 tr|G3X6N3|G3X6N3_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=1 SV=1 84 41 237 63.64
7 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 102 40 390 63.84
8 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 97 34 358 66.90
9 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 108 39 1231 69.15
10 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 56 31 142 33.11
11 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 63 25 204 69.06
12 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 95 34 1614 71.37
13 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 28 20 58 15.91
14 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 52 22 297 65.95
15 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 23 14 36 18.29
16 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 16 12 35 15.12
17 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 21 13 37 10.60
18 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 26 14 52 33.77
19 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 25 14 74 28.54
20 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 13 10 30 30.82
21 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 18 14 37 23.25
22 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 37 13 1017 69.67
23 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 20 12 56 32.28
24 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 16 12 39 32.03
25 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 17 10 61 38.16
26 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 11 7 25 55.86
27 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 25 10 131 40.42
28 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 12 7 21 12.25
29 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 20 6 75 61.00
30 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 11 9 17 13.42
31 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 26 11 80 58.88
32 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 5 5 7 10.72
33 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 10 6 26 17.23
34 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 7 5 14 9.07
35 tr|Q3SZQ8|Q3SZQ8_BOVIN Endopin 2 OS=Bos taurus GN=SERPINA3-7 PE=2 SV=1 6 6 9 15.83
36 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 15 10 27 19.69
37 tr|A5D9D2|A5D9D2_BOVIN Complement component 4 binding protein, alpha chain OS=Bos taurus GN=C4BPA PE=2 SV=1 9 7 12 10.98
38 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 8 6 15 22.97
39 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 10 4 102 36.05
40 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 6 4 17 22.13
41 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 10 4 28 44.53
42 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 5 4 6 11.49
43 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 5 4 8 10.32
44 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 5 3 15 14.17
45 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 7 4 16 28.27
46 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 5 3 8 11.68
47 tr|G3N0S9|G3N0S9_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC515150 PE=4 SV=1 5 5 11 26.13
48 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 8 4 18 77.02
49 sp|Q9TTE1|SPA31_BOVIN Serpin A3-1 OS=Bos taurus GN=SERPINA3-1 PE=1 SV=3 3 3 5 14.36
50 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 4 3 9 17.82
51 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=1 SV=2 4 4 4 3.94
52 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 7 3 17 21.02
53 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 2 2 2 12.28
54 tr|A0A140T8C8|A0A140T8C8_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=1 2 2 3 2.74
55 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 2 2 3 7.51
56 tr|A0A1K0FUD3|A0A1K0FUD3_BOVIN Globin C1 OS=Bos taurus GN=GLNC1 PE=3 SV=1 4 3 5 12.68
57 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 3 2 7 7.67
58 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 4 3 6 20.93
59 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 5 2 7 45.32
60 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 3 2 7 30.22
61 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 3 2 6 9.16
62 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 3 3 4 3.83
63 tr|G3MZE0|G3MZE0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 3 3 5 33.33
64 tr|F1MZ96|F1MZ96_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 4 2 6 36.67
65 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 1 1 1 8.42
66 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 3 1 8 68.81
67 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 2 1 17 74.02
68 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 6 3 11 74.79
69 sp|P01030|CO4_BOVIN Complement C4 (Fragments) OS=Bos taurus GN=C4 PE=1 SV=2 1 1 1 19.35
70 tr|G3MZH0|G3MZH0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 3 3 3 56.06
71 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 2 0.61
72 tr|A5PJT7|A5PJT7_BOVIN ECM1 protein OS=Bos taurus GN=ECM1 PE=2 SV=1 1 1 1 1.93
73 tr|F1MM86|F1MM86_BOVIN Complement component C6 OS=Bos taurus GN=C6 PE=4 SV=1 1 1 3 1.93
74 tr|F1MIW8|F1MIW8_BOVIN Desmoglein-1 OS=Bos taurus GN=DSG1 PE=4 SV=2 1 1 1 0.86
75 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 2 1 5 1.31
76 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 1 1 2 16.67
77 sp|Q58D62|FETUB_BOVIN Fetuin-B OS=Bos taurus GN=FETUB PE=1 SV=1 1 1 2 6.46
78 tr|A0A140T843|A0A140T843_BOVIN Beta-2-glycoprotein 1 OS=Bos taurus GN=APOH PE=4 SV=1 1 1 1 4.35
79 sp|Q2KIX7|HP251_BOVIN Protein HP-25 homolog 1 OS=Bos taurus PE=1 SV=1 1 1 1 7.07
80 tr|G3MWT1|G3MWT1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 3 33.58
81 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 3 3 4 5.66
82 tr|F1MH61|F1MH61_BOVIN Uncharacterized protein OS=Bos taurus GN=FAM98B PE=4 SV=2 0 0 0 3.32
83 tr|F1MDH3|F1MDH3_BOVIN Uncharacterized protein OS=Bos taurus GN=TLN1 PE=1 SV=2 1 1 1 0.00
Low fertility heifer number 3
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Protein N Representative Accession Name Confident Peptides Confident Sequences Confident Spectra %Seq Cov - peptides >95% conf
1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 321 128 1767 77.28
2 sp|P02769|ALBU_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=1 SV=4 398 130 6047 90.61
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 204 109 658 63.58
4 tr|G3X6N3|G3X6N3_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=1 SV=1 88 44 263 67.47
5 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC506828 PE=4 SV=2 56 32 155 33.85
6 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=1 SV=2 86 34 289 60.00
7 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=IGLL1 PE=1 SV=2 95 34 1360 71.37
8 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=1 SV=1 75 34 290 49.92
9 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=4 SV=1 61 30 219 75.47
10 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein (Fragment) OS=Bos taurus GN=IGHM PE=1 SV=1 74 27 805 69.67
11 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 81 27 290 60.46
12 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=C4A PE=1 SV=2 39 26 91 18.84
13 tr|G5E5A9|G5E5A9_BOVIN Fibronectin OS=Bos taurus GN=FN1 PE=1 SV=1 26 20 44 11.34
14 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein (Fragment) OS=Bos taurus PE=1 SV=1 49 23 212 66.87
15 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=4 SV=2 23 15 48 19.45
16 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 15 11 32 17.14
17 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 23 14 70 34.64
18 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 21 13 31 12.54
19 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 15 10 41 29.62
20 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 16 10 32 10.97
21 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=4 SV=2 16 11 28 26.71
22 tr|G5E513|G5E513_BOVIN Uncharacterized protein (Fragment) OS=Bos taurus GN=IGHM PE=1 SV=1 24 10 107 62.58
23 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 16 11 47 25.32
24 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 17 9 67 36.49
25 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 16 8 32 13.36
26 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 9 7 16 12.75
27 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=3 SV=2 9 8 13 9.85
28 tr|Q3ZBS7|Q3ZBS7_BOVIN Uncharacterized protein OS=Bos taurus GN=VTN PE=2 SV=1 14 8 36 19.96
29 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=4 SV=1 7 6 10 20.00
30 tr|D4QBB4|D4QBB4_BOVIN Hemoglobin beta OS=Bos taurus GN=HBB PE=3 SV=1 12 9 25 60.00
31 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 27 8 92 66.00
32 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 14 7 61 40.42
33 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 6 6 12 12.16
34 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100300806 PE=4 SV=1 13 7 33 44.53
35 tr|F1MNV5|F1MNV5_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=2 12 8 27 18.81
36 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 12 8 22 16.80
37 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=1 SV=1 7 6 12 19.14
38 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 11 8 15 23.37
39 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 5 4 6 11.09
40 tr|F1N1I6|F1N1I6_BOVIN Gelsolin OS=Bos taurus GN=GSN PE=1 SV=1 3 3 3 4.35
41 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 6 3 17 11.93
42 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 4 3 27 30.47
43 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 5 3 8 16.74
44 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 8 4 19 19.17
45 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 9 5 12 17.86
46 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 6 4 15 27.75
47 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 8 5 15 18.06
48 tr|Q32T06|Q32T06_BOVIN Endopin 2C OS=Bos taurus PE=2 SV=1 3 3 7 6.28
49 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 9 4 19 77.02
50 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 3 2 10 13.37
51 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 11 4 32 88.30
52 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 5 2 10 71.24
53 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 3 2 6 74.36
54 tr|G5E604|G5E604_BOVIN Uncharacterized protein (Fragment) OS=Bos taurus PE=1 SV=1 5 2 16 43.93
55 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 4 2 14 15.92
56 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=2 SV=1 3 3 5 10.40
57 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 3 2 7 5.66
58 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein (Fragment) OS=Bos taurus PE=4 SV=2 3 2 6 12.22
59 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 3 2 6 23.96
60 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein (Fragment) OS=Bos taurus PE=4 SV=1 4 2 8 30.22
61 sp|P17690|APOH_BOVIN Beta-2-glycoprotein 1 OS=Bos taurus GN=APOH PE=1 SV=4 2 2 2 6.96
62 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 2 1 11 72.30
63 tr|A6QM09|A6QM09_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 4 3 6 63.36
64 sp|P01030|CO4_BOVIN Complement C4 (Fragments) OS=Bos taurus GN=C4 PE=1 SV=2 1 1 3 24.89
65 sp|P01045|KNG2_BOVIN Kininogen-2 OS=Bos taurus GN=KNG2 PE=1 SV=1 1 1 1 9.69
66 tr|G3MZH0|G3MZH0_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100300806 PE=4 SV=1 2 1 2 40.15
67 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=4 SV=2 1 1 1 1.01
68 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 1 1 1 1.56
69 tr|Q3SZH5|Q3SZH5_BOVIN Angiotensinogen OS=Bos taurus GN=AGT PE=2 SV=1 1 1 1 3.54
70 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 2 1 4 3.77
71 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 1 1 1 3.29
72 tr|F1MM86|F1MM86_BOVIN Complement component C6 OS=Bos taurus GN=C6 PE=4 SV=1 1 1 3 1.93
73 sp|Q95121|PEDF_BOVIN Pigment epithelium-derived factor OS=Bos taurus GN=SERPINF1 PE=1 SV=1 1 1 1 7.21
74 tr|E1BMJ0|E1BMJ0_BOVIN Uncharacterized protein OS=Bos taurus GN=SERPING1 PE=3 SV=2 2 1 4 3.42
75 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 2 1 6 8.20
76 sp|Q58D62|FETUB_BOVIN Fetuin-B OS=Bos taurus GN=FETUB PE=1 SV=1 1 1 1 6.46
77 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein (Fragment) OS=Bos taurus PE=4 SV=2 1 1 1 0.61
78 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 1 1 4 1.31
79 tr|A5PK72|A5PK72_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 1 1 1 59.75
80 tr|B5B3R8|B5B3R8_BOVIN Alpha S1 casein OS=Bos taurus GN=CSN1S1 PE=2 SV=1 1 1 1 0.00
81 tr|A4IFI0|A4IFI0_BOVIN IGLL1 protein OS=Bos taurus GN=IGLL1 PE=2 SV=1 4 2 9 67.23
82 tr|A5D9D2|A5D9D2_BOVIN Complement component 4 binding protein, alpha chain OS=Bos taurus GN=C4BPA PE=2 SV=1 0 0 0 0.00
83 sp|A0JN39|COPB_BOVIN Coatomer subunit beta OS=Bos taurus GN=COPB1 PE=1 SV=1 0 0 0 0.00
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Protein N Representative Accession Name Confident Peptides Confident Sequences Confident Spectra %Seq Cov - peptides >95% conf
1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 362 135 1986 77.88
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 372 128 4476 92.42
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 192 102 565 59.60
4 tr|B8Y9S9|B8Y9S9_BOVIN Embryo-specif ic f ibronectin 1 transcript variant OS=Bos taurus GN=FN1 PE=1 SV=1 72 48 169 26.48
5 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 114 47 638 59.35
6 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 112 42 488 63.03
7 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 76 42 202 43.24
8 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 116 37 428 67.36
9 sp|Q29443|TRFE_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=2 SV=1 55 32 139 49.29
10 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 88 33 1613 71.37
11 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 89 36 1158 69.58
12 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 65 29 227 74.34
13 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 55 25 320 60.43
14 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 28 20 55 14.88
15 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 27 16 53 33.55
16 sp|Q3T052|ITIH4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H4 OS=Bos taurus GN=ITIH4 PE=1 SV=1 22 16 38 27.51
17 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 16 13 24 11.08
18 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 15 11 30 34.59
19 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 35 12 760 69.92
20 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 14 10 30 12.17
21 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 13 8 35 21.13
22 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 8 8 10 9.85
23 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 17 11 35 33.26
24 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 15 10 30 12.47
25 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 14 8 54 27.30
26 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 20 7 105 40.42
27 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 8 7 12 13.90
28 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 22 6 67 61.00
29 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 9 6 14 11.15
30 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 9 5 24 25.74
31 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 7 5 14 37.93
32 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 9 7 17 15.88
33 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 11 7 24 12.67
34 tr|A0A0A0MPA0|A0A0A0MPA0_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC784932 PE=1 SV=1 5 5 7 9.35
35 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 8 4 15 19.17
36 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 7 5 18 12.18
37 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 19 8 62 58.88
38 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 7 5 21 12.03
39 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 15 7 37 60.58
40 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 7 5 12 19.92
41 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 6 4 31 33.91
42 tr|G8JKW7|G8JKW7_BOVIN Uncharacterized protein OS=Bos taurus GN=SERPINA3 PE=3 SV=1 3 3 5 15.05
43 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 6 3 20 21.02
44 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 5 3 11 18.85
45 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 5 3 10 23.56
46 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 6 5 7 7.62
47 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 5 4 8 9.25
48 sp|P34955|A1AT_BOVIN Alpha-1-antiproteinase OS=Bos taurus GN=SERPINA1 PE=1 SV=1 3 2 7 6.49
49 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 5 4 7 13.95
50 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 3 2 5 7.67
51 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 6 2 20 71.90
52 tr|G5E5V1|G5E5V1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 5 2 11 35.71
53 sp|O02659|MBL2_BOVIN Mannose-binding protein C OS=Bos taurus GN=MBL PE=2 SV=1 3 2 6 8.03
54 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 2 3 30.22
55 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 3 2 3 5.05
56 tr|A0A140T8C8|A0A140T8C8_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=1 3 2 5 2.74
57 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 2 2 2 4.00
58 tr|E1BNR0|E1BNR0_BOVIN Uncharacterized protein OS=Bos taurus GN=APOB PE=1 SV=2 2 2 2 0.48
59 tr|F5XVA9|F5XVA9_BOVIN von Willebrand factor OS=Bos taurus GN=VWF PE=2 SV=1 3 2 3 1.00
60 tr|F1MZ96|F1MZ96_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 3 2 4 36.67
61 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 1 1 1 2.19
62 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 1 1 1 4.74
63 tr|A5D9D2|A5D9D2_BOVIN Complement component 4 binding protein, alpha chain OS=Bos taurus GN=C4BPA PE=2 SV=1 1 1 1 1.48
64 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 4 2 14 88.63
65 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 5 2 12 73.93
66 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 2 9.56
67 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 1 4 45.32
68 sp|Q9TTE1|SPA31_BOVIN Serpin A3-1 OS=Bos taurus GN=SERPINA3-1 PE=1 SV=3 1 1 2 11.19
69 tr|G3MZH0|G3MZH0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 2 3 56.06
70 tr|F1N1I6|F1N1I6_BOVIN Gelsolin OS=Bos taurus GN=GSN PE=1 SV=1 1 1 1 1.41
71 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 2 0.61
72 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 1 1 2 3.47
73 tr|E1BAI7|E1BAI7_BOVIN Uncharacterized protein OS=Bos taurus GN=TMOD2 PE=4 SV=2 2 1 3 1.99
74 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 2 1 4 3.77
75 tr|E1BPB7|E1BPB7_BOVIN Uncharacterized protein OS=Bos taurus GN=KLHL8 PE=4 SV=1 1 1 1 1.14
76 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 2 1 4 1.31
77 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 2 1 4 16.67
78 tr|A7MB82|A7MB82_BOVIN C1QTNF3 protein OS=Bos taurus GN=C1QTNF3 PE=2 SV=1 2 1 3 5.29
79 tr|Q56JW3|Q56JW3_BOVIN Nucleoside-diphosphate kinase NBR-A OS=Bos taurus GN=LOC574091 PE=2 SV=1 1 1 1 6.78
80 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 2 1 18 79.41
81 tr|G3N148|G3N148_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 2 35.97
82 tr|F1MM86|F1MM86_BOVIN Complement component C6 OS=Bos taurus GN=C6 PE=4 SV=1 1 1 1 1.93
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Protein N Representative Accession Name Confident Peptides Confident Sequences Confident Spectra %Seq Cov - peptides >95% conf
1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 278 114 1076 69.74
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 290 107 2795 91.76
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 156 88 410 55.27
4 tr|B8Y9S9|B8Y9S9_BOVIN Embryo-specif ic f ibronectin 1 transcript variant OS=Bos taurus GN=FN1 PE=1 SV=1 84 52 195 26.60
5 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 114 49 628 60.98
6 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 111 36 1894 69.92
7 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 118 45 492 63.64
8 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 122 39 466 66.44
9 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 86 34 1036 71.37
10 tr|F1MI18|F1MI18_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 46 30 107 26.73
11 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 73 26 275 75.09
12 sp|Q29443|TRFE_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=2 SV=1 36 25 89 38.35
13 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 36 17 144 51.25
14 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 44 23 157 66.56
15 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 43 18 230 75.49
16 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 28 15 65 28.04
17 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 15 12 27 8.73
18 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 13 9 18 8.77
19 sp|P02662|CASA1_BOVIN Alpha-S1-casein OS=Bos taurus GN=CSN1S1 PE=1 SV=2 23 10 122 60.75
20 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 11 8 26 38.61
21 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 17 14 23 35.11
22 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 11 9 15 7.69
23 sp|Q9TTE1|SPA31_BOVIN Serpin A3-1 OS=Bos taurus GN=SERPINA3-1 PE=1 SV=3 11 8 20 20.44
24 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 10 7 30 17.21
25 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 7 6 15 7.37
26 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 18 6 55 61.00
27 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 6 5 8 6.03
28 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 8 5 14 13.92
29 tr|G5E5H7|G5E5H7_BOVIN Uncharacterized protein OS=Bos taurus GN=PAEP PE=3 SV=1 13 7 45 43.26
30 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 13 8 34 25.63
31 sp|P02666|CASB_BOVIN Beta-casein OS=Bos taurus GN=CSN2 PE=1 SV=2 11 7 32 45.54
32 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 7 5 11 6.66
33 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 9 4 17 19.17
34 sp|O46375|TTHY_BOVIN Transthyretin OS=Bos taurus GN=TTR PE=1 SV=1 7 5 18 46.94
35 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 6 4 15 30.47
36 sp|P02663|CASA2_BOVIN Alpha-S2-casein OS=Bos taurus GN=CSN1S2 PE=1 SV=2 8 4 19 23.42
37 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 7 3 20 21.02
38 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 9 4 19 76.92
39 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 6 4 11 16.74
40 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 5 3 13 5.67
41 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 4 3 7 4.97
42 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 12 4 28 44.53
43 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 8 5 25 9.28
44 sp|P34955|A1AT_BOVIN Alpha-1-antiproteinase OS=Bos taurus GN=SERPINA1 PE=1 SV=1 3 2 7 6.49
45 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 10 3 16 77.02
46 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 7 2 19 45.32
47 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 3 3 5 23.45
48 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 6 3 11 23.56
49 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 3 3 6 46.04
50 tr|A0A140T8A9|A0A140T8A9_BOVIN Kappa-casein OS=Bos taurus GN=CSN3 PE=3 SV=1 6 4 21 20.00
51 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 6 5 9 10.89
52 tr|A0A0A0MPA0|A0A0A0MPA0_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC784932 PE=1 SV=1 3 2 8 9.35
53 sp|O02659|MBL2_BOVIN Mannose-binding protein C OS=Bos taurus GN=MBL PE=2 SV=1 3 2 4 8.03
54 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 2 2 4 3.52
55 tr|F1MZ96|F1MZ96_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 2 2 7 51.25
56 tr|G3MZE0|G3MZE0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 4 3 6 33.33
57 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 2 2 3 5.05
58 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 1 1 2 3.41
59 tr|A4IFI0|A4IFI0_BOVIN IGLL1 protein OS=Bos taurus GN=IGLL1 PE=2 SV=1 2 1 5 61.28
60 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 1 1 6 73.77
61 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 1 1 2 16.67
62 tr|A5PJT7|A5PJT7_BOVIN ECM1 protein OS=Bos taurus GN=ECM1 PE=2 SV=1 1 1 1 1.93
63 tr|Q68RU0|Q68RU0_BOVIN Ovarian and testicular apolipoprotein N OS=Bos taurus GN=ApoN PE=2 SV=1 1 1 2 3.47
64 tr|G3MXL3|G3MXL3_BOVIN Uncharacterized protein OS=Bos taurus GN=KRT3 PE=1 SV=1 1 1 1 1.95
65 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 3 1 7 85.67
66 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=1 SV=2 2 2 3 0.60
67 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 1 1 1 1.28
68 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 2 1 2 8.20
69 tr|A6QM09|A6QM09_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 1 1 2 55.60
70 tr|F1N1I6|F1N1I6_BOVIN Gelsolin OS=Bos taurus GN=GSN PE=1 SV=1 1 1 1 1.41
71 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 1 1 1 0.00
72 tr|A0A140T8C8|A0A140T8C8_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=1 1 1 1 0.00
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Protein N Representative Accession Name Confident Peptides Confident Sequences Confident Spectra %Seq Cov - peptides >95% conf
1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 333 128 1779 76.89
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 332 116 4363 92.42
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 186 103 539 60.20
4 tr|B8Y9S9|B8Y9S9_BOVIN Embryo-specif ic f ibronectin 1 transcript variant OS=Bos taurus GN=FN1 PE=1 SV=1 72 50 159 24.30
5 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 122 49 1057 61.79
6 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 118 43 673 63.84
7 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 79 36 1170 71.37
8 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 125 38 523 66.90
9 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 57 36 166 30.61
10 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 84 35 1157 70.02
11 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 80 27 320 73.58
12 sp|Q29443|TRFE_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=2 SV=1 40 24 100 38.92
13 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 35 23 77 14.30
14 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 49 24 221 62.58
15 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 19 15 31 12.30
16 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 22 13 51 28.92
17 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 30 11 791 69.67
18 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 22 9 92 43.33
19 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 13 10 23 13.95
20 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 11 10 19 12.35
21 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 13 9 21 9.50
22 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 11 6 24 18.60
23 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 10 9 17 23.41
24 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 13 8 36 23.68
25 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 18 6 47 61.00
26 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 6 6 8 7.88
27 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 9 6 18 46.90
28 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 11 8 21 20.48
29 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 12 8 43 18.08
30 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 12 8 32 17.72
31 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 10 7 14 10.89
32 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 8 5 23 19.17
33 sp|P02662|CASA1_BOVIN Alpha-S1-casein OS=Bos taurus GN=CSN1S1 PE=1 SV=2 10 5 35 22.43
34 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 5 4 6 7.68
35 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 7 4 25 33.91
36 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 13 7 28 45.32
37 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 5 3 8 11.68
38 tr|A0A140T8C8|A0A140T8C8_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=1 6 3 9 5.47
39 tr|Q5J801|Q5J801_BOVIN Endopin 2B OS=Bos taurus PE=2 SV=1 3 3 7 7.19
40 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 7 4 14 23.56
41 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 10 4 28 44.53
42 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 5 3 19 7.35
43 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 6 4 12 13.37
44 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 5 3 9 3.20
45 tr|F1N1I6|F1N1I6_BOVIN Gelsolin OS=Bos taurus GN=GSN PE=1 SV=1 2 2 2 2.69
46 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 5 3 19 21.02
47 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 5 4 7 10.57
48 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 3 3 6 10.63
49 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 6 4 15 18.85
50 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 3 2 3 5.05
51 tr|Q705V4|Q705V4_BOVIN Kappa-casein (Fragment) OS=Bos taurus GN=csn3 PE=4 SV=1 3 2 4 17.61
52 tr|A0A140T843|A0A140T843_BOVIN Beta-2-glycoprotein 1 OS=Bos taurus GN=APOH PE=4 SV=1 3 2 5 6.96
53 tr|T1T0C1|T1T0C1_BOVIN Beta-casein OS=Bos taurus GN=csn2 PE=2 SV=1 4 3 8 14.73
54 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 4 3 4 4.07
55 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 2 2 2 4.84
56 sp|Q9TTE1|SPA31_BOVIN Serpin A3-1 OS=Bos taurus GN=SERPINA3-1 PE=1 SV=3 3 2 11 6.81
57 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 2 2 25.90
58 tr|A0A1K0FUD3|A0A1K0FUD3_BOVIN Globin C1 OS=Bos taurus GN=GLNC1 PE=3 SV=1 3 3 5 18.31
59 sp|P02663|CASA2_BOVIN Alpha-S2-casein OS=Bos taurus GN=CSN1S2 PE=1 SV=2 1 1 2 3.60
60 tr|Q68RU0|Q68RU0_BOVIN Ovarian and testicular apolipoprotein N OS=Bos taurus GN=ApoN PE=2 SV=1 1 1 1 3.47
61 sp|P34955|A1AT_BOVIN Alpha-1-antiproteinase OS=Bos taurus GN=SERPINA1 PE=1 SV=1 2 1 3 2.40
62 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 2 1 3 3.41
63 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 2 1 4 16.67
64 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 1 1 1 3.68
65 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 5 4 10 20.93
66 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 3 1 7 87.31
67 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 4 2 7 73.08
68 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 4 2 11 71.06
69 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 1 1 8 79.17
70 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 4 1 12 43.93
71 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 1 1 1 3.47
72 sp|O02659|MBL2_BOVIN Mannose-binding protein C OS=Bos taurus GN=MBL PE=2 SV=1 2 1 3 4.42
73 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 2 1 4 3.77
74 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 2 1 5 1.31
75 tr|A5PJT7|A5PJT7_BOVIN ECM1 protein OS=Bos taurus GN=ECM1 PE=2 SV=1 1 1 2 1.93
76 tr|A5PK72|A5PK72_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 1 1 1 56.78
77 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 2 1 2 2.01
78 tr|Q56JW3|Q56JW3_BOVIN Nucleoside-diphosphate kinase NBR-A OS=Bos taurus GN=LOC574091 PE=2 SV=1 1 1 1 6.78
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1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 377 145 2249 77.28
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 325 111 3798 92.42
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 173 98 492 61.11
4 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 90 40 411 52.68
5 tr|B8Y9S9|B8Y9S9_BOVIN Embryo-specif ic f ibronectin 1 transcript variant OS=Bos taurus GN=FN1 PE=1 SV=1 67 43 151 23.50
6 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 101 41 381 68.08
7 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 119 45 2268 75.05
8 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 89 35 1656 77.35
9 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 97 34 358 66.44
10 sp|Q29443|TRFE_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=2 SV=1 55 31 150 51.42
11 tr|F1MI18|F1MI18_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 63 34 166 33.96
12 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 55 27 194 71.32
13 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 50 22 252 67.48
14 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 40 21 108 36.42
15 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 28 22 53 14.82
16 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 44 15 1684 69.67
17 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 17 11 28 8.82
18 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 19 13 44 32.03
19 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 17 8 75 42.08
20 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 11 9 20 10.14
21 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 16 10 26 12.90
22 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 11 8 16 11.14
23 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 10 7 12 12.14
24 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 18 6 65 61.00
25 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 11 7 17 23.06
26 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 10 7 26 24.23
27 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 10 7 27 19.61
28 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 24 9 87 58.88
29 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 13 5 35 44.53
30 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 9 7 20 17.09
31 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 6 4 10 9.37
32 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 10 8 16 11.55
33 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 6 3 16 14.17
34 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 5 3 5 16.74
35 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 6 3 11 23.56
36 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 6 3 36 29.61
37 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 10 4 39 21.02
38 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 4 3 5 6.40
39 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 5 3 10 23.45
40 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 5 3 8 18.85
41 tr|Q32T06|Q32T06_BOVIN Endopin 2C OS=Bos taurus PE=2 SV=1 3 3 6 6.28
42 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 7 5 16 13.03
43 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 3 3 5 4.80
44 tr|G5E5V1|G5E5V1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 6 3 15 35.71
45 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 4 3 4 9.25
46 tr|A0A140T8C8|A0A140T8C8_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=1 3 2 4 2.74
47 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 2 2 3 8.03
48 sp|P00978|AMBP_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=1 SV=2 2 2 4 7.67
49 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 6 2 19 70.91
50 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 7 4 12 77.35
51 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 3 3 4 5.78
52 tr|G3MZE0|G3MZE0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 2 3 22.22
53 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 1 25.90
54 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 2 1 10 87.31
55 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 2 1 30 75.49
56 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 1 1 1 77.02
57 tr|A4IFI0|A4IFI0_BOVIN IGLL1 protein OS=Bos taurus GN=IGLL1 PE=2 SV=1 6 2 12 72.77
58 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 3 1 6 45.32
59 tr|F1MH40|F1MH40_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 1 1 3 35.83
60 tr|G3MZH0|G3MZH0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 1 40.15
61 tr|F1N1I6|F1N1I6_BOVIN Gelsolin OS=Bos taurus GN=GSN PE=1 SV=1 1 1 1 1.41
62 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 1 1 1 3.68
63 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 1 1 1 1.81
64 tr|A0A1K0FUD3|A0A1K0FUD3_BOVIN Globin C1 OS=Bos taurus GN=GLNC1 PE=3 SV=1 2 1 3 4.93
65 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 4 2 6 4.06
66 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 1 1 2 1.31
67 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 1 1 1 1.28
68 sp|O02659|MBL2_BOVIN Mannose-binding protein C OS=Bos taurus GN=MBL PE=2 SV=1 2 1 2 4.42
69 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 1 1 2 16.67
70 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 2 1 2 5.94
71 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 2 0.61
72 tr|Q56JW3|Q56JW3_BOVIN Nucleoside-diphosphate kinase NBR-A OS=Bos taurus GN=LOC574091 PE=2 SV=1 1 1 1 6.78
73 tr|A5PJT7|A5PJT7_BOVIN ECM1 protein OS=Bos taurus GN=ECM1 PE=2 SV=1 1 1 1 1.93
74 tr|F1MF64|F1MF64_BOVIN Uncharacterized protein OS=Bos taurus GN=NBEA PE=4 SV=2 1 1 1 0.25
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1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 324 136 1730 78.15
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 341 117 4379 92.42
3 tr|A0A0F6QNP7|A0A0F6QNP7_BOVIN Complement component 3 OS=Bos taurus GN=C3 PE=2 SV=1 158 97 437 57.01
4 tr|B8Y9S9|B8Y9S9_BOVIN Embryo-specif ic f ibronectin 1 transcript variant OS=Bos taurus GN=FN1 PE=1 SV=1 65 43 143 24.55
5 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 111 48 710 58.21
6 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 114 40 467 67.36
7 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 121 46 577 65.86
8 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 101 36 2437 70.44
9 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 100 38 1945 77.35
10 sp|Q29443|TRFE_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=2 SV=1 53 29 137 49.57
11 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 59 32 143 32.16
12 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 61 28 197 75.47
13 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 51 23 372 60.43
14 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 23 17 49 11.14
15 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 36 16 222 74.18
16 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 16 12 26 19.21
17 tr|F1MZ96|F1MZ96_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 29 12 183 47.08
18 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 21 15 52 34.70
19 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 26 14 61 33.55
20 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 11 8 21 21.87
21 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 16 11 24 8.98
22 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 11 8 17 10.23
23 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 13 8 26 20.04
24 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 11 6 39 61.00
25 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 11 7 29 27.86
26 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 8 5 22 13.03
27 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 14 9 20 12.47
28 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 6 4 11 31.72
29 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 6 6 6 10.08
30 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 5 5 5 17.89
31 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 6 5 7 9.07
32 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 8 6 13 18.90
33 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 5 3 17 17.82
34 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 11 8 15 14.17
35 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 3 3 4 4.56
36 sp|P02662|CASA1_BOVIN Alpha-S1-casein OS=Bos taurus GN=CSN1S1 PE=1 SV=2 3 3 8 15.42
37 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 7 3 23 21.02
38 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 9 6 22 13.08
39 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 5 3 6 4.97
40 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 17 7 53 52.34
41 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 7 4 16 28.27
42 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 7 4 14 76.92
43 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 6 4 18 19.17
44 tr|Q32T06|Q32T06_BOVIN Endopin 2C OS=Bos taurus PE=2 SV=1 3 3 6 6.28
45 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 8 3 20 74.04
46 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 6 3 20 29.61
47 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 5 2 12 40.29
48 tr|Q705V4|Q705V4_BOVIN Kappa-casein (Fragment) OS=Bos taurus GN=csn3 PE=4 SV=1 2 2 2 17.61
49 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 5 3 6 18.85
50 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 12 6 33 60.58
51 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 2 2 4 4.87
52 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 3 2 3 8.84
53 sp|P34955|A1AT_BOVIN Alpha-1-antiproteinase OS=Bos taurus GN=SERPINA1 PE=1 SV=1 4 3 8 8.65
54 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 2 2 2 9.16
55 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 5 2 5 7.31
56 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 5 3 6 8.35
57 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 3 2 5 25.90
58 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 2 2 3 7.09
59 tr|T1T0C1|T1T0C1_BOVIN Beta-casein OS=Bos taurus GN=csn2 PE=2 SV=1 2 1 3 11.61
60 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 2 2 2 6.05
61 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 4 1 11 88.30
62 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 2 2 5 44.17
63 sp|P01030|CO4_BOVIN Complement C4 (Fragments) OS=Bos taurus GN=C4 PE=1 SV=2 1 1 2 16.96
64 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 2 1 3 3.47
65 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 2 1 6 3.41
66 sp|O46375|TTHY_BOVIN Transthyretin OS=Bos taurus GN=TTR PE=1 SV=1 1 1 1 15.65
67 sp|A5PKL1|OXR1_BOVIN Oxidation resistance protein 1 OS=Bos taurus GN=OXR1 PE=2 SV=2 0 0 0 1.15
68 tr|E1BDZ3|E1BDZ3_BOVIN Uncharacterized protein OS=Bos taurus GN=CHD9 PE=4 SV=1 1 1 2 0.55
69 sp|Q2KIX7|HP251_BOVIN Protein HP-25 homolog 1 OS=Bos taurus PE=1 SV=1 3 2 5 10.85
70 tr|G3N148|G3N148_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 1 35.97
71 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 1 1 2 16.67
72 tr|F1MKE9|F1MKE9_BOVIN Spectrin beta chain OS=Bos taurus GN=SPTB PE=3 SV=2 0 0 0 0.39
73 tr|Q58DG7|Q58DG7_BOVIN TBP-associated factor 6 isoform alpha OS=Bos taurus GN=TAF6 PE=2 SV=1 1 1 1 1.33
74 tr|F1N0S9|F1N0S9_BOVIN Uncharacterized protein OS=Bos taurus GN=FAM98A PE=4 SV=2 1 1 1 2.72
75 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 1 1 1 3.65
76 tr|A5PJT7|A5PJT7_BOVIN ECM1 protein OS=Bos taurus GN=ECM1 PE=2 SV=1 1 1 1 1.93
77 tr|G3MZE0|G3MZE0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 2 2 33.33
78 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 1 0.61
79 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 1 1 2 1.31
80 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 2 1 21 74.02
81 tr|Q56JW3|Q56JW3_BOVIN Nucleoside-diphosphate kinase NBR-A OS=Bos taurus GN=LOC574091 PE=2 SV=1 1 1 2 6.78
82 tr|A6QM09|A6QM09_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 4 3 9 66.38
83 tr|F1MF64|F1MF64_BOVIN Uncharacterized protein OS=Bos taurus GN=NBEA PE=4 SV=2 0 0 0 0.25
84 tr|F1N037|F1N037_BOVIN Calcium-binding and coiled-coil domain-containing protein 1 OS=Bos taurus GN=CALCOCO1 PE=4 SV=1 0 0 0 1.03
85 tr|F1MUD4|F1MUD4_BOVIN Uncharacterized protein OS=Bos taurus GN=USP19 PE=4 SV=2 1 1 1 0.00
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1 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 382 126 5420 92.42
2 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 213 110 669 64.30
3 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 288 114 1292 72.91
4 tr|B8Y9S9|B8Y9S9_BOVIN Embryo-specif ic f ibronectin 1 transcript variant OS=Bos taurus GN=FN1 PE=1 SV=1 75 47 168 26.85
5 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 110 45 818 57.07
6 tr|G3X6N3|G3X6N3_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=1 SV=1 77 41 220 62.78
7 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 110 39 474 66.90
8 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 107 40 591 58.38
9 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 61 25 874 66.58
10 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 86 33 1774 64.10
11 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 57 29 200 76.23
12 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 39 24 95 24.46
13 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 29 23 70 17.81
14 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 26 18 57 21.75
15 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 71 31 472 69.33
16 tr|G3X6K8|G3X6K8_BOVIN Haptoglobin OS=Bos taurus GN=HP PE=3 SV=1 22 15 40 36.16
17 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 18 12 49 39.36
18 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 22 14 56 34.64
19 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 16 12 26 9.14
20 tr|A7E350|A7E350_BOVIN PLG protein OS=Bos taurus GN=PLG PE=1 SV=1 10 9 15 11.05
21 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 18 11 35 16.05
22 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 15 9 29 68.97
23 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 25 9 96 53.17
24 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 27 11 133 44.17
25 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 16 11 40 34.70
26 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 15 9 50 36.21
27 tr|A0A1K0FUD3|A0A1K0FUD3_BOVIN Globin C1 OS=Bos taurus GN=GLNC1 PE=3 SV=1 9 8 13 78.17
28 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 8 6 14 15.13
29 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 13 9 23 22.08
30 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 12 6 33 61.00
31 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 17 11 41 23.42
32 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 7 5 13 9.07
33 tr|Q3SZQ8|Q3SZQ8_BOVIN Endopin 2 OS=Bos taurus GN=SERPINA3-7 PE=2 SV=1 7 5 10 14.15
34 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 8 6 13 22.76
35 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 15 11 20 12.68
36 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 6 3 16 17.82
37 sp|P02666|CASB_BOVIN Beta-casein OS=Bos taurus GN=CSN2 PE=1 SV=2 4 3 7 17.86
38 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 5 4 9 5.41
39 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 4 3 4 30.47
40 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 4 3 8 11.93
41 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 5 5 6 9.12
42 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 8 6 13 14.17
43 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 5 3 11 23.56
44 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=1 SV=2 7 7 8 4.23
45 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 7 4 11 9.25
46 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 12 5 32 60.58
47 sp|P34955|A1AT_BOVIN Alpha-1-antiproteinase OS=Bos taurus GN=SERPINA1 PE=1 SV=1 3 2 8 6.49
48 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 3 2 5 13.99
49 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 3 2 7 7.51
50 sp|Q9TTE1|SPA31_BOVIN Serpin A3-1 OS=Bos taurus GN=SERPINA3-1 PE=1 SV=3 4 3 6 10.46
51 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 8 3 19 40.29
52 tr|F1MNV5|F1MNV5_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=2 7 5 10 5.73
53 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 6 4 15 14.17
54 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 5 3 16 15.92
55 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 3 2 5 4.20
56 tr|A6QM09|A6QM09_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 4 3 5 56.03
57 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 4 2 9 66.81
58 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 6 2 10 67.95
59 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 3 3 3 13.95
60 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 1 1 1 1.81
61 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 1 1 1 3.77
62 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 4 3 14 88.30
63 sp|P01030|CO4_BOVIN Complement C4 (Fragments) OS=Bos taurus GN=C4 PE=1 SV=2 1 1 1 21.85
64 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 3 1 6 37.38
65 tr|G3MXL3|G3MXL3_BOVIN Uncharacterized protein OS=Bos taurus GN=KRT3 PE=1 SV=1 1 1 1 1.95
66 tr|F1MM86|F1MM86_BOVIN Complement component C6 OS=Bos taurus GN=C6 PE=4 SV=1 1 1 1 1.93
67 tr|E1BMJ0|E1BMJ0_BOVIN Uncharacterized protein OS=Bos taurus GN=SERPING1 PE=3 SV=2 1 1 2 3.42
68 tr|A0A140T843|A0A140T843_BOVIN Beta-2-glycoprotein 1 OS=Bos taurus GN=APOH PE=4 SV=1 2 1 5 4.35
69 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 2 2 4 13.52
70 tr|B5B3R8|B5B3R8_BOVIN Alpha S1 casein OS=Bos taurus GN=CSN1S1 PE=2 SV=1 1 1 2 5.61
71 sp|P23805|CONG_BOVIN Conglutinin OS=Bos taurus GN=CGN1 PE=1 SV=2 3 2 6 5.93
72 tr|G3MZE0|G3MZE0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 2 2 22.22
73 tr|K4JDT2|K4JDT2_BOVIN Alpha-2-macroglobulin variant 20 OS=Bos taurus GN=A2M PE=2 SV=1 3 1 6 69.58
74 sp|Q2KIX7|HP251_BOVIN Protein HP-25 homolog 1 OS=Bos taurus PE=1 SV=1 3 3 3 16.51
75 tr|A5PJT7|A5PJT7_BOVIN ECM1 protein OS=Bos taurus GN=ECM1 PE=2 SV=1 1 1 1 1.93
76 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 3 0.61
77 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 1 1 1 1.31
78 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 1 10.79
79 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 2 1 10 71.32
80 tr|A0A0M4MD57|A0A0M4MD57_BOVIN Haptoglobin OS=Bos taurus GN=HP PE=2 SV=1 2 1 2 36.16
81 tr|Q05B55|Q05B55_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 1 1 1 44.17
82 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 1 1 1 0.00
83 tr|G5E5V1|G5E5V1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 2 2 39.29
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1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 330 130 1766 77.15
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 399 129 5237 92.42
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 187 101 563 62.85
4 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 111 46 747 57.07
5 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 115 36 430 66.44
6 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 112 42 558 58.59
7 tr|B8Y9S9|B8Y9S9_BOVIN Embryo-specif ic f ibronectin 1 transcript variant OS=Bos taurus GN=FN1 PE=1 SV=1 59 38 136 20.32
8 sp|Q29443|TRFE_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=2 SV=1 54 32 144 50.00
9 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 79 34 1140 76.92
10 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 77 30 1290 69.67
11 tr|F1MI18|F1MI18_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 48 29 136 28.48
12 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 45 32 96 19.36
13 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 61 27 242 75.47
14 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 45 23 223 58.28
15 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 28 10 121 59.08
16 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 23 15 69 32.46
17 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 20 11 44 30.02
18 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 14 9 21 13.64
19 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 18 11 26 9.47
20 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 11 8 21 9.50
21 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 20 7 110 40.42
22 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 14 8 54 34.26
23 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 18 6 65 61.00
24 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 6 6 7 7.51
25 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 12 9 24 10.88
26 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 11 8 22 20.08
27 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 12 8 32 20.68
28 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 8 7 10 12.62
29 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 12 8 19 17.59
30 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 9 6 16 8.83
31 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 8 5 21 13.03
32 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 9 8 11 13.55
33 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 8 4 20 19.17
34 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 6 4 15 22.13
35 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 7 4 16 22.28
36 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 5 4 8 8.29
37 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 8 7 9 13.62
38 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 7 4 10 28.27
39 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 6 4 6 7.62
40 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 6 3 8 11.68
41 tr|F1MY85|F1MY85_BOVIN Complement C5a anaphylatoxin OS=Bos taurus GN=C5 PE=1 SV=2 8 6 10 3.70
42 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 10 4 23 44.53
43 sp|Q9TTE1|SPA31_BOVIN Serpin A3-1 OS=Bos taurus GN=SERPINA3-1 PE=1 SV=3 4 3 8 7.30
44 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 3 3 3 5.44
45 sp|P34955|A1AT_BOVIN Alpha-1-antiproteinase OS=Bos taurus GN=SERPINA1 PE=1 SV=1 3 2 5 6.49
46 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 4 2 8 13.95
47 tr|F1MMK9|F1MMK9_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=4 SV=2 3 2 8 7.67
48 tr|K4JF16|K4JF16_BOVIN Alpha-2-macroglobulin variant 23 OS=Bos taurus GN=A2M PE=2 SV=1 4 2 12 70.24
49 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 7 3 9 74.79
50 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 5 3 9 73.62
51 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 5 2 32 26.18
52 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 6 3 16 52.34
53 tr|F1N1I6|F1N1I6_BOVIN Gelsolin OS=Bos taurus GN=GSN PE=1 SV=1 2 2 2 2.43
54 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 4 2 14 15.92
55 sp|Q3MHN2|CO9_BOVIN Complement component C9 OS=Bos taurus GN=C9 PE=2 SV=1 3 2 5 4.20
56 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 2 2 2 14.68
57 sp|O02659|MBL2_BOVIN Mannose-binding protein C OS=Bos taurus GN=MBL PE=2 SV=1 2 2 2 8.03
58 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 3 2 5 7.31
59 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 2 2 30.22
60 tr|A0A140T8C8|A0A140T8C8_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=1 3 2 3 4.03
61 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 1 1 1 2.90
62 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 3 1 10 88.30
63 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 3 1 10 79.17
64 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 1 1 3 3.47
65 tr|A6QPP2|A6QPP2_BOVIN SERPIND1 protein OS=Bos taurus GN=SERPIND1 PE=2 SV=1 1 1 2 1.81
66 tr|V6F9A3|V6F9A3_BOVIN Apolipoprotein C-III OS=Bos taurus GN=ApoC3 PE=4 SV=1 1 1 1 16.67
67 tr|Q6T182|Q6T182_BOVIN Sex hormone-binding globulin (Fragment) OS=Bos taurus GN=SHBG PE=2 SV=1 2 1 4 3.77
68 tr|E1BMJ0|E1BMJ0_BOVIN Uncharacterized protein OS=Bos taurus GN=SERPING1 PE=3 SV=2 1 1 1 3.42
69 tr|B5B3R8|B5B3R8_BOVIN Alpha S1 casein OS=Bos taurus GN=CSN1S1 PE=2 SV=1 1 1 2 5.61
70 tr|A0A140T843|A0A140T843_BOVIN Beta-2-glycoprotein 1 OS=Bos taurus GN=APOH PE=4 SV=1 2 1 4 4.35
71 tr|A5PJT7|A5PJT7_BOVIN ECM1 protein OS=Bos taurus GN=ECM1 PE=2 SV=1 1 1 2 1.93
72 sp|Q2KIX7|HP251_BOVIN Protein HP-25 homolog 1 OS=Bos taurus PE=1 SV=1 2 2 3 12.74
73 tr|Q56JW3|Q56JW3_BOVIN Nucleoside-diphosphate kinase NBR-A OS=Bos taurus GN=LOC574091 PE=2 SV=1 1 1 1 6.78
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1 sp|Q7SIH1|A2MG_BOVIN Alpha-2-macroglobulin OS=Bos taurus GN=A2M PE=1 SV=2 343 136 1875 77.02
2 tr|A0A140T897|A0A140T897_BOVIN Serum albumin OS=Bos taurus GN=ALB PE=3 SV=1 311 108 3627 92.42
3 sp|Q2UVX4|CO3_BOVIN Complement C3 OS=Bos taurus GN=C3 PE=1 SV=2 164 93 440 59.06
4 tr|A5PJE3|A5PJE3_BOVIN Fibrinogen alpha chain OS=Bos taurus GN=FGA PE=2 SV=1 113 50 809 62.60
5 tr|B8Y9S9|B8Y9S9_BOVIN Embryo-specif ic f ibronectin 1 transcript variant OS=Bos taurus GN=FN1 PE=1 SV=1 68 41 147 23.59
6 tr|Q3SZZ9|Q3SZZ9_BOVIN FGG protein OS=Bos taurus GN=FGG PE=1 SV=1 125 40 475 67.36
7 tr|F1MAV0|F1MAV0_BOVIN Fibrinogen beta chain OS=Bos taurus GN=FGB PE=4 SV=2 123 47 591 64.24
8 tr|F1MLW7|F1MLW7_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC100297192 PE=1 SV=2 95 34 1539 77.78
9 tr|G5E513|G5E513_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 110 39 2276 66.30
10 sp|Q29443|TRFE_BOVIN Serotransferrin OS=Bos taurus GN=TF PE=2 SV=1 52 30 140 47.59
11 tr|F1MJK3|F1MJK3_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 55 33 144 34.32
12 tr|V6F9A2|V6F9A2_BOVIN Apolipoprotein A-I preproprotein OS=Bos taurus GN=APOA1 PE=3 SV=1 61 26 199 73.58
13 tr|G3N0V0|G3N0V0_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 60 25 248 69.33
14 tr|E1BH06|E1BH06_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC617696 PE=1 SV=2 24 18 48 13.73
15 tr|F1N514|F1N514_BOVIN Uncharacterized protein OS=Bos taurus GN=CD5L PE=1 SV=2 35 19 94 35.76
16 tr|G5E5T5|G5E5T5_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 41 15 1705 69.92
17 tr|F1N076|F1N076_BOVIN Uncharacterized protein OS=Bos taurus GN=CP PE=1 SV=2 11 9 19 10.97
18 tr|A5D7Q2|A5D7Q2_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 17 13 34 34.70
19 sp|Q28085|CFAH_BOVIN Complement factor H OS=Bos taurus GN=CFH PE=1 SV=3 18 12 32 8.90
20 tr|B0JYP6|B0JYP6_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 24 10 132 44.17
21 tr|F1MNW4|F1MNW4_BOVIN Inter-alpha-trypsin inhibitor heavy chain H2 OS=Bos taurus GN=ITIH2 PE=1 SV=2 15 10 21 11.63
22 tr|Q5EA67|Q5EA67_BOVIN Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Bos taurus GN=ITIH4 PE=2 SV=1 10 7 16 9.72
23 sp|Q3SZV7|HEMO_BOVIN Hemopexin OS=Bos taurus GN=HPX PE=2 SV=1 13 8 25 21.13
24 tr|A5D9E9|A5D9E9_BOVIN Complement component 1, r subcomponent OS=Bos taurus GN=C1R PE=2 SV=1 11 10 16 16.74
25 tr|E1B726|E1B726_BOVIN Plasminogen OS=Bos taurus GN=PLG PE=1 SV=2 6 5 7 8.62
26 sp|Q2KJF1|A1BG_BOVIN Alpha-1B-glycoprotein OS=Bos taurus GN=A1BG PE=1 SV=1 9 6 17 18.09
27 tr|D4QBB4|D4QBB4_BOVIN Globin A1 OS=Bos taurus GN=HBB PE=3 SV=1 9 6 18 51.03
28 sp|A7E3W2|LG3BP_BOVIN Galectin-3-binding protein OS=Bos taurus GN=LGALS3BP PE=1 SV=1 7 5 13 10.81
29 tr|F1MMP5|F1MMP5_BOVIN Inter-alpha-trypsin inhibitor heavy chain H1 OS=Bos taurus GN=ITIH1 PE=4 SV=1 11 8 15 10.04
30 tr|Q3ZBS7|Q3ZBS7_BOVIN Vitronectin OS=Bos taurus GN=VTN PE=1 SV=1 7 5 14 13.03
31 sp|P81644|APOA2_BOVIN Apolipoprotein A-II OS=Bos taurus GN=APOA2 PE=1 SV=2 10 6 26 61.00
32 sp|Q3Y5Z3|ADIPO_BOVIN Adiponectin OS=Bos taurus GN=ADIPOQ PE=1 SV=1 7 4 17 19.17
33 tr|G3N0S9|G3N0S9_BOVIN Uncharacterized protein OS=Bos taurus GN=LOC515150 PE=4 SV=1 8 6 14 29.15
34 tr|G3MZH0|G3MZH0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 11 4 31 48.48
35 tr|G5E5H2|G5E5H2_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 11 5 28 45.32
36 sp|Q5E9E3|C1QA_BOVIN Complement C1q subcomponent subunit A OS=Bos taurus GN=C1QA PE=2 SV=1 7 5 13 22.13
37 tr|Q3SYR8|Q3SYR8_BOVIN Immunoglobulin J chain OS=Bos taurus GN=IGJ PE=1 SV=1 9 3 33 21.02
38 tr|Q1RMH5|Q1RMH5_BOVIN C1QC protein (Fragment) OS=Bos taurus GN=C1QC PE=2 SV=1 4 3 7 11.68
39 tr|Q1RMN8|Q1RMN8_BOVIN Immunoglobulin light chain, lambda gene cluster OS=Bos taurus GN=IGL@ PE=2 SV=1 8 4 11 76.92
40 sp|Q9TTE1|SPA31_BOVIN Serpin A3-1 OS=Bos taurus GN=SERPINA3-1 PE=1 SV=3 5 4 12 9.25
41 tr|I7CT57|I7CT57_BOVIN Vitamin D binding protein OS=Bos taurus PE=2 SV=1 13 9 26 13.92
42 tr|B0JYN6|B0JYN6_BOVIN Alpha-2-HS-glycoprotein OS=Bos taurus GN=AHSG PE=2 SV=1 8 6 21 19.50
43 sp|Q2KIT0|HP20_BOVIN Protein HP-20 homolog OS=Bos taurus PE=2 SV=1 5 3 6 23.56
44 tr|F1MLW8|F1MLW8_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 6 3 14 30.47
45 sp|Q29437|AOCX_BOVIN Primary amine oxidase, liver isozyme OS=Bos taurus PE=1 SV=1 7 5 9 7.87
46 tr|Q3T101|Q3T101_BOVIN IGL@ protein OS=Bos taurus GN=IGL@ PE=1 SV=1 6 2 10 76.60
47 tr|A6QM09|A6QM09_BOVIN Putative uncharacterized protein OS=Bos taurus PE=2 SV=1 4 3 6 62.93
48 sp|P28800|A2AP_BOVIN Alpha-2-antiplasmin OS=Bos taurus GN=SERPINF2 PE=1 SV=2 4 3 5 4.88
49 sp|P00735|THRB_BOVIN Prothrombin OS=Bos taurus GN=F2 PE=1 SV=2 2 2 2 3.68
50 sp|P81187|CFAB_BOVIN Complement factor B OS=Bos taurus GN=CFB PE=1 SV=2 2 2 2 4.07
51 sp|O02659|MBL2_BOVIN Mannose-binding protein C OS=Bos taurus GN=MBL PE=2 SV=1 3 2 4 8.03
52 tr|A0A1K0FUD3|A0A1K0FUD3_BOVIN Globin C1 OS=Bos taurus GN=GLNC1 PE=3 SV=1 3 2 5 13.38
53 tr|G3MWT1|G3MWT1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 5 3 12 36.50
54 tr|F1MNV5|F1MNV5_BOVIN Kininogen-1 OS=Bos taurus GN=KNG1 PE=1 SV=2 4 3 7 5.73
55 tr|G3MXG6|G3MXG6_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 2 2 4 30.22
56 tr|G3X6K8|G3X6K8_BOVIN Haptoglobin OS=Bos taurus GN=HP PE=3 SV=1 3 3 3 6.48
57 tr|B7FEK7|B7FEK7_BOVIN 43kDa collectin OS=Bos taurus GN=CL43 PE=4 SV=1 2 2 5 7.16
58 sp|P34955|A1AT_BOVIN Alpha-1-antiproteinase OS=Bos taurus GN=SERPINA1 PE=1 SV=1 3 2 5 2.40
59 sp|Q2KIU3|HP252_BOVIN Protein HP-25 homolog 2 OS=Bos taurus PE=2 SV=1 5 3 5 13.95
60 tr|F1N3Q7|F1N3Q7_BOVIN Apolipoprotein A-IV OS=Bos taurus GN=APOA4 PE=3 SV=1 1 1 1 3.68
61 tr|F1MSZ6|F1MSZ6_BOVIN Antithrombin-III OS=Bos taurus GN=SERPINC1 PE=3 SV=1 1 1 1 5.38
62 sp|P00978|AMBP_BOVIN Protein AMBP OS=Bos taurus GN=AMBP PE=1 SV=2 2 1 3 3.41
63 tr|B0JYQ0|B0JYQ0_BOVIN ALB protein OS=Bos taurus GN=ALB PE=2 SV=1 3 2 10 88.47
64 tr|K4JDR8|K4JDR8_BOVIN Alpha-2-macroglobulin variant 5 OS=Bos taurus GN=A2M PE=2 SV=1 2 1 21 79.17
65 tr|G5E604|G5E604_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=1 4 1 10 43.93
66 tr|Q5J801|Q5J801_BOVIN Endopin 2B OS=Bos taurus PE=2 SV=1 1 1 1 7.19
67 tr|F1MD73|F1MD73_BOVIN Uncharacterized protein OS=Bos taurus PE=1 SV=2 1 1 1 0.86
68 tr|Q5GN72|Q5GN72_BOVIN Alpha-1-acid glycoprotein OS=Bos taurus GN=agp PE=2 SV=2 2 1 3 5.94
69 tr|F1MVK1|F1MVK1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 1 8.67
70 sp|Q29S21|K2C7_BOVIN Keratin, type II cytoskeletal 7 OS=Bos taurus GN=KRT7 PE=2 SV=1 1 1 3 2.58
71 tr|Q2KIF2|Q2KIF2_BOVIN Leucine-rich alpha-2-glycoprotein 1 OS=Bos taurus GN=LRG1 PE=1 SV=1 2 1 3 3.47
72 tr|E1BMJ0|E1BMJ0_BOVIN Uncharacterized protein OS=Bos taurus GN=SERPING1 PE=3 SV=2 1 1 3 3.42
73 tr|A7MB82|A7MB82_BOVIN C1QTNF3 protein OS=Bos taurus GN=C1QTNF3 PE=2 SV=1 1 1 1 5.29
74 tr|E1BDK9|E1BDK9_BOVIN Uncharacterized protein OS=Bos taurus GN=RETSAT PE=4 SV=1 2 1 3 1.31
75 tr|F1MRZ1|F1MRZ1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=2 1 1 2 0.61
76 tr|Q56JW3|Q56JW3_BOVIN Nucleoside-diphosphate kinase NBR-A OS=Bos taurus GN=LOC574091 PE=2 SV=1 1 1 1 6.78
77 tr|A5PJT7|A5PJT7_BOVIN ECM1 protein OS=Bos taurus GN=ECM1 PE=2 SV=1 1 1 2 1.93
78 tr|F1MDH3|F1MDH3_BOVIN Uncharacterized protein OS=Bos taurus GN=TLN1 PE=1 SV=2 1 1 1 0.24
79 tr|G3N1R1|G3N1R1_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 2 44.53
80 tr|Q05B55|Q05B55_BOVIN IGK protein OS=Bos taurus GN=IGK PE=2 SV=1 0 0 0 33.75
81 tr|G3MZE0|G3MZE0_BOVIN Uncharacterized protein OS=Bos taurus PE=4 SV=1 1 1 2 15.87
82 tr|A5D9D2|A5D9D2_BOVIN Complement component 4 binding protein, alpha chain OS=Bos taurus GN=C4BPA PE=2 SV=1 0 0 0 0.00
Low fertility heifer number 12
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Chapter 5.2 
Supplemental Table S5.2.1: The RT-PCR array data for inflammatory mediator gene expression in bovine endometrial epithelial cells 
(bEEL) when co-incubated with plasma exosomes from high and low fertility heifers for 24 h. 
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Supplemental Table S5.2.2: The RT-PCR array data for inflammatory mediator gene expression in bovine endometrial stromal cells 
(bCSC) when co-incubated with plasma exosomes from high and low fertility heifers for 24 h. 
 
 
 
 
